Sentence,class,file
"Original Article CPD available at http://www.learnataagbi.org Cognitive decline in the elderly after surgery and anaesthesia: results from the Oxford Project to Investigate Memory and Ageing(OPTIMA) cohort D. Patel,1A.",Non-OADS,/arxiv_data1/oa_pdf/d1/36/ANAE-71-1144.PMC5213281.pdf
"10, 1377–1391 http://dx.doi.org/10.1080/00140139.2015.1137637 Utilising psychophysical techniques to investigate the effects of age, typeface  design, size and display polarity on glance legibility Jonathan Dobresa, Nadine Chahineb, Bryan Reimera, David Gouldb, Bruce Mehlera and Joseph F. Coughlina amassachusetts i nstitute of Technology AgeLab, new England University Transportation c enter, c ambridge, m A, UsA; bmonotype i maging, i nc.,  Woburn, m A, UsA ABSTRACT Psychophysical research on text legibility has historically investigated factors such as size, colour  and contrast, but there has been relatively little direct empirical evaluation of typographic design itself, particularly in the emerging context of glance reading.",Non-OADS,/arxiv_data1/oa_pdf/d9/b3/terg-59-1377.PMC5213401.pdf
"This is an open Access article distributed under the terms of the creative c ommons Attribution-nonc ommercial-noDerivatives License (http://creativecommons.org/ licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not  altered, transformed, or built upon in any way.KEYWORDS measurement; Hmi design;  reading; psychophysics;  typographyARTICLE HISTORY received 21 August 2015 Accepted 26 December 2015 CONTACT Jonathan Dobres  jdobres@mit.edu  supplemental data for this article can be accessed at http://dx.doi.org/10.1080/00140139.2015.1137637Background Graphical interface design necessitates a unique balance  between artistic sensibility and pragmatic concern to meet  specific needs.",Non-OADS,/arxiv_data1/oa_pdf/d9/b3/terg-59-1377.PMC5213401.pdf
http://hdl.handle.net/1887/20022.,Non-OADS,/arxiv_data1/oa_pdf/d9/b3/terg-59-1377.PMC5213401.pdf
"Accessed  November 13. http://www.neuro.mcw.edu/mcword/ Merkle, edgar C., and Barbara S. Chaparro.",Non-OADS,/arxiv_data1/oa_pdf/d9/b3/terg-59-1377.PMC5213401.pdf
"Accessed June 14. http://usabilitynews.org/examining-legibility-of-the-letter-e-and-number-0-using-classification-tree-analysis/ Gould, J. D., L. Alfaro, V. Barnes, R. Finn, N. Grischkowsky, and A.  Minuto.",OADS,/arxiv_data1/oa_pdf/d9/b3/terg-59-1377.PMC5213401.pdf
http://www.R-project.org/.,Non-OADS,/arxiv_data1/oa_pdf/d9/b3/terg-59-1377.PMC5213401.pdf
"X.P.Ye Depar tment ofBiosy stems Engineer ing&SoilScience TheUniversi tyofTennessee, 2506 E.J.Chapman Drive Knoxvi lle,TN37996 (USA) E-mail :xye2@u tk.edu Supp orting informa tionandtheORCIDidentification numb er(s) forthe autho r(s)ofthisarticle canbefoundunde rhttp://dx.doi.org/ 10.1002 / cssc.2 01601020.",Non-OADS,/arxiv_data1/oa_pdf/53/d6/CSSC-9-3268.PMC5213446.pdf
"In addition, CD44 is listed as an interactor of IGFBP-3 in the Human Protein Reference Database(http://www.hprd.org).",Non-OADS,/arxiv_data1/oa_pdf/74/e0/MC-56-681.PMC5213668.pdf
"There are 2  different isoforms of the catalytic α subunit, that is, the α1 sub- unit that is mainly localized to the cytosol and the α2 subunit Cellular Biology Circulation Research is available at http://circres.ahajournals.org DOI: 10.1161/CIRCRESAHA.116.309937Rationale:  The AMP-activated protein kinase (AMPK) is stimulated by hypoxia, and although the AMPKα1  catalytic subunit has been implicated in angiogenesis, little is known about the role played by the AMPKα2 subunit  in vascular repair.",Non-OADS,/arxiv_data1/oa_pdf/07/5a/res-120-99.PMC5213742.pdf
The online-only Data Supplement is available with this article at http://circres.ahajournals.org/lookup/suppl/doi:10.1161/CIRCRESAHA.,OADS,/arxiv_data1/oa_pdf/07/5a/res-120-99.PMC5213742.pdf
"Published by Informa UK Limited, trading as Taylor & Francis Group This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License(http://creativecommons.org/licenses/by-nc-nd/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.CONTACT Caragh Brosnan Caragh.brosnan@newcastle.edu.au School of Humanities & Social Science, Faculty of Education and Arts, University of Newcastle, Callaghan, NSW 2308, AustraliaHEALTH SOCIOLOGY REVIEW, 2016 VOL.",Non-OADS,/arxiv_data1/oa_pdf/d9/29/rhsr-25-171.PMC5213743.pdf
"2, 171 –186 http://dx.doi.org/10.1080/14461242.2016.1171161",Non-OADS,/arxiv_data1/oa_pdf/d9/29/rhsr-25-171.PMC5213743.pdf
"Published with license by Taylor & Francis Group, LLC © Alejandra Leivas, Antonio Perez-Martinez, Mar /C19ıa Jes/C19us Blanchard, Estela Mart /C19ın-Clavero, Luc /C19ıa Fern /C19andez,Juan Jos /C19e Lahuerta, and Joaqu /C19ın Martinez-Lopez.This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered , transformed, or built upon in any way.ONCOIMMUNOLOGY 2016, VOL.",Non-OADS,/arxiv_data1/oa_pdf/e8/bd/koni-05-12-1250051.PMC5213771.pdf
"12, e1250051 (9 pages)http://dx.doi.org/10.1080/2162402X.2016.1250051",Non-OADS,/arxiv_data1/oa_pdf/e8/bd/koni-05-12-1250051.PMC5213771.pdf
Trends Immunol 2001; 22:633-40; PMID:11698225; http://dx.doi.org/10.1016/S1471-4906(01)02060-9 2.,Non-OADS,/arxiv_data1/oa_pdf/e8/bd/koni-05-12-1250051.PMC5213771.pdf
Nat Rev Cancer 2002;2:850-61; PMID:12415255; http://dx.doi.org/10.1038/nrc928 3.,Non-OADS,/arxiv_data1/oa_pdf/e8/bd/koni-05-12-1250051.PMC5213771.pdf
Blood 2008; 111:1309-17; PMID:17947507; http://dx.doi.org/10.1182/blood-2007-03-078535 4.,Non-OADS,/arxiv_data1/oa_pdf/e8/bd/koni-05-12-1250051.PMC5213771.pdf
Clin Cancer Res 2008; 14:4650-7;PMID:18628480; http://dx.doi.org/10.1158/1078-0432.CCR-07-4405 5.,Non-OADS,/arxiv_data1/oa_pdf/e8/bd/koni-05-12-1250051.PMC5213771.pdf
Cancer Immu- nol Immunother 2011; 60:61-73; PMID:20848094; http://dx.doi.org/ 10.1007/s00262-010-0919-9 6.,Non-OADS,/arxiv_data1/oa_pdf/e8/bd/koni-05-12-1250051.PMC5213771.pdf
Cancer Immunol Immunother 2008; 57:1849-59; PMID:18392823; http://dx.doi.org/10.1007/s00262-008-0512-7 7.,Non-OADS,/arxiv_data1/oa_pdf/e8/bd/koni-05-12-1250051.PMC5213771.pdf
Haematologica2012; 97:1020-8; PMID:22271890; http://dx.doi.org/10.3324/haematol.2011.054254 8.,Non-OADS,/arxiv_data1/oa_pdf/e8/bd/koni-05-12-1250051.PMC5213771.pdf
J Immunother 2015; 38:24-36; PMID:25415285; http://dx.doi.org/10.1097/CJI.0000000000000059 9.,Non-OADS,/arxiv_data1/oa_pdf/e8/bd/koni-05-12-1250051.PMC5213771.pdf
Br J Haematol 2008; 143:641-53;PMID:18950462; http://dx.doi.org/10.1111/j.1365-2141.2008.07340.x 10.,Non-OADS,/arxiv_data1/oa_pdf/e8/bd/koni-05-12-1250051.PMC5213771.pdf
Cytotherapy 2015; 17:1594-603;PMID:26341478; http://dx.doi.org/10.1016/j.jcyt.2015.07.011 11.,Non-OADS,/arxiv_data1/oa_pdf/e8/bd/koni-05-12-1250051.PMC5213771.pdf
J Pediatr Hematol Oncol 2015; 37:79-93; PMID:25590232; http://dx.doi.org/10.1097/MPH.000000000000030312.,Non-OADS,/arxiv_data1/oa_pdf/e8/bd/koni-05-12-1250051.PMC5213771.pdf
"Shimasaki N, Coustan-Smith E, Kamiya T, Campana D. Expanded and armed natural killer cells for multiple myeloma immunotherapy.Cytotherapy 2016; (11):1422-1434; PMID:27497701; http://dx.doi.org/10.1016/j.jcyt.2016.06.013 13.",OADS,/arxiv_data1/oa_pdf/e8/bd/koni-05-12-1250051.PMC5213771.pdf
Haematologica 2012; 97:1348-56; PMID: 22419581; http://dx.doi.org/10.3324/haematol.2011.056747 14.,Non-OADS,/arxiv_data1/oa_pdf/e8/bd/koni-05-12-1250051.PMC5213771.pdf
Cancer Res 2009; 69:4010-7; PMID:19383914; http://dx.doi.org/10.1158/0008-5472.CAN-08-3712 15.,Non-OADS,/arxiv_data1/oa_pdf/e8/bd/koni-05-12-1250051.PMC5213771.pdf
N Engl J Med 2016; 374:194; PMID:26760100; http://dx.doi.org/10.1056/NEJMc1507847 16.,OADS,/arxiv_data1/oa_pdf/e8/bd/koni-05-12-1250051.PMC5213771.pdf
Br J Hae-matol 2016; 172:685-98; PMID:26791002; http://dx.doi.org/10.1111/ bjh.13889 17.,OADS,/arxiv_data1/oa_pdf/e8/bd/koni-05-12-1250051.PMC5213771.pdf
Leukemia 2009; 23:2147-52;PMID:19626046; http://dx.doi.org/10.1038/leu.2009.147 18.,Non-OADS,/arxiv_data1/oa_pdf/e8/bd/koni-05-12-1250051.PMC5213771.pdf
J Cancer 2011; 2:383-5;PMID:21750690; http://dx.doi.org/10.7150/jca.2.383 19.,Non-OADS,/arxiv_data1/oa_pdf/e8/bd/koni-05-12-1250051.PMC5213771.pdf
Blood 2009; 113:6120-7; PMID:19202127; http://dx.doi.org/10.1182/blood-2008-11-190421 20.,Non-OADS,/arxiv_data1/oa_pdf/e8/bd/koni-05-12-1250051.PMC5213771.pdf
Science2015; 350:981-5; PMID:26472762; http://dx.doi.org/10.1126/science.,Non-OADS,/arxiv_data1/oa_pdf/e8/bd/koni-05-12-1250051.PMC5213771.pdf
Clin Immunol 2004; 112:258-67; PMID:15308119; http://dx.doi.org/10.1016/j.clim.,OADS,/arxiv_data1/oa_pdf/e8/bd/koni-05-12-1250051.PMC5213771.pdf
Blood 2006; 107:2409-14; PMID:16304057; http://dx.doi.org/10.1182/blood-2005-06-2399 23.,Non-OADS,/arxiv_data1/oa_pdf/e8/bd/koni-05-12-1250051.PMC5213771.pdf
Cancer ImmunolImmunother 2015; 64:213-24; PMID:25341809; http://dx.doi.org/10.1007/s00262-014-1623-y 24.,Non-OADS,/arxiv_data1/oa_pdf/e8/bd/koni-05-12-1250051.PMC5213771.pdf
Pathol Oncol Res 2015; 21:929-34; PMID:25743259; http://dx.doi.org/10.1007/s12253-015-9921-z 25.,Non-OADS,/arxiv_data1/oa_pdf/e8/bd/koni-05-12-1250051.PMC5213771.pdf
Blood 2005; 106:376-83; PMID:15755898; http://dx.doi.org/10.1182/blood-2004-12-4797 26.,Non-OADS,/arxiv_data1/oa_pdf/e8/bd/koni-05-12-1250051.PMC5213771.pdf
Leukemia 2003; 17:2318-57; PMID:14562125; http://dx.doi.org/10.1038/sj.leu.2403135ONCOIMMUNOLOGY e1250051-9,Non-OADS,/arxiv_data1/oa_pdf/e8/bd/koni-05-12-1250051.PMC5213771.pdf
Up to 16 allergens have been described in peanut (http://www.allergen.org).,OADS,/arxiv_data1/oa_pdf/14/b9/MNFR-60-2722.PMC5213772.pdf
"3, 299 –319 http://dx.doi.org/10.1080/0964704X.2015.1121697 © 2016 Frank W. Stahnisch.",Non-OADS,/arxiv_data1/oa_pdf/62/95/njhn-25-299.PMC5213806.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.",Non-OADS,/arxiv_data1/oa_pdf/62/95/njhn-25-299.PMC5213806.pdf
Clinical trial registration NCT02805478 ( http://www.clin icaltrials.gov ).,Non-OADS,/arxiv_data1/oa_pdf/d2/47/mbp-22-12.PMC5213843.pdf
Available at: http://www.who.int/mediacentre/factsheets/fs311/en .,Non-OADS,/arxiv_data1/oa_pdf/d2/47/mbp-22-12.PMC5213843.pdf
"In addition, 22 people die every day on average from the lack of available organs for transplant (https://www.donatelife.net/), which reveals a fundamental problem in organ transplantation: discrepancy between the demand and availability of organs.This situation has been the major driving force behind the rise of organ engineering approach to create transplantable grafts that may potentially be used as alternatives to donor organs.",Non-OADS,/arxiv_data1/oa_pdf/20/28/cootr-22-79.PMC5213875.pdf
"Vitamin B1-de ﬁcient mice show impairment of hippocampus-dependent memory formation and loss of hippocampal neurons and dendritic spines:potential microendophenotypes of Wernicke –Korsakoff syndrome Hiroyoshi Inaba1,#, Takuya Kishimoto1,#, Satoru Oishi1,#, Kan Nagata1,#, Shunsuke Hasegawa1,2, Tamae Watanabe1and Satoshi Kida1,2,* 1Faculty of Applied Bioscience, Department of Bioscience, Tokyo University of Agriculture, Tokyo, Japan;2Core Research for Evolutional Science and Technology, Japan Science and Technology Agency, Saitama, Japan Received May 27, 2016; accepted July 28, 2016 http://dx.doi.org/10.1080/09168451.2016.1224639 Patients with severe Wernicke –Korsakoff syn- drome (WKS) associated with vitamin B1 (thiamine)deﬁciency (TD) show enduring impairment of mem- ory formation.",Non-OADS,/arxiv_data1/oa_pdf/29/5c/tbbb-80-2425.PMC5213968.pdf
"This is an Open Access article distributed under the terms of the Creativ e Commons Attribution-NonCommercial-NoDerivatives License ( http://creativecommons.org/licenses/ by-nc-nd/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in a ny medium, provided the original work is properly cited, and is not alter ed, trans- formed, or built upon in any way.",Non-OADS,/arxiv_data1/oa_pdf/29/5c/tbbb-80-2425.PMC5213968.pdf
"ORCID Satoshi Kida http://orcid.org/0000-0002-8038-9583 References [1] Suzuki U, Shimamura T, Odake S. Über Oryzanin, ein Bestandteil der Reiskleie und seine physiologische Bedeutung[Over Oryzanin, a component of the rice bran and its physiologi- cal meaning].",Non-OADS,/arxiv_data1/oa_pdf/29/5c/tbbb-80-2425.PMC5213968.pdf
"Journal of Neurophysiology ,94(1), 712–721, http://doi.org/10.1152/jn.00093.2005 .",Non-OADS,/arxiv_data1/oa_pdf/8e/06/i1534-7362-16-15-23.PMC5213993.pdf
"The Journal of Physiology , 351, 217–250, http://doi.org/10.1111/ (ISSN)1469-7793 .",Non-OADS,/arxiv_data1/oa_pdf/8e/06/i1534-7362-16-15-23.PMC5213993.pdf
"The Journal of Physiology , http://doi.org/ 10.1113/jphysiol.2007.139881 .",Non-OADS,/arxiv_data1/oa_pdf/8e/06/i1534-7362-16-15-23.PMC5213993.pdf
"Journal of Neurophysiology ,115(3), 1220–1227, http://doi.org/ 10.1152/jn.00774.2015 .",Non-OADS,/arxiv_data1/oa_pdf/8e/06/i1534-7362-16-15-23.PMC5213993.pdf
"The accuracy and precision of saccades to small and large targets.Vision Research , http://doi.org/10.1016/ 0042-6989(94)00255-K .",OADS,/arxiv_data1/oa_pdf/8e/06/i1534-7362-16-15-23.PMC5213993.pdf
"Journal of Neurophysiology ,91(2), 591–603, http://doi.org/10.1152/jn.00801.2003 .",Non-OADS,/arxiv_data1/oa_pdf/8e/06/i1534-7362-16-15-23.PMC5213993.pdf
"Vision Research ,39(17), 2929–2946, http://doi.org/10.1016/S0042-6989(99)00029-2 .",Non-OADS,/arxiv_data1/oa_pdf/8e/06/i1534-7362-16-15-23.PMC5213993.pdf
"Journal of Neurophysiology ,95(1), 418–427, http://doi.org/10.1152/jn.00596.2005 .",Non-OADS,/arxiv_data1/oa_pdf/8e/06/i1534-7362-16-15-23.PMC5213993.pdf
"Review of General Psychology ,14(2), 92– 104, http://doi.org/10.1037/a0019491 .Stahl, J. S. (2001).",Non-OADS,/arxiv_data1/oa_pdf/8e/06/i1534-7362-16-15-23.PMC5213993.pdf
"Experimental Brain Research ,136, 200–210, http://doi.org/10.1007/s002210000593 .",Non-OADS,/arxiv_data1/oa_pdf/8e/06/i1534-7362-16-15-23.PMC5213993.pdf
"Journal of the Optical Society of America ,55(9), 1158–1164, http://doi.org/10.1364/JOSA.55.001158 .",Non-OADS,/arxiv_data1/oa_pdf/8e/06/i1534-7362-16-15-23.PMC5213993.pdf
"Vision Research ,18(9), 1165–1172, http://doi.org/10.1016/ 0042-6989(78)90100-1 .Journal of Vision (2016) 16(15):23, 1–12 Shanidze, Ghahghaei, & Verghese 12",Non-OADS,/arxiv_data1/oa_pdf/8e/06/i1534-7362-16-15-23.PMC5213993.pdf
URL http://www.cbs.nl/nl- NL/menu/home/default.htm.,Non-OADS,/arxiv_data1/oa_pdf/54/18/PD-36-1091.PMC5213994.pdf
"1, 111 –128, http://dx.doi.org/10.1080/09297049.2015.1063595 © 2015 The Author(s).",Non-OADS,/arxiv_data1/oa_pdf/07/a2/ncny-23-111.PMC5214099.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution- NonCommercial-NoDerivatives License ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.",Non-OADS,/arxiv_data1/oa_pdf/07/a2/ncny-23-111.PMC5214099.pdf
"12, e1245266 (11 pages)http://dx.doi.org/10.1080/2162402X.2016.1245266",Non-OADS,/arxiv_data1/oa_pdf/34/2b/koni-05-12-1245266.PMC5214164.pdf
ORCID Tero A. J €arvinen http://orcid.org/0000-0002-4027-1759ONCOIMMUNOLOGY e1245266-9,Non-OADS,/arxiv_data1/oa_pdf/34/2b/koni-05-12-1245266.PMC5214164.pdf
Curr Genomics 2013; 14:453-67; PMID:24396277; http://dx.doi.org/10.2174/1389202911314050010 2.,OADS,/arxiv_data1/oa_pdf/34/2b/koni-05-12-1245266.PMC5214164.pdf
N Engl J Med 2011; 365:2507-18; PMID:22204726; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/34/2b/koni-05-12-1245266.PMC5214164.pdf
FEBS Lett 1996; 393:101-4; PMID:8804434; http://dx.doi.org/10.1016/0014-5793(96)00861-7 4.,OADS,/arxiv_data1/oa_pdf/34/2b/koni-05-12-1245266.PMC5214164.pdf
Oncogene 2006; 25:5648-55; PMID:16636666;http://dx.doi.org/10.1038/sj.onc.1209572 5.,OADS,/arxiv_data1/oa_pdf/34/2b/koni-05-12-1245266.PMC5214164.pdf
FEBS J 2009; 276:6271-84;PMID:19780834; http://dx.doi.org/10.1111/j.1742-4658.2009.07335.x 6.,OADS,/arxiv_data1/oa_pdf/34/2b/koni-05-12-1245266.PMC5214164.pdf
J Clin Invest 2003; 111:1723-32; PMID:12782675; http://dx.doi.org/ 10.1172/JCI200317220 7.,Non-OADS,/arxiv_data1/oa_pdf/34/2b/koni-05-12-1245266.PMC5214164.pdf
FASEB J 2007; 21:1088-98;PMID:17242158; http://dx.doi.org/10.1096/fj.06-7060com 8.,Non-OADS,/arxiv_data1/oa_pdf/34/2b/koni-05-12-1245266.PMC5214164.pdf
Mol Carcinog 2005; 44:151-61; PMID:16167351; http://dx.doi.org/10.1002/mc.20134 9.,Non-OADS,/arxiv_data1/oa_pdf/34/2b/koni-05-12-1245266.PMC5214164.pdf
J ClinInvest 1987; 80:1545-9; PMID:2824565; http://dx.doi.org/10.1172/ JCI113240 10.,Non-OADS,/arxiv_data1/oa_pdf/34/2b/koni-05-12-1245266.PMC5214164.pdf
Mol Carcinog 2001; 31:224-32; PMID:11536372; http://dx.doi.org/10.1002/mc.1057 11.,Non-OADS,/arxiv_data1/oa_pdf/34/2b/koni-05-12-1245266.PMC5214164.pdf
Proc Natl Acad Sci U S A 2001; 98:10326-31; PMID:11517338; http://dx.doi.org/10.1073/ pnas.191199198 12.,OADS,/arxiv_data1/oa_pdf/34/2b/koni-05-12-1245266.PMC5214164.pdf
Neoplasia 2012; 14:271-82; PMID:22577343; http://dx.doi.org/10.1593/neo.12166 13.,Non-OADS,/arxiv_data1/oa_pdf/34/2b/koni-05-12-1245266.PMC5214164.pdf
Int J Oncol 2008; 32:1073-83;PMID:18425334; http://dx.doi.org/10.3892/ijo.32.5.1073 14.,Non-OADS,/arxiv_data1/oa_pdf/34/2b/koni-05-12-1245266.PMC5214164.pdf
Am J Pathol 2001; 158:305-16; PMID:11141505; http://dx.doi.org/10.1016/S0002-9440(10)63970-3 16.,OADS,/arxiv_data1/oa_pdf/34/2b/koni-05-12-1245266.PMC5214164.pdf
JLeukoc Biol 2015; 98:73-83; PMID:25926688; http://dx.doi.org/ 10.1189/jlb.2A0514-257RR 17.,Non-OADS,/arxiv_data1/oa_pdf/34/2b/koni-05-12-1245266.PMC5214164.pdf
Mol Ther 2012; 20:679-86; PMID:22186789; http://dx.doi.org/10.1038/mt.2011.269 18.,Non-OADS,/arxiv_data1/oa_pdf/34/2b/koni-05-12-1245266.PMC5214164.pdf
Nat Rev Cancer 2003; 3:434-43; PMID:12778133; http://dx.doi.org/10.1038/nrc1095 21.,Non-OADS,/arxiv_data1/oa_pdf/34/2b/koni-05-12-1245266.PMC5214164.pdf
Carcinogenesis 1998; 19:2107-13; PMID:9886564; http://dx.doi.org/10.1093/carcin/19.12.2107 22.,Non-OADS,/arxiv_data1/oa_pdf/34/2b/koni-05-12-1245266.PMC5214164.pdf
Proc Natl Acad Sci U S A 2008; 105:652-6; PMID:18178624; http://dx.doi.org/10.1073/ pnas.0708594105 24.,OADS,/arxiv_data1/oa_pdf/34/2b/koni-05-12-1245266.PMC5214164.pdf
J Immunol 2013; 191:2299-307; PMID:23904158; http://dx.doi.org/10.4049/jimmunol.1300472 25.,Non-OADS,/arxiv_data1/oa_pdf/34/2b/koni-05-12-1245266.PMC5214164.pdf
J Exp Med 1998; 187:129-34;PMID:9419219; http://dx.doi.org/10.1084/jem.187.1.129 26.,Non-OADS,/arxiv_data1/oa_pdf/34/2b/koni-05-12-1245266.PMC5214164.pdf
Cancer Res 2009; 69:2010-17; PMID:19244111; http://dx.doi.org/ 10.1158/0008-5472.CAN-08-3479 27.,Non-OADS,/arxiv_data1/oa_pdf/34/2b/koni-05-12-1245266.PMC5214164.pdf
J Immunol 2014; 193:5470-9; PMID:25355923; http://dx.doi.org/10.4049/jimmunol.1401629 28.,Non-OADS,/arxiv_data1/oa_pdf/34/2b/koni-05-12-1245266.PMC5214164.pdf
Blood 2006; 108:983-5; PMID:16627761; http://dx.doi.org/10.1182/blood-2005-09-3824 29.,Non-OADS,/arxiv_data1/oa_pdf/34/2b/koni-05-12-1245266.PMC5214164.pdf
J Exp Med 2003; 198:747-55; PMID:12953094; http://dx.doi.org/10.1084/jem.20021282 30.,Non-OADS,/arxiv_data1/oa_pdf/34/2b/koni-05-12-1245266.PMC5214164.pdf
Cancer Res 2008; 68:3924-30; PMID:18483278; http://dx.doi.org/ 10.1158/0008-5472.CAN-07-3059 31.,Non-OADS,/arxiv_data1/oa_pdf/34/2b/koni-05-12-1245266.PMC5214164.pdf
J Exp Med 2015; 212:351-67; PMID:25667306; http://dx.doi.org/10.1084/jem.20140835e1245266-10 M. V€AH€ATUPA ET AL.,OADS,/arxiv_data1/oa_pdf/34/2b/koni-05-12-1245266.PMC5214164.pdf
Cancer Res 2010;70:10112-20; PMID:21159633; http://dx.doi.org/10.1158/0008-5472.CAN-10-0775 33.,Non-OADS,/arxiv_data1/oa_pdf/34/2b/koni-05-12-1245266.PMC5214164.pdf
Eur J Immunol 2015; 45:922-31; PMID:25487261; http://dx.doi.org/ 10.1002/eji.201445052 34.,Non-OADS,/arxiv_data1/oa_pdf/34/2b/koni-05-12-1245266.PMC5214164.pdf
Oncology 2014; 87:21-9; PMID:24968881; http://dx.doi.org/10.1159/000360993 35.,Non-OADS,/arxiv_data1/oa_pdf/34/2b/koni-05-12-1245266.PMC5214164.pdf
Mol Ther 2016; 24:1478-83; http://dx.doi.org/10.1038/mt.2016.86 36.,OADS,/arxiv_data1/oa_pdf/34/2b/koni-05-12-1245266.PMC5214164.pdf
PLoS One 2012; 7:e40738; PMID:22808247; http://dx.doi.org/10.1371/journal.pone.0040738 37.,Non-OADS,/arxiv_data1/oa_pdf/34/2b/koni-05-12-1245266.PMC5214164.pdf
Biomed Res Int 2015; 2015:148651; PMID:26167473; http://dx.doi.org/10.1155/ 2015/148651 38.,Non-OADS,/arxiv_data1/oa_pdf/34/2b/koni-05-12-1245266.PMC5214164.pdf
Oncoimmunology 2012; 1:162-71; PMID:22720237; http://dx.doi.org/ 10.4161/onci.1.2.18481 40.,Non-OADS,/arxiv_data1/oa_pdf/34/2b/koni-05-12-1245266.PMC5214164.pdf
2016 [Epub ahead of print] PubMed; PMID:27527873; http://dx.doi.org/10.18632/oncotarget.11106ONCOIMMUNOLOGY e1245266-11,Non-OADS,/arxiv_data1/oa_pdf/34/2b/koni-05-12-1245266.PMC5214164.pdf
"But despite calls for more cross-disciplinary learning and greater integration (e.g., http://commonfund.nih.gov/behaviorchange/index (Rowson, 2011 )), and the initiation of new journals, university departments and centres devoted to behaviour change © 2016 The Author(s).",Non-OADS,/arxiv_data1/oa_pdf/aa/a7/rhpr-10-425.PMC5214166.pdf
"4, 425 –446 http://dx.doi.org/10.1080/17437199.2016.1219673",Non-OADS,/arxiv_data1/oa_pdf/aa/a7/rhpr-10-425.PMC5214166.pdf
"(e.g., http://www.mdrc.org/project/center-applied-behavioral-science-cabs#overview ), a fully-fledged applied science of behaviour change has yet to emerge.",Non-OADS,/arxiv_data1/oa_pdf/aa/a7/rhpr-10-425.PMC5214166.pdf
"The gossip character then slaps her head saying how stupid she has been, and then gossips about the correct behaviour toanyone who will listen (see the related ads at http://ehg.lshtm.ac.uk/behavior-centred-design/ ).",Non-OADS,/arxiv_data1/oa_pdf/aa/a7/rhpr-10-425.PMC5214166.pdf
"Published by Informa UK Limited, trading as Taylor & Francis Group This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License(http://creativecommons.org/licenses/by-nc-nd/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.CONTACT Mika Pantzar mika.pantzar@helsinki.",Non-OADS,/arxiv_data1/oa_pdf/bd/de/rhsr-26-022.PMC5214173.pdf
"1, 22 –37 http://dx.doi.org/10.1080/14461242.2016.1184580",Non-OADS,/arxiv_data1/oa_pdf/bd/de/rhsr-26-022.PMC5214173.pdf
"Available at SSRN: http://ssrn.com/abstract=2666324 Michelson, W. ( 2005 ).Time  use.",OADS,/arxiv_data1/oa_pdf/bd/de/rhsr-26-022.PMC5214173.pdf
"Scientific Reports ,6, 32239, http://doi.org/10.1038/ srep32239 .",Non-OADS,/arxiv_data1/oa_pdf/08/56/i1534-7362-16-15-16.PMC5214222.pdf
"Available at: http://www.who.int/blindness/causes/priority.Accessed July 1, 2015.",Non-OADS,/arxiv_data1/oa_pdf/87/a6/i1552-5783-57-15-6911.PMC5214225.pdf
"We also found night-time systolic BP to have a stronger association than daytime systolic BP and study BP with other echocardiographic markers of sub- clinical cardiac damage such as LA volume and LV mass (Supplementary Table 1, Supplemental digital content 1, http://links.lww.com/BPMJ/A27 ).",Non-OADS,/arxiv_data1/oa_pdf/df/ca/mbp-22-18.PMC5214226.pdf
"The reproducibility of BPprofiles defined by the absolute BP level was better, but still just 40% (Supplementary Tables 2 –4, Supplemental digital content 2, http://links.lww.com/BPMJ/A28 ).",Non-OADS,/arxiv_data1/oa_pdf/df/ca/mbp-22-18.PMC5214226.pdf
"1, 1 –16 http://dx.doi.org/10.1080/17450128.2016.1262978 © 2016 The Author(s).",Non-OADS,/arxiv_data1/oa_pdf/28/11/rvch-12-001.PMC5214285.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.",Non-OADS,/arxiv_data1/oa_pdf/28/11/rvch-12-001.PMC5214285.pdf
ORCID Elizabeth J. Levey http://orcid.org/0000-0002-5577-250514 E. J. LEVEY ET AL.,OADS,/arxiv_data1/oa_pdf/28/11/rvch-12-001.PMC5214285.pdf
"Retrieved from IRIN: The inside story on emergencies website http://www.irinnews.org/analysis/2015/10/07/ what-happened-liberia ’s-ebola-orphans Colman, I., Garad, Y., Zeng, Y., Naicker, K., Weeks, M., Patten, S. B., .",Non-OADS,/arxiv_data1/oa_pdf/28/11/rvch-12-001.PMC5214285.pdf
"Retrieved from http://www.lisgis.net/page_ info.php?7d5f44532cbfc489b8db9e12e44eb820=MzQy Lyons-Ruth, K. ( 1996 ).",Non-OADS,/arxiv_data1/oa_pdf/28/11/rvch-12-001.PMC5214285.pdf
Retrieved from http://www.undp.,Non-OADS,/arxiv_data1/oa_pdf/28/11/rvch-12-001.PMC5214285.pdf
"Retrieved from http://www.unicef.org/media/media_45279.html Werner, E. E. ( 1989 ).",Non-OADS,/arxiv_data1/oa_pdf/28/11/rvch-12-001.PMC5214285.pdf
"[12] Tosolve these biases, wepropos eanew approa chthat di- rectly comp ares theactivity ofthed-andl-glucose conjuga tes[a]L.N.Lameijer ,Dr.S.L.Hopk ins,T.G.Brev/C216,S.H.C.Askes, Dr.S.Bonne t Leiden Institute ofChemistr y,Leiden Universi ty Gorlaeu sLaboratorie s,P.O.Box 9502, 2300 RALeiden (The Neth erlands) E-mail :bonne t@chem .leidenu niv.nl Supportin ginformat ionforthisarticle isavailab leontheWWW under http://dx.doi.or g/10.10 02/chem.20 1603066.",Non-OADS,/arxiv_data1/oa_pdf/2f/a3/CHEM-22-18484.PMC5214309.pdf
"4, 272–286, http://dx.doi.org/10.1080/19012276.2016.1162107 © 2016 Informa UK Limited, trading as Taylor & Francis Group.",Non-OADS,/arxiv_data1/oa_pdf/1a/e1/rnpy-68-272.PMC5214335.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDeriva- tives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and  reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.Parental reflective functioning in fathers who  use intimate partner violence: Findings from a  Norwegian clinical sample HENNING MOHAUPT1,3 , & FANNY DUCKERT1,2 *Correspondence address: Henning Mohaupt, Alcohol and Drug Research Western Norway (KORFOR), Stavanger University  Hospital, P O Box 8100, 4068 Stavanger, Norway.",Non-OADS,/arxiv_data1/oa_pdf/1a/e1/rnpy-68-272.PMC5214335.pdf
"ORCID Henning Mohaupt   http://orcid.org/0000-0001-9326-6892 REFERENCES Abidin, R. A.",Non-OADS,/arxiv_data1/oa_pdf/1a/e1/rnpy-68-272.PMC5214335.pdf
Retrieved from http://www.sirus.no/filestore/Dummy_graphics/sirusrap.9.09.pdf .,Non-OADS,/arxiv_data1/oa_pdf/1a/e1/rnpy-68-272.PMC5214335.pdf
Supplementary material for this paper is available at: http://dx.doi.org/10.1080/00324728.2016.1206210 Keywords : childlessness; cohort fertility; education trends; Eastern Europe; Western Europe [Submitted June 2015; Final version accepted April 2016] 1.,Non-OADS,/arxiv_data1/oa_pdf/93/19/rpst-70-275.PMC5214374.pdf
"3, 275 –291, http://dx.doi.org/10.1080/00324728.2016.1206210 © 2016 The Author(s).",Non-OADS,/arxiv_data1/oa_pdf/93/19/rpst-70-275.PMC5214374.pdf
"Published by Informa UK Limited, trading as Taylor & Francis Group This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License(http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.",Non-OADS,/arxiv_data1/oa_pdf/93/19/rpst-70-275.PMC5214374.pdf
"Available: http://www.oecd.org/edu/Education- at-a-Glance-2014.pdf Pooley, S. 2013.",Non-OADS,/arxiv_data1/oa_pdf/93/19/rpst-70-275.PMC5214374.pdf
Available: http://www.uis.,Non-OADS,/arxiv_data1/oa_pdf/93/19/rpst-70-275.PMC5214374.pdf
Available: http://www.eurrep.,Non-OADS,/arxiv_data1/oa_pdf/93/19/rpst-70-275.PMC5214374.pdf
"10, 1043 –1055 http://dx.doi.org/10.1080/21678707.2016.1229181 © 2016 The Author(s).",Non-OADS,/arxiv_data1/oa_pdf/0e/06/ieod-4-1043.PMC5214376.pdf
"Published by Informa UK Limited, trading as Taylor & Francis Group This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.",Non-OADS,/arxiv_data1/oa_pdf/0e/06/ieod-4-1043.PMC5214376.pdf
ORCID Walter E. Kaufmann http://orcid.org/0000-0001-6116-5050 David B. Everman http://orcid.org/0000-0001-8331-992X Steven A. Skinner http://orcid.org/0000-0003-3844-07921052 W. E. KAUFMANN ET AL.,Non-OADS,/arxiv_data1/oa_pdf/0e/06/ieod-4-1043.PMC5214376.pdf
Available from: http://edisonpharma.com/wp-con tent/files_mf/1409757666RettSyndromepressrelease140903.pdf 82.,Non-OADS,/arxiv_data1/oa_pdf/0e/06/ieod-4-1043.PMC5214376.pdf
Available from: https://clinicaltrials.gov/ct2/show/NCT02715115 115.,Non-OADS,/arxiv_data1/oa_pdf/0e/06/ieod-4-1043.PMC5214376.pdf
Available from: http://www.neurenpharma.,Non-OADS,/arxiv_data1/oa_pdf/0e/06/ieod-4-1043.PMC5214376.pdf
"doi:http://dx.doi.org/10.1097/00004583-200401000-00014 Bipeta, R., Y erramilli, S. S., Pingali, S., Karredla, A. R., & Ali, M. O.",Non-OADS,/arxiv_data1/oa_pdf/8e/9a/JCLP-72-1129.PMC5214379.pdf
"doi:http://dx.doi.org/10.1080/10401230802017043 Storch, E. A., Geffken, G. R., Merlo, L. J., Jacob, M. L., Murphy, T. K., Goodman, W .",Non-OADS,/arxiv_data1/oa_pdf/8e/9a/JCLP-72-1129.PMC5214379.pdf
"doi:http://dx.doi.org/10.1016/j.jaac.2012.02.016 Storch, E. A., Lehmkuhl, H. D., Ricketts, E., Geffken, G. R., Marien, W ., & Murphy, T. K. (2010).",OADS,/arxiv_data1/oa_pdf/8e/9a/JCLP-72-1129.PMC5214379.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/18/9c/copd-12-123.PMC5214516.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of COPD 2017:12 123–133International Journal of COPD Dove press submit your manuscript | www.dovepress.co m Dove press  123OrIg Inal researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/COPD.S10399 8 Barriers and facilitators influencing self- management among COPD patients: a mixed  methods exploration in primary and affiliated  specialist care Chantal F Hillebregt1 auke J Vlonk1 Marc a Bruijnzeels1 Onno CP van schayck2 niels h Chavannes3 1Jan van es Institute (JVeI),   Netherlands Expert Center Integrated  Primary Care, almere, 2Department  of general Practice, school for Public  health and Primary Care (C aPhrI),   Maastricht University Medical  Center, Maastricht, 3Department  of Public health and Primary Care,   leiden University Medical Center,   leiden, the netherlandsAbstract:  Self-management is becoming increasingly important in COPD health care although  it remains difficult to embed self-management into routine clinical care.",Non-OADS,/arxiv_data1/oa_pdf/18/9c/copd-12-123.PMC5214516.pdf
"Keywords:  self-management, health communication, chronic disease management, chronic  obstructive pulmonary disease, mixed methods, barriers and facilitators, primary health care,  specialist care Introduction According to the World Health Organization, COPD is listed among the top three  leading causes of death in 2030.1 COPD is currently ranked sixth in the Dutch mortality  ranking list.2,3 Because of the aging population, it is expected that the number of COPD  patients will increase by 38% between 2005 and 2025.4 Apart from the expected  loss in both years of life and health-related quality of life among many patients, this Correspondence: Chantal F Hillebregt Jan van es Institute (JVeI), netherlands  Expert Center Integrated Primary Care,  Wisselweg 33, 1314 CB Almere,  the netherlands Tel +31 36 767 0360 email hillebregt77@gmail.co m Journal name: International Journal of COPD Article Designation: Original Research Y ear: 2017 Volume: 12 Running head verso: Hillebregt et al Running head recto: Self-management barriers and facilitators among COPD patients DOI: http://dx.doi.org/10.2147/COPD.S103998",Non-OADS,/arxiv_data1/oa_pdf/18/9c/copd-12-123.PMC5214516.pdf
"International Journal of COPD Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journa lThe International Journal of COPD is an international, peer-reviewed  journal of therapeutics and pharmacology focusing on concise rapid  reporting of clinical studies and reviews in COPD.",Non-OADS,/arxiv_data1/oa_pdf/18/9c/copd-12-123.PMC5214516.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/18/9c/copd-12-123.PMC5214516.pdf
Available from: http://www.bie.ala.org.au/species/EXCOECARIA+AGALLOCHA#tab_ classification.,Non-OADS,/arxiv_data1/oa_pdf/06/bf/PRev-10-123.PMC5214557.pdf
Available from: http://www.toxicologycentre.com/English/plants/Botanical/komatti.html.,Non-OADS,/arxiv_data1/oa_pdf/06/bf/PRev-10-123.PMC5214557.pdf
Available from: http://www.ars-grin.gov/cgi-bin/npgs/html/taxon.pl?410154.,OADS,/arxiv_data1/oa_pdf/06/bf/PRev-10-123.PMC5214557.pdf
Available from: http://www.keys.trin.org.au/key -server/data/0e0f0504-0103-430d-8004-060d 07080d04/media/Html/taxon/Excoecaria_agallocha.htm.,OADS,/arxiv_data1/oa_pdf/06/bf/PRev-10-123.PMC5214557.pdf
Available from: http://www.amap-collaboratif.cirad.fr/pages_logiciels/Mangrove_web/ especes/e/excag/excag.html.,OADS,/arxiv_data1/oa_pdf/06/bf/PRev-10-123.PMC5214557.pdf
Available from: http://www.wildsingapore.com/wildfacts/plants/mangrove/excoecaria/ excoecaria.htm.,Non-OADS,/arxiv_data1/oa_pdf/06/bf/PRev-10-123.PMC5214557.pdf
Available from: http://www.catalogueoflife.org/col.,Non-OADS,/arxiv_data1/oa_pdf/8b/90/PRev-10-139.PMC5214558.pdf
Available from: http://www.theplantlist.org/.,Non-OADS,/arxiv_data1/oa_pdf/8b/90/PRev-10-139.PMC5214558.pdf
"After  the article’s publication, it was brought to the journal’s attention by a reader that several sections of the article have been directly copied and/or  paraphrased without sufficient attribution including, http://flipper.diff.org/apptagsaccount/items/7017, http://horticultureandsoilscience.wikia.com/ wiki/Nerium, https://en.wikipedia.org/wiki/Bufadienolide and https://en.wikipedia.org/wiki/Oleandrin.",Non-OADS,/arxiv_data1/oa_pdf/16/89/PRev-10-147.PMC5214560.pdf
Available from: http://www.chiro.org/ nutrition/ABSTRACTS/Quercetin_A_Review.shtml.,Non-OADS,/arxiv_data1/oa_pdf/a3/8a/PRev-10-84.PMC5214562.pdf
Available from: http://www.who.int/ cancer/country-profiles/en/].,Non-OADS,/arxiv_data1/oa_pdf/0d/46/PRev-10-90.PMC5214563.pdf
Available from: http://www.zjueducn/ c165055/content_2304737html.,Non-OADS,/arxiv_data1/oa_pdf/0d/46/PRev-10-90.PMC5214563.pdf
Available from: http://www.ascopost.com/issues/april-15-2013/ homoharringtonineomacetaxine-the-little-drug-that-could/].,Non-OADS,/arxiv_data1/oa_pdf/0d/46/PRev-10-90.PMC5214563.pdf
"6, 585 –596 http://dx.doi.org/10.1080/19491034.2016.1260803",Non-OADS,/arxiv_data1/oa_pdf/ad/71/kncl-07-06-1260803.PMC5214577.pdf
ORCID Phillip A. Yates http://orcid.org/0000-0003-2016-9789 References [1] Fawcett DW.,Non-OADS,/arxiv_data1/oa_pdf/ad/71/kncl-07-06-1260803.PMC5214577.pdf
"Am J Anat (1966); 119:129-45;PMID:6007824; http://dx.doi.org/10.1002/aja.1001190108 [2] Goldman RD, Gruenbaum Y, Moir RD, Shumaker DK, Spann TP.",OADS,/arxiv_data1/oa_pdf/ad/71/kncl-07-06-1260803.PMC5214577.pdf
"Genes Dev (2002); 16:533-47;PMID:11877373; http://dx.doi.org/10.1101/gad.960502 [3] Krohne G, Benavente R, Scheer U, Dabauvalle MC.",OADS,/arxiv_data1/oa_pdf/ad/71/kncl-07-06-1260803.PMC5214577.pdf
"Eur J Cell Biol (2005); 84:163-179;PMID:15819398; http://dx.doi.org/10.1016/j.ejcb.2004.12.005 [4] McKeon FD, Kirschner MW, Caput D. Homologies in both primary and secondary structure between nuclearenvelope and intermediate ﬁlament proteins.",OADS,/arxiv_data1/oa_pdf/ad/71/kncl-07-06-1260803.PMC5214577.pdf
"Nature (1986); 319:463-8; PMID:3453101; http://dx.doi.org/10.1038/319463a0 [5] Furukawa K, Inagaki H, Hotta Y. Identi ﬁcation and clon- ing of an mRNA coding for a germ cell-speci ﬁc A-type lamin in mice.",OADS,/arxiv_data1/oa_pdf/ad/71/kncl-07-06-1260803.PMC5214577.pdf
"Exp Cell Res (1994); 212:426-30; PMID:8187835; http://dx.doi.org/10.1006/excr.1994.1164[6] Machiels BM, Zorenc AH, Endert JM, Kuijpers HJ, van Eys GJ, Ramaekers FC, Broers JL.",OADS,/arxiv_data1/oa_pdf/ad/71/kncl-07-06-1260803.PMC5214577.pdf
"J BiolChem (1996); 271:9249-53; PMID:8621584; http://dx.doi.org/10.1074/jbc.271.16.9249 [7] Pollard KM, Chan EK, Grant BJ, Sullivan KF, Tan EM, Glass CA.",OADS,/arxiv_data1/oa_pdf/ad/71/kncl-07-06-1260803.PMC5214577.pdf
"Mol Cell Biol (1990); 10:2164-75; PMID:2325650; http://dx.doi.org/10.1128/MCB.10.5.2164 [8] Furukawa K, Hotta Y. cDNA cloning of a germ cell spe- ciﬁc lamin B3 from mouse spermatocytes and analysis of its function by ectopic expression in somatic cells.",OADS,/arxiv_data1/oa_pdf/ad/71/kncl-07-06-1260803.PMC5214577.pdf
"J Cell Biol(2002); 156:603-8; PMID:11854306; http://dx.doi.org/10.1083/jcb.200112047 [10] Bridger JM, Foeger N, Kill IR, Herrmann H. The nuclear lamina.",OADS,/arxiv_data1/oa_pdf/ad/71/kncl-07-06-1260803.PMC5214577.pdf
"Nat Rev Genet (2006); 7:940-52;PMID:17139325; http://dx.doi.org/10.1038/nrg1906 [13] Cao K, Park C. Cellular Basis of Laminopathies (2012); 1-7 [14] Sarkar PK, Shinton RA.",OADS,/arxiv_data1/oa_pdf/ad/71/kncl-07-06-1260803.PMC5214577.pdf
Med Chir Trans (1886); 69:473-7; PMID:20896687; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ad/71/kncl-07-06-1260803.PMC5214577.pdf
"Nature(2003); 423:293-8; PMID:12714972; http://dx.doi.org/10.1038/nature01629 [17] Sinensky M, Fantle K, Trujillo M, McLain T, Kupfer A, Dalton M. The processing pathway of prelamin A. J CellSci (1994); 107:( Pt 1, 61-7; PMID:8175923 [18] De Sandre-Giovannoli A, Bernard R, Cau P, Navarro C, Amiel J, Boccaccio I, Lyonnet S, Stewart CL, Munnich A,Le Merrer M, et al.",OADS,/arxiv_data1/oa_pdf/ad/71/kncl-07-06-1260803.PMC5214577.pdf
"Science (2003); 300:2055; PMID:12702809;http://dx.doi.org/10.1126/science.1084125 [19] D ’Apice MR, Tenconi R, Mammi I, van den Ende J, Novelli G. Paternal origin of LMNA mutations in594 D. WU ET AL.",OADS,/arxiv_data1/oa_pdf/ad/71/kncl-07-06-1260803.PMC5214577.pdf
"Clin Genet (2004); 65: 52-4; http://dx.doi.org/10.1111/j..2004.00181.x [20] Cao K, Capell BC, Erdos MR, Djabali K, Collins FS.",Non-OADS,/arxiv_data1/oa_pdf/ad/71/kncl-07-06-1260803.PMC5214577.pdf
"Proc Natl Acad Sci U S A (2007);104:4949-54; PMID:17360355; http://dx.doi.org/10.1073/ pnas.0611640104 [21] Goldman RD, Shumaker DK, Erdos MR, Eriksson M, Goldman AE, Gordon LB, Gruenbaum Y, Khuon S, Men-dez M, Varga R, et al.",OADS,/arxiv_data1/oa_pdf/ad/71/kncl-07-06-1260803.PMC5214577.pdf
Genome Res (2013); 23:260-9;PMID:23152449; http://dx.doi.org/10.1101/gr.138032.112 [23] DeBusk FL.,OADS,/arxiv_data1/oa_pdf/ad/71/kncl-07-06-1260803.PMC5214577.pdf
"J Pediatr (1972); 80:697-724; PMID:4552697; http://dx.doi.org/ 10.1016/S0022-3476(72)80229-4 [24] Baker PB, Baba N, Boesel CP.",OADS,/arxiv_data1/oa_pdf/ad/71/kncl-07-06-1260803.PMC5214577.pdf
"Circulation (2014); 130:27-34; PMID:24795390;http://dx.doi.org/10.1161/C IRCULATIONAHA.113.008285 [26] Ullrich NJ, Gordon LB.",Non-OADS,/arxiv_data1/oa_pdf/ad/71/kncl-07-06-1260803.PMC5214577.pdf
Handb Clin Neurol (2015); 132:249-64;PMID:26564085; http://dx.doi.org/10.1016/B978-0-444-62702-5.00018-4 [27] Zhou P. Determining protein half-lives.,OADS,/arxiv_data1/oa_pdf/ad/71/kncl-07-06-1260803.PMC5214577.pdf
"FASEB J (2013); 27:2145-55; PMID:23430973; http://dx.doi.org/ 10.1096/fj.12-218214 [30] Dechat T, Adam SA, Taimen P, Shimi T, Goldman RD.",OADS,/arxiv_data1/oa_pdf/ad/71/kncl-07-06-1260803.PMC5214577.pdf
"Cold Spring Harb Perspect Biol (2010);2:a000547; PMID:20826548; http://dx.doi.org/10.1101/cshperspect.a000547 [31] Rodriguez-Contreras D, Aslan H, Feng X, Tran K, Yates PA, Kamhawi S, Landfear SM.",OADS,/arxiv_data1/oa_pdf/ad/71/kncl-07-06-1260803.PMC5214577.pdf
"FASEB J (2015);29:11-24; PMID:25300620; http://dx.doi.org/10.1096/ fj.14-251991 [32] De Felipe P, Luke GA, Hughes LE, Gani D, Halpin C, Ryan MD.",Non-OADS,/arxiv_data1/oa_pdf/ad/71/kncl-07-06-1260803.PMC5214577.pdf
"Trends Biotechnol (2006);24:68-75; PMID:16380176; http://dx.doi.org/10.1016/j.tibtech.2005.12.006 [33] Ryan MD, King AM, Thomas GP.",OADS,/arxiv_data1/oa_pdf/ad/71/kncl-07-06-1260803.PMC5214577.pdf
"J Gen Virol(1991); 72:(Pt 11, 2727-32; PMID:1658199; http://dx.doi.org/10.1099/0022-1317-72-11-2727 [34] Donnelly ML, Luke G, Mehrotra A, Li X, Hughes LE, Gani D, Ryan MD.",Non-OADS,/arxiv_data1/oa_pdf/ad/71/kncl-07-06-1260803.PMC5214577.pdf
"J Gen Virol (2001); 82:1013-25; PMID:11297676; http://dx.doi.org/10.1099/0022-1317-82-5-1013 [35] de Felipe P, Luke GA, Brown JD, Ryan MD.",Non-OADS,/arxiv_data1/oa_pdf/ad/71/kncl-07-06-1260803.PMC5214577.pdf
"Biotechnol J (2010);5:213-23; PMID:19946875; http://dx.doi.org/10.1002/ biot.200900134 [36] Kim JH, Lee SR, Li LH, Park HJ, Park JH, Lee KY, Kim MK, Shin BA, Choi SY.",OADS,/arxiv_data1/oa_pdf/ad/71/kncl-07-06-1260803.PMC5214577.pdf
"J Clin Invest (2006); 116:2115-21;PMID:16862216; http://dx.doi.org/10.1172/JCI28968 [40] Capell BC, Erdos MR, Madigan JP, Fiordalisi JJ, Varga R, Conneely KN, Gordon LB, Der CJ, Cox AD, Collins FS.",Non-OADS,/arxiv_data1/oa_pdf/ad/71/kncl-07-06-1260803.PMC5214577.pdf
"Disruption of lamin B1 and lamin B2 process-ing and localization by farnesyltransferase inhibitors.Nucleus (2013); 4:142-50; PMID:23475125; http://dx.doi.org/10.4161/nucl.24089 [43] Adam SA, Butin-Israeli V, Cleland MM, Shimi T, Gold- man RD.",OADS,/arxiv_data1/oa_pdf/ad/71/kncl-07-06-1260803.PMC5214577.pdf
"Nucleus (2013); 4:142-50; PMID:23475125; http://dx.doi.org/10.4161/nucl.24089 [44] Cao K, Blair CD, Faddah DA, Kieckhaefer JE, Olive M, Erdos MR, Nabel EG, Collins FS.",OADS,/arxiv_data1/oa_pdf/ad/71/kncl-07-06-1260803.PMC5214577.pdf
"J Cell Biol (2003); 162:1223-32;PMID:14504265; http://dx.doi.org/10.1083/jcb.200303113 [48] Jung H-J, Nobumori C, Goulbourne CN, Tu Y, Lee JM, Tatar A, Wu D, Yoshinaga Y, de Jong PJ, Cof ﬁnier C, et al.",OADS,/arxiv_data1/oa_pdf/ad/71/kncl-07-06-1260803.PMC5214577.pdf
Nature (2015); 527:1-17; ; http://dx.doi.org/10.1038/nature15548 [50] GREENBERG JR. High Stability of Messenger RNA in Growing Cultured Cells.,OADS,/arxiv_data1/oa_pdf/ad/71/kncl-07-06-1260803.PMC5214577.pdf
"Nature (1972); 240:102-4;PMID:4564814; http://dx.doi.org/10.1038/240102a0 [51] Wu D, Flannery AR, Cai H, Ko E, Cao K. Nuclear locali- zation signal deletion mutants of lamin A and progerinreveal insights into lamin A processing and emerin tar- geting.",OADS,/arxiv_data1/oa_pdf/ad/71/kncl-07-06-1260803.PMC5214577.pdf
"Thus, for the analyses of com-paring stopover vegetation with average values, we used a full tracking data set with tracks up until 2014 and estimated vegetation data re- ported in 16-day periods (23 periods per year; available at http://modis.gsfc.nasa.gov/data/dataprod/mod13.php).",OADS,/arxiv_data1/oa_pdf/8b/f9/1601360.PMC5214581.pdf
Climate data at 1° resolution were obtainedfrom the National Centers for Environmental Prediction “Final ”Op- erational Global Analysis (http://rda.ucar.edu/datasets/ds083.2/) and are available from 1999 onward.,OADS,/arxiv_data1/oa_pdf/8b/f9/1601360.PMC5214581.pdf
2000 onward (available at ftp://disc2.nascom.nasa.gov/data/TRMM/ Gridded/Derived_Products/3B42RT/Daily/).,OADS,/arxiv_data1/oa_pdf/8b/f9/1601360.PMC5214581.pdf
SUPPLEMENTARY MATERIALS Supplementary material for this article is available at http://advances.sciencemag.org/cgi/ content/full/3/1/e1601360/DC1fig.,Non-OADS,/arxiv_data1/oa_pdf/8b/f9/1601360.PMC5214581.pdf
The climate data used to project NDVI is available at http://cmip-pcmdi.llnl.gov/cmip5/data_portal.html.,OADS,/arxiv_data1/oa_pdf/8b/f9/1601360.PMC5214581.pdf
"Supplementary Information accompanies this paper on the Leukemia website (http://www.nature.com/leu) OPEN Novel evidence that the mannan-binding lectin pathway of complement activation plays a pivotal role in triggering mobilization of hematopoietic stem/progenitor cells by activation of both the complement and coagulation cascades Leukemia (2017) 31,262 –265; doi:10.1038/leu.2016.278 Hematopoietic stem progenitor cells (HSPCs) circulate at low levels in peripheral blood (PB) and follow changes in circadian rhythm.1Evidence has accumulated that their egress from stem cell niches is signi ﬁcantly augmented in a complement cascade (ComC)-dependent manner.2The number of HSPCs circulating in PB increases during infection, tissue or organ injuries and particularly after administration of pharmacological drugs, such as granulocyte-colony stimulating factor (G-CSF) or the CXCR4 receptor antagonist AMD3100, and pharmacological mobilization is a means to obtaining HSPCs for hematopoietic transplants.3However, the mobilization process is still not well understood.",Non-OADS,/arxiv_data1/oa_pdf/dc/c4/leu2016278a.PMC5214582.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/ © The Author(s) 2017 Supplementary Information accompanies this paper on the Leukemia website (http://www.nature.com/leu)Letters to the Editor 265 © 2017 Macmillan Publishers Limited, part of Springer Nature.",Non-OADS,/arxiv_data1/oa_pdf/dc/c4/leu2016278a.PMC5214582.pdf
Supportin ginformation forthisarticle canbefound under : http://dx.do i.org/10.1002/a nie.2016086 43.,Non-OADS,/arxiv_data1/oa_pdf/2b/2f/ANIE-55-15840.PMC5214583.pdf
"The prediction scores of thismutation were evaluated using wANNOVAR (http://wannovar.usc.edu/); the results were: SIFT_score = 0 (Damaging), Poly-phen2_HDIV_score = 0.979 (Damaging), Polyphen2_HVAR_score = 0.982 (Damaging), MutationTaster_score = 1 (Damaging) and CADD_phred = 34.",OADS,/arxiv_data1/oa_pdf/68/61/hgv201644.PMC5214593.pdf
HGV DATABASE The relevant data from this Data Report are hosted at the Human Genome Variation Database at http://dx.doi.org/10.6084/m9.,OADS,/arxiv_data1/oa_pdf/68/61/hgv201644.PMC5214593.pdf
"To view a copy of this license, visit http:// creativecommons.org/licenses/by-nc-sa/4.0/ © The Author(s) 2017 Supplementary Information for this article can be found on the Human Genome Variation website (http://www.nature.com/hgv)Novel PLP1 mutation in connatal type Pelizaeus-Merzbacher disease YL u et al 3 Ofﬁcial journal of the Japan Society of Human Genetics Human Genome Variation (2017) 16044",Non-OADS,/arxiv_data1/oa_pdf/68/61/hgv201644.PMC5214593.pdf
Suicide Life Threat Behav 2015:1–16; available from https://www.researchgate.net/publication/274838376_Combat_Exposure_and_Risk_for_Suicidal_Thoughts_ and_Behaviors_Among_Military_Personnel_and_ Veterans_A_Systematic_Review_and_Meta-Analysis?pli=1&loginT=5iBquxqGc4eH3pda3JGhId4CyuiC8tFT_7MNL5KgseDicOiprdZ9Ow**&uid=1aaf0b11-b6f3-4531-a8f4-5f262c08a00f&cp=re289_fw_sl2_p22&ch=reg; accessed 8 April 2015.,Non-OADS,/arxiv_data1/oa_pdf/ea/89/bcr-38-e158.PMC5214620.pdf
Limited access  death master file available through value-added online products; 2015; available fromhttp://www.ntis.gov/prod- ucts/ssa-online/; accessed 25 May 2015.,Non-OADS,/arxiv_data1/oa_pdf/ea/89/bcr-38-e158.PMC5214620.pdf
2015; available from https://www.dmdc.osd.mil/dcas/pages/casualties.xhtml; accessed 25 May 2015.,OADS,/arxiv_data1/oa_pdf/ea/89/bcr-38-e158.PMC5214620.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/71/4e/mder-10-001.PMC5214700.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/71/4e/mder-10-001.PMC5214700.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Medical Devices: Evidence and Research 2017:10 1–9Medical Devices: Evidence and Research Dovepress submit your manuscript | www.dovepress.com Dovepress 1 ORIGINAL RESEARCH open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/MDER.S119868 Tidal breathing patterns derived from structured  light plethysmography in COPD patients  compared with healthy subjects Shayan Motamedi-Fakhr1 Rachel C Wilson1 Richard Iles2 1PneumaCare Ltd, Ely, UK; 2Cambridge  University Hospitals NHS Foundation  Trust, Cambridge, UKPurpose: Differences in tidal breathing patterns have been reported between patients with  chronic obstructive pulmonary disease (COPD) and healthy individuals using traditional mea- surement techniques.",Non-OADS,/arxiv_data1/oa_pdf/71/4e/mder-10-001.PMC5214700.pdf
"However, Correspondence:  Shayan Motamedi-Fakhr PneumaCare Ltd, Prospect House, 3 St  Thomas’ Place, Cambridgeshire Business Park, Ely, Cambridgeshire, CB7 4EX, UKTel +44 1223 967 414Email Shayan.Motamedi@pneumacare.comJournal name: Medical Devices: Evidence and Research Article Designation: ORIGINAL RESEARCHY ear: 2017V olume: 10Running head verso: Motamedi-Fakhr et alRunning head recto: SLP in COPD versus healthy patientsDOI: http://dx.doi.org/10.2147/MDER.S119868 Video abstract Point your SmartPhone at the code above.",Non-OADS,/arxiv_data1/oa_pdf/71/4e/mder-10-001.PMC5214700.pdf
Or use: http://youtu.be/Nzozep4-Zrw,Non-OADS,/arxiv_data1/oa_pdf/71/4e/mder-10-001.PMC5214700.pdf
"Medical Devices: Evidence and Research 2017:10submit your manuscript | www.dovepress.com Dovepress Dovepress Medical Devices: Evidence and Research Publish your work in this journal Submit your manuscript here: https://www.dovepress.com/medical-devices-evidence-and-research-journalMedical Devices: Evidence and Research is an international, peer- reviewed, open access journal that focuses on the evidence, technology, research, and expert opinion supporting the use and application of   medical devices in the diagnosis, monitoring, treatment and management of clinical conditions and physiological processes.",Non-OADS,/arxiv_data1/oa_pdf/71/4e/mder-10-001.PMC5214700.pdf
Availble  from: http://www.bmva.org/bmvc/2010/conference/paper85/paper85.pdf.,Non-OADS,/arxiv_data1/oa_pdf/71/4e/mder-10-001.PMC5214700.pdf
Available from: http://www.ersbuyersguide.org/articles/previous-issues/20122013/item/non-invasive-assessment-of-lung-function.,Non-OADS,/arxiv_data1/oa_pdf/71/4e/mder-10-001.PMC5214700.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/1a/23/jpr-10-047.PMC5214701.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/1a/23/jpr-10-047.PMC5214701.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Journal of Pain Research  2017:10 47–52Journal of Pain Research Dovepress submit your manuscript | www.dovepress.com Dovepress  47 ORIGINAL RESEARCH open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/JPR.S122380The relationship between findings on magnetic  resonance imaging and previous history of low  back pain Juichi T onosu1  Hiroyuki Oka2  Ko Matsudaira2  Akiro Higashikawa1  Hiroshi Okazaki1  Sakae Tanaka3 1Department of Orthopedic Surgery,   Kanto Rosai Hospital, Kawasaki,   2Department of Medical Research and  Management for Musculoskeletal Pain,   22nd Century Medical and Research Center,  3Department of Orthopedic  Surgery, Faculty of Medicine, The University of T okyo, T okyo, JapanAbstract:  The objective of this study was to evaluate the relationship between magnetic reso- nance imaging (MRI) findings and previous low back pain (LBP) in participants without current  LBP .",Non-OADS,/arxiv_data1/oa_pdf/1a/23/jpr-10-047.PMC5214701.pdf
"Some reports have shown that disk degeneration was associated with LBP , 5–7 while others have shown  that there was no relationship between disk degeneration and LBP .8,9 Although these  reports focused on the relationship between disk degeneration and current LBP , there are a few reports on the relationship between MRI findings, including disk degeneration Correspondence: Juichi Tonosu   Department of Orthopedic Surgery,  Kanto Rosai Hospital, 211-8510, 1-1, Kizukisumiyoshicho, Nakahara-ku, Kawasaki, Kanagawa, Japan   Tel +81 44 411 3131   Fax +81 44 433 3150   Email juichitohnosu@yahoo.co.jpJournal name: Journal of Pain Research  Article Designation: ORIGINAL RESEARCHY ear: 2017V olume: 10Running head verso: Tonosu et alRunning head recto: Relationship between MRI findings and previous history of LBPDOI: http://dx.doi.org/10.2147/JPR.S122380",Non-OADS,/arxiv_data1/oa_pdf/1a/23/jpr-10-047.PMC5214701.pdf
"Journal of Pain Research  2017:10submit your manuscript | www.dovepress.com Dovepress Dovepress Journal of Pain Research  Publish your work in this journal Submit your manuscript here:  https://www.dovepress.com/journal-of-pain-research-journal The Journal of Pain Research is an international, peer reviewed, open  access, online journal that welcomes laboratory and clinical findings   in the fields of pain research and the prevention and management of pain.",Non-OADS,/arxiv_data1/oa_pdf/1a/23/jpr-10-047.PMC5214701.pdf
Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.Dovepress 52 T onosu et al were associated with previous LBP .,Non-OADS,/arxiv_data1/oa_pdf/1a/23/jpr-10-047.PMC5214701.pdf
"ORIGINAL ARTICLE Copyright © 2017 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1226-3303 eISSN 2005-6648 http://www.kjim.orgKorean J Intern Med 2017;32:137-145 https://doi.org/10.3904/kjim.2014.160 INTRODUCTION Selective immunoglobulin A (IgA) deficiency, a common  primary immunodeficiency, is not infrequently diag - nosed in Caucasians (prevalence, 1:300 to 3,000) [1].",Non-OADS,/arxiv_data1/oa_pdf/46/a6/kjim-2014-160.PMC5214712.pdf
"1, January 2017 https://doi.org/10.3904/kjim.2014.160dren who developed allergic rhinitis or atopic eczema  had lower salivary IgA levels [6].",Non-OADS,/arxiv_data1/oa_pdf/46/a6/kjim-2014-160.PMC5214712.pdf
"IgA & allergy www.kjim.org https://doi.org/10.3904/kjim.2014.160Allergy skin prick tests Allergy skin prick tests were performed using 55 com - mon allergens, including HDM Dp and Df.",OADS,/arxiv_data1/oa_pdf/46/a6/kjim-2014-160.PMC5214712.pdf
"1, January 2017 https://doi.org/10.3904/kjim.2014.160of subjects sensitized to Df (both  p < 0.01) (Fig.",Non-OADS,/arxiv_data1/oa_pdf/46/a6/kjim-2014-160.PMC5214712.pdf
"IgA & allergy www.kjim.org https://doi.org/10.3904/kjim.2014.160The relationship between serum IgA level and AHR  in young subjects with AHR  As we found no significant relationship between IgA  level and AHR, and as both the IgA level and AHR were  associated with age, the subjects aged ≤ 45 years were  selected for analysis of AHR data to exclude any effect  of age.",Non-OADS,/arxiv_data1/oa_pdf/46/a6/kjim-2014-160.PMC5214712.pdf
"1, January 2017 https://doi.org/10.3904/kjim.2014.160ever, higher serum IgA levels were associated with low - er proportions of subjects with moderate/severe AHR:  24/34 (70.6%), 78/149 (52.3%), and 24/51 (47.1%) in the three  groups, respectively ( X2 = 4.008,  p = 0.045) (Fig.",Non-OADS,/arxiv_data1/oa_pdf/46/a6/kjim-2014-160.PMC5214712.pdf
"IgA & allergy www.kjim.org https://doi.org/10.3904/kjim.2014.160tions, only 500 of the 1,136 patients (44.0%) exhibited  AHR.",Non-OADS,/arxiv_data1/oa_pdf/46/a6/kjim-2014-160.PMC5214712.pdf
"1, January 2017 https://doi.org/10.3904/kjim.2014.160other diseases such as allergic bronchopulmonary as - pergillosis and Churg-Strauss syndrome.",Non-OADS,/arxiv_data1/oa_pdf/46/a6/kjim-2014-160.PMC5214712.pdf
IgA & allergy www.kjim.org https://doi.org/10.3904/kjim.2014.16017.,Non-OADS,/arxiv_data1/oa_pdf/46/a6/kjim-2014-160.PMC5214712.pdf
"ORIGINAL ARTICLE Copyright © 2017 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1226-3303 eISSN 2005-6648 http://www.kjim.orgINTRODUCTION The prognosis of patients with chronic thromboembol - ic pulmonary hypertension (CTEPH) is variable, but the  condition may be life threatening in some cases.",Non-OADS,/arxiv_data1/oa_pdf/13/5a/kjim-2014-175.PMC5214713.pdf
"Keywords:  Hypertension, pulmonary; Pulmonary embolism; EchocardiographyThe predictive value of echocardiography for  chronic thromboembol ic pulmonary hyperten - sion after acute pulmonary embolism in Korea Jin Sup Park, Jinhee Ahn, Jung Hyun Choi, Hye Won Lee, Jun-Hyok Oh, Han Cheol Lee, Kwang Soo Cha,  and Taek Jong HongKorean J Intern Med 2017;32:85-94 https://doi.org/10.3904/kjim.2014.175",Non-OADS,/arxiv_data1/oa_pdf/13/5a/kjim-2014-175.PMC5214713.pdf
"1, January 2017 https://doi.org/10.3904/kjim.2014.175of this disease.",Non-OADS,/arxiv_data1/oa_pdf/13/5a/kjim-2014-175.PMC5214713.pdf
Echocardiography on pulmonary hypertension www.kjim.org https://doi.org/10.3904/kjim.2014.175APE and deep vein thrombosis (image acquisition be - ginning with a scanning delay of ~15 to 20 seconds after  the start of the injection of contrast medium) [8].,Non-OADS,/arxiv_data1/oa_pdf/13/5a/kjim-2014-175.PMC5214713.pdf
"1, January 2017 https://doi.org/10.3904/kjim.2014.175Table 1.",Non-OADS,/arxiv_data1/oa_pdf/13/5a/kjim-2014-175.PMC5214713.pdf
"Echocardiography on pulmonary hypertension www.kjim.org https://doi.org/10.3904/kjim.2014.175apy, use of oral contraceptives, pregnancy, history of  trauma) and permanent risk factors (e.g., prior VTE, ma - lignancy, spinal cord injury, stroke, heart failure, family  history of VTE) for APE and developing CTEPH did not  differ between groups.",Non-OADS,/arxiv_data1/oa_pdf/13/5a/kjim-2014-175.PMC5214713.pdf
"1, January 2017 https://doi.org/10.3904/kjim.2014.175statistically significant.",Non-OADS,/arxiv_data1/oa_pdf/13/5a/kjim-2014-175.PMC5214713.pdf
"Echocardiography on pulmonary hypertension www.kjim.org https://doi.org/10.3904/kjim.2014.175(OR, 7.81; 95% CI, 2.50 to 24.42), D-shaped LV (OR, 6.33;  95% CI, 2.06 to 19.4), and elevated RVSP (OR, 1.06; 95%  CI, 1.03 to 1.09).",Non-OADS,/arxiv_data1/oa_pdf/13/5a/kjim-2014-175.PMC5214713.pdf
"1, January 2017 https://doi.org/10.3904/kjim.2014.175DISCUSSION In this study, CTEPH appeared to be surprisingly com - mon, with a higher incidence than in any other previous  studies: 6.1% of patients who had an episode of APE.",Non-OADS,/arxiv_data1/oa_pdf/13/5a/kjim-2014-175.PMC5214713.pdf
Echocardiography on pulmonary hypertension www.kjim.org https://doi.org/10.3904/kjim.2014.175High-risk APE may lead patients and physicians to  be more cautious in the management of the condition.,Non-OADS,/arxiv_data1/oa_pdf/13/5a/kjim-2014-175.PMC5214713.pdf
"1, January 2017 https://doi.org/10.3904/kjim.2014.1756.",Non-OADS,/arxiv_data1/oa_pdf/13/5a/kjim-2014-175.PMC5214713.pdf
"ORIGINAL ARTICLE Copyright © 2017 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1226-3303 eISSN 2005-6648 http://www.kjim.orgDepartment of Internal Medicine,  1Kangbuk Samsung Hospital,  Sungkyunkwan University School  of Medicine, Seoul; 2Hanyang  University Guri Hospital, Guri;  3Konyang University College of  Medicine, Daejeon; 4Kyung Hee  University School of Medicine,  Seoul; 5Dankook University College  of Medicine, Cheonan; 6Dongguk  University College of Medicine,  Gyeongju; 7Inje University College of  Medicine, Busan; 8Soonchunhyang  University College of Medicine, Asan;  9Ewha Womans University School  of Medicine, Seoul; 10Jeju National  University College of Medicine,  Jeju; 11Hallym University College of  Medicine, Chuncheon; 12Samsung  Medical Center, Sungkyunkwan  University School of Medicine, Seoul,  Korea Received : August 31, 2014 Revised : November 10, 2014 Accepted : September 1, 2015 Correspondence to  Dong Il Park, M.D.",Non-OADS,/arxiv_data1/oa_pdf/bc/a0/kjim-2014-262.PMC5214714.pdf
"Keywords:  Colitis, ulcerative; Young-onset; Clinical feature; OutcomeComparing the clinical outcomes of young-onset  and adult-onset ulcerative colitis: a multi-center  Korean Association for the Study for Intestinal  Diseases study  Ji Yeon Kim1, Dong Il Park1, Dong Soo Han2, Kyu-Chan Huh3, Chang Kyun Lee4, Jeong Eun Shin5,    Jae Hak Kim6, You Sun Kim7, Yunho Jung8, Sung-Ae Jung9, Hyun Joo Song10, Hyun Joo Jang11,   Young-Ho Kim12, and Sung No Hong12Korean J Intern Med 2017;32:69-78  https://doi.org/10.3904/kjim.2014.262",Non-OADS,/arxiv_data1/oa_pdf/bc/a0/kjim-2014-262.PMC5214714.pdf
"1, January 2017 https://doi.org/10.3904/kjim.2014.262INTRODUCTION Ulcerative colitis (UC) is a chronic and relapsing inflam - matory disease of the colon and rectum that affects con - tinuously.",Non-OADS,/arxiv_data1/oa_pdf/bc/a0/kjim-2014-262.PMC5214714.pdf
"The effect of age of onset in UC www.kjim.org https://doi.org/10.3904/kjim.2014.262lated admission and operation and, prior use of oral ste - roids, intravenous (IV) steroids, immunosuppressants,  or infliximab.",Non-OADS,/arxiv_data1/oa_pdf/bc/a0/kjim-2014-262.PMC5214714.pdf
"1, January 2017 https://doi.org/10.3904/kjim.2014.262extensive UC at diagnosis were more frequent in the YO  group than they were in the AO group (28.6% vs. 10.3%, p  = 0.000; 52.7% vs. 25.8%, p = 0.000, respectively) (Table 2).",Non-OADS,/arxiv_data1/oa_pdf/bc/a0/kjim-2014-262.PMC5214714.pdf
"The effect of age of onset in UC www.kjim.org https://doi.org/10.3904/kjim.2014.262vere outcomes (HR, 2.18; 95% CI, 1.27 to 3.71; p = 0.040).",OADS,/arxiv_data1/oa_pdf/bc/a0/kjim-2014-262.PMC5214714.pdf
"1, January 2017 https://doi.org/10.3904/kjim.2014.262Inpatient Samples; therefore, it is possible that their  findings resulted from analysis of elderly patients with  many comorbidities, and a secondary diagnosis of IBD.",Non-OADS,/arxiv_data1/oa_pdf/bc/a0/kjim-2014-262.PMC5214714.pdf
The effect of age of onset in UC www.kjim.org https://doi.org/10.3904/kjim.2014.262the need for UC-related operation.,Non-OADS,/arxiv_data1/oa_pdf/bc/a0/kjim-2014-262.PMC5214714.pdf
"1, January 2017 https://doi.org/10.3904/kjim.2014.262 This study has several limitations.",Non-OADS,/arxiv_data1/oa_pdf/bc/a0/kjim-2014-262.PMC5214714.pdf
The effect of age of onset in UC www.kjim.org https://doi.org/10.3904/kjim.2014.262ison of demographic and clinical characteristics of pa - tients with early vs. adult vs. late onset ulcerative colitis.,Non-OADS,/arxiv_data1/oa_pdf/bc/a0/kjim-2014-262.PMC5214714.pdf
"1, January 2017 https://doi.org/10.3904/kjim.2014.26234.",Non-OADS,/arxiv_data1/oa_pdf/bc/a0/kjim-2014-262.PMC5214714.pdf
The effect of age of onset in UCwww.kjim.org https://doi.org/10.3904/kjim.2014.262Supplementary Table 1.,Non-OADS,/arxiv_data1/oa_pdf/bc/a0/kjim-2014-262.PMC5214714.pdf
"1, January 2017 https://doi.org/10.3904/kjim.2014.262Supplementary Table 2.",Non-OADS,/arxiv_data1/oa_pdf/bc/a0/kjim-2014-262.PMC5214714.pdf
The effect of age of onset in UCwww.kjim.org https://doi.org/10.3904/kjim.2014.262Supplementary Table 3.,Non-OADS,/arxiv_data1/oa_pdf/bc/a0/kjim-2014-262.PMC5214714.pdf
"1, January 2017 https://doi.org/10.3904/kjim.2014.262Supplementary Table 4.",Non-OADS,/arxiv_data1/oa_pdf/bc/a0/kjim-2014-262.PMC5214714.pdf
The effect of age of onset in UCwww.kjim.org https://doi.org/10.3904/kjim.2014.262Supplementary Table 5.,Non-OADS,/arxiv_data1/oa_pdf/bc/a0/kjim-2014-262.PMC5214714.pdf
"LETTER TO THE EDITOR Copyright © 2017 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1226-3303 eISSN 2005-6648 http://www.kjim.orgDepartment of Internal Medicine,  College of Medicine, The Catholic  University of Korea, Seoul, Korea Minimal change nephrotic syndrome showing  complete remission after resection of a neurofi - broma in a type I neurofibromatosis patient  Ji In Hyun, Ji Won Min, Hye Min Lee, Yong Kyun Kim, Eu Jin Choi, and Ho Cheol Song  Received : February  2, 2015 Revised : March  9, 2015 Accepted : April  15, 2015 Correspondence to  Ho Choel Song, M.D.",Non-OADS,/arxiv_data1/oa_pdf/24/22/kjim-2015-016.PMC5214715.pdf
1A); and on Korean J Intern Med 2017;32:186-189 https://doi.org/ 10.3904/kjim.2015.016,Non-OADS,/arxiv_data1/oa_pdf/24/22/kjim-2015-016.PMC5214715.pdf
"187 www.kjim.org https://doi.org/ 10.3904/kjim.2015.016Hyun JI, et al.",OADS,/arxiv_data1/oa_pdf/24/22/kjim-2015-016.PMC5214715.pdf
              188 www.kjim.org https://doi.org/ 10.3904/kjim.2015.016The Korean Journal of Internal Medicine Vol.,Non-OADS,/arxiv_data1/oa_pdf/24/22/kjim-2015-016.PMC5214715.pdf
"189 www.kjim.org https://doi.org/ 10.3904/kjim.2015.016Hyun JI, et al.",Non-OADS,/arxiv_data1/oa_pdf/24/22/kjim-2015-016.PMC5214715.pdf
"ORIGINAL ARTICLE Copyright © 2017 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1226-3303 eISSN 2005-6648 http://www.kjim.orgKorean J Intern Med 2017;32:102-108  https://doi.org/10.3904/kjim.2015.090 INTRODUCTION Vitamin D is a pleiotropic hormone that affects both  classical and nonclassical tissues, principally through  the vitamin D receptor [1,2].",Non-OADS,/arxiv_data1/oa_pdf/7f/cb/kjim-2015-090.PMC5214716.pdf
Serum vitamin D level and thyroid cancer www.kjim.org https://doi.org/10.3904/kjim.2015.090tamin D levels and an increased prevalence of thyroid  cancer has been inconsistent [12-18].,Non-OADS,/arxiv_data1/oa_pdf/7f/cb/kjim-2015-090.PMC5214716.pdf
"1, January 2017 https://doi.org/10.3904/kjim.2015.090Statistical analysis Continuous variables are expressed as mean ± standard  deviation and categorical variables are presented as  number (%).",OADS,/arxiv_data1/oa_pdf/7f/cb/kjim-2015-090.PMC5214716.pdf
Serum vitamin D level and thyroid cancer www.kjim.org https://doi.org/10.3904/kjim.2015.090Table 3.,Non-OADS,/arxiv_data1/oa_pdf/7f/cb/kjim-2015-090.PMC5214716.pdf
"1, January 2017 https://doi.org/10.3904/kjim.2015.090sociations between thyroid cancer prevalence and various  clinical parameters using a binary logistic regression  model.",OADS,/arxiv_data1/oa_pdf/7f/cb/kjim-2015-090.PMC5214716.pdf
Serum vitamin D level and thyroid cancer www.kjim.org https://doi.org/10.3904/kjim.2015.090them were treated at another hospital.,Non-OADS,/arxiv_data1/oa_pdf/7f/cb/kjim-2015-090.PMC5214716.pdf
"1, January 2017 https://doi.org/10.3904/kjim.2015.090cinoma.",Non-OADS,/arxiv_data1/oa_pdf/7f/cb/kjim-2015-090.PMC5214716.pdf
"LETTER TO THE EDITOR Copyright © 2017 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1226-3303 eISSN 2005-6648 http://www.kjim.orgDepartment of Internal Medicine,  Konkuk University School of  Medicine, Seoul, KoreaAcute cor pulmonale due to pulmonary tumor  thrombotic microangiopathy in two patients with  breast cancer Sung Young Moon, Kang Hoon Lee, Jong Sik Lee, Hyun Suk Yang, Hong Ghi Lee, Yo Han Cho,  and So Young Yoon Received : April 27, 2015 Revised : July 3, 2015 Accepted : July 6, 2015 Correspondence to So Young Yoon, M.D.",Non-OADS,/arxiv_data1/oa_pdf/a1/bc/kjim-2015-107.PMC5214717.pdf
On chest computed Korean J Intern Med 2017;32:190-194 https://doi.org/10.3904/kjim.2015.107,Non-OADS,/arxiv_data1/oa_pdf/a1/bc/kjim-2015-107.PMC5214717.pdf
"191 www.kjim.org https://doi.org/10.3904/kjim.2015.107Moon SY, et al.",OADS,/arxiv_data1/oa_pdf/a1/bc/kjim-2015-107.PMC5214717.pdf
              192 www.kjim.org https://doi.org/10.3904/kjim.2015.107The Korean Journal of Internal Medicine Vol.,Non-OADS,/arxiv_data1/oa_pdf/a1/bc/kjim-2015-107.PMC5214717.pdf
"193 www.kjim.org https://doi.org/10.3904/kjim.2015.107Moon SY, et al.",OADS,/arxiv_data1/oa_pdf/a1/bc/kjim-2015-107.PMC5214717.pdf
              194 www.kjim.org https://doi.org/10.3904/kjim.2015.107The Korean Journal of Internal Medicine Vol.,Non-OADS,/arxiv_data1/oa_pdf/a1/bc/kjim-2015-107.PMC5214717.pdf
"ORIGINAL ARTICLE Copyright © 2017 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1226-3303 eISSN 2005-6648 http://www.kjim.org1Division of Infectious Diseases,  Hallym University Kangdong Sacred  Heart Hospital, Seoul; 2Division  of Infectious Diseases, Samsung  Medical Center, Sungkyunkwan  University School of Medicine, Seoul;  3Division of Infectious Diseases,  Samsung Changwon Hospital,  Sungkyunkwan University School of  Medicine, Changwon; 4Department  of Laboratory Medicine, Samsung  Medical Center, Sungkyunkwan  University School of Medicine, Seoul,  Korea Received : April 27, 2015 Revised : January 15, 2016 Accepted : January 22, 2016 Correspondence to  Cheol-In Kang, M.D.",Non-OADS,/arxiv_data1/oa_pdf/36/af/kjim-2015-113.PMC5214718.pdf
"Keywords:  Drug resistance, multiple; Extended-spectrum β-lactamase; Esch - erichia coli; Community-onset infectionRisk factors and molecular epidemiology of   community-onset, multidrug resistance extend - ed-spectrum β-lactamase-producing Escherichia  coli infections So Yeon Park1,2, Cheol-In Kang2, Yu Mi Wi3, Doo Ryeon Chung2, Kyong Ran Peck2, Nam-Yong Lee4, and  Jae-Hoon Song2Korean J Intern Med 2017;32:146-157  https://doi.org/10.3904/kjim.2015.113",Non-OADS,/arxiv_data1/oa_pdf/36/af/kjim-2015-113.PMC5214718.pdf
Community-onset MDR ESBL-EC www.kjim.org https://doi.org/10.3904/kjim.2015.113INTRODUCTION Extended-spectrum β-lactamase-producing Escherich - ia coli  (ESBL-EC) have become increasingly prevalent  nosocomial pathogens [1-3].,Non-OADS,/arxiv_data1/oa_pdf/36/af/kjim-2015-113.PMC5214718.pdf
"1, January 2017 https://doi.org/10.3904/kjim.2015.113classified by McCabe and Jackson criteria [16], presence  of severe sepsis or septic shock at presentation, severity  of illness at presentation according to the Pitt bactere - mia score [2], and receipt of any antimicrobial therapy  prior to onset of the infection.",Non-OADS,/arxiv_data1/oa_pdf/36/af/kjim-2015-113.PMC5214718.pdf
"Community-onset MDR ESBL-EC www.kjim.org https://doi.org/10.3904/kjim.2015.113Statistical analysis The Student t test or the Mann-Whitney test was used  to compare continuous variables, and the chi-square or  Fisher exact test was used to compare categorical vari - ables.",Non-OADS,/arxiv_data1/oa_pdf/36/af/kjim-2015-113.PMC5214718.pdf
"1, January 2017 https://doi.org/10.3904/kjim.2015.113Table 1.",Non-OADS,/arxiv_data1/oa_pdf/36/af/kjim-2015-113.PMC5214718.pdf
"Community-onset MDR ESBL-EC www.kjim.org https://doi.org/10.3904/kjim.2015.113clonal clusters were identified, consisting of two or  three isolates for each cluster.",OADS,/arxiv_data1/oa_pdf/36/af/kjim-2015-113.PMC5214718.pdf
"1, January 2017 https://doi.org/10.3904/kjim.2015.113studies have suggested that the prevalence of communi - ty-onset ESBL-EC infections varies widely by geographic  region, and most ESBL-producing isolates show co-re - sistance to multiple antibiotics [5,9,24,25].",Non-OADS,/arxiv_data1/oa_pdf/36/af/kjim-2015-113.PMC5214718.pdf
Community-onset MDR ESBL-EC www.kjim.org https://doi.org/10.3904/kjim.2015.113related.,Non-OADS,/arxiv_data1/oa_pdf/36/af/kjim-2015-113.PMC5214718.pdf
"1, January 2017 https://doi.org/10.3904/kjim.2015.113fact that one in four ESBL-EC isolates in this study was  MDR.",OADS,/arxiv_data1/oa_pdf/36/af/kjim-2015-113.PMC5214718.pdf
Community-onset MDR ESBL-EC www.kjim.org https://doi.org/10.3904/kjim.2015.113Conflict of interest No potential conflict of interest relevant to this article  was reported.,Non-OADS,/arxiv_data1/oa_pdf/36/af/kjim-2015-113.PMC5214718.pdf
"1, January 2017 https://doi.org/10.3904/kjim.2015.113vival and function after suspected gram-negative sepsis.",Non-OADS,/arxiv_data1/oa_pdf/36/af/kjim-2015-113.PMC5214718.pdf
Community-onset MDR ESBL-EC www.kjim.org https://doi.org/10.3904/kjim.2015.113teriaceae into the hospital.,Non-OADS,/arxiv_data1/oa_pdf/36/af/kjim-2015-113.PMC5214718.pdf
"ORIGINAL ARTICLE Copyright © 2017 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1226-3303 eISSN 2005-6648 http://www.kjim.orgINTRODUCTION Pulmonary embolism (PE)—as a subset of venous throm - boembolism (VTE)—is a common, potentially lethal  disorder that affects hospitalized and non-hospi talized  patients.",Non-OADS,/arxiv_data1/oa_pdf/a8/e3/kjim-2015-118.PMC5214719.pdf
"Keywords:  Coagulation; Infection; Protein S; Provoked; Pulmonary embolismRisk factors associated with provoked pulmonary  embolism Endri Gjonbrataj1,*, Ji Na Kim2,*, Juarda Gjonbrataj1,3, Hye In Jung1, Hyun Jung Kim1, and Won-Il Choi1Korean J Intern Med 2017;32:95-101 https://doi.org/10.3904/kjim.2015.118",Non-OADS,/arxiv_data1/oa_pdf/a8/e3/kjim-2015-118.PMC5214719.pdf
"1, January 2017 https://doi.org/10.3904/kjim.2015.118age, personal history of VTE, active malignancy, or other  disabling conditions such as heart or respiratory failure,  coagulation disorders, hormone replacement therapy,  oral contraception, immobilization, and surgery or trau- ma within the last 3 months [6].",Non-OADS,/arxiv_data1/oa_pdf/a8/e3/kjim-2015-118.PMC5214719.pdf
Risk factors in pulmonary embolism www.kjim.org https://doi.org/10.3904/kjim.2015.118at the time of PE diagnosis.,Non-OADS,/arxiv_data1/oa_pdf/a8/e3/kjim-2015-118.PMC5214719.pdf
"1, January 2017 https://doi.org/10.3904/kjim.2015.118Table 1.",Non-OADS,/arxiv_data1/oa_pdf/a8/e3/kjim-2015-118.PMC5214719.pdf
"Risk factors in pulmonary embolism www.kjim.org https://doi.org/10.3904/kjim.2015.118(71%), whereas the DIC score was higher in patients with  provoked PE (2.4) than in those with unprovoked PE  (1.9).",Non-OADS,/arxiv_data1/oa_pdf/a8/e3/kjim-2015-118.PMC5214719.pdf
"1, January 2017 https://doi.org/10.3904/kjim.2015.118voked and unprovoked PE developed shock during their  clinical course.",Non-OADS,/arxiv_data1/oa_pdf/a8/e3/kjim-2015-118.PMC5214719.pdf
Risk factors in pulmonary embolism www.kjim.org https://doi.org/10.3904/kjim.2015.11811.,Non-OADS,/arxiv_data1/oa_pdf/a8/e3/kjim-2015-118.PMC5214719.pdf
"LETTER TO THE EDITOR Copyright © 2017 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1226-3303 eISSN 2005-6648 http://www.kjim.orgDivision of Cardiology,  Cardiovascular Center, Seoul  National University Bundang  Hospital, Seongnam, KoreaA novel c.563 T>G, p.L189R lamin A/C mutation in  identical twins with dilated cardiomyopathy  Euijae Lee, Kyung-Taek Park, Jinwoo Kang, Hyunkyung Park, Jin Joo Park, Il-Young Oh,   and Yeonyee E. Yoon  Received : May  24, 2015 Revised : July 30, 2015 Accepted : August  6, 2015 Correspondence to  Yeonyee E. Yoon, M.D.",Non-OADS,/arxiv_data1/oa_pdf/20/cb/kjim-2015-146.PMC5214720.pdf
The patient’s father was diagnosed  with heart failure with conduction ab - normality in his thirties and was sched - uled to undergo pacemaker implanta -Korean J Intern Med 2017;32:178-181 https://doi.org/10.3904/kjim.2015.146,Non-OADS,/arxiv_data1/oa_pdf/20/cb/kjim-2015-146.PMC5214720.pdf
"179 www.kjim.org  https://doi.org/10.3904/kjim.2015.146Lee E, et al.",OADS,/arxiv_data1/oa_pdf/20/cb/kjim-2015-146.PMC5214720.pdf
              180 www.kjim.org https://doi.org/10.3904/kjim.2015.146The Korean Journal of Internal Medicine Vol.,Non-OADS,/arxiv_data1/oa_pdf/20/cb/kjim-2015-146.PMC5214720.pdf
"181 www.kjim.org  https://doi.org/10.3904/kjim.2015.146Lee E, et al.",Non-OADS,/arxiv_data1/oa_pdf/20/cb/kjim-2015-146.PMC5214720.pdf
"ORIGINAL ARTICLE Copyright © 2017 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1226-3303 eISSN 2005-6648 http://www.kjim.orgINTRODUCTION Despite the steady improvements in surgical techniques  and postoperative patient care over the past decade,  postoperative bile leakage remains a complication of  various hepatobiliary surgeries.",Non-OADS,/arxiv_data1/oa_pdf/d8/74/kjim-2015-165.PMC5214721.pdf
"Keywords:  Bile leakage; Hepatobiliary surgery; Stents; Sphincterotomy, endoscopic The outcome of endoscopic management of bile  leakage after hepatobiliary surgery Seon Ung Yun, Young Koog Cheon, Chan Sup Shim, Tae Yoon Lee, Hyung Min Yu, Hyun Ah Chung,   Se Woong Kwon, Taek Gun Jeong, Sang Hee An, Gyung Won Jeong, and Ji Wan KimKorean J Intern Med 2017;32:79-84 https://doi.org/ 10.3904/kjim.2015.165",Non-OADS,/arxiv_data1/oa_pdf/d8/74/kjim-2015-165.PMC5214721.pdf
"1, January 2017 https://doi.org/ 10.3904/kjim.2015.165as bilomas), therapeutic biliary endoscopy, and surgery.",Non-OADS,/arxiv_data1/oa_pdf/d8/74/kjim-2015-165.PMC5214721.pdf
Endoscopic management of bile leakage www.kjim.org https://doi.org/ 10.3904/kjim.2015.165and one had undergone partial resection (5%) because of  rectosigmoid carcinoma with liver metasta sis (Fig.,Non-OADS,/arxiv_data1/oa_pdf/d8/74/kjim-2015-165.PMC5214721.pdf
"1, January 2017 https://doi.org/ 10.3904/kjim.2015.165could not be removed.",Non-OADS,/arxiv_data1/oa_pdf/d8/74/kjim-2015-165.PMC5214721.pdf
"Endoscopic management of bile leakage www.kjim.org https://doi.org/ 10.3904/kjim.2015.165The length, size, and type of plastic stent used varied.",Non-OADS,/arxiv_data1/oa_pdf/d8/74/kjim-2015-165.PMC5214721.pdf
"1, January 2017 https://doi.org/ 10.3904/kjim.2015.165Makuuchi M. Randomized trial of the usefulness of a  bile leakage test during hepatic resection.",Non-OADS,/arxiv_data1/oa_pdf/d8/74/kjim-2015-165.PMC5214721.pdf
"ORIGINAL ARTICLE Copyright © 2017 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1226-3303 eISSN 2005-6648 http://www.kjim.orgINTRODUCTION The current guidelines for managing metabolic acidosis  suggest that patients with chronic kidney disease (CKD) and serum bicarbonate concentrations of < 22 mmol/L  should be treated with oral bicarbonate supplementa - tion to maintain their serum bicarbonate concentration  within the normal range, unless this treatment is con -Department of Internal Medicine,  1College of Medicine, St. Vincent’s  Hospital, The Catholic University of  Korea, Suwon; 2College of Medicine,  Bucheon St. Mary’s Hospital,  The Catholic University of Korea,  Bucheon; 3Chung-Ang University  College of Medicine, Seoul; 4College  of Medicine, Uijeongbu St. Mary’s  Hospital, The Catholic University  of Korea, Uijeongbu; 5College of  Medicine, Seoul St. Mary’s Hospital,  The Catholic University of Korea,  Seoul; 6Kyungpook National  University School of Medicine,  Daegu; 7Chonnam National  University Medical School, Gwangju;  8Yonsei University College of  Medicine, Seoul; 9Seoul National  University College of Medicine,  Seoul, Korea  Received : June 11, 2015 Revised : July 31, 2015 Accepted : August 4, 2015 Correspondence to  Young Soo Kim, M.D.",Non-OADS,/arxiv_data1/oa_pdf/8d/46/kjim-2015-168.PMC5214722.pdf
"Keywords:  Renal dialysis; Bicarbonates; Alkalosis; MortalityThe impact of high serum bicarbonate levels on  mortality in hemodialysis patients Kyung Yoon Chang1, Hyung Wook Kim1, Woo Jeong Kim1, Yong Kyun Kim2, Su-Hyun Kim3,   Ho Chul Song2, Young Ok Kim4, Dong Chan Jin1, Euy Jin Choi2, Chul Woo Yang5, Yong-Lim Kim6,   Nam-Ho Kim7, Shin-Wook Kang8, Yon-Su Kim9, and Young Soo Kim4 Korean J Intern Med 2017;32:109-116 https://doi.org/10.3904/kjim.2015.168",Non-OADS,/arxiv_data1/oa_pdf/8d/46/kjim-2015-168.PMC5214722.pdf
"1, January 2017 https://doi.org/10.3904/kjim.2015.168traindicated [1].",Non-OADS,/arxiv_data1/oa_pdf/8d/46/kjim-2015-168.PMC5214722.pdf
"High serum bicarbonate and mortality www.kjim.org https://doi.org/10.3904/kjim.2015.168used, as appropriate, to evaluated differences in the con - tinuous variables.",Non-OADS,/arxiv_data1/oa_pdf/8d/46/kjim-2015-168.PMC5214722.pdf
"1, January 2017 https://doi.org/10.3904/kjim.2015.168between quartiles 1, 2, 3, and 4 using the log-rank test.",OADS,/arxiv_data1/oa_pdf/8d/46/kjim-2015-168.PMC5214722.pdf
"High serum bicarbonate and mortality www.kjim.org https://doi.org/10.3904/kjim.2015.168years), male sex, diabetes mellitus, cardiovascular dis - ease, BMI, serum hemoglobin, serum albumin, serum  creatinine, serum phosphorus, and nPCR.",Non-OADS,/arxiv_data1/oa_pdf/8d/46/kjim-2015-168.PMC5214722.pdf
"1, January 2017 https://doi.org/10.3904/kjim.2015.168DISCUSSION As serum bicarbonate levels continuously decrease  during the interdialytic interval, HD patients may ex - perience intermittent metabolic acidosis and intradia - lytic alkalosis.",Non-OADS,/arxiv_data1/oa_pdf/8d/46/kjim-2015-168.PMC5214722.pdf
"High serum bicarbonate and mortality www.kjim.org https://doi.org/10.3904/kjim.2015.168nPCR was related to the mortality of the chronic HD pa - tients in univariate analysis ( p = 0.04); however, was not  related to the mortality in the multivariate analysis ( p =  0.361).",OADS,/arxiv_data1/oa_pdf/8d/46/kjim-2015-168.PMC5214722.pdf
"1, January 2017 https://doi.org/10.3904/kjim.2015.168was reported.",OADS,/arxiv_data1/oa_pdf/8d/46/kjim-2015-168.PMC5214722.pdf
"ORIGINAL ARTICLE Copyright © 2017 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1226-3303 eISSN 2005-6648 http://www.kjim.orgINTRODUCTION Since imatinib mesylate (IM), the first BCR-ABL1 tyro- sine kinase inhibitor (TKI), became a first-line therapy  for chronic phase (CP) chronic myeloid leukemia (CML),  more potent second generation (2G) TKIs have been  introduced into routine practice.",Non-OADS,/arxiv_data1/oa_pdf/eb/90/kjim-2015-187.PMC5214723.pdf
"Keywords:  Leukemia, myelogenous, chronic, BCR-ABL positive; Allogeneic stem  cell transplantation; Post-transplant relapseBCR-ABL1  transcripts (MR4.5) at post-transplant   3 months as an early predictor for long-term   outcomes in chronic myeloid leukemia Sung-Eun Lee1,2, Soo Young Choi1, Soo-Hyun Kim1, Hye-Young Song1, Hea-Lyun Yoo1, Mi-Young Lee1,  Ki-Hoon Kang1, Hee-Jeong Hwang1, Eun-Jung Jang1, and Dong-Wook Kim1,2Korean J Intern Med 2017;32:125-136 https://doi.org/10.3904/kjim.2015.187",Non-OADS,/arxiv_data1/oa_pdf/eb/90/kjim-2015-187.PMC5214723.pdf
"1, January 2017 https://doi.org/10.3904/kjim.2015.187Several studies have suggested that early detection of  BCR-ABL1  transcripts by qRT-PCR is associated with an  increased risk of relapse [7,8].",Non-OADS,/arxiv_data1/oa_pdf/eb/90/kjim-2015-187.PMC5214723.pdf
"Post-transplant BCR-ABL1  transcripts www.kjim.org https://doi.org/10.3904/kjim.2015.187the day of transplantation, with patients alive at the time  of last follow-up being administratively censored, and  event-free survival (EFS) was counted from day 0 to any  type of relapse or death while in remission.",Non-OADS,/arxiv_data1/oa_pdf/eb/90/kjim-2015-187.PMC5214723.pdf
"Statistical studies were performed with the  SPSS version 13.0 (SPSS Inc., Chicago, IL, USA) and the  cumulative incidence analyses were carried out with R  (freely distributed on the web, http://cran.r-project.org/).",OADS,/arxiv_data1/oa_pdf/eb/90/kjim-2015-187.PMC5214723.pdf
"1, January 2017 https://doi.org/10.3904/kjim.2015.187Table 1.",Non-OADS,/arxiv_data1/oa_pdf/eb/90/kjim-2015-187.PMC5214723.pdf
Post-transplant BCR-ABL1  transcripts www.kjim.org https://doi.org/10.3904/kjim.2015.187MR4.5 group showed a higher European Group for Blood  and Marrow Transplantation (EBMT) score and more  frequent use of peripheral blood stem cells (PBSCs) as  a source (Table 1).Engraftment and GVHD Transplant outcomes are shown in Table 2.,Non-OADS,/arxiv_data1/oa_pdf/eb/90/kjim-2015-187.PMC5214723.pdf
"1, January 2017 https://doi.org/10.3904/kjim.2015.187Table 3.",Non-OADS,/arxiv_data1/oa_pdf/eb/90/kjim-2015-187.PMC5214723.pdf
"Post-transplant BCR-ABL1  transcripts www.kjim.org https://doi.org/10.3904/kjim.2015.18713 and 19 days after SCT, respectively.",Non-OADS,/arxiv_data1/oa_pdf/eb/90/kjim-2015-187.PMC5214723.pdf
"1, January 2017 https://doi.org/10.3904/kjim.2015.187Table 4.",Non-OADS,/arxiv_data1/oa_pdf/eb/90/kjim-2015-187.PMC5214723.pdf
"Post-transplant BCR-ABL1  transcripts www.kjim.org https://doi.org/10.3904/kjim.2015.187and 57.3%, respectively.",OADS,/arxiv_data1/oa_pdf/eb/90/kjim-2015-187.PMC5214723.pdf
"1, January 2017 https://doi.org/10.3904/kjim.2015.187pre-emptive treatment was applied upon achieving tran - scripts levels  in excess of 0.1% that were confirmed by  the finding of Philadelphia chromosome-positive meta - phases in the bone marrow [10].",Non-OADS,/arxiv_data1/oa_pdf/eb/90/kjim-2015-187.PMC5214723.pdf
Post-transplant BCR-ABL1  transcripts www.kjim.org https://doi.org/10.3904/kjim.2015.187Conflict of interest No potential conflict of interest relevant to this article  was reported.,Non-OADS,/arxiv_data1/oa_pdf/eb/90/kjim-2015-187.PMC5214723.pdf
"1, January 2017 https://doi.org/10.3904/kjim.2015.187of donor leukocytes for relapse of chronic myeloid leu - kemia after bone marrow transplantation: separation of  graft-versus-leukemia responses from graft-versus-host  disease.",Non-OADS,/arxiv_data1/oa_pdf/eb/90/kjim-2015-187.PMC5214723.pdf
Post-transplant BCR-ABL1  transcriptswww.kjim.org https://doi.org/10.3904/kjim.2015.187Supplemen tary Figure 1.,Non-OADS,/arxiv_data1/oa_pdf/eb/90/kjim-2015-187.PMC5214723.pdf
"LETTER TO THE EDITOR Copyright © 2017 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1226-3303 eISSN 2005-6648 http://www.kjim.orgDepartment of Pulmonary and  Critical Care Medicine, Kyung Hee  University College of Medicine,  Seoul, KoreaPresence of bilirubin in bronchobiliary fistula  easily confirmed with urinary dipstick test and  treated with embolization   Min Je Kim, Seon Hye Kim, In Kyoung Hwang, Hyung Oh Kim, Na Eun Jang, Seung Sook Paik,   and Myung Jae Park Received : June  25, 2015 Revised : July 20, 2015 Accepted : July 22, 2015 Correspondence to Myung Jae Park, M.D.",Non-OADS,/arxiv_data1/oa_pdf/7a/fd/kjim-2015-188.PMC5214724.pdf
Chest X-ray scans demon - strated peribronchial infiltration in the Korean J Intern Med 2017;32:182-185 https://doi.org/10.3904/ kjim.2015.188,Non-OADS,/arxiv_data1/oa_pdf/7a/fd/kjim-2015-188.PMC5214724.pdf
BBF established by urinalysis https://doi.org/10.3904/kjim.2015.188Figure 1 .,Non-OADS,/arxiv_data1/oa_pdf/7a/fd/kjim-2015-188.PMC5214724.pdf
"1, January 2017 https://doi.org/10.3904/kjim.2015.188Clinical diagnosis is usually made by the presence of  bile in the sputum, referred to as biloptysis.",Non-OADS,/arxiv_data1/oa_pdf/7a/fd/kjim-2015-188.PMC5214724.pdf
BBF established by urinalysis https://doi.org/10.3904/kjim.2015.188bolization and BBF obliteration with a silicon spigot un - der bronchoscopic guidance have been reported as new  therapeutic methods.,Non-OADS,/arxiv_data1/oa_pdf/7a/fd/kjim-2015-188.PMC5214724.pdf
"ORIGINAL ARTICLE Copyright © 2017 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1226-3303 eISSN 2005-6648 http://www.kjim.orgINTRODUCTION Primary Sjogren’s syndrome (pSS) is an autoimmune  disease that affects the exocrine glands, leading to the  development of keratoconjunctivitis sicca and xerosto - mia [1].",Non-OADS,/arxiv_data1/oa_pdf/2a/ba/kjim-2015-219.PMC5214725.pdf
"Keywords:  Sjogren’s syndrome; Autonomic nervous system; Fatigue; Heart rate  variabilityAutonomic dysfunction in primary Sjogren’s syn - drome: a prospective cohort analysis of 154 Korean  patients Jung Hee Koh, Seung-Ki Kwok, Jennifer Lee, and Sung-Hwan Park Korean J Intern Med 2017;32:165-173 https://doi.org/10.3904/kjim.2015.219",Non-OADS,/arxiv_data1/oa_pdf/2a/ba/kjim-2015-219.PMC5214725.pdf
"1, January 2017 https://doi.org/10.3904/kjim.2015.219al neuropathy has been reported in approximately 20%  of patients with pSS [4].",Non-OADS,/arxiv_data1/oa_pdf/2a/ba/kjim-2015-219.PMC5214725.pdf
"Dysautonomia in Sjogren’s syndrome www.kjim.org https://doi.org/10.3904/kjim.2015.219Seongnam, Korea).",Non-OADS,/arxiv_data1/oa_pdf/2a/ba/kjim-2015-219.PMC5214725.pdf
"1, January 2017 https://doi.org/10.3904/kjim.2015.219Sjogren’s syndrome A antibody) in 90.3% and anti-La/ SSB (anti-La/Sjogren’s syndrome B antibody) in 46.8%  of the participants.",OADS,/arxiv_data1/oa_pdf/2a/ba/kjim-2015-219.PMC5214725.pdf
Dysautonomia in Sjogren’s syndrome www.kjim.org https://doi.org/10.3904/kjim.2015.219to 7]) than in those without autonomic dysfunction  (p =  0.024) (Table 2).,Non-OADS,/arxiv_data1/oa_pdf/2a/ba/kjim-2015-219.PMC5214725.pdf
"1, January 2017 https://doi.org/10.3904/kjim.2015.219tion between them.",Non-OADS,/arxiv_data1/oa_pdf/2a/ba/kjim-2015-219.PMC5214725.pdf
Dysautonomia in Sjogren’s syndrome www.kjim.org https://doi.org/10.3904/kjim.2015.219associated with higher ESSPRI pain scores.,Non-OADS,/arxiv_data1/oa_pdf/2a/ba/kjim-2015-219.PMC5214725.pdf
"1, January 2017 https://doi.org/10.3904/kjim.2015.219system in primary Sjogren’s syndrome.",OADS,/arxiv_data1/oa_pdf/2a/ba/kjim-2015-219.PMC5214725.pdf
"Dysautonomia in Sjogren’s syndrome www.kjim.org https://doi.org/10.3904/kjim.2015.219primary Sjogren’s syndrome: prevalence, clinical and lab - oratory associations.",OADS,/arxiv_data1/oa_pdf/2a/ba/kjim-2015-219.PMC5214725.pdf
"1, January 2017 https://doi.org/10.3904/kjim.2015.219Supplementary Table 1.",Non-OADS,/arxiv_data1/oa_pdf/2a/ba/kjim-2015-219.PMC5214725.pdf
"ORIGINAL ARTICLE Copyright © 2017 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1226-3303 eISSN 2005-6648 http://www.kjim.orgINTRODUCTION Ankylosing spondylitis (AS) is a chronic inflammatory  disease that primarily affects the axial skeleton.",Non-OADS,/arxiv_data1/oa_pdf/6b/49/kjim-2015-229.PMC5214726.pdf
"Keywords:  Spondylitis, ankylosing; Hip; Body mass indexCharacteristics of hip involvement in patients  with ankylosing spondylitis in Korea Hyemin Jeong, Yeong Hee Eun, In Young Kim, Hyungjin Kim, Jaejoon Lee, Eun-Mi Koh,  and Hoon-Suk ChaKorean J Intern Med 2017;32:158-164 https://doi.org/10.3904/kjim.2015.229",Non-OADS,/arxiv_data1/oa_pdf/6b/49/kjim-2015-229.PMC5214726.pdf
"Hip arthritis in ankylosing spondylitis www.kjim.org https://doi.org/10.3904/kjim.2015.229and axial disease are associated with hip joint involve - ment and hip replacement surgery in AS [1,3].",Non-OADS,/arxiv_data1/oa_pdf/6b/49/kjim-2015-229.PMC5214726.pdf
"1, January 2017 https://doi.org/10.3904/kjim.2015.229presented as the mean ± SD, and variables were coma - pared using t tests.",OADS,/arxiv_data1/oa_pdf/6b/49/kjim-2015-229.PMC5214726.pdf
"Hip arthritis in ankylosing spondylitis www.kjim.org https://doi.org/10.3904/kjim.2015.229was higher in patients with hip joint replacement sur - gery (2.6 ± 0.4 vs. 1.8 ± 0.7, p = 0.012).",Non-OADS,/arxiv_data1/oa_pdf/6b/49/kjim-2015-229.PMC5214726.pdf
"1, January 2017 https://doi.org/10.3904/kjim.2015.229positively correlate with BMI, and the concentrations of  adipokines are increased in patients with metabolic syn - drome [14].",Non-OADS,/arxiv_data1/oa_pdf/6b/49/kjim-2015-229.PMC5214726.pdf
Hip arthritis in ankylosing spondylitis www.kjim.org https://doi.org/10.3904/kjim.2015.229sponse factors.,Non-OADS,/arxiv_data1/oa_pdf/6b/49/kjim-2015-229.PMC5214726.pdf
"1, January 2017 https://doi.org/10.3904/kjim.2015.2298.",Non-OADS,/arxiv_data1/oa_pdf/6b/49/kjim-2015-229.PMC5214726.pdf
"ORIGINAL ARTICLE Copyright © 2017 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1226-3303 eISSN 2005-6648 http://www.kjim.orgINTRODUCTION Mortality rates of patients undergoing hemodialysis  (HD) are 20% during the first year of treatment and 70%  after 5 years [1].",Non-OADS,/arxiv_data1/oa_pdf/1a/ad/kjim-2015-278.PMC5214727.pdf
"In-Cheol Yoon, Hye-Min Choi, and Dong-Jin OhKorean J Intern Med 2017;32:117-124  https://doi.org/10.3904/kjim.2015.278",Non-OADS,/arxiv_data1/oa_pdf/1a/ad/kjim-2015-278.PMC5214727.pdf
"1, January 2017 https://doi.org/10.3904/kjim.2015.278Therefore, a unique challenge in patients undergoing  HD is how and when blood pressure (BP) should be  measured.",Non-OADS,/arxiv_data1/oa_pdf/1a/ad/kjim-2015-278.PMC5214727.pdf
"Home BP monitoring in HD patients www.kjim.org https://doi.org/10.3904/kjim.2015.2782-, 3-hour and immediately after HD.",Non-OADS,/arxiv_data1/oa_pdf/1a/ad/kjim-2015-278.PMC5214727.pdf
"1, January 2017 https://doi.org/10.3904/kjim.2015.278mmHg, respectively.",OADS,/arxiv_data1/oa_pdf/1a/ad/kjim-2015-278.PMC5214727.pdf
"Home BP monitoring in HD patients www.kjim.org https://doi.org/10.3904/kjim.2015.278Diagnostic performance of mean pre-HD, post-HD,  intra-HD, pre-intra-post-HD, pre-post-HD SBP with  2-week HBP as the reference standard The areas under the ROC curve (95% CI) for pre-HD,  post-HD, intra-HD, pre-intra-post-HD, and pre-post- HD SBP were 0.745 (0.541 to 0.880), 0.701 (0.514 to 0.835),  0.738 (0.533 to 0.862), 0.812 (0.651 to 0.964), and 0.801  (0.643 to 0.960), respectively (Table 3).",Non-OADS,/arxiv_data1/oa_pdf/1a/ad/kjim-2015-278.PMC5214727.pdf
"1, January 2017 https://doi.org/10.3904/kjim.2015.278curacy for predicting mean 2-week HSBP in patients  undergoing HD.",Non-OADS,/arxiv_data1/oa_pdf/1a/ad/kjim-2015-278.PMC5214727.pdf
Home BP monitoring in HD patients www.kjim.org https://doi.org/10.3904/kjim.2015.278by HBP to manage HT in patients undergoing HD.,Non-OADS,/arxiv_data1/oa_pdf/1a/ad/kjim-2015-278.PMC5214727.pdf
"1, January 2017 https://doi.org/10.3904/kjim.2015.27812.",Non-OADS,/arxiv_data1/oa_pdf/1a/ad/kjim-2015-278.PMC5214727.pdf
"LETTER TO THE EDITOR Copyright © 2017 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1226-3303 eISSN 2005-6648 http://www.kjim.orgDivision of Gastroenterology and  Hepatology, Department of Internal  Medicine, College of Medicine, The  Catholic University of Korea, Seoul,  KoreaRecurrent pyogenic liver abscess as a presenting  manifestation of colorectal cancer Hee Yeon Kim, Chang Wook Kim, Dong Ryul Kim, Young Wook Cho, Jae-Young Cho, Woo Jung Kim,  and Hyung Gyu Choi Received : September  1, 2015 Revised : September  17, 2015 Accepted : September  18, 2015 Correspondence to Chang Wook Kim, M.D.",Non-OADS,/arxiv_data1/oa_pdf/32/fc/kjim-2015-301.PMC5214728.pdf
"His WBC count was 25,660/ μL, with 80.4% neutrophils, and the Korean J Intern Med 2017;32:174-177  https://doi.org/10.3904/kjim.2015.301",Non-OADS,/arxiv_data1/oa_pdf/32/fc/kjim-2015-301.PMC5214728.pdf
"175 www.kjim.org https://doi.org/10.3904/kjim.2015.301Kim HY, et al.",OADS,/arxiv_data1/oa_pdf/32/fc/kjim-2015-301.PMC5214728.pdf
              176 www.kjim.org https://doi.org/10.3904/kjim.2015.301The Korean Journal of Internal Medicine Vol.,Non-OADS,/arxiv_data1/oa_pdf/32/fc/kjim-2015-301.PMC5214728.pdf
"177 www.kjim.org https://doi.org/10.3904/kjim.2015.301Kim HY, et al.",OADS,/arxiv_data1/oa_pdf/32/fc/kjim-2015-301.PMC5214728.pdf
"Copyright © 2017 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1226-3303 eISSN 2005-6648 http://www.kjim.org REVIEWKorean J Intern Med 2017;32:11-25 https://doi.org/10.3904/kjim.2016.174 INTRODUCTION Chronic kidney disease (CKD) has become a worldwide  health-care concern that calls for prompt initiatives and  firm commitments to find effective treatments.",Non-OADS,/arxiv_data1/oa_pdf/cc/f7/kjim-2016-174.PMC5214729.pdf
12 https://doi.org/10.3904/kjim.2016.174The Korean Journal of Internal Medicine Vol.,Non-OADS,/arxiv_data1/oa_pdf/cc/f7/kjim-2016-174.PMC5214729.pdf
"New therapy for DN https://doi.org/10.3904/kjim.2016.174 www.kjim.orgphy, fibrosis, and eventual tubular atrophy, occur along  with glomerular changes [13].",Non-OADS,/arxiv_data1/oa_pdf/cc/f7/kjim-2016-174.PMC5214729.pdf
14 https://doi.org/10.3904/kjim.2016.174The Korean Journal of Internal Medicine Vol.,Non-OADS,/arxiv_data1/oa_pdf/cc/f7/kjim-2016-174.PMC5214729.pdf
"New therapy for DN https://doi.org/10.3904/kjim.2016.174 www.kjim.orgDiabetes (BEAM) and Bardoxolone Methyl Evaluation  in Patients with Chronic Kidney Disease and Type 2  Diabetes: the Occurrence of Renal Events (BEACON)  trials, owing to the development of various degrees of  side effects ranging from trivial muscle cramps to seri - ous issues including heart failure, non-fatal myocardial  infarction, stroke, and cardiovascular mortality.",Non-OADS,/arxiv_data1/oa_pdf/cc/f7/kjim-2016-174.PMC5214729.pdf
16 https://doi.org/10.3904/kjim.2016.174The Korean Journal of Internal Medicine Vol.,Non-OADS,/arxiv_data1/oa_pdf/cc/f7/kjim-2016-174.PMC5214729.pdf
New therapy for DN https://doi.org/10.3904/kjim.2016.174 www.kjim.orgoutcomes are needed (Fig.,Non-OADS,/arxiv_data1/oa_pdf/cc/f7/kjim-2016-174.PMC5214729.pdf
18 https://doi.org/10.3904/kjim.2016.174The Korean Journal of Internal Medicine Vol.,Non-OADS,/arxiv_data1/oa_pdf/cc/f7/kjim-2016-174.PMC5214729.pdf
"New therapy for DN https://doi.org/10.3904/kjim.2016.174 www.kjim.orgnases, including a compound molecule that consists of  three proteins: STE-related adaptor (STRAD), mouse  protein 25 (MO25), and the tumor-suppressor liver ki - nase B1 (LKB1).",Non-OADS,/arxiv_data1/oa_pdf/cc/f7/kjim-2016-174.PMC5214729.pdf
20 https://doi.org/10.3904/kjim.2016.174The Korean Journal of Internal Medicine Vol.,Non-OADS,/arxiv_data1/oa_pdf/cc/f7/kjim-2016-174.PMC5214729.pdf
"New therapy for DN https://doi.org/10.3904/kjim.2016.174 www.kjim.orgConventional activators of AMPK include 5-amino - imidazole-4-carboxamide ribonucleoside, metformin,  adiponectin, and resveratrol, which have been shown  to provide additional renoprotective effects in addition  to their intrinsic activities [72].",Non-OADS,/arxiv_data1/oa_pdf/cc/f7/kjim-2016-174.PMC5214729.pdf
22 https://doi.org/10.3904/kjim.2016.174The Korean Journal of Internal Medicine Vol.,Non-OADS,/arxiv_data1/oa_pdf/cc/f7/kjim-2016-174.PMC5214729.pdf
New therapy for DN https://doi.org/10.3904/kjim.2016.174 www.kjim.orgnal function on the efficacy and safety of aliskiren added  to losartan in patients with type 2 diabetes and nephrop - athy.,Non-OADS,/arxiv_data1/oa_pdf/cc/f7/kjim-2016-174.PMC5214729.pdf
24 https://doi.org/10.3904/kjim.2016.174The Korean Journal of Internal Medicine Vol.,Non-OADS,/arxiv_data1/oa_pdf/cc/f7/kjim-2016-174.PMC5214729.pdf
New therapy for DN https://doi.org/10.3904/kjim.2016.174 www.kjim.orgChem 2007;282:32539-32548.,Non-OADS,/arxiv_data1/oa_pdf/cc/f7/kjim-2016-174.PMC5214729.pdf
"pISSN 1226-3303 eISSN 2005-6648 http://www.kjim.org REVIEW Copyright © 2017 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.Korean J Intern Med 2017;32:42-61 https://doi.org/10.3904/kjim.2016.198 INTRODUCTION Socioeconomic burden of rare genetic diseases is in - creasing.",Non-OADS,/arxiv_data1/oa_pdf/c2/32/kjim-2016-198.PMC5214730.pdf
"An overview of CRISPR-Cas9 and its applications www.kjim.org https://doi.org/10.3904/kjim.2016.198the PMI include combating cancers, while the accrual of  knowledge pertaining to health and diseases represents  the long-term focus.",Non-OADS,/arxiv_data1/oa_pdf/c2/32/kjim-2016-198.PMC5214730.pdf
        44  www.kjim.org https://doi.org/10.3904/kjim.2016.198The Korean Journal of Internal Medicine Vol.,Non-OADS,/arxiv_data1/oa_pdf/c2/32/kjim-2016-198.PMC5214730.pdf
"An overview of CRISPR-Cas9 and its applications www.kjim.org https://doi.org/10.3904/kjim.2016.198tomized sgRNA can cleave genomic DNA at specific loci,  enabling precise genome editing.",Non-OADS,/arxiv_data1/oa_pdf/c2/32/kjim-2016-198.PMC5214730.pdf
        46  www.kjim.org https://doi.org/10.3904/kjim.2016.198The Korean Journal of Internal Medicine Vol.,Non-OADS,/arxiv_data1/oa_pdf/c2/32/kjim-2016-198.PMC5214730.pdf
"An overview of CRISPR-Cas9 and its applications www.kjim.org https://doi.org/10.3904/kjim.2016.198modeling, and therapeutics.",OADS,/arxiv_data1/oa_pdf/c2/32/kjim-2016-198.PMC5214730.pdf
        48  www.kjim.org https://doi.org/10.3904/kjim.2016.198The Korean Journal of Internal Medicine Vol.,Non-OADS,/arxiv_data1/oa_pdf/c2/32/kjim-2016-198.PMC5214730.pdf
An overview of CRISPR-Cas9 and its applications www.kjim.org https://doi.org/10.3904/kjim.2016.198Table 2.,Non-OADS,/arxiv_data1/oa_pdf/c2/32/kjim-2016-198.PMC5214730.pdf
        50  www.kjim.org https://doi.org/10.3904/kjim.2016.198The Korean Journal of Internal Medicine Vol.,Non-OADS,/arxiv_data1/oa_pdf/c2/32/kjim-2016-198.PMC5214730.pdf
An overview of CRISPR-Cas9 and its applications www.kjim.org https://doi.org/10.3904/kjim.2016.198directly into fertilized zygotes [42].,OADS,/arxiv_data1/oa_pdf/c2/32/kjim-2016-198.PMC5214730.pdf
        52  www.kjim.org https://doi.org/10.3904/kjim.2016.198The Korean Journal of Internal Medicine Vol.,Non-OADS,/arxiv_data1/oa_pdf/c2/32/kjim-2016-198.PMC5214730.pdf
An overview of CRISPR-Cas9 and its applications www.kjim.org https://doi.org/10.3904/kjim.2016.198sgRNA library CRISPR-Cas9 can also be applied to the systematic anal - ysis of gene functions in human cells.,OADS,/arxiv_data1/oa_pdf/c2/32/kjim-2016-198.PMC5214730.pdf
        54  www.kjim.org https://doi.org/10.3904/kjim.2016.198The Korean Journal of Internal Medicine Vol.,Non-OADS,/arxiv_data1/oa_pdf/c2/32/kjim-2016-198.PMC5214730.pdf
"An overview of CRISPR-Cas9 and its applications www.kjim.org https://doi.org/10.3904/kjim.2016.198sion of a key enzyme in the NHEJ pathway increases  the efficiency of HDR-mediated genome editing up to  19-fold [133,134].",Non-OADS,/arxiv_data1/oa_pdf/c2/32/kjim-2016-198.PMC5214730.pdf
        56  www.kjim.org https://doi.org/10.3904/kjim.2016.198The Korean Journal of Internal Medicine Vol.,Non-OADS,/arxiv_data1/oa_pdf/c2/32/kjim-2016-198.PMC5214730.pdf
An overview of CRISPR-Cas9 and its applications www.kjim.org https://doi.org/10.3904/kjim.2016.198maturation by trans-encoded small RNA and host factor  RNase III.,Non-OADS,/arxiv_data1/oa_pdf/c2/32/kjim-2016-198.PMC5214730.pdf
        58  www.kjim.org https://doi.org/10.3904/kjim.2016.198The Korean Journal of Internal Medicine Vol.,Non-OADS,/arxiv_data1/oa_pdf/c2/32/kjim-2016-198.PMC5214730.pdf
An overview of CRISPR-Cas9 and its applications www.kjim.org https://doi.org/10.3904/kjim.2016.19876.,Non-OADS,/arxiv_data1/oa_pdf/c2/32/kjim-2016-198.PMC5214730.pdf
        60  www.kjim.org https://doi.org/10.3904/kjim.2016.198The Korean Journal of Internal Medicine Vol.,Non-OADS,/arxiv_data1/oa_pdf/c2/32/kjim-2016-198.PMC5214730.pdf
An overview of CRISPR-Cas9 and its applications www.kjim.org https://doi.org/10.3904/kjim.2016.198stem cells.,OADS,/arxiv_data1/oa_pdf/c2/32/kjim-2016-198.PMC5214730.pdf
"Copyright © 2017 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1226-3303 eISSN 2005-6648 http://www.kjim.org REVIEWKorean J Intern Med 2017;32:1-10 https://doi.org/10.3904/kjim.2016.200 INTRODUCTION Photodynamic therapy (PDT) was first introduced to  treat esophageal cancer in the early 1980s [1].",Non-OADS,/arxiv_data1/oa_pdf/18/97/kjim-2016-200.PMC5214731.pdf
2  www.kjim.org https://doi.org/10.3904/kjim.2016.200The Korean Journal of Internal Medicine Vol.,Non-OADS,/arxiv_data1/oa_pdf/18/97/kjim-2016-200.PMC5214731.pdf
Photodynamic therapy for gastrointestinal disorders www.kjim.org https://doi.org/10.3904/kjim.2016.200Table 1.,Non-OADS,/arxiv_data1/oa_pdf/18/97/kjim-2016-200.PMC5214731.pdf
4  www.kjim.org https://doi.org/10.3904/kjim.2016.200The Korean Journal of Internal Medicine Vol.,Non-OADS,/arxiv_data1/oa_pdf/18/97/kjim-2016-200.PMC5214731.pdf
Photodynamic therapy for gastrointestinal disorders www.kjim.org https://doi.org/10.3904/kjim.2016.200acid (ALA) can provide good visualization of gastric ma - lignant lesions to determine the extent of the lesions.,Non-OADS,/arxiv_data1/oa_pdf/18/97/kjim-2016-200.PMC5214731.pdf
6  www.kjim.org https://doi.org/10.3904/kjim.2016.200The Korean Journal of Internal Medicine Vol.,Non-OADS,/arxiv_data1/oa_pdf/18/97/kjim-2016-200.PMC5214731.pdf
Photodynamic therapy for gastrointestinal disorders www.kjim.org https://doi.org/10.3904/kjim.2016.200NOVEL APPLICATIONS OF PDD AND PDT IN GI  MALIGNANCY Much research has been done to extend the application  of photodynamic techniques to the early diagnosis and  treatment of GI malignancy.,Non-OADS,/arxiv_data1/oa_pdf/18/97/kjim-2016-200.PMC5214731.pdf
8  www.kjim.org https://doi.org/10.3904/kjim.2016.200The Korean Journal of Internal Medicine Vol.,Non-OADS,/arxiv_data1/oa_pdf/18/97/kjim-2016-200.PMC5214731.pdf
Photodynamic therapy for gastrointestinal disorders www.kjim.org https://doi.org/10.3904/kjim.2016.200namic therapy in the palliation of obstructing esophageal  cancer.,Non-OADS,/arxiv_data1/oa_pdf/18/97/kjim-2016-200.PMC5214731.pdf
10  www.kjim.org https://doi.org/10.3904/kjim.2016.200The Korean Journal of Internal Medicine Vol.,Non-OADS,/arxiv_data1/oa_pdf/18/97/kjim-2016-200.PMC5214731.pdf
"pISSN 1226-3303 eISSN 2005-6648 http://www.kjim.org REVIEW Copyright © 2017 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.Korean J Intern Med 2017;32:26-41 https://doi.org/10.3904/kjim.2016.203 INTRODUCTION Gestational diabetes mellitus (GDM) is defined as any  degree of glucose intolerance with onset or first recog - nition during pregnancy [1].",Non-OADS,/arxiv_data1/oa_pdf/b2/3b/kjim-2016-203.PMC5214732.pdf
Prevention of T2DM in women with GDM www.kjim.org https://doi.org/10.3904/kjim.2016.203sensitivity compared with their counterparts without  GDM after delivery [6].,Non-OADS,/arxiv_data1/oa_pdf/b2/3b/kjim-2016-203.PMC5214732.pdf
        28  www.kjim.org https://doi.org/10.3904/kjim.2016.203The Korean Journal of Internal Medicine Vol.,Non-OADS,/arxiv_data1/oa_pdf/b2/3b/kjim-2016-203.PMC5214732.pdf
Prevention of T2DM in women with GDM www.kjim.org https://doi.org/10.3904/kjim.2016.203stasis between Asians and Europeans.,Non-OADS,/arxiv_data1/oa_pdf/b2/3b/kjim-2016-203.PMC5214732.pdf
        30  www.kjim.org https://doi.org/10.3904/kjim.2016.203The Korean Journal of Internal Medicine Vol.,Non-OADS,/arxiv_data1/oa_pdf/b2/3b/kjim-2016-203.PMC5214732.pdf
Prevention of T2DM in women with GDM www.kjim.org https://doi.org/10.3904/kjim.2016.203Table 1.,Non-OADS,/arxiv_data1/oa_pdf/b2/3b/kjim-2016-203.PMC5214732.pdf
        32  www.kjim.org https://doi.org/10.3904/kjim.2016.203The Korean Journal of Internal Medicine Vol.,Non-OADS,/arxiv_data1/oa_pdf/b2/3b/kjim-2016-203.PMC5214732.pdf
Prevention of T2DM in women with GDM www.kjim.org https://doi.org/10.3904/kjim.2016.203diabetes when β-cells fail to compensate.,Non-OADS,/arxiv_data1/oa_pdf/b2/3b/kjim-2016-203.PMC5214732.pdf
        34  www.kjim.org https://doi.org/10.3904/kjim.2016.203The Korean Journal of Internal Medicine Vol.,Non-OADS,/arxiv_data1/oa_pdf/b2/3b/kjim-2016-203.PMC5214732.pdf
Prevention of T2DM in women with GDM www.kjim.org https://doi.org/10.3904/kjim.2016.2030.58 kg.,Non-OADS,/arxiv_data1/oa_pdf/b2/3b/kjim-2016-203.PMC5214732.pdf
        36  www.kjim.org https://doi.org/10.3904/kjim.2016.203The Korean Journal of Internal Medicine Vol.,Non-OADS,/arxiv_data1/oa_pdf/b2/3b/kjim-2016-203.PMC5214732.pdf
Prevention of T2DM in women with GDM www.kjim.org https://doi.org/10.3904/kjim.2016.203National Diabetes Data Group vs Carpenter-Coustan cri - teria to diagnose gestational diabetes.,Non-OADS,/arxiv_data1/oa_pdf/b2/3b/kjim-2016-203.PMC5214732.pdf
        38  www.kjim.org https://doi.org/10.3904/kjim.2016.203The Korean Journal of Internal Medicine Vol.,Non-OADS,/arxiv_data1/oa_pdf/b2/3b/kjim-2016-203.PMC5214732.pdf
Prevention of T2DM in women with GDM www.kjim.org https://doi.org/10.3904/kjim.2016.203dence and risk factors associated with abnormal postpar - tum glucose tolerance in women with gestational diabe - tes.,Non-OADS,/arxiv_data1/oa_pdf/b2/3b/kjim-2016-203.PMC5214732.pdf
        40  www.kjim.org https://doi.org/10.3904/kjim.2016.203The Korean Journal of Internal Medicine Vol.,Non-OADS,/arxiv_data1/oa_pdf/b2/3b/kjim-2016-203.PMC5214732.pdf
Prevention of T2DM in women with GDM www.kjim.org https://doi.org/10.3904/kjim.2016.203106.,Non-OADS,/arxiv_data1/oa_pdf/b2/3b/kjim-2016-203.PMC5214732.pdf
"GUIDELINE pISSN 1226-3303 eISSN 2005-6648 http://www.kjim.orgCopyright © 2017 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.Korean J Intern Med 2017;32:199-210 https://doi.org/10.3904/kjim.2016.218 Evidence-based guidelines for fall prevention in  Korea Kwang-Il Kim1,*, Hye-Kyung Jung2,*, Chang Oh Kim3, Soo-Kyung Kim4, Hyun-Ho Cho5, Dae Yul Kim6,  Yong-Chan Ha7, Sung-Hee Hwang8, Chang Won Won9, Jae-Young Lim10, Hyun Jung Kim11, Jae Gyu Kim12;  and The Korean Association of Internal Medicine, The Korean Geriatrics Society 1Department of Internal Medicine,  Seoul National University College  of Medicine, Seoul; 2Department of  Internal Medicine, Ewha Womans  University School of Medicine,  Seoul; 3Department of Internal  Medicine, Yonsei University College  of Medicine, Seoul; 4Division of  Endocrinology, Department of  Internal Medicine, CHA Bundang  Medical Center, CHA University,  Seongnam; 5Korean Physicians’  Association, Seoul; 6Department  of Rehabilitation Medicine, Asan  Medical Center, University of  Ulsan College of Medicine, Seoul;  7Department of Orthopaedic Surgery,  Chung-Ang University College  of Medicine, Seoul; 8Department  of Neurology, Hallym University  College of Medicine, Chuncheon;  9Department of Family Medicine,  Kyung Hee University School of  Medicine, Seoul; 10Department  of Rehabilitation, Seoul National  University Bundang Hospital,  Seongnam; 11Department of  Preventive Medicine, Korea  University College of Medicine,  Seoul; 12Department of Internal  Medicine, Chung-Ang University  College of Medicine, Seoul, Korea Correspondence to Jae Gyu Kim, M.D.",Non-OADS,/arxiv_data1/oa_pdf/31/99/kjim-2016-218.PMC5214733.pdf
200  www.kjim.org https://doi.org/10.3904/kjim.2016.218The Korean Journal of Internal Medicine Vol.,Non-OADS,/arxiv_data1/oa_pdf/31/99/kjim-2016-218.PMC5214733.pdf
Guidelines for fall prevention www.kjim.org https://doi.org/10.3904/kjim.2016.218were not involved in the nominal group technique.,Non-OADS,/arxiv_data1/oa_pdf/31/99/kjim-2016-218.PMC5214733.pdf
202  www.kjim.org https://doi.org/10.3904/kjim.2016.218The Korean Journal of Internal Medicine Vol.,Non-OADS,/arxiv_data1/oa_pdf/31/99/kjim-2016-218.PMC5214733.pdf
Guidelines for fall prevention www.kjim.org https://doi.org/10.3904/kjim.2016.218The fall prevention guidelines will be updated peri - odically if new study outcomes become available.,Non-OADS,/arxiv_data1/oa_pdf/31/99/kjim-2016-218.PMC5214733.pdf
204  www.kjim.org https://doi.org/10.3904/kjim.2016.218The Korean Journal of Internal Medicine Vol.,Non-OADS,/arxiv_data1/oa_pdf/31/99/kjim-2016-218.PMC5214733.pdf
Guidelines for fall prevention www.kjim.org https://doi.org/10.3904/kjim.2016.218mend automatically performing an in-depth multifac - torial risk assessment in conjunction with comprehen - sive management of identified risks to prevent falls in  community-dwelling older adults because the likeli - hood of benefit is expected to be small [25].,Non-OADS,/arxiv_data1/oa_pdf/31/99/kjim-2016-218.PMC5214733.pdf
206  www.kjim.org https://doi.org/10.3904/kjim.2016.218The Korean Journal of Internal Medicine Vol.,Non-OADS,/arxiv_data1/oa_pdf/31/99/kjim-2016-218.PMC5214733.pdf
Guidelines for fall prevention www.kjim.org https://doi.org/10.3904/kjim.2016.2186.,Non-OADS,/arxiv_data1/oa_pdf/31/99/kjim-2016-218.PMC5214733.pdf
208  www.kjim.org https://doi.org/10.3904/kjim.2016.218The Korean Journal of Internal Medicine Vol.,Non-OADS,/arxiv_data1/oa_pdf/31/99/kjim-2016-218.PMC5214733.pdf
Available from:  https://www.cdc.gov/injury/wisqars.,OADS,/arxiv_data1/oa_pdf/31/99/kjim-2016-218.PMC5214733.pdf
Available from: http://www.agreetrust.org/wp-content/ uploads/2013/06/AGREE_II_Korean.pdf .,Non-OADS,/arxiv_data1/oa_pdf/31/99/kjim-2016-218.PMC5214733.pdf
Guidelines for fall prevention www.kjim.org https://doi.org/10.3904/kjim.2016.218Intern Med 2012;157:197-204.,Non-OADS,/arxiv_data1/oa_pdf/31/99/kjim-2016-218.PMC5214733.pdf
210  www.kjim.org https://doi.org/10.3904/kjim.2016.218The Korean Journal of Internal Medicine Vol.,Non-OADS,/arxiv_data1/oa_pdf/31/99/kjim-2016-218.PMC5214733.pdf
Guidelines for fall preventionwww.kjim.org https://doi.org/10.3904/kjim.2016.218Appendix 1.,Non-OADS,/arxiv_data1/oa_pdf/31/99/kjim-2016-218.PMC5214733.pdf
       www.kjim.org https://doi.org/10.3904/kjim.2016.218The Korean Journal of Internal Medicine Vol.,Non-OADS,/arxiv_data1/oa_pdf/31/99/kjim-2016-218.PMC5214733.pdf
"pISSN 1226-3303 eISSN 2005-6648 http://www.kjim.org REVIEW Copyright © 2017 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.Korean J Intern Med 2017;32:62-66 https://doi.org/10.3904/kjim.2016.224 INTRODUCTION In the decade and a half since the Edmonton protocol  report of 1-year insulin independence following pan - creatic islet transplantation in seven consecutive type 1  diabetes mellitus patients [1], the position of islet trans - plantation in clinical medicine has been reappraised [2- 5].",Non-OADS,/arxiv_data1/oa_pdf/df/47/kjim-2016-224.PMC5214734.pdf
"Islet transplantation www.kjim.org https://doi.org/10.3904/kjim.2016.224treatments [9], and it also holds promise as an interven - tion for preventing diabetes after partial pancreatecto - my for benign pancreatic tumors [10].",Non-OADS,/arxiv_data1/oa_pdf/df/47/kjim-2016-224.PMC5214734.pdf
        64  www.kjim.org https://doi.org/10.3904/kjim.2016.224The Korean Journal of Internal Medicine Vol.,Non-OADS,/arxiv_data1/oa_pdf/df/47/kjim-2016-224.PMC5214734.pdf
Islet transplantation www.kjim.org https://doi.org/10.3904/kjim.2016.224effects of intraportal islet transplantation beyond the  simple replacement of islet cell mass.,Non-OADS,/arxiv_data1/oa_pdf/df/47/kjim-2016-224.PMC5214734.pdf
        66  www.kjim.org https://doi.org/10.3904/kjim.2016.224The Korean Journal of Internal Medicine Vol.,Non-OADS,/arxiv_data1/oa_pdf/df/47/kjim-2016-224.PMC5214734.pdf
"Copyright © 2017 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1226-3303 eISSN 2005-6648 http://www.kjim.orgIMAGE OF INTERESTKorean J Intern Med 2017;32:197-198   https://doi.org/10.3904/kjim.2016.241 A 42-year-old woman presented with  recurrent acid regurgitation and heart - burn.",Non-OADS,/arxiv_data1/oa_pdf/64/6e/kjim-2016-241.PMC5214735.pdf
198 www.kjim.org https://doi.org/10.3904/kjim.2016.241The Korean Journal of Internal Medicine Vol.,Non-OADS,/arxiv_data1/oa_pdf/64/6e/kjim-2016-241.PMC5214735.pdf
"Copyright © 2017 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1226-3303 eISSN 2005-6648 http://www.kjim.orgIMAGE OF INTERESTKorean J Intern Med 2017;32:195-196 https://doi.org/10.3904/kjim.2016.258 A 43-year-old woman was referred to  our emergency department with acute  onset of dyspnea, palpitation and chest  discomfort.",Non-OADS,/arxiv_data1/oa_pdf/24/4e/kjim-2016-258.PMC5214736.pdf
"1, January 2017 https://doi.org/10.3904/kjim.2016.258rately displayed on MDCT along with a large PDA.",OADS,/arxiv_data1/oa_pdf/24/4e/kjim-2016-258.PMC5214736.pdf
Conservative treatment of PA dissection https://doi.org/10.3904/kjim.2016.258 Supplemen tary Video 1.,Non-OADS,/arxiv_data1/oa_pdf/24/4e/kjim-2016-258.PMC5214736.pdf
"Copyright © 2017 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 1226-3303 eISSN 2005-6648 http://www.kjim.org EDITORIAL  The role of early molecular predictor in trans - plant-eligible chronic myelogenous leukemia Sung-Hyun Kim  Division of Hematology and  Oncology, Department of Internal  Medicine, Dong-A University  College of Medicine, Busan, Korea Received : December 19, 2016 Accepted : December 23, 2016 Correspondence to Sung-Hyun Kim, M.D.",Non-OADS,/arxiv_data1/oa_pdf/1c/44/kjim-2016-419.PMC5214737.pdf
"In 2005, experts suggested har - monizing the different methodologies See Article on Page 125-136Korean J Intern Med 2017;32:67-68 https://doi.org/10.3904/kjim.2016.419",Non-OADS,/arxiv_data1/oa_pdf/1c/44/kjim-2016-419.PMC5214737.pdf
"1, January 2017 https://doi.org/10.3904/kjim.2016.419for measuring BCR-ABL1 transcripts and using a con - version factor so that individual laboratories can express  BCR-ABL1 transcript levels on an internationally agreed  scale, that is, an International Scale (IS) [6].",Non-OADS,/arxiv_data1/oa_pdf/1c/44/kjim-2016-419.PMC5214737.pdf
"RETRACTIONCopyright © 2017 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/ by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/89/a0/kjim-2016-425.PMC5214738.pdf
pISSN 1226-3303 eISSN 2005-6648 http://www.kjim.orgKorean J Intern Med 2017;32:211 https://doi.org/10.3904/kjim.2016.425 Korean J Intern Med 2015;30:554-555 http://dx.doi.org/10.3904/kjim.2015.30.4.554 This article has been retracted following a review by the Editorial Board.,Non-OADS,/arxiv_data1/oa_pdf/89/a0/kjim-2016-425.PMC5214738.pdf
"12, e1250991 (13 pages)http://dx.doi.org/10.1080/2162402X.2016.1250991",Non-OADS,/arxiv_data1/oa_pdf/f1/90/koni-05-12-1250991.PMC5214764.pdf
Biochem Biophys Res Com-mun 1993; 191:601-9; PMID:8461016; http://dx.doi.org/10.1006/ bbrc.1993.1260 3.,OADS,/arxiv_data1/oa_pdf/f1/90/koni-05-12-1250991.PMC5214764.pdf
Blood 2004; 104:478-86; PMID:15044252; http://dx.doi.org/10.1182/blood-2003-12-4395 5.,Non-OADS,/arxiv_data1/oa_pdf/f1/90/koni-05-12-1250991.PMC5214764.pdf
Autoimmun Rev 2004; 3:215-20; PMID:15110234;http://dx.doi.org/10.1016/j.autrev.2003.09.001 6.,OADS,/arxiv_data1/oa_pdf/f1/90/koni-05-12-1250991.PMC5214764.pdf
J Leukoc Biol 2006; 79:4-6; PMID:16380600;http://dx.doi.org/10.1189/jlb.0805455 7.,Non-OADS,/arxiv_data1/oa_pdf/f1/90/koni-05-12-1250991.PMC5214764.pdf
J Immunol 2002; 168:5005-13; PMID:11994452; http://dx.doi.org/ 10.4049/jimmunol.168.10.50059.,Non-OADS,/arxiv_data1/oa_pdf/f1/90/koni-05-12-1250991.PMC5214764.pdf
Nature 1988; 335:642- 4; PMID:3262830; http://dx.doi.org/10.1038/335642a0 10.,Non-OADS,/arxiv_data1/oa_pdf/f1/90/koni-05-12-1250991.PMC5214764.pdf
Immunology 2001; 103:270-80; PMID:11454056; http://dx.doi.org/10.1046/j.1365-2567.2001.01243.x 11.,Non-OADS,/arxiv_data1/oa_pdf/f1/90/koni-05-12-1250991.PMC5214764.pdf
PLoS Negl Trop Dis 2011; 5:e1294; PMID:21886854; http://dx.doi.org/10.1371/ journal.pntd.0001294 12.,Non-OADS,/arxiv_data1/oa_pdf/f1/90/koni-05-12-1250991.PMC5214764.pdf
Distinct CD4 CCD8Cdouble-posi- tive T cells in the blood and liver of patients during chronic hepatitisB and C. PLoS One 2011; 6:e20145; PMID:21647449; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f1/90/koni-05-12-1250991.PMC5214764.pdf
J Infect Dis 1998; 178:1158-62; PMID:9806050; http://dx.doi.org/10.1086/515674 14.,OADS,/arxiv_data1/oa_pdf/f1/90/koni-05-12-1250991.PMC5214764.pdf
Blood 2009; 114:3841-53; PMID:19700667; http://dx.doi.org/10.1182/blood-2009- 02-202481 15.,Non-OADS,/arxiv_data1/oa_pdf/f1/90/koni-05-12-1250991.PMC5214764.pdf
Arthritis Rheum 2007; 56:3459-67; PMID:17907151;http://dx.doi.org/10.1002/art.22927 1 6 .,Non-OADS,/arxiv_data1/oa_pdf/f1/90/koni-05-12-1250991.PMC5214764.pdf
PLoS One 2014; 9:e93293; PMID:24667579; http://dx.doi.org/10.1371/journal.,Non-OADS,/arxiv_data1/oa_pdf/f1/90/koni-05-12-1250991.PMC5214764.pdf
Clin Exp Immunol 2014; 177:404-11; PMID:24730443; http://dx.doi.org/ 10.1111/cei.12345 18.,Non-OADS,/arxiv_data1/oa_pdf/f1/90/koni-05-12-1250991.PMC5214764.pdf
Eur J Gastroenterol Hepatol 2004; 16:961-8;PMID:15371918; http://dx.doi.org/10.1097/00042737-200410000- 00003 19.,Non-OADS,/arxiv_data1/oa_pdf/f1/90/koni-05-12-1250991.PMC5214764.pdf
PLoS Biol 2014; 12:e1001833; PMID:24714093; http://dx.doi.org/10.1371/journal.pbio.1001833 20.,Non-OADS,/arxiv_data1/oa_pdf/f1/90/koni-05-12-1250991.PMC5214764.pdf
Int J Cancer 2009; 125:374-80; PMID:19358272; http://dx.doi.org/10.1002/ijc.24366ONCOIMMUNOLOGY e1250991-11,Non-OADS,/arxiv_data1/oa_pdf/f1/90/koni-05-12-1250991.PMC5214764.pdf
PLoSOne 2010; 5:e8437; PMID:20052413; http://dx.doi.org/10.1371/ journal.pone.0008437 24.,Non-OADS,/arxiv_data1/oa_pdf/f1/90/koni-05-12-1250991.PMC5214764.pdf
Am J Clin Pathol 2006; 126:805-14; PMID:17050078; http://dx.doi.org/10.1309/Y8KD32QGRYFN1XQX 25.,OADS,/arxiv_data1/oa_pdf/f1/90/koni-05-12-1250991.PMC5214764.pdf
Int JCancer 2011; 128:2923-32; PMID:20824715; http://dx.doi.org/ 10.1002/ijc.25640 26.,OADS,/arxiv_data1/oa_pdf/f1/90/koni-05-12-1250991.PMC5214764.pdf
J Leukoc Biol 2015;97:31-8; PMID:25360000; http://dx.doi.org/10.1189/jlb.1RU0814-382 27.,Non-OADS,/arxiv_data1/oa_pdf/f1/90/koni-05-12-1250991.PMC5214764.pdf
"Eur J Immunol 2016; 46:1770-82; PMID:27094152; http://dx.doi.org/10.1002/eji.201546061 28. van Kooten C, Banchereau J. CD40-CD40 ligand.",Non-OADS,/arxiv_data1/oa_pdf/f1/90/koni-05-12-1250991.PMC5214764.pdf
Blood 2013; 122:405-12; PMID:23719298; http://dx.doi.org/10.1182/blood- 2013-02-483586 30.,Non-OADS,/arxiv_data1/oa_pdf/f1/90/koni-05-12-1250991.PMC5214764.pdf
Eur J Immunol 1992; 22:2573-8; PMID:1382991; http://dx.doi.org/10.1002/eji.1830221016 32.,Non-OADS,/arxiv_data1/oa_pdf/f1/90/koni-05-12-1250991.PMC5214764.pdf
J Exp Med 1998; 188:1679-89; PMID:9802980; http://dx.doi.org/10.1084/ jem.188.9.1679 33.,Non-OADS,/arxiv_data1/oa_pdf/f1/90/koni-05-12-1250991.PMC5214764.pdf
Nat Rev Immunol 2007; 7:479- 85; PMID:17479128; http://dx.doi.org/10.1038/nri2091 34.,Non-OADS,/arxiv_data1/oa_pdf/f1/90/koni-05-12-1250991.PMC5214764.pdf
Semin Immunol 2013; 25:273-81; PMID:24246226; http://dx.doi.org/10.1016/j.smim.2013.10.022 35.,Non-OADS,/arxiv_data1/oa_pdf/f1/90/koni-05-12-1250991.PMC5214764.pdf
Science 2002; 297:2060-3; PMID:12242444; http://dx.doi.org/10.1126/science.1072615 36.,OADS,/arxiv_data1/oa_pdf/f1/90/koni-05-12-1250991.PMC5214764.pdf
Cell Mol Life Sci 2001; 58:4-43; PMID:11229815; http://dx.doi.org/ 10.1007/PL00000776 37.,OADS,/arxiv_data1/oa_pdf/f1/90/koni-05-12-1250991.PMC5214764.pdf
Eur J Immunol 2006; 36:810-6; PMID:16541472; http://dx.doi.org/10.1002/eji.200535744 38.,Non-OADS,/arxiv_data1/oa_pdf/f1/90/koni-05-12-1250991.PMC5214764.pdf
J Immunol 2012; 189:161-73; PMID:22634617; http://dx.doi.org/10.4049/jimmunol.1200301 39.,Non-OADS,/arxiv_data1/oa_pdf/f1/90/koni-05-12-1250991.PMC5214764.pdf
J Exp Med 1982; 155:914-23; PMID:6977612; http://dx.doi.org/10.1084/jem.155.3.914 41.,Non-OADS,/arxiv_data1/oa_pdf/f1/90/koni-05-12-1250991.PMC5214764.pdf
Science 1995; 268:720-2; PMID:7537388; http://dx.doi.org/10.1126/science.7537388 43.,OADS,/arxiv_data1/oa_pdf/f1/90/koni-05-12-1250991.PMC5214764.pdf
Eur J Immunol 1998; 28:508-15; PMID:9521060; http://dx.doi.org/10.1002/(SICI)1521-4141(199802)28:02%3c508::AID-IMMU508%3e3.0.CO;2-I 44.,Non-OADS,/arxiv_data1/oa_pdf/f1/90/koni-05-12-1250991.PMC5214764.pdf
Int Immunol 1993; 5:657-63; PMID:7688562; http://dx.doi.org/10.1093/intimm/5.6.657 45.,Non-OADS,/arxiv_data1/oa_pdf/f1/90/koni-05-12-1250991.PMC5214764.pdf
J Immunol 2006; 177:5236-47; PMID:17015709; http://dx.doi.org/10.4049/jimmunol.177.8.5236 46.,Non-OADS,/arxiv_data1/oa_pdf/f1/90/koni-05-12-1250991.PMC5214764.pdf
J Immu- nol 2007; 179:5886-96; PMID:17947662; http://dx.doi.org/10.4049/ jimmunol.179.9.5886 47.,Non-OADS,/arxiv_data1/oa_pdf/f1/90/koni-05-12-1250991.PMC5214764.pdf
Oncotarget 2016; PMID:27331871;http://dx.doi.org/10.18632/oncotarget.10094 49.,OADS,/arxiv_data1/oa_pdf/f1/90/koni-05-12-1250991.PMC5214764.pdf
J Clin Investig 2013;123:1457-74; PMID:23454746; http://dx.doi.org/10.1172/JCI65579 50.,Non-OADS,/arxiv_data1/oa_pdf/f1/90/koni-05-12-1250991.PMC5214764.pdf
Oncoimmunology 2015; 4:e1032492; PMID:26451312; http://dx.doi.org/10.1080/2162402X.2015.1032492 51.,Non-OADS,/arxiv_data1/oa_pdf/f1/90/koni-05-12-1250991.PMC5214764.pdf
J Immunother Cancer 2016; 4:40; PMID:27437104; http://dx.doi.org/10.1186/s40425-016-0145-x 54.,Non-OADS,/arxiv_data1/oa_pdf/f1/90/koni-05-12-1250991.PMC5214764.pdf
J Autoimmun 2011; 36:228- 38; PMID:21316922; http://dx.doi.org/10.1016/j.jaut.2011.01.005 55.,OADS,/arxiv_data1/oa_pdf/f1/90/koni-05-12-1250991.PMC5214764.pdf
Immunity 2014; 41:529-42; PMID:25367570; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f1/90/koni-05-12-1250991.PMC5214764.pdf
J Immunol 2006; 177:3625-34; PMID:16951322; http://dx.doi.org/10.4049/jimmunol.177.6.3625e1250991-12 T. PARROT ET AL.,OADS,/arxiv_data1/oa_pdf/f1/90/koni-05-12-1250991.PMC5214764.pdf
Biol Res 2012; 45:33-43; PMID:22688982; http://dx.doi.org/10.4067/S0716-97602012000100005 58.,Non-OADS,/arxiv_data1/oa_pdf/f1/90/koni-05-12-1250991.PMC5214764.pdf
Eur J Immunol 2008; 38:2251-62; PMID:18600823; http://dx.doi.org/ 10.1002/eji.200838199 59.,Non-OADS,/arxiv_data1/oa_pdf/f1/90/koni-05-12-1250991.PMC5214764.pdf
J Immunol 2007; 178:2844-52; PMID:17312128; http://dx.doi.org/10.4049/jimmunol.178.5.2844 60.,Non-OADS,/arxiv_data1/oa_pdf/f1/90/koni-05-12-1250991.PMC5214764.pdf
Oncoimmunology 2013; 2:e27009;PMID:24498563; http://dx.doi.org/10.4161/onci.27009 61.,Non-OADS,/arxiv_data1/oa_pdf/f1/90/koni-05-12-1250991.PMC5214764.pdf
Eur J Immunol 2013; 43:1511-7; PMID:23765345; http://dx.doi.org/10.1002/eji.201243218 62.,Non-OADS,/arxiv_data1/oa_pdf/f1/90/koni-05-12-1250991.PMC5214764.pdf
J Immunol 2010; 185:4977-82; PMID:20962266; http://dx.doi.org/10.4049/jimmunol.1001323 63.,Non-OADS,/arxiv_data1/oa_pdf/f1/90/koni-05-12-1250991.PMC5214764.pdf
J Clin Oncol 2008; 26:4410-7; PMID:18802153; http://dx.doi.org/10.1200/JCO.2007.15.0284 64.,Non-OADS,/arxiv_data1/oa_pdf/f1/90/koni-05-12-1250991.PMC5214764.pdf
PLoS One 2009; 4:e6412; PMID:19641607;http://dx.doi.org/10.1371/journal.pone.0006412 65.,Non-OADS,/arxiv_data1/oa_pdf/f1/90/koni-05-12-1250991.PMC5214764.pdf
Gynecol Oncol 2008; 108:106-11; PMID:17945335; http://dx.doi.org/ 10.1016/j.ygyno.2007.08.089 66.,Non-OADS,/arxiv_data1/oa_pdf/f1/90/koni-05-12-1250991.PMC5214764.pdf
J Immunol 2012; 188:2102-10; PMID:22291187; http://dx.doi.org/10.4049/jimmunol.,Non-OADS,/arxiv_data1/oa_pdf/f1/90/koni-05-12-1250991.PMC5214764.pdf
Cancer Immunol Immunother 2008; 57:185-95; PMID:17646986;http://dx.doi.org/10.1007/s00262-007-0361-9ONCOIMMUNOLOGY e1250991-13,Non-OADS,/arxiv_data1/oa_pdf/f1/90/koni-05-12-1250991.PMC5214764.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/87/52/ijn-12-197.PMC5214799.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of Nanomedicine 2017:12 197–206International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  197OrIg INal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/IJN.S12124 9 Hyaluronan-modified superparamagnetic iron  oxide nanoparticles for bimodal breast cancer  imaging and photothermal therapy  Rui-Meng Yang1,* Chao-Ping Fu2,* Jin-Zhi Fang1 Xiang-Dong Xu1 Xin-hua Wei1 Wen-Jie Tang1 Xin-Qing Jiang1 Li-Ming Zhang2 1Department of Radiology, Guangzhou  First People’s Hospital, Guangzhou  Medical University, 2School of  Materials Science and Engineering,   School of Chemistry, Sun Yat-sen  University, Guangzhou, China *These authors contributed equally  to this workAbstract:  Theranostic nanoparticles with both imaging and therapeutic abilities are highly  promising in successful diagnosis and treatment of the most devastating cancers.",Non-OADS,/arxiv_data1/oa_pdf/87/52/ijn-12-197.PMC5214799.pdf
"Correspondence: Xin-Qing Jiang Department of Radiology, Guangzhou  First People’s Hospital, Guangzhou  Medical University, #1 Panfu Road,  Guangzhou 510180, China Tel +86 20 8104 4902 email jiangxinqing888@163.co m  Li-Ming Zhang School of Materials Science and  Engineering, School of Chemistry, Sun  Yat-sen University, #135 Xingang West  Road, Guangzhou 510275, China Tel +86 20 8411 2454 email ceszhlm@mail.sysu.edu.c n Journal name: International Journal of Nanomedicine Article Designation: Original Research Y ear: 2017 Volume: 12 Running head verso: Y ang et al Running head recto: HA-SPIONs for effective cancer diagnosis and treatment DOI: http://dx.doi.org/10.2147/IJN.S121249",Non-OADS,/arxiv_data1/oa_pdf/87/52/ijn-12-197.PMC5214799.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology   in diagnostics, therapeutics, and drug delivery systems throughout   the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/87/52/ijn-12-197.PMC5214799.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/87/52/ijn-12-197.PMC5214799.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License ( http://creativecommons.org/licenses/by-nc/3.0/ ), which permits unre- stricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/6a/25/koni-05-12-1249560.PMC5214806.pdf
"12, e1249560 (13 pages)http://dx.doi.org/10.1080/2162402X.2016.1249560",Non-OADS,/arxiv_data1/oa_pdf/6a/25/koni-05-12-1249560.PMC5214806.pdf
ORCID James M. Billingsley http://orcid.org/0000-0003-0928-1454References 1.,Non-OADS,/arxiv_data1/oa_pdf/6a/25/koni-05-12-1249560.PMC5214806.pdf
Nat Rev Cancer 2014; 14:535-46; PMID:25056707; http://dx.doi.org/10.1038/nrc3775 2.,Non-OADS,/arxiv_data1/oa_pdf/6a/25/koni-05-12-1249560.PMC5214806.pdf
J Clin Oncol 2007; 25:5570-7; PMID:18065729; http://dx.do i.org/10.1200/JCO.2007.12.5435 3.,Non-OADS,/arxiv_data1/oa_pdf/6a/25/koni-05-12-1249560.PMC5214806.pdf
Ann Oncol 2012; 23 Suppl 8:viii28-34; PMID:22918925; http://dx.doi.org/ 10.1093/annonc/mds260 4.,Non-OADS,/arxiv_data1/oa_pdf/6a/25/koni-05-12-1249560.PMC5214806.pdf
Nature 2011; 480:480-9; PMID:22193102; http://dx.doi.org/ 10.1038/nature10673 5.,Non-OADS,/arxiv_data1/oa_pdf/6a/25/koni-05-12-1249560.PMC5214806.pdf
N Engl J Med 2015; 372:2018- 28; PMID:25891174; http://dx.doi.org/10.1056/NEJMoa1501824 7.,Non-OADS,/arxiv_data1/oa_pdf/6a/25/koni-05-12-1249560.PMC5214806.pdf
J Clin Invest 2015; 125:3384-91; PMID:26325035; http://dx.doi.org/10.1172/JCI80011 8.,Non-OADS,/arxiv_data1/oa_pdf/6a/25/koni-05-12-1249560.PMC5214806.pdf
Immunity 2014; 41:682-4; PMID:25517610;http://dx.doi.org/10.1016/j.immuni.2014.11.005 9.,OADS,/arxiv_data1/oa_pdf/6a/25/koni-05-12-1249560.PMC5214806.pdf
CombinedNivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.N Engl J Med 2015; 373:23-34; PMID:26027431; http://dx.doi.org/ 10.1056/NEJMoa1504030 10.,Non-OADS,/arxiv_data1/oa_pdf/6a/25/koni-05-12-1249560.PMC5214806.pdf
Annu Rev Immunol 2006; 24:175- 208; PMID:16551247; http://dx.doi.org/10.1146/annurev.immunol.,Non-OADS,/arxiv_data1/oa_pdf/6a/25/koni-05-12-1249560.PMC5214806.pdf
J Clin Invest 2015; 125:3401-12; PMID:26214521; http://dx.doi.org/10.1172/JCI80009 13.,Non-OADS,/arxiv_data1/oa_pdf/6a/25/koni-05-12-1249560.PMC5214806.pdf
Nat Rev Clin Oncol 2014; 11:509-24; PMID:25001465; http://dx.doi.org/10.1038/ nrclinonc.2014.111 14.,Non-OADS,/arxiv_data1/oa_pdf/6a/25/koni-05-12-1249560.PMC5214806.pdf
Nat Rev Drug Discov 2014; 13:759-80; PMID:25233993; http://dx.doi.org/10.1038/nrd4278 15.,Non-OADS,/arxiv_data1/oa_pdf/6a/25/koni-05-12-1249560.PMC5214806.pdf
Hum Vaccin Immunother 2013; 9:2263-76; PMID:23921513; http://dx.doi.org/10.4161/hv.25181 16.,Non-OADS,/arxiv_data1/oa_pdf/6a/25/koni-05-12-1249560.PMC5214806.pdf
Science 2004;303:1526-9; PMID:14976262; http://dx.doi.org/10.1126/science.,OADS,/arxiv_data1/oa_pdf/6a/25/koni-05-12-1249560.PMC5214806.pdf
Eur J Immunol 2004; 34:537-47; PMID: 14768059; http://dx.doi.org/10.1002/eji.200324198 18.,Non-OADS,/arxiv_data1/oa_pdf/6a/25/koni-05-12-1249560.PMC5214806.pdf
J Gene Med 2012; 14:428-39; PMID:22262664; http://dx.doi.org/10.1002/jgm.2605 19.,OADS,/arxiv_data1/oa_pdf/6a/25/koni-05-12-1249560.PMC5214806.pdf
J Immunother 2011; 34:1-15; PMID:21150709; http://dx.doi.org/10.1097/CJI.0b013e3181f7dbe8 20.,Non-OADS,/arxiv_data1/oa_pdf/6a/25/koni-05-12-1249560.PMC5214806.pdf
Gene Ther 2007; 14:1175-80; PMID:17476302; http://dx.doi.org/10.1038/sj.gt.3302964 21.,OADS,/arxiv_data1/oa_pdf/6a/25/koni-05-12-1249560.PMC5214806.pdf
Eur J Immu-nol 2006; 36:2807-16; PMID:17013976; http://dx.doi.org/10.1002/ eji.200635910 22.,Non-OADS,/arxiv_data1/oa_pdf/6a/25/koni-05-12-1249560.PMC5214806.pdf
Cell Mol Life Sci 2004; 61:2418-24; PMID:15378210; http://dx.doi.org/10.1007/s00018-004-4255-0 23.,OADS,/arxiv_data1/oa_pdf/6a/25/koni-05-12-1249560.PMC5214806.pdf
Expert Opin Biol Ther 2004; 4:1285-94; PMID:15268662; http://dx.doi.org/10.1517/14712598.4.8.1285 24.,Non-OADS,/arxiv_data1/oa_pdf/6a/25/koni-05-12-1249560.PMC5214806.pdf
Eur J Immunol 2000; 30:1-7; PMID:10602021; http://dx.doi.org/10.1002/1521-4141(200001)30:1%3c1::AID-IMMU1%3e3.0.CO;2- 25.,Non-OADS,/arxiv_data1/oa_pdf/6a/25/koni-05-12-1249560.PMC5214806.pdf
Int J Cancer 2015; 137(2):372-84; PMID:25530186; http://dx.doi.org/10.1002/ijc.29402 26.,Non-OADS,/arxiv_data1/oa_pdf/6a/25/koni-05-12-1249560.PMC5214806.pdf
J Immunother Cancer 2015; 3:26; PMID:26082837; http://dx.doi.org/10.1186/s40425-015-0068-y 27.,Non-OADS,/arxiv_data1/oa_pdf/6a/25/koni-05-12-1249560.PMC5214806.pdf
BMC Biol 2010; 8:84; PMID:20619006; http://dx.doi.org/10.1186/1741-7007-8-84 28.,Non-OADS,/arxiv_data1/oa_pdf/6a/25/koni-05-12-1249560.PMC5214806.pdf
Nat Immunol 2009; 10:116-25; PMID:19029902; http://dx.doi.org/10.1038/ni.1688 29.,Non-OADS,/arxiv_data1/oa_pdf/6a/25/koni-05-12-1249560.PMC5214806.pdf
Mol Syst Biol 2013; 9:659; PMID:23591775; http://dx.doi.org/10.1038/msb.2013.15 30.,Non-OADS,/arxiv_data1/oa_pdf/6a/25/koni-05-12-1249560.PMC5214806.pdf
J Exp Med 2008; 205:3119-31; PMID:19047440; http://dx.doi.org/10.1084/jem.20082292 31.,Non-OADS,/arxiv_data1/oa_pdf/6a/25/koni-05-12-1249560.PMC5214806.pdf
Nat Immunol 2011; 12:786-95; PMID:21743478; http://dx.doi.org/10.1038/ni.2067 32.,Non-OADS,/arxiv_data1/oa_pdf/6a/25/koni-05-12-1249560.PMC5214806.pdf
Nat Immunol 2014; 15:195-204; PMID: 24336226; http://dx.doi.org/10.1038/ni.2789 33.,Non-OADS,/arxiv_data1/oa_pdf/6a/25/koni-05-12-1249560.PMC5214806.pdf
Nat Rev Immunol 2014; 14:271-80; PMID:24662387; http://dx.doi.org/10.1038/nri3642 34.,Non-OADS,/arxiv_data1/oa_pdf/6a/25/koni-05-12-1249560.PMC5214806.pdf
Lung Cancer 2013; 81:468-74;PMID:23850196; http://dx.doi.org/10.1016/j.lungcan.2013.06.00535.,Non-OADS,/arxiv_data1/oa_pdf/6a/25/koni-05-12-1249560.PMC5214806.pdf
J Immunol Res 2014; 2014:659294; PMID:25436215; http://dx.doi.org/10.1155/2014/659294 36.,Non-OADS,/arxiv_data1/oa_pdf/6a/25/koni-05-12-1249560.PMC5214806.pdf
Cancer Res 2009; 69:9202-10; PMID: 19951989; http://dx.doi.org/10.1158/0008-5472.CAN-09-1378 38.,Non-OADS,/arxiv_data1/oa_pdf/6a/25/koni-05-12-1249560.PMC5214806.pdf
PLoS One 2012; 7:e34392; PMID:22479623; http://dx.doi.org/10.1371/journal.pone.0034392 39.,Non-OADS,/arxiv_data1/oa_pdf/6a/25/koni-05-12-1249560.PMC5214806.pdf
Oncogene 2013; 32:903-9; PMID:22430205; http://dx.doi.org/10.1038/onc.2012.99 40.,Non-OADS,/arxiv_data1/oa_pdf/6a/25/koni-05-12-1249560.PMC5214806.pdf
Nature 1999; 401:708-12; PMID:10537110; http://dx.doi.org/10.1038/44385 41.,Non-OADS,/arxiv_data1/oa_pdf/6a/25/koni-05-12-1249560.PMC5214806.pdf
J Exp Med 1997; 186:1407-18; PMID:9348298; http://dx.doi.org/10.1084/jem.186.9.1407 42.,Non-OADS,/arxiv_data1/oa_pdf/6a/25/koni-05-12-1249560.PMC5214806.pdf
Ann Surg Oncol 2009; 16:614-22; PMID:19130139; http://dx.doi.org/ 10.1245/s10434-008-0267-6 44.,Non-OADS,/arxiv_data1/oa_pdf/6a/25/koni-05-12-1249560.PMC5214806.pdf
Br J Cancer 2011; 104:1288-95; PMID:21448173; http://dx.doi.org/10.1038/bjc.2011.100 45.,Non-OADS,/arxiv_data1/oa_pdf/6a/25/koni-05-12-1249560.PMC5214806.pdf
PLoS One 2013; 8:e83069;PMID:24386144; http://dx.doi.org/10.1371/journal.pone.0083069 46.,Non-OADS,/arxiv_data1/oa_pdf/6a/25/koni-05-12-1249560.PMC5214806.pdf
Br J Cancer 2013; 109:416-21; PMID:23799847; http://dx.doi.org/10.1038/bjc.2013.332 47.,Non-OADS,/arxiv_data1/oa_pdf/6a/25/koni-05-12-1249560.PMC5214806.pdf
Immunity 2010; 33:516-29; PMID:21029962; http://dx.doi.org/10.1016/j.immuni.,OADS,/arxiv_data1/oa_pdf/6a/25/koni-05-12-1249560.PMC5214806.pdf
Nat Rev Genet 2001; 2:418-27; PMID:11389458; http://dx.doi.org/10.1038/35076576 49.,Non-OADS,/arxiv_data1/oa_pdf/6a/25/koni-05-12-1249560.PMC5214806.pdf
Nat Rev Genet 2006;7:55-65; PMID:16369572; http://dx.doi.org/10.1038/nrg1749 50.,Non-OADS,/arxiv_data1/oa_pdf/6a/25/koni-05-12-1249560.PMC5214806.pdf
PLoS Comput Biol 2012; 8:e1002375; PMID:22383865; http://dx.doi.org/10.1371/journal.pcbi.1002375e1249560-12 H. S. HONG ET AL.,OADS,/arxiv_data1/oa_pdf/6a/25/koni-05-12-1249560.PMC5214806.pdf
Science 2004; 303:799-805; PMID:14764868; http://dx.doi.org/10.1126/science.1094068 52.,OADS,/arxiv_data1/oa_pdf/6a/25/koni-05-12-1249560.PMC5214806.pdf
Nat Rev Cancer 2013; 13:739-52; PMID:24060865; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/6a/25/koni-05-12-1249560.PMC5214806.pdf
"Annu Rev Med 2015; 66:97-110; PMID:25341012; http://dx.doi.org/10.1146/annurev-med-051013-052304 54. de Goeje PL, Bezemer K, Heuvers ME, Dingemans AC, Groen HJ, Smit EF, Hoogsteden HC, Hendriks RW, Aerts JG, Hegmans JP.",OADS,/arxiv_data1/oa_pdf/6a/25/koni-05-12-1249560.PMC5214806.pdf
Oncoimmunology 2015; 4:e1014242; PMID:26140237; http://dx.doi.org/10.1080/2162402X.2015.1014242 55.,Non-OADS,/arxiv_data1/oa_pdf/6a/25/koni-05-12-1249560.PMC5214806.pdf
Cancer Immunol Immunother 2009; 58:49-59; PMID:18446337; http://dx.doi.org/10.1007/s00262-008-0523-4 56.,Non-OADS,/arxiv_data1/oa_pdf/6a/25/koni-05-12-1249560.PMC5214806.pdf
Cell 2011; 144:646-74; PMID:21376230; http://dx.doi.org/10.1016/j.cell.2011.02.013 57.,OADS,/arxiv_data1/oa_pdf/6a/25/koni-05-12-1249560.PMC5214806.pdf
BMC Cancer 2015; 15:386; PMID: 25956656; http://dx.doi.org/10.1186/s12885-015-1403-x 59.,Non-OADS,/arxiv_data1/oa_pdf/6a/25/koni-05-12-1249560.PMC5214806.pdf
PLoS One2014; 9:e106914; PMID:25238252; http://dx.doi.org/10.1371/journal.pone.0106914 60.,Non-OADS,/arxiv_data1/oa_pdf/6a/25/koni-05-12-1249560.PMC5214806.pdf
J Immunol 2007; 178:4112-9; PMID:17371966; http://dx.doi.org/10.4049/jimmunol.178.7.4112 61.,Non-OADS,/arxiv_data1/oa_pdf/6a/25/koni-05-12-1249560.PMC5214806.pdf
Immun Ageing 2008; 5:6; PMID:18657274; http://dx.doi.org/10.1186/1742-4933-5-6 62.,Non-OADS,/arxiv_data1/oa_pdf/6a/25/koni-05-12-1249560.PMC5214806.pdf
Clin Cancer Res 2011; 17:5867-77; PMID:21807633; http://dx.doi.org/10.1158/1078-0432.CCR-11-0737 63.,Non-OADS,/arxiv_data1/oa_pdf/6a/25/koni-05-12-1249560.PMC5214806.pdf
Oncoimmunology 2012; 1:1414-6; PMID:23243612; http://dx.doi.org/10.4161/onci.21096 64.,Non-OADS,/arxiv_data1/oa_pdf/6a/25/koni-05-12-1249560.PMC5214806.pdf
Nat Immunol 2016; 17:204- 13; PMID:26726811; http://dx.doi.org/10.1038/ni.3328 65.,Non-OADS,/arxiv_data1/oa_pdf/6a/25/koni-05-12-1249560.PMC5214806.pdf
Immunity2015; 43:1186-98; PMID:26682988; http://dx.doi.org/10.1016/j.immuni.2015.11.012 66.,OADS,/arxiv_data1/oa_pdf/6a/25/koni-05-12-1249560.PMC5214806.pdf
J Natl Cancer Inst2000; 92:205-16; PMID:10655437; http://dx.doi.org/10.1093/jnci/ 92.3.205 67.,Non-OADS,/arxiv_data1/oa_pdf/6a/25/koni-05-12-1249560.PMC5214806.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered , transformed, or built upon in any way.ONCOIMMUNOLOGY 2016, VOL.",Non-OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
"12, e1251539 (13 pages)http://dx.doi.org/10.1080/2162402X.2016.1251539",Non-OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
Cancer Discov 2013; 3:388-98; PMID:23550147;http://dx.doi.org/10.1158/2159-8290.CD-12-0548 2.,Non-OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
Curr Opin Pharmacol 2015; 24:113- 8; PMID:26342910; http://dx.doi.org/10.1016/j.coph.2015.08.006 3.,OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
Curr Opin Immunol 2012; 24:633-9;PMID:22818942; http://dx.doi.org/10.1016/j.coi.2012.06.004 4.,OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
J Immunotoxicol 2008; 5:361-7; PMID:19404870; http://dx.doi.org/10.1080/15476910802482870 5.,Non-OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
Immunotherapy 2014; 6:675-8; PMID:25186600; http://dx.doi.org/ 10.2217/imt.14.44 6.,Non-OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
J Clin Invest 2011; 121:1822- 6; PMID:21540550; http://dx.doi.org/10.1172/JCI46110 7.,Non-OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
Mol Ther 2010; 18:843-51; PMID:20179677;http://dx.doi.org/10.1038/mt.2010.24 8.,OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
J Hematol Oncol 2013; 6:47; PMID:23829929; http://dx.doi.org/10.1186/1756-8722-6-47 9.,Non-OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
Immuno-therapy 2012; 4:899-902; PMID:23046233; http://dx.doi.org/10.2217/imt.12.91 10.,Non-OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
Cancer Immunol Res 2015; 3:356-67; PMID:25600436; http://dx.doi.org/10.1158/2326-6066.CIR-14-0186 11.,Non-OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
Hum Gene Ther 2013; 24:824-39; PMID:23978226;http://dx.doi.org/10.1089/hum.2012.202 1 2 .,OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
J Immunother 2013; 36:112-23; PMID:23377665; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
Mol Ther 2011; 19:2133-43; PMID:21772253; http://dx.doi.org/10.1038/mt.2011.131 14.,Non-OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
Gene Ther 2015; 22:209-15; PMID:25427612; http://dx.doi.org/10.1038/gt.2014.104 15.,OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
Sci Transl Med 2013; 5:177ra38; PMID:23515080; http://dx.doi.org/10.1126/scitranslmed.3005930 16.,OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
Sci Transl Med 2014; 6:224ra25;PMID:24553386; http://dx.doi.org/10.1126/scitranslmed.3008226 17.,Non-OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
N Engl J Med 2013; 368:1509-18; PMID:23527958; http://dx.doi.org/10.1056/NEJMoa1215134 18.,OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
J Clin Oncol 2015; 33:540-9; PMID:25154820; http://dx.doi.org/10.1200/JCO.2014.56.2025 1 9 .,Non-OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
J Clin Oncol 2006; 24: e20-2; PMID:16648493; http://dx.doi.org/10.1200/JCO.2006.05.9964 2 0 .,Non-OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
Biochem Soc Trans 2016; 44:951-9; PMID:27284065; http://dx.doi.org/10.1042/BST20160037 21.,OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
Mol Ther 2013; 21:904-12; PMID:23423337; http://dx.doi.org/10.1038/mt.2013.17 22.,Non-OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
Int J Hematol 2016; 104:6-17;PMID:27262700; http://dx.doi.org/10.1007/s12185-016-2039-6 23.,Non-OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
Med Oncol 2001; 18:209-19; PMID:11917945; http://dx.doi.org/10.1385/ MO:18:3:209 24.,Non-OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
Blood 2014; 124:188-95; PMID:24876563; http://dx.doi.org/10.1182/blood-2014-05-552729 25.,Non-OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
Sci Transl Med 2011; 3:95ra73; PMID:21832238; http://dx.doi.org/10.1126/scitranslmed.3002842 26.,Non-OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
Int J Hematol 2014; 99:361-71;PMID:24311149; http://dx.doi.org/10.1007/s12185-013-1479-5 27.,Non-OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
Blood 2012; 119:2709-20; PMID:22160384; http://dx.doi.org/10.1182/blood-2011-10-384388 2 8 .,Non-OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
N Engl J Med 2014; 371:1507-17; PMID:25317870; http://dx.doi.org/10.1056/NEJMoa1407222 29.,Non-OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
Lancet 2015; 385:517-28; PMID:25319501; http://dx.doi.org/ 10.1016/S0140-6736(14)61403-3 30.,Non-OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
Mol Ther Oncolytics 2016; 3:16006; PMID:27162934; http://dx.doi.org/10.1038/mto.2016.6 31.,Non-OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
Blood 2016; 127:3321-30;PMID:27207799; http://dx.doi.org/10.1182/blood-2016-04-703751 32.,Non-OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
N Engl J Med 2011; 364:1844-54; PMID:21561350; http://dx.doi.org/10.1056/NEJMra0904569 33.,Non-OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
Curr Opin Immu- nol 2012; 24:580-4; PMID:22981681; http://dx.doi.org/10.1016/j.coi.2012.08.008 34.,OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
Cancer Immunol Res 2013; 1:43-53; PMID:24409448; http://dx.doi.org/10.1158/2326-6066.CIR- 13-0008 35.,Non-OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
Mol Ther Nucleic Acids 2013; 2:e105; PMID:23839099; http://dx.doi.org/10.1038/mtna.2013.32 36.,Non-OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
J Clin Immunol 2012; 32:1059-70; PMID:22526592;http://dx.doi.org/10.1007/s10875-012-9689-9e1251539-10 Q. ZHANG ET AL.,OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
Nat Biotechnol2013; 31:71-5; PMID:23242161; http://dx.doi.org/10.1038/nbt.2459 38.,OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
Immunotherapy 2011; 3:33-48; PMID:21174556; http://dx.doi.org/10.2217/imt.10.81 39.,Non-OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
Cancer Res 2015; 75:3596-607; PMID:26330166; http://dx.doi.org/10.1158/0008-5472.CAN-15-0159 40.,Non-OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
Cancer Res 2015; 75:3505-18;PMID:26330164; http://dx.doi.org/10.1158/0008-5472.CAN-15-0139 41.,Non-OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
Pharmaceuticals (Basel) 2015; 8:230-49; PMID:26110321; http://dx.doi.org/10.3390/ph8020230 42.,Non-OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
Sci Transl Med 2013; 5:215ra172;PMID:24337479; http://dx.doi.org/10.1126/scitranslmed.3006597 43.,Non-OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
Multifacto- rial T-cell hypofunction that is reversible can limit the ef ﬁcacy of chi- meric antigen receptor-transduced human T cells in solid tumors.Clin Cancer Res 2014; 20:4262-73; PMID:24919573; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
Front Pharmacol 2014; 5:254; PMID:25505885; http://dx.doi.org/10.3389/fphar.2014.00254 45.,Non-OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
Front Pharmacol 2014; 5:235; PMID:25389405; http://dx.doi.org/10.3389/fphar.2014.00235 46.,Non-OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
N Engl J Med 2011; 365:1673- 83; PMID:22047558; http://dx.doi.org/10.1056/NEJMoa1106152 47.,OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
Blood 2006; 107:2294-302;PMID:16282341; http://dx.doi.org/10.1182/blood-2005-08-3503 48.,Non-OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
Biol Blood Marrow Transplant 2007; 13:913-24; PMID:17640595; http://dx.doi.org/ 10.1016/j.bbmt.2007.04.005 50.,Non-OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
Blood 2005; 105:4247-54; PMID:15728125;http://dx.doi.org/10.1182/blood-2004-11-4564 51.,Non-OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
Cancer Res 2010;70:9053-61; PMID:20926399; http://dx.doi.org/10.1158/0008-5472.,Non-OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
Gene Ther 2009;16:596-604; PMID:19158846; http://dx.doi.org/10.1038/gt.2008.189 53.,OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
Sci China Life Sci 2016; 59:360-9; PMID:26968709; http://dx.doi.org/10.1007/s11427-016-5025-6 54.,Non-OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
World J Gastroenterol 2016; 22:4619-25;PMID:27217694; http://dx.doi.org/10.3748/wjg.v22.i19.4619 55.,Non-OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
Gastric Cancer 2015; 18:691-7; PMID:25224659; http://dx.doi.org/10.1007/s10120-014-0430-7 56.,Non-OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
Clin Lab Med 2013; 33:867-73; PMID:24267191; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
J Natl Cancer Inst 2015; 107:364; PMID:25424197; http://dx.doi.org/10.1093/jnci/dju364 60.,Non-OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
Cancer Res 2009; 69:4559-62; PMID:19487277; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
Br J Cancer 2013; 109:2217-27; PMID:24008668; http://dx.doi.org/10.1038/bjc.2013.536 62.,Non-OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
BMC Immunol 2015; 16:1; PMID:25636521; http://dx.doi.org/10.1186/s12865-014-0064-x 63.,Non-OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
Gene Ther 2015; 22:675-84; PMID:25830550; http://dx.doi.org/10.1038/gt.2015.29 64.,OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
J Exp Clin Cancer Res 2016; 35:16; PMID:26795388; http://dx.doi.org/10.1186/s13046-016-0291-5 66.,Non-OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
"Anami K, Oue N, Noguchi T, Sakamoto N, Sentani K, Hayashi T, Hinoi T, Okajima M, Graff JM, Yasui W. Search for transmembrane protein in gastric cancer by the Escherichia coli ampicillin secretion trap: expression of DSC2 in gastric cancer with intestinal phenotype.J Pathol 2010; 221:275-84; PMID:20527021; http://dx.doi.org/10.1002/path.2717 67.",OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
J Cancer Res Clin Oncol 2009; 135:1323-30;PMID:19330352; http://dx.doi.org/10.1007/s00432-009-0573-9 68.,Non-OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
Clin Cancer Res 2008; 14:8112-22;PMID:19088026; http://dx.doi.org/10.1158/1078-0432.CCR-07-4910 69.,Non-OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
Oncotarget 2015; 6:171-84;PMID:25426558; http://dx.doi.org/10.18632/oncotarget.2767 70.,OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
Sci China Life Sci 2016; 59:468-79; PMID:26968708; http://dx.doi.org/10.1007/s11427-016-5023-8 71.,Non-OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
Expert Rev Mol Diagn 2005; 5:701-13; PMID:16149873; http://dx.doi.org/ 10.1586/14737159.5.5.701 72.,Non-OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
Biomark Med 2012; 6:339-48; PMID:22731908; http://dx.doi.org/10.2217/ bmm.12.24 73.,Non-OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
Immunol Res 2011; 51:161- 9; PMID:22038530; http://dx.doi.org/10.1007/s12026-011-8253-7 74.,Non-OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
Arch Pathol Lab Med 2014; 138:1015-26; PMID:24437456; http://dx.doi.org/10.5858/ arpa.2013-0452-OA 76.,Non-OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
Hum Pathol 2013; 44:151-63; PMID:22939578; http://dx.doi.org/ 10.1016/j.humpath.2012.04.017 77.,OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
Mod Pathol 2008; 21:1379-86; PMID:18552820; http://dx.doi.org/10.1038/ modpathol.2008.107 78.,Non-OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
J Exp Med 2004; 200:297-306; PMID:15289501; http://dx.doi.org/10.1084/jem.20031435 79.,Non-OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
Mol Ther 2012; 20:633-43; PMID:22127019; http://dx.doi.org/10.1038/mt.2011.256 80.,OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
Cancer Immunol Res 2014;2:112-20; PMID:24579088; http://dx.doi.org/10.1158/2326-6066.,Non-OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
Mol Ther 2016; 24(9):1602-14; PMID:27401141; http://dx.doi.org/10.1038/mt.2016.146 82.,OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
Cancer Immunol Res 2013; 1:26- 31; PMID:24777247; http://dx.doi.org/10.1158/2326-6066.CIR-13-000683.,Non-OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
Engineered T cells for pancreatic cancer treatment.HPB (Oxford) 2011; 13:643-50; PMID:21843265; http://dx.doi.org/10.1111/j.1477-2574.2011.00344.x 84.,Non-OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
Hum Gene Ther 2014; 25:1003-12; PMID:24694017; http://dx.doi.org/10.1089/hum.2013.209 85.,OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
Gastroenterology 2012; 143:1095-107.e2; PMID:22750462; PMID:22750462; http://dx.doi.org/10.1053/j.,Non-OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
Gas- troenterology 2012; 143:1375-84.e1-5; http://dx.doi.org/10.1053/j.,Non-OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
Immunity2016; 44:1444-54; PMID:27332733; http://dx.doi.org/; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
Nat Med 2015; 21:524-9; PMID:25849134; http://dx.doi.org/10.1038/nm.3833 89.,OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
Curr Pharm Des 2012; 18:2472-81; PMID:22372499; http://dx.doi.org/10.2174/13816128112092472 90.,Non-OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
Oncoimmunology 2012;1:48-55; PMID:22720211; http://dx.doi.org/10.4161/onci.1.1.18344 93.,Non-OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
Livermyeloid-derived suppressor cells expand in response to liver metas-tases in mice and inhibit the anti-tumor ef ﬁcacy of anti-CEA CAR- T. Cancer Immunol Immunother 2015; 64:817-29; PMID:25850344; http://dx.doi.org/10.1007/s00262-015-1692-6 94.,Non-OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
Clin Cancer Res 2015; 21:3149-59; PMID:25850950; http://dx.doi.org/ 10.1158/1078-0432.CCR-14-1421 95.,Non-OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
Clin Cancer Res 2014; 20:6418-28; PMID:25320357; http://dx.doi.org/; http://dx.doi.org/ 10.1158/1078-0432.CCR-14-1170 96.,Non-OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
Br J Can- cer 2001; 84:1377-83; PMID:11355950; http://dx.doi.org/10.1054/bjoc.2000.1580e1251539-12 Q. ZHANG ET AL.,OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
Gastroenterology 2013; 145:456-65; PMID:23639914; http://dx.doi.org/10.1053/j.,Non-OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
Int J Hepatol 2012; 2012:859076; PMID:22655201; http://dx.doi.org/ 10.1155/2012/859076 99.,OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
Mol Ther 2014; 22:1018-28; PMID:24686242; http://dx.doi.org/10.1038/mt.2014.41 102.,OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
Mol Ther 2014; 22:623-33; PMID:24213558; http://dx.doi.org/ 10.1038/mt.2013.262 103.,OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
Cancer Gene Ther 2016; 23:142-8; PMID:27080226; http://dx.doi.org/10.1038/cgt.2016.14 104.,Non-OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
Oncol Lett 2012; 3:961-9; PMID:22783373; http://dx.doi.org/10.3892/ol.2012.628ONCOIMMUNOLOGY e1251539-13,Non-OADS,/arxiv_data1/oa_pdf/60/02/koni-05-12-1251539.PMC5214859.pdf
Available from: http://www.data.,OADS,/arxiv_data1/oa_pdf/be/aa/APJON-3-309.PMC5214862.pdf
Available from: http://www.who.int/sdhconference/ discussion_paper/en/index.html.,Non-OADS,/arxiv_data1/oa_pdf/be/aa/APJON-3-309.PMC5214862.pdf
Available from: http://www.who.int/ healthinfo/en/.,Non-OADS,/arxiv_data1/oa_pdf/be/aa/APJON-3-309.PMC5214862.pdf
Available from: http://www.inctr.org/about‑inctr/ cancer‑in‑developing‑countries/.,Non-OADS,/arxiv_data1/oa_pdf/be/aa/APJON-3-309.PMC5214862.pdf
Available from: http://www.cano‑acio.ca/about_us.,Non-OADS,/arxiv_data1/oa_pdf/e9/a5/APJON-3-316.PMC5214864.pdf
Available from: http://www.cancerview.ca/ systemperformancereport.,Non-OADS,/arxiv_data1/oa_pdf/e9/a5/APJON-3-316.PMC5214864.pdf
Available from:  http://www.cancerview.ca.,Non-OADS,/arxiv_data1/oa_pdf/e9/a5/APJON-3-316.PMC5214864.pdf
Available from: http://www.cano‑acio.ca/ practice‑standards.,Non-OADS,/arxiv_data1/oa_pdf/e9/a5/APJON-3-316.PMC5214864.pdf
Avaiable  from: https://www.cnsa.org.au/about‑us/cnsa‑history.,Non-OADS,/arxiv_data1/oa_pdf/e9/a5/APJON-3-316.PMC5214864.pdf
Avaiable from:  http://www.cancernurse.eu/.,Non-OADS,/arxiv_data1/oa_pdf/e9/a5/APJON-3-316.PMC5214864.pdf
Available from:  http://www.euro.who.int/_data/assets/pdf_file/0004/197113/ EHR2012‑Eng.pdf.,OADS,/arxiv_data1/oa_pdf/e9/a5/APJON-3-316.PMC5214864.pdf
Available from:  http://www.globocan.iarc.fr/Default.aspx.,Non-OADS,/arxiv_data1/oa_pdf/e9/a5/APJON-3-316.PMC5214864.pdf
Available from: http://www.who.int/gho/health_ financing/out_pocket_expenditure/en.,Non-OADS,/arxiv_data1/oa_pdf/e9/a5/APJON-3-316.PMC5214864.pdf
Avaiable from: http://www.c.ymcdn.com/sites/www.isncc.,Non-OADS,/arxiv_data1/oa_pdf/e9/a5/APJON-3-316.PMC5214864.pdf
Available from: https://www.iaea.org/ newscenter/news/investing‑in‑cancer‑care‑saves‑lives‑and  strengthens‑economies‑in‑developing‑world.,Non-OADS,/arxiv_data1/oa_pdf/e9/a5/APJON-3-316.PMC5214864.pdf
Available from: https://www.aids.gov/pdf/ viral‑hepatitis‑action‑plan.pdf.,Non-OADS,/arxiv_data1/oa_pdf/6a/7a/APJON-3-324.PMC5214865.pdf
Available from: https://www.cdc.gov/hepatitis/ pdfs/iom‑hepatitisandlivercancerreport.pdf.,Non-OADS,/arxiv_data1/oa_pdf/6a/7a/APJON-3-324.PMC5214865.pdf
Available from: http://www.who.int/ mediacentre/factsheets/fs297/en/.,Non-OADS,/arxiv_data1/oa_pdf/6a/7a/APJON-3-324.PMC5214865.pdf
Available from: http://www.chinadigitaltimes.net/china/ hepatitis‑b/.,Non-OADS,/arxiv_data1/oa_pdf/6a/7a/APJON-3-324.PMC5214865.pdf
Available from: http://www.h21.hani.co.kr/arti/ special/special_general/33067.html.,Non-OADS,/arxiv_data1/oa_pdf/6a/7a/APJON-3-324.PMC5214865.pdf
Available from: http://www.unaids.org/sites/default/files/ media_asset/UNAIDS_Global_Report_2013_en_1.pdf.,OADS,/arxiv_data1/oa_pdf/7c/3d/APJON-3-344.PMC5214867.pdf
Available from: http://www.who.int/hiv/pub/ guidelines/hepatitis/en/.,Non-OADS,/arxiv_data1/oa_pdf/7c/3d/APJON-3-344.PMC5214867.pdf
Available from: http://www.globocan.iarc.fr.,Non-OADS,/arxiv_data1/oa_pdf/7c/3d/APJON-3-344.PMC5214867.pdf
Available from: http://www.unaids.org/en/media/unaids/ contentassets/documents/epidemiology/2013/gr2013/ UNAIDS_Global_Report_2013_en.pdf.,Non-OADS,/arxiv_data1/oa_pdf/7c/3d/APJON-3-344.PMC5214867.pdf
Available from: http://www.pdf.,Non-OADS,/arxiv_data1/oa_pdf/7c/3d/APJON-3-344.PMC5214867.pdf
Available from: http://www.stigmaindex.org/ sites/default/files/newsattachments/Malawi.,Non-OADS,/arxiv_data1/oa_pdf/7c/3d/APJON-3-344.PMC5214867.pdf
Available from:  http://www.cmwf.org.,Non-OADS,/arxiv_data1/oa_pdf/8e/5e/APJON-3-352.PMC5214868.pdf
"Accessed November 10, 2016 Availabe from http://www.ihi.",Non-OADS,/arxiv_data1/oa_pdf/16/7e/APJON-3-357.PMC5214869.pdf
Available from: http://www.cdc.gov/getsmart/ healthcare/implementation/clinicianguide.html 22.,Non-OADS,/arxiv_data1/oa_pdf/16/7e/APJON-3-357.PMC5214869.pdf
Available  from: http://www.nccn.org.,Non-OADS,/arxiv_data1/oa_pdf/16/7e/APJON-3-357.PMC5214869.pdf
Available from: http://www.americannursetoday.com/ make‑your‑nursing‑care‑malpractice‑proof/[Last accessed  on 2016 Nov 10].,Non-OADS,/arxiv_data1/oa_pdf/16/7e/APJON-3-357.PMC5214869.pdf
Available from:  http://www.ganjoho.jp/data/reg_stat/statistics/brochure/2014/ cancer_statistics_2014_ fig_E.pdf.,OADS,/arxiv_data1/oa_pdf/8f/97/APJON-3-370.PMC5214871.pdf
Available from: http://www.ctep.cancer.,Non-OADS,/arxiv_data1/oa_pdf/8f/97/APJON-3-370.PMC5214871.pdf
"4, 408 –424 http://dx.doi.org/10.1080/17437199.2016.1183506",Non-OADS,/arxiv_data1/oa_pdf/5b/3f/rhpr-10-408.PMC5214881.pdf
"http://www.nber.org/papers/w13330 Custers, R., & Aarts, H. ( 2005 ).",OADS,/arxiv_data1/oa_pdf/5b/3f/rhpr-10-408.PMC5214881.pdf
"Retrieved from http://onlinelibrary.wiley.com.proxy.library.uu.nl/doi/10.1002/14651858.CD011045.pub2/abstract Janz, N. K., & Becker, M. H. ( 1984 ).",OADS,/arxiv_data1/oa_pdf/5b/3f/rhpr-10-408.PMC5214881.pdf
"Retrieved from http://doi.org/10.1037/bul0000030 Wiers, R. W., Eberl, C., Rinck, M., Becker, E. S., & Lindenmeyer, J.",OADS,/arxiv_data1/oa_pdf/5b/3f/rhpr-10-408.PMC5214881.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/4b/b3/amep-8-011.PMC5214887.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/4b/b3/amep-8-011.PMC5214887.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Advances in Medical Education and Practice 2017:8 11–19Advances in Medical Education and Practice Dovepress submit your manuscript | www.dovepress.com Dovepress 11 REviEw open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/AMEP .S109099 Neonatal resuscitation: advances in training and  practice Taylor Sawyer Rachel A Umoren Megan M Gray Department of Pediatrics, Division  of Neonatology, Neonatal Education and Simulation-based Training (NEST) Program, University of washington  School of Medicine, Seattle, wA, USAAbstract:  Each year in the US, some four hundred thousand newborns need help breath- ing when they are born.",Non-OADS,/arxiv_data1/oa_pdf/4b/b3/amep-8-011.PMC5214887.pdf
"6 The NRP program then translates the AHA guidelines into an  e ducational curriculum and develops a NRP flow diagram, which is published in the Correspondence: Taylor Sawyer Department of Pediatrics, Division of Neonatology, Neonatal Education and Simulation-based Training (NEST) Program, University of washington School of Medicine, 1959 NE Pacific Street, RR451 HSB, Box 356320, Seattle, wA 98195-6320, USATel +1 206 543 3200Fax +1 206 543 8926Email tlsawyer@uw.eduJournal name: Advances in Medical Education and Practice Article Designation: ReviewY ear: 2017V olume: 8Running head verso: Sawyer et alRunning head recto: Advances in neonatal resuscitationDOI: http://dx.doi.org/10.2147/AMEP .S109099",Non-OADS,/arxiv_data1/oa_pdf/4b/b3/amep-8-011.PMC5214887.pdf
"http://journals.lww.com/academicmedicine/Fulltext/2015/08000/Learn,_See,_Practice,_Prove,_Do,_Maintain___An.13.aspx.",Non-OADS,/arxiv_data1/oa_pdf/4b/b3/amep-8-011.PMC5214887.pdf
"Advances in Medical Education and Practice Publish your work in this journal Submit your manuscript here: http://www.dovepress.com/advances-in-medical-education-and-practice-journalAdvances in Medical Education and Practice is an international, peer-  reviewed, open access journal that aims to present and publish research on Medical Education covering medical, dental, nursing and allied   health care professional education.",Non-OADS,/arxiv_data1/oa_pdf/4b/b3/amep-8-011.PMC5214887.pdf
Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.Advances in Medical Education and Practice 2017:8submit your manuscript | www.dovepress.com Dovepress Dovepress Dovepress 19 Advances in neonatal resuscitation,Non-OADS,/arxiv_data1/oa_pdf/4b/b3/amep-8-011.PMC5214887.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/c7/4d/amep-8-021.PMC5214898.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/c7/4d/amep-8-021.PMC5214898.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Advances in Medical Education and Practice 2017:8 21–23Advances in Medical Education and Practice Dovepress submit your manuscript | www.dovepress.com Dovepress 21 EXPERT OPINION open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/AMEP .S110353 Situational judgment tests reliably measure  professional attributes important for clinical  practice Katie Petty-Saphon1 Kim A Walker2 Fiona Patterson3,4 Vicki Ashworth4 Helena Edwards4 1Medical Schools Council, London,   UK; 2United Kingdom Foundation  Programme Office, Birmingham, UK;   3Department of Psychology, University  of Cambridge, Cambridge, UK; 4Work  Psychology Group, Derby, UKAbstract: Over the course of more than 40 years, international research has consistently shown  situational judgment tests (SJTs) to be a reliable and valid selection method for assessing a range  of professional attributes.",Non-OADS,/arxiv_data1/oa_pdf/c7/4d/amep-8-021.PMC5214898.pdf
"4 The job analysis report and all Correspondence: Fiona Patterson Work Psychology Group, 27 Brunel Parkway, Pride Park, Derby, DE24 8HR, UKTel +44 1332 295 687Email f.patterson@workpsychologygroup.comJournal name: Advances in Medical Education and Practice Article Designation: EXPERT OPINIONY ear: 2017V olume: 8Running head verso: Petty-Saphon et alRunning head recto: SJTs reliably measure professional attributesDOI: http://dx.doi.org/10.2147/AMEP .S110353 Video abstract Point your SmartPhone at the code above.",Non-OADS,/arxiv_data1/oa_pdf/c7/4d/amep-8-021.PMC5214898.pdf
Or use: http://youtu.be/rCDr7h_AWnM,Non-OADS,/arxiv_data1/oa_pdf/c7/4d/amep-8-021.PMC5214898.pdf
"Advances in Medical Education and Practice Publish your work in this journal Submit your manuscript here: http://www.dovepress.com/advances-in-medical-education-and-practice-journalAdvances in Medical Education and Practice is an international, peer-  reviewed, open access journal that aims to present and publish research on Medical Education covering medical, dental, nursing and allied   health care professional education.",Non-OADS,/arxiv_data1/oa_pdf/c7/4d/amep-8-021.PMC5214898.pdf
Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.Advances in Medical Education and Practice 2017:8submit your manuscript | www.dovepress.com Dovepress Dovepress Dovepress 23 SJTs reliably measure professional attributes  2.,Non-OADS,/arxiv_data1/oa_pdf/c7/4d/amep-8-021.PMC5214898.pdf
Available from: http://www.foundationpro   gramme.nhs.uk/pages/medical-students/SJT -EPM.,Non-OADS,/arxiv_data1/oa_pdf/c7/4d/amep-8-021.PMC5214898.pdf
www.kjpp.net Korean J Physiol Pharmacol 2017;21(1):1-9 1Korean J Physiol Pharmacol 2017;21(1):1-9 https://doi.org/10.4196/kjpp.2017.21.1.1 Author contributions: Y.L.,Non-OADS,/arxiv_data1/oa_pdf/b6/cc/kjpp-21-1.PMC5214900.pdf
2 https://doi.org/10.4196/kjpp.2017.21.1.1 Korean J Physiol Pharmacol 2017;21(1):1-9Yu C et al 17].,Non-OADS,/arxiv_data1/oa_pdf/b6/cc/kjpp-21-1.PMC5214900.pdf
4 https://doi.org/10.4196/kjpp.2017.21.1.1 Korean J Physiol Pharmacol 2017;21(1):1-9Yu C et al Anti-inflammatory effects of atractylodin on CP and  DP rats Neutrophil infiltration and proinflammatory cytokines  levels may lead to inflammation.,Non-OADS,/arxiv_data1/oa_pdf/b6/cc/kjpp-21-1.PMC5214900.pdf
"6 https://doi.org/10.4196/kjpp.2017.21.1.1 Korean J Physiol Pharmacol 2017;21(1):1-9Yu C et al challenge, the present study was designed to establish both CP  and DP rat models with co-occurring intestinal inflammation in both models to investigate the effects of atractylodin on the jejunal inflammation and co-occurring intestinal dysmotility.",Non-OADS,/arxiv_data1/oa_pdf/b6/cc/kjpp-21-1.PMC5214900.pdf
8 https://doi.org/10.4196/kjpp.2017.21.1.1 Korean J Physiol Pharmacol 2017;21(1):1-9Yu C et al macrocepha1 Lae[J].,Non-OADS,/arxiv_data1/oa_pdf/b6/cc/kjpp-21-1.PMC5214900.pdf
"www.kjpp.net Korean J Physiol Pharmacol 2017;21(1):107-115 107Korean J Physiol Pharmacol 2017;21(1):107-115 https://doi.org/10.4196/kjpp.2017.21.1.107 Author contributions:  M.H.P ., S.H.S.",Non-OADS,/arxiv_data1/oa_pdf/72/e7/kjpp-21-107.PMC5214901.pdf
108 https://doi.org/10.4196/kjpp.2017.21.1.107 Korean J Physiol Pharmacol 2017;21(1):107-115Park MH et al industry in order to improve the safety and success rate of new  drugs.,Non-OADS,/arxiv_data1/oa_pdf/72/e7/kjpp-21-107.PMC5214901.pdf
110 https://doi.org/10.4196/kjpp.2017.21.1.107 Korean J Physiol Pharmacol 2017;21(1):107-115Park MH et al various clinical studies were used in the DDI modeling and  simulation for caffeine and ciprofloxacin [25-27] .,Non-OADS,/arxiv_data1/oa_pdf/72/e7/kjpp-21-107.PMC5214901.pdf
"112 https://doi.org/10.4196/kjpp.2017.21.1.107 Korean J Physiol Pharmacol 2017;21(1):107-115Park MH et al 750 mg), the DDI model predicted a mean value of 10% and  50% increase in terms of Cmax and AUC of caffeine compared  to the PK result of caffeine alone.",Non-OADS,/arxiv_data1/oa_pdf/72/e7/kjpp-21-107.PMC5214901.pdf
114 https://doi.org/10.4196/kjpp.2017.21.1.107 Korean J Physiol Pharmacol 2017;21(1):107-115Park MH et al appropriate PBPK model with the parameter sensitivity analysis  as well as in vivo  data could provide the increased confidence in  DDI simulation outcome.,Non-OADS,/arxiv_data1/oa_pdf/72/e7/kjpp-21-107.PMC5214901.pdf
www.kjpp.net Korean J Physiol Pharmacol 2017;21(1):11-17 11Korean J Physiol Pharmacol 2017;21(1):11-17 https://doi.org/10.4196/kjpp.2017.21.1.11 Author contributions: J.H.Choi designed the study.,Non-OADS,/arxiv_data1/oa_pdf/0f/22/kjpp-21-11.PMC5214902.pdf
12 https://doi.org/10.4196/kjpp.2017.21.1.11 Korean J Physiol Pharmacol 2017;21(1):11-17Jung ES et al Table 1.,Non-OADS,/arxiv_data1/oa_pdf/0f/22/kjpp-21-11.PMC5214902.pdf
"14 https://doi.org/10.4196/kjpp.2017.21.1.11 Korean J Physiol Pharmacol 2017;21(1):11-17Jung ES et al onset, body mass index, or disease location in Korean patients  with CD ( Table 3 ).",Non-OADS,/arxiv_data1/oa_pdf/0f/22/kjpp-21-11.PMC5214902.pdf
16 https://doi.org/10.4196/kjpp.2017.21.1.11 Korean J Physiol Pharmacol 2017;21(1):11-17Jung ES et al autophagy gene IRGM and multiple other replicating loci contribute  to Crohn's disease susceptibility.,Non-OADS,/arxiv_data1/oa_pdf/0f/22/kjpp-21-11.PMC5214902.pdf
www.kjpp.net Korean J Physiol Pharmacol 2017;21(1):117-124 117Korean J Physiol Pharmacol 2017;21(1):117-124 https://doi.org/10.4196/kjpp.2017.21.1.117 Author contributions: Y.C.K.,Non-OADS,/arxiv_data1/oa_pdf/f4/b4/kjpp-21-117.PMC5214903.pdf
118 https://doi.org/10.4196/kjpp.2017.21.1.117 Korean J Physiol Pharmacol 2017;21(1):117-124Youn CK et al production of oxygen radicals [4] .,Non-OADS,/arxiv_data1/oa_pdf/f4/b4/kjpp-21-117.PMC5214903.pdf
120 https://doi.org/10.4196/kjpp.2017.21.1.117 Korean J Physiol Pharmacol 2017;21(1):117-124Youn CK et al We further analyzed the effects of silymarin on iNOS  expression by Western blot and RT-PCR analyses.,Non-OADS,/arxiv_data1/oa_pdf/f4/b4/kjpp-21-117.PMC5214903.pdf
"122 https://doi.org/10.4196/kjpp.2017.21.1.117 Korean J Physiol Pharmacol 2017;21(1):117-124Youn CK et al protective role of silymarin against these conditions is likely  due, at least in part, to an anti-inflammatory effect.",Non-OADS,/arxiv_data1/oa_pdf/f4/b4/kjpp-21-117.PMC5214903.pdf
124 https://doi.org/10.4196/kjpp.2017.21.1.117 Korean J Physiol Pharmacol 2017;21(1):117-124Youn CK et al decreasing NO and proinflammatory cytokine production with less  cytoxicity in LPS-stimulated RAW 264.7 macrophages and LPS-induced septicemia mice.,Non-OADS,/arxiv_data1/oa_pdf/f4/b4/kjpp-21-117.PMC5214903.pdf
www.kjpp.net Korean J Physiol Pharmacol 2017;21(1):125-131 125Korean J Physiol Pharmacol 2017;21(1):125-131 https://doi.org/10.4196/kjpp.2017.21.1.125 Author contributions: H.J.K.,Non-OADS,/arxiv_data1/oa_pdf/1e/06/kjpp-21-125.PMC5214904.pdf
"126 https://doi.org/10.4196/kjpp.2017.21.1.125 Korean J Physiol Pharmacol 2017;21(1):125-131Hong N et al receptor agonist pilocarpine is used to induce SE, which is  followed by its neuropathological features, such as neuronal death, reactive gliosis, and remodeling of synaptic circuitry.",Non-OADS,/arxiv_data1/oa_pdf/1e/06/kjpp-21-125.PMC5214904.pdf
128 https://doi.org/10.4196/kjpp.2017.21.1.125 Korean J Physiol Pharmacol 2017;21(1):125-131Hong N et al violet staining ( Fig.,Non-OADS,/arxiv_data1/oa_pdf/1e/06/kjpp-21-125.PMC5214904.pdf
130 https://doi.org/10.4196/kjpp.2017.21.1.125 Korean J Physiol Pharmacol 2017;21(1):125-131Hong N et al subfields at 3 days after SE.,Non-OADS,/arxiv_data1/oa_pdf/1e/06/kjpp-21-125.PMC5214904.pdf
www.kjpp.net Korean J Physiol Pharmacol 2017;21(1):133-140 133Korean J Physiol Pharmacol 2017;21(1):133-140 https://doi.org/10.4196/kjpp.2017.21.1.133 Author contributions: J.Y.K.,Non-OADS,/arxiv_data1/oa_pdf/6e/b7/kjpp-21-133.PMC5214905.pdf
134 https://doi.org/10.4196/kjpp.2017.21.1.133 Korean J Physiol Pharmacol 2017;21(1):133-140Ko J et al The permeability ratio has been shown to differ depending on  whether the I-V curve has a doubly rectifying shape or an inward rectifying shape.,Non-OADS,/arxiv_data1/oa_pdf/6e/b7/kjpp-21-133.PMC5214905.pdf
136 https://doi.org/10.4196/kjpp.2017.21.1.133 Korean J Physiol Pharmacol 2017;21(1):133-140Ko J et al these values returned to those of the control after washout of EA.,Non-OADS,/arxiv_data1/oa_pdf/6e/b7/kjpp-21-133.PMC5214905.pdf
138 https://doi.org/10.4196/kjpp.2017.21.1.133 Korean J Physiol Pharmacol 2017;21(1):133-140Ko J et al calcium increase was larger when TRPC4 or TRPC5 channels  were expressed compared with control conditions.,Non-OADS,/arxiv_data1/oa_pdf/6e/b7/kjpp-21-133.PMC5214905.pdf
140 https://doi.org/10.4196/kjpp.2017.21.1.133 Korean J Physiol Pharmacol 2017;21(1):133-140Ko J et al permeability in heteromeric channel complexes.,OADS,/arxiv_data1/oa_pdf/6e/b7/kjpp-21-133.PMC5214905.pdf
www.kjpp.net Korean J Physiol Pharmacol 2017;21(1):141 141Korean J Physiol Pharmacol 2017;21(1):141 https://doi.org/10.4196/kjpp.2017.21.1.141 Corrigendum to:  Korean J Physiol Pharmacol 2016;20(6):629-639 https://doi.org/10.4196/kjpp.2016.20.6.629 The original version of this article contained misspelled name of authors.,Non-OADS,/arxiv_data1/oa_pdf/19/c9/kjpp-21-141.PMC5214906.pdf
www.kjpp.net Korean J Physiol Pharmacol 2017;21(1):19-26 19Korean J Physiol Pharmacol 2017;21(1):19-26 https://doi.org/10.4196/kjpp.2017.21.1.19 Author contributions:H.J.R.,Non-OADS,/arxiv_data1/oa_pdf/ff/83/kjpp-21-19.PMC5214907.pdf
"20 https://doi.org/10.4196/kjpp.2017.21.1.19 Korean J Physiol Pharmacol 2017;21(1):19-26Ra HJ et al proteoglycans and activates procollagenase in articular cartilage  [7,8].",Non-OADS,/arxiv_data1/oa_pdf/ff/83/kjpp-21-19.PMC5214907.pdf
22 https://doi.org/10.4196/kjpp.2017.21.1.19 Korean J Physiol Pharmacol 2017;21(1):19-26Ra HJ et al measurement of MMP-3 protein by western blot analysis.,Non-OADS,/arxiv_data1/oa_pdf/ff/83/kjpp-21-19.PMC5214907.pdf
24 https://doi.org/10.4196/kjpp.2017.21.1.19 Korean J Physiol Pharmacol 2017;21(1):19-26Ra HJ et al control of this condition.,Non-OADS,/arxiv_data1/oa_pdf/ff/83/kjpp-21-19.PMC5214907.pdf
26 https://doi.org/10.4196/kjpp.2017.21.1.19 Korean J Physiol Pharmacol 2017;21(1):19-26Ra HJ et al pathway.,Non-OADS,/arxiv_data1/oa_pdf/ff/83/kjpp-21-19.PMC5214907.pdf
www.kjpp.net Korean J Physiol Pharmacol 2017;21(1):27-36 27Korean J Physiol Pharmacol 2017;21(1):27-36 https://doi.org/10.4196/kjpp.2017.21.1.27 Author contributions: J.H.W.,Non-OADS,/arxiv_data1/oa_pdf/6c/e4/kjpp-21-27.PMC5214908.pdf
28 https://doi.org/10.4196/kjpp.2017.21.1.27 Korean J Physiol Pharmacol 2017;21(1):27-36Woo JH et al by BZ [8] .,Non-OADS,/arxiv_data1/oa_pdf/6c/e4/kjpp-21-27.PMC5214908.pdf
"30 https://doi.org/10.4196/kjpp.2017.21.1.27 Korean J Physiol Pharmacol 2017;21(1):27-36Woo JH et al Western blotting of GAD and GABAA receptors  subunits The groups were administered orally to DCA (10, 25 and  50 mg/kg) and diazepam (0.2 mg/kg) before 1 h and 30 min  respectively injected to all mice (0.1 ml/10 g).",Non-OADS,/arxiv_data1/oa_pdf/6c/e4/kjpp-21-27.PMC5214908.pdf
"32 https://doi.org/10.4196/kjpp.2017.21.1.27 Korean J Physiol Pharmacol 2017;21(1):27-36Woo JH et al θ-waves in REM and NREM sleep, by approximately 79.7% and  78.9%, respectively, compared with that of the control ( Fig.",Non-OADS,/arxiv_data1/oa_pdf/6c/e4/kjpp-21-27.PMC5214908.pdf
"34 https://doi.org/10.4196/kjpp.2017.21.1.27 Korean J Physiol Pharmacol 2017;21(1):27-36Woo JH et al dependent manner, similar to muscimol, both at the hypnotic (42  mg/kg) and sub-hypnotic (28 mg/kg) dosages.",Non-OADS,/arxiv_data1/oa_pdf/6c/e4/kjpp-21-27.PMC5214908.pdf
36 https://doi.org/10.4196/kjpp.2017.21.1.27 Korean J Physiol Pharmacol 2017;21(1):27-36Woo JH et al impairment with long-term administration of extract of Angelica  gigas or decursinol in mice.,Non-OADS,/arxiv_data1/oa_pdf/6c/e4/kjpp-21-27.PMC5214908.pdf
www.kjpp.net Korean J Physiol Pharmacol 2017;21(1):37-44 37Korean J Physiol Pharmacol 2017;21(1):37-44 https://doi.org/10.4196/kjpp.2017.21.1.37 Author contributions: J.M.H.,Non-OADS,/arxiv_data1/oa_pdf/df/d6/kjpp-21-37.PMC5214909.pdf
38 https://doi.org/10.4196/kjpp.2017.21.1.37 Korean J Physiol Pharmacol 2017;21(1):37-44Ha JM et al aging [3].,Non-OADS,/arxiv_data1/oa_pdf/df/d6/kjpp-21-37.PMC5214909.pdf
"Collagen gel contraction was measured as a decrease in the gel area using Scion Image software (compliments of Scion Corporation, Frederick, MD; http://www.scioncorp.com).",OADS,/arxiv_data1/oa_pdf/df/d6/kjpp-21-37.PMC5214909.pdf
"40 https://doi.org/10.4196/kjpp.2017.21.1.37 Korean J Physiol Pharmacol 2017;21(1):37-44Ha JM et al Regulation of KLF8 promoter activity by KLF4 and  Akt1 The analysis of KLF8 promoter revealed that many cis-acting  elements, such as C-Ets-1, CAAT/enhance binding protein β  (C/EBPβ), retinoic acid receptor α (RXRα), Ap1, Sp1, KLF4,  and NFκB, were located in the promoter region (up to – 1312)  (Fig.",Non-OADS,/arxiv_data1/oa_pdf/df/d6/kjpp-21-37.PMC5214909.pdf
42 https://doi.org/10.4196/kjpp.2017.21.1.37 Korean J Physiol Pharmacol 2017;21(1):37-44Ha JM et al (Fig.,Non-OADS,/arxiv_data1/oa_pdf/df/d6/kjpp-21-37.PMC5214909.pdf
44 https://doi.org/10.4196/kjpp.2017.21.1.37 Korean J Physiol Pharmacol 2017;21(1):37-44Ha JM et al cell differentiation markers but accelerates neointimal formation  following vascular injury.,Non-OADS,/arxiv_data1/oa_pdf/df/d6/kjpp-21-37.PMC5214909.pdf
www.kjpp.net Korean J Physiol Pharmacol 2017;21(1):45-54 45Korean J Physiol Pharmacol 2017;21(1):45-54 https://doi.org/10.4196/kjpp.2017.21.1.45 Author contributions: J.W.,Non-OADS,/arxiv_data1/oa_pdf/1b/8a/kjpp-21-45.PMC5214910.pdf
"46 https://doi.org/10.4196/kjpp.2017.21.1.45 Korean J Physiol Pharmacol 2017;21(1):45-54Wang J et al Cytochrome P450 3A subfamily, play crucial roles in the oxidation  and elimination of DEX [12] .",Non-OADS,/arxiv_data1/oa_pdf/1b/8a/kjpp-21-45.PMC5214910.pdf
"48 https://doi.org/10.4196/kjpp.2017.21.1.45 Korean J Physiol Pharmacol 2017;21(1):45-54Wang J et al RESUL TS In vitro  metabolism of DTX-LP We first examined the in vitro  metabolism of DTX-LP in liver  homogenates, lung homogenates and liver microsomes using  DTX-IN as the control.",Non-OADS,/arxiv_data1/oa_pdf/1b/8a/kjpp-21-45.PMC5214910.pdf
50 https://doi.org/10.4196/kjpp.2017.21.1.45 Korean J Physiol Pharmacol 2017;21(1):45-54Wang J et al (Table 5 ).,Non-OADS,/arxiv_data1/oa_pdf/1b/8a/kjpp-21-45.PMC5214910.pdf
"52 https://doi.org/10.4196/kjpp.2017.21.1.45 Korean J Physiol Pharmacol 2017;21(1):45-54Wang J et al ([m+H]+), indicating a break in the C-13 side chain resulting in  a C-13 side chain (296) and a baccatin structure (527, [m+H]+)  [24].",Non-OADS,/arxiv_data1/oa_pdf/1b/8a/kjpp-21-45.PMC5214910.pdf
SUPPLEmENTARY m ATERIALS Supplementary data including three figures can be found with  this article online at http://pdf.medrang.co.kr/paper/pdf/Kjpp/Kjpp021-01-06-s001 .pdf.,OADS,/arxiv_data1/oa_pdf/1b/8a/kjpp-21-45.PMC5214910.pdf
54 https://doi.org/10.4196/kjpp.2017.21.1.45 Korean J Physiol Pharmacol 2017;21(1):45-54Wang J et al 17.,Non-OADS,/arxiv_data1/oa_pdf/1b/8a/kjpp-21-45.PMC5214910.pdf
www.kjpp.net Korean J Physiol Pharmacol 2017;21(1):55-64 55Korean J Physiol Pharmacol 2017;21(1):55-64 https://doi.org/10.4196/kjpp.2017.21.1.55 Author contributions: K.Y.S.,Non-OADS,/arxiv_data1/oa_pdf/8e/ad/kjpp-21-55.PMC5214911.pdf
56 https://doi.org/10.4196/kjpp.2017.21.1.55 Korean J Physiol Pharmacol 2017;21(1):55-64Shin KY et al is related to an upregulation of calcium signaling and results in  memory loss [6-8] .,Non-OADS,/arxiv_data1/oa_pdf/8e/ad/kjpp-21-55.PMC5214911.pdf
58 https://doi.org/10.4196/kjpp.2017.21.1.55 Korean J Physiol Pharmacol 2017;21(1):55-64Shin KY et al USA).,Non-OADS,/arxiv_data1/oa_pdf/8e/ad/kjpp-21-55.PMC5214911.pdf
60 https://doi.org/10.4196/kjpp.2017.21.1.55 Korean J Physiol Pharmacol 2017;21(1):55-64Shin KY et al (16.01±1.41 sec) and zone 4 (17.40±2.43 sec).,Non-OADS,/arxiv_data1/oa_pdf/8e/ad/kjpp-21-55.PMC5214911.pdf
"62 https://doi.org/10.4196/kjpp.2017.21.1.55 Korean J Physiol Pharmacol 2017;21(1):55-64Shin KY et al improvement observed after DHED treatment in memory- impaired rat models, including a scopolamine-induced amnesia model and an amyloid-infused model.",Non-OADS,/arxiv_data1/oa_pdf/8e/ad/kjpp-21-55.PMC5214911.pdf
64 https://doi.org/10.4196/kjpp.2017.21.1.55 Korean J Physiol Pharmacol 2017;21(1):55-64Shin KY et al Neurotoxicity of Alzheimer's disease A β peptides is induced by  small changes in the A β42 to Aβ40 ratio.,Non-OADS,/arxiv_data1/oa_pdf/8e/ad/kjpp-21-55.PMC5214911.pdf
"www.kjpp.net Korean J Physiol Pharmacol 2017;21(1):65-74 65Korean J Physiol Pharmacol 2017;21(1):65-74 https://doi.org/10.4196/kjpp.2017.21.1.65 Author contributions: M.J.K., S.K.H., D.K.A.",Non-OADS,/arxiv_data1/oa_pdf/ee/90/kjpp-21-65.PMC5214912.pdf
66 https://doi.org/10.4196/kjpp.2017.21.1.65 Korean J Physiol Pharmacol 2017;21(1):65-74Kim MJ et al not induce hyperalgesia or allodynia under normal conditions.,Non-OADS,/arxiv_data1/oa_pdf/ee/90/kjpp-21-65.PMC5214912.pdf
"68 https://doi.org/10.4196/kjpp.2017.21.1.65 Korean J Physiol Pharmacol 2017;21(1):65-74Kim MJ et al in sterile saline, and bumetanide was dissolved in sterile saline  containing 70% DMSO.",Non-OADS,/arxiv_data1/oa_pdf/ee/90/kjpp-21-65.PMC5214912.pdf
70 https://doi.org/10.4196/kjpp.2017.21.1.65 Korean J Physiol Pharmacol 2017;21(1):65-74Kim MJ et al bicuculline-induced paradoxical anti-allodynic effects in IL- 1β-treated rats.,Non-OADS,/arxiv_data1/oa_pdf/ee/90/kjpp-21-65.PMC5214912.pdf
72 https://doi.org/10.4196/kjpp.2017.21.1.65 Korean J Physiol Pharmacol 2017;21(1):65-74Kim MJ et al participation of NKCC1 in the switch from anti-nociception  to pro-nociception is supported by several previous studies.,Non-OADS,/arxiv_data1/oa_pdf/ee/90/kjpp-21-65.PMC5214912.pdf
74 https://doi.org/10.4196/kjpp.2017.21.1.65 Korean J Physiol Pharmacol 2017;21(1):65-74Kim MJ et al following intraplantar formalin.,Non-OADS,/arxiv_data1/oa_pdf/ee/90/kjpp-21-65.PMC5214912.pdf
"www.kjpp.net Korean J Physiol Pharmacol 2017;21(1):75-82 75Korean J Physiol Pharmacol 2017;21(1):75-82 https://doi.org/10.4196/kjpp.2017.21.1.75 Author contributions: Conception and design of study: J.S.C., K.W.S.",Non-OADS,/arxiv_data1/oa_pdf/a6/53/kjpp-21-75.PMC5214913.pdf
76 https://doi.org/10.4196/kjpp.2017.21.1.75 Korean J Physiol Pharmacol 2017;21(1):75-82Joo YS et al action potential [16].,Non-OADS,/arxiv_data1/oa_pdf/a6/53/kjpp-21-75.PMC5214913.pdf
78 https://doi.org/10.4196/kjpp.2017.21.1.75 Korean J Physiol Pharmacol 2017;21(1):75-82Joo YS et al RESUL TS Concentration-response relationships for blocking of  hERG currents by acepromazine Fig.,Non-OADS,/arxiv_data1/oa_pdf/a6/53/kjpp-21-75.PMC5214913.pdf
80 https://doi.org/10.4196/kjpp.2017.21.1.75 Korean J Physiol Pharmacol 2017;21(1):75-82Joo YS et al presence of acepromazine.,Non-OADS,/arxiv_data1/oa_pdf/a6/53/kjpp-21-75.PMC5214913.pdf
82 https://doi.org/10.4196/kjpp.2017.21.1.75 Korean J Physiol Pharmacol 2017;21(1):75-82Joo YS et al Lachâtre G. Identification of acepromazine in hair: an illustration of  the difficulties encountered in investigating drug-facilitated crimes.,Non-OADS,/arxiv_data1/oa_pdf/a6/53/kjpp-21-75.PMC5214913.pdf
"www.kjpp.net Korean J Physiol Pharmacol 2017;21(1):83-90 83Korean J Physiol Pharmacol 2017;21(1):83-90 https://doi.org/10.4196/kjpp.2017.21.1.83 Author contributions: M.C.N., performed the experiments and wrote  manuscript.",Non-OADS,/arxiv_data1/oa_pdf/9f/05/kjpp-21-83.PMC5214914.pdf
84 https://doi.org/10.4196/kjpp.2017.21.1.83 Korean J Physiol Pharmacol 2017;21(1):83-90Nguyen MC and Ryoo S expression/activity constrains NO bioavailability and impairs  endothelial functions.,Non-OADS,/arxiv_data1/oa_pdf/9f/05/kjpp-21-83.PMC5214914.pdf
"86 https://doi.org/10.4196/kjpp.2017.21.1.83 Korean J Physiol Pharmacol 2017;21(1):83-90Nguyen MC and Ryoo S Piceatannol induced an increase in the dimer stability  and phosphorylation at Ser1177 of eNOS To understand the mechanisms by which Piceatannol- dependent arginase inhibition improved eNOS-derived NO  production, we performed western blot analysis of eNOS Ser1177 phosphorylation, a critical post-translational modification that enhanced eNOS activity.",Non-OADS,/arxiv_data1/oa_pdf/9f/05/kjpp-21-83.PMC5214914.pdf
88 https://doi.org/10.4196/kjpp.2017.21.1.83 Korean J Physiol Pharmacol 2017;21(1):83-90Nguyen MC and Ryoo S DISCUSSION There is emerging evidence showing that enhanced arginase  expression/activity is associated with vascular diseases.,Non-OADS,/arxiv_data1/oa_pdf/9f/05/kjpp-21-83.PMC5214914.pdf
90 https://doi.org/10.4196/kjpp.2017.21.1.83 Korean J Physiol Pharmacol 2017;21(1):83-90Nguyen MC and Ryoo S 34.,Non-OADS,/arxiv_data1/oa_pdf/9f/05/kjpp-21-83.PMC5214914.pdf
www.kjpp.net Korean J Physiol Pharmacol 2017;21(1):91-97 91Korean J Physiol Pharmacol 2017;21(1):91-97 https://doi.org/10.4196/kjpp.2017.21.1.91 Author contributions: R.V.,Non-OADS,/arxiv_data1/oa_pdf/e9/6f/kjpp-21-91.PMC5214915.pdf
92 https://doi.org/10.4196/kjpp.2017.21.1.91 Korean J Physiol Pharmacol 2017;21(1):91-97Vorn R and Yoo HY glucose with short-term exposure.,Non-OADS,/arxiv_data1/oa_pdf/e9/6f/kjpp-21-91.PMC5214915.pdf
94 https://doi.org/10.4196/kjpp.2017.21.1.91 Korean J Physiol Pharmacol 2017;21(1):91-97Vorn R and Yoo HY Fig.,Non-OADS,/arxiv_data1/oa_pdf/e9/6f/kjpp-21-91.PMC5214915.pdf
"96 https://doi.org/10.4196/kjpp.2017.21.1.91 Korean J Physiol Pharmacol 2017;21(1):91-97Vorn R and Yoo HY The effects of HG on PhE-induced contraction vary depending  on the experimental conditions [14-16,23,24] .",Non-OADS,/arxiv_data1/oa_pdf/e9/6f/kjpp-21-91.PMC5214915.pdf
www.kjpp.net Korean J Physiol Pharmacol 2017;21(1):99-106 99Korean J Physiol Pharmacol 2017;21(1):99-106 https://doi.org/10.4196/kjpp.2017.21.1.99 Author contributions: J.I.K.,Non-OADS,/arxiv_data1/oa_pdf/08/fc/kjpp-21-99.PMC5214916.pdf
"100 https://doi.org/10.4196/kjpp.2017.21.1.99 Korean J Physiol Pharmacol 2017;21(1):99-106Kim JI to Ang II [13,14] .",Non-OADS,/arxiv_data1/oa_pdf/08/fc/kjpp-21-99.PMC5214916.pdf
"102 https://doi.org/10.4196/kjpp.2017.21.1.99 Korean J Physiol Pharmacol 2017;21(1):99-106Kim JI HDL cholesterol, triglycerides, free fatty acids did not show any  difference between groups ( Fig.",Non-OADS,/arxiv_data1/oa_pdf/08/fc/kjpp-21-99.PMC5214916.pdf
"104 https://doi.org/10.4196/kjpp.2017.21.1.99 Korean J Physiol Pharmacol 2017;21(1):99-106Kim JI of angiotensinogen into adipocytes [28] , vascular oxidative stress  and endothelial dysfunction [29] , and increased VSM reactivity  [13,14,30]  .",Non-OADS,/arxiv_data1/oa_pdf/08/fc/kjpp-21-99.PMC5214916.pdf
106 https://doi.org/10.4196/kjpp.2017.21.1.99 Korean J Physiol Pharmacol 2017;21(1):99-106Kim JI 21.,Non-OADS,/arxiv_data1/oa_pdf/08/fc/kjpp-21-99.PMC5214916.pdf
"2, 196 –206 http://dx.doi.org/10.1080/02640414.2016.1161205 © 2016 The Author(s).",Non-OADS,/arxiv_data1/oa_pdf/d4/76/rjsp-35-196.PMC5214925.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.",Non-OADS,/arxiv_data1/oa_pdf/d4/76/rjsp-35-196.PMC5214925.pdf
"To view a copy of this license, visit http://creativecommons.org/li censes/by-nc-nd/4.0/Sterile signals weakly prime and activate the NLRP3 in ﬂammasome JS Bezbradica et al 126 Cellular & Molecular Immunology",Non-OADS,/arxiv_data1/oa_pdf/a3/38/cmi201611a.PMC5214936.pdf
"To view a copy of this license, visit http://creativecommons.org/li censes/by-nc-nd/4.0/Innate recognition of Toxoplasma gondii in mice and men AS h e r et al 42 Cellular & Molecular Immunology",Non-OADS,/arxiv_data1/oa_pdf/e3/23/cmi201612a.PMC5214937.pdf
"To view a copy of this license, visit http://creativecommons.org/li censes/by-nc-nd/4.0/Interleukin-1 and type I IFN KD Mayer-Barber and B Yan 35 Cellular & Molecular Immunology",Non-OADS,/arxiv_data1/oa_pdf/98/35/cmi201625a.PMC5214938.pdf
"To view a copy of this license, visithttp://creativecommons.org/licenses/by-nc-nd/4.0/Post-translational modi ﬁcations of in ﬂammasomes JY a n g et al 79 Cellular & Molecular Immunology",Non-OADS,/arxiv_data1/oa_pdf/cc/38/cmi201629a.PMC5214939.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ Supplementary Information for this article can be found on the Cellular & Molecular Immunology website (http://www.nature.com/cmi)Role of Sam68 in TLR signaling JA Tomalka et al 117 Cellular & Molecular Immunology",Non-OADS,/arxiv_data1/oa_pdf/ae/07/cmi201632a.PMC5214940.pdf
"To view a copy of this license, visithttp://creativecommons.org/licenses/by-nc-nd/4.0/ rThe Author(s) 2017Dual-function alarmins in the heart of in ﬂammation and disease D Bertheloot and E Latz 64 Cellular & Molecular Immunology",Non-OADS,/arxiv_data1/oa_pdf/d9/45/cmi201634a.PMC5214941.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/AIM2 regulates intestinal homeostasis RA Ratsimandresy et al 142 Cellular & Molecular Immunology",Non-OADS,/arxiv_data1/oa_pdf/85/f3/cmi201635a.PMC5214942.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/ rThe Author(s) 2017Bystander innate immune responses to pathogens AM Holmgren et al 21 Cellular & Molecular Immunology",Non-OADS,/arxiv_data1/oa_pdf/82/48/cmi201636a.PMC5214943.pdf
"To view a copy of this license, visithttp://creativecommons.org/licenses/by-nc-nd/4.0/ rThe Author(s) 2017 Supplementary Information for this article can be found on the Cellular & Molecular Immunology website (http://www.nature.com/cmi)T cells mediate lethal encephalitis in TCRV-infected mice DDC Ireland et al 106 Cellular & Molecular Immunology",Non-OADS,/arxiv_data1/oa_pdf/79/4d/cmi201641a.PMC5214944.pdf
ASC sequences were obtained from the NCBI database (http://www.ncbi.nlm.nih.gov).,OADS,/arxiv_data1/oa_pdf/5d/bd/cmi201650a.PMC5214946.pdf
"To viewa copy of this license, visit http://creativecommons.org/ licenses/by-nc-sa/4.0/ rThe Author(s) 2017Pathogen recognition receptors in zebra ﬁsh YL iet al 89 Cellular & Molecular Immunology",Non-OADS,/arxiv_data1/oa_pdf/5d/bd/cmi201650a.PMC5214946.pdf
"To view a copy of this license,visit http://creativecommons.org/licenses/by-nc-sa/4.0/ rThe Author(s) 2017Viral evasion of innate immune responses MH Christensen and SR Paludan 13 Cellular & Molecular Immunology",Non-OADS,/arxiv_data1/oa_pdf/05/ac/cmi20166a.PMC5214947.pdf
SUPPLEMENTARY MATERIALS Supplementary material for this article is available at http://advances.sciencemag.org/cgi/ content/full/3/1/e1601689/DC1fig.,Non-OADS,/arxiv_data1/oa_pdf/72/7f/1601689.PMC5214956.pdf
Data and materials availability: The raw data are available at http://www.marine-g eo.org/tools/new_search/index.php?,OADS,/arxiv_data1/oa_pdf/72/7f/1601689.PMC5214956.pdf
R package version 2.3-0. http://CRAN.R-project.org/ package =vegan 2015.,Non-OADS,/arxiv_data1/oa_pdf/87/40/icb201671a.PMC5214975.pdf
http://www.R-project.org/ 2015.,Non-OADS,/arxiv_data1/oa_pdf/87/40/icb201671a.PMC5214975.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/ rThe Author(s) 2017 The Supplementary Information that accompanies this paper is available o n the Immunology and Cell Biology webs ite (http://www.nature.com/icb)EBV-speci ﬁcC D 8+TCRαβrepertoires THO Nguyen et al 86 Immunology and Cell Biology",Non-OADS,/arxiv_data1/oa_pdf/87/40/icb201671a.PMC5214975.pdf
Annotation ﬁles corresponding to COSMIC database (hg19-cosmic-v54-120711.vcf) and dbSNP database (dbsnp-132- b37.leftAligned.vcf) were retrieved from MuTect website (http://www.broadinstitute.org/cancer/cga/mutect-download) and utilized with MuTect software for variant calls.,OADS,/arxiv_data1/oa_pdf/c9/5b/leu2016160a.PMC5214979.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/ © The Author(s) 2017 Supplementary Information accompanies this paper on the Leukemia website (http://www.nature.com/leu)Ordering of mutations in MLL-PTD AML Q-Y Sun et al 10 Leukemia (2017) 1 –10",Non-OADS,/arxiv_data1/oa_pdf/c9/5b/leu2016160a.PMC5214979.pdf
"4, 460 –477 http://dx.doi.org/10.1080/17437199.2016.1219672",Non-OADS,/arxiv_data1/oa_pdf/9d/f4/rhpr-10-460.PMC5214986.pdf
"ORCiD Cecilia Cheng http://orcid.org/0000-0002-7250-2224 References Bandura, A.",Non-OADS,/arxiv_data1/oa_pdf/9d/f4/rhpr-10-460.PMC5214986.pdf
"Retrieved from http://www.geerthofstede.com/research--vsm Holmbeck, G. N., Thill, A. W., Bachanas, P., Garber, J., Miller, K. B., Abad, M., …Zukerman, J.",OADS,/arxiv_data1/oa_pdf/9d/f4/rhpr-10-460.PMC5214986.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License ( http://creativecommons.org/licenses/by-nc/3.0/ ), which permits unre- stricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/49/24/koni-05-12-1232236.PMC5214994.pdf
"12, e1232236 (8 pages)http://dx.doi.org/10.1080/2162402X.2016.1232236",Non-OADS,/arxiv_data1/oa_pdf/49/24/koni-05-12-1232236.PMC5214994.pdf
” ORCID Romain Vuillefroy de Silly http://orcid.org/0000-0001-6573-9752 References 1.,Non-OADS,/arxiv_data1/oa_pdf/49/24/koni-05-12-1232236.PMC5214994.pdf
J Cell Physiol 2009; 219:271-5; PMID:19160417; http://dx.doi.org/ 10.1002/jcp.216902.,Non-OADS,/arxiv_data1/oa_pdf/49/24/koni-05-12-1232236.PMC5214994.pdf
Immunol Res 2013; 55:58-70;PMID:22961658; http://dx.doi.org/10.1007/s12026-012-8349-8 3.,Non-OADS,/arxiv_data1/oa_pdf/49/24/koni-05-12-1232236.PMC5214994.pdf
J Cell Mol Med 2011; 15:1239-53; PMID:21251211; http://dx.doi.org/10.1111/j.1582-4934.2011.01258.x 4.,Non-OADS,/arxiv_data1/oa_pdf/49/24/koni-05-12-1232236.PMC5214994.pdf
N Engl J Med 2011; 364:656-65; PMID:21323543; http://dx.doi.org/10.1056/NEJMra0910283 5.,Non-OADS,/arxiv_data1/oa_pdf/49/24/koni-05-12-1232236.PMC5214994.pdf
Int J Radiat Biol 2006; 82:699-757; PMID:17118889; http://dx.doi.org/ 10.1080/09553000601002324 6.,OADS,/arxiv_data1/oa_pdf/49/24/koni-05-12-1232236.PMC5214994.pdf
Cancer 2000; 88:2606-18; PMID:10861440; http://dx.doi.org/10.1002/1097-0142(20000601)88:11%3c2606::AID-CNCR25%3e3.0.CO;2-W 7.,Non-OADS,/arxiv_data1/oa_pdf/49/24/koni-05-12-1232236.PMC5214994.pdf
Curr Opin Pharmacol 2013; 13:646-53;PMID:23660374; http://dx.doi.org/10.1016/j.coph.2013.04.009 8.,OADS,/arxiv_data1/oa_pdf/49/24/koni-05-12-1232236.PMC5214994.pdf
Cancer Cell 2009; 15:501-13; PMID:19477429; http://dx.doi.org/10.1016/j.ccr.2009.03.018 9.,Non-OADS,/arxiv_data1/oa_pdf/49/24/koni-05-12-1232236.PMC5214994.pdf
Nat Rev Cancer 2002; 2:38-47; PMID:11902584; http://dx.doi.org/10.1038/ nrc704 10.,Non-OADS,/arxiv_data1/oa_pdf/49/24/koni-05-12-1232236.PMC5214994.pdf
Oncogene 2010; 29:625-34; PMID:19946328; http://dx.doi.org/10.1038/onc.2009.441 11.,Non-OADS,/arxiv_data1/oa_pdf/49/24/koni-05-12-1232236.PMC5214994.pdf
Am J Physiol Cell Physiol 2015; 309:C569-79; PMID:26310815; http://dx.doi.org/10.1152/ajpcell.00207.2015 12.,Non-OADS,/arxiv_data1/oa_pdf/49/24/koni-05-12-1232236.PMC5214994.pdf
Oncogene 2016; PMID:27345407; http://dx.doi.org/10.1038/onc.2016.225 13.,OADS,/arxiv_data1/oa_pdf/49/24/koni-05-12-1232236.PMC5214994.pdf
Immunology 2014;143:512-9; PMID:25196648; http://dx.doi.org/10.1111/imm.12380 14.,Non-OADS,/arxiv_data1/oa_pdf/49/24/koni-05-12-1232236.PMC5214994.pdf
J Immunol Res 2016; 2016:5134329; PMID:26966693; http://dx.doi.org/10.1155/2016/5134329 15.,Non-OADS,/arxiv_data1/oa_pdf/49/24/koni-05-12-1232236.PMC5214994.pdf
Cell 2011; 146:772-84; PMID:21871655;http://dx.doi.org/10.1016/j.cell.2011.07.033 16.,OADS,/arxiv_data1/oa_pdf/49/24/koni-05-12-1232236.PMC5214994.pdf
Nat Rev Cancer 2003; 3:721-32; PMID:13130303; http://dx.doi.org/10.1038/nrc1187 17.,Non-OADS,/arxiv_data1/oa_pdf/49/24/koni-05-12-1232236.PMC5214994.pdf
J Biol Chem 2005; 280:22205-11; PMID:15824109; http://dx.doi.org/10.1074/jbc.M503220200 18.,OADS,/arxiv_data1/oa_pdf/49/24/koni-05-12-1232236.PMC5214994.pdf
J Exp Med 2012; 209:2441-53; PMID:23183047; http://dx.doi.org/10.1084/jem.20112607 20.,Non-OADS,/arxiv_data1/oa_pdf/49/24/koni-05-12-1232236.PMC5214994.pdf
Nat Immu- nol 2013; 14:1173-82; PMID:24076634; http://dx.doi.org/10.1038/ni.2714 21.,OADS,/arxiv_data1/oa_pdf/49/24/koni-05-12-1232236.PMC5214994.pdf
Cell 2013; 153:1239-51; PMID:23746840; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/49/24/koni-05-12-1232236.PMC5214994.pdf
J Immunol 2013; 191:3681-93; PMID:23997225; http://dx.doi.org/10.4049/jimmunol.1201954 24.,Non-OADS,/arxiv_data1/oa_pdf/49/24/koni-05-12-1232236.PMC5214994.pdf
J Biol Chem 2003; 278:29655-60;PMID:12777372; http://dx.doi.org/10.1074/jbc.M212770200 25.,OADS,/arxiv_data1/oa_pdf/49/24/koni-05-12-1232236.PMC5214994.pdf
EMBO J 2012; 31:1379-93;PMID:22252129; http://dx.doi.org/10.1038/emboj.2011.499 26.,Non-OADS,/arxiv_data1/oa_pdf/49/24/koni-05-12-1232236.PMC5214994.pdf
Differential effects of physiologically relevant hyp-oxic conditions on T lymphocyte development and effector functions.J Immunol 2001; 167:6140-9; PMID:11714773; http://dx.doi.org/ 10.4049/jimmunol.167.11.6140 29.,Non-OADS,/arxiv_data1/oa_pdf/49/24/koni-05-12-1232236.PMC5214994.pdf
Annu Rev Immu- nol 1998; 16:201-23; PMID:9597129; http://dx.doi.org/10.1146/ annurev.immunol.16.1.201 30.,Non-OADS,/arxiv_data1/oa_pdf/49/24/koni-05-12-1232236.PMC5214994.pdf
J Exp Med 2015; 212:1345-60; PMID:26261266; http://dx.doi.org/10.1084/jem.20151159 31.,Non-OADS,/arxiv_data1/oa_pdf/49/24/koni-05-12-1232236.PMC5214994.pdf
Crit Care Med1994; 22:197-203; PMID:8306676; http://dx.doi.org/10.1097/00003246-199402000-00008 32.,Non-OADS,/arxiv_data1/oa_pdf/49/24/koni-05-12-1232236.PMC5214994.pdf
Int J Immunopharmacol 1996; 18:545-52; PMID:9080248; http://dx.doi.org/10.1016/S0192-0561(96)00057-4 33.,Non-OADS,/arxiv_data1/oa_pdf/49/24/koni-05-12-1232236.PMC5214994.pdf
J Immunol2003; 171:6534-40; PMID:14662854; http://dx.doi.org/10.4049/jimmunol.171.12.6534 35.,Non-OADS,/arxiv_data1/oa_pdf/49/24/koni-05-12-1232236.PMC5214994.pdf
Am JRespir Cell Mol Biol 2010; 42:123-8; PMID:19372249; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/49/24/koni-05-12-1232236.PMC5214994.pdf
Immunol Lett 2010; 131:97- 105; PMID:20206208; http://dx.doi.org/10.1016/j.imlet.2010.02.008 37.,Non-OADS,/arxiv_data1/oa_pdf/49/24/koni-05-12-1232236.PMC5214994.pdf
JImmunol 2003; 170:695-702; PMID:12517930; http://dx.doi.org/ 10.4049/jimmunol.170.2.695 38.,Non-OADS,/arxiv_data1/oa_pdf/49/24/koni-05-12-1232236.PMC5214994.pdf
J Leukoc Biol 2010; 87:265-73; PMID:19892848; http://dx.doi.org/10.1189/jlb.0509304 39.,Non-OADS,/arxiv_data1/oa_pdf/49/24/koni-05-12-1232236.PMC5214994.pdf
Eur J Immunol 2013; 43:1588-97; PMID:23519896; http://dx.doi.org/10.1002/eji.201242754 40.,Non-OADS,/arxiv_data1/oa_pdf/49/24/koni-05-12-1232236.PMC5214994.pdf
IntImmunol 2014; 26:83-91; PMID:24150242; http://dx.doi.org/10.1093/ intimm/dxt045 41.,Non-OADS,/arxiv_data1/oa_pdf/49/24/koni-05-12-1232236.PMC5214994.pdf
J Immunol 2016; 196:106-14; PMID:26621861; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/49/24/koni-05-12-1232236.PMC5214994.pdf
J Clin Invest 2016; 126(7):2678-2688; PMID:27294526; http://dx.doi.org/10.1172/JCI85834 43.,Non-OADS,/arxiv_data1/oa_pdf/49/24/koni-05-12-1232236.PMC5214994.pdf
J Immunol 2006; 177:4962- 5; PMID:17015677; http://dx.doi.org/10.4049/jimmunol.177.8.4962 44.,Non-OADS,/arxiv_data1/oa_pdf/49/24/koni-05-12-1232236.PMC5214994.pdf
Cancer Cell 2006; 10:413-23; PMID:17097563;http://dx.doi.org/10.1016/j.ccr.2006.08.026 46.,Non-OADS,/arxiv_data1/oa_pdf/49/24/koni-05-12-1232236.PMC5214994.pdf
Nat Rev Cancer 2012; 12:9-22; PMID:22169972; http://dx.doi.org/10.1038/nrc3183 47.,Non-OADS,/arxiv_data1/oa_pdf/49/24/koni-05-12-1232236.PMC5214994.pdf
J Clin Invest 2013; 123:2078-93; PMID:23563312;http://dx.doi.org/10.1172/JCI66715 48.,Non-OADS,/arxiv_data1/oa_pdf/49/24/koni-05-12-1232236.PMC5214994.pdf
Immu- nol Lett 2015; 167:72-86; PMID:26209187; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/49/24/koni-05-12-1232236.PMC5214994.pdf
Biotechnol Bioeng 2004; 87:437-50; PMID:15286980; http://dx.doi.org/10.1002/bit.20166 50.,OADS,/arxiv_data1/oa_pdf/49/24/koni-05-12-1232236.PMC5214994.pdf
J Clin Invest 2005; 115:1616-26; PMID:15931392; http://dx.doi.org/10.1172/JCI24480 51.,Non-OADS,/arxiv_data1/oa_pdf/49/24/koni-05-12-1232236.PMC5214994.pdf
Nat Med 2011; 17:1290-7; PMID:21926977; http://dx.doi.org/10.1038/nm.2446 52.,OADS,/arxiv_data1/oa_pdf/49/24/koni-05-12-1232236.PMC5214994.pdf
Cell Metabolism 2016; 23:63-76; PMID:26674251; http://dx.doi.org/ 10.1016/j.cmet.2015.11.002 53.,OADS,/arxiv_data1/oa_pdf/49/24/koni-05-12-1232236.PMC5214994.pdf
J Immunol 2009; 182:3510-21; PMID:19265129; http://dx.doi.org/10.4049/jimmunol.0800854 54.,Non-OADS,/arxiv_data1/oa_pdf/49/24/koni-05-12-1232236.PMC5214994.pdf
Cancer Res 2011; 71:5976-86; PMID:21810913; http://dx.doi.org/10.1158/0008-5472.CAN-11-1094 55.,Non-OADS,/arxiv_data1/oa_pdf/49/24/koni-05-12-1232236.PMC5214994.pdf
Cancer Res 2012; 72:4629-41; PMID:22962263; http://dx.doi.org/10.1158/0008-5472.CAN-12-1383 5 6 .,Non-OADS,/arxiv_data1/oa_pdf/49/24/koni-05-12-1232236.PMC5214994.pdf
J Immunol 2007; 179:845-53; PMID:17617575; http://dx.doi.org/ 10.4049/jimmunol.179.2.845 58.,Non-OADS,/arxiv_data1/oa_pdf/49/24/koni-05-12-1232236.PMC5214994.pdf
J Immunol2015; 194:3475-86; PMID:25725111; http://dx.doi.org/10.4049/ jimmunol.1402711 59.,Non-OADS,/arxiv_data1/oa_pdf/49/24/koni-05-12-1232236.PMC5214994.pdf
J Exp Med 2016; PMID:27377586; http://dx.doi.org/ 10.1084/jem.20151916 60.,OADS,/arxiv_data1/oa_pdf/49/24/koni-05-12-1232236.PMC5214994.pdf
PLoS One 2007; 2:e853;PMID:17786224; http://dx.doi.org/10.1371/journal.pone.0000853 61.,Non-OADS,/arxiv_data1/oa_pdf/49/24/koni-05-12-1232236.PMC5214994.pdf
Proc Natl Acad SciU S A 2005; 102:17071-6; PMID:16286658; http://dx.doi.org/ 10.1073/pnas.0506070102 62.,OADS,/arxiv_data1/oa_pdf/49/24/koni-05-12-1232236.PMC5214994.pdf
J Physiol 2005; 564:131-43; PMID:15677684; http://dx.doi.org/10.1113/jphysiol.2004.081893 63.,Non-OADS,/arxiv_data1/oa_pdf/49/24/koni-05-12-1232236.PMC5214994.pdf
J Immunol 2015; 195:1372-6; PMID:26179900; http://dx.doi.org/10.4049/jimmunol.1402552 65.,Non-OADS,/arxiv_data1/oa_pdf/49/24/koni-05-12-1232236.PMC5214994.pdf
Annu Rev Immunol 2004;22:657-82; PMID:15032592; http://dx.doi.org/10.1146/annurev.,Non-OADS,/arxiv_data1/oa_pdf/49/24/koni-05-12-1232236.PMC5214994.pdf
Immunity 2013; 38:225-36; PMID:23415911; http://dx.doi.org/10.1016/j.immuni.2012.10.020 67.,OADS,/arxiv_data1/oa_pdf/49/24/koni-05-12-1232236.PMC5214994.pdf
Antioxid Redox Signal 2013; 18:1497-534;PMID:22938635; http://dx.doi.org/10.1089/ars.2011.4073 68.,Non-OADS,/arxiv_data1/oa_pdf/49/24/koni-05-12-1232236.PMC5214994.pdf
J Cell Biol 2007; 177:1029-36; PMID:17562787; http://dx.doi.org/10.1083/jcb.200609074 69.,OADS,/arxiv_data1/oa_pdf/49/24/koni-05-12-1232236.PMC5214994.pdf
Cancer Res 2011; 71:801-11; PMID:21266358; http://dx.doi.org/10.1158/0008-5472.CAN-10-1733 70.,Non-OADS,/arxiv_data1/oa_pdf/49/24/koni-05-12-1232236.PMC5214994.pdf
Clin Cancer Res 2015; 21:3113-20; PMID:25908780; http://dx.doi.org/10.1158/ 1078-0432.CCR-15-0263 72.,Non-OADS,/arxiv_data1/oa_pdf/49/24/koni-05-12-1232236.PMC5214994.pdf
EMBO Mol Med 2015; 7:368-79; PMID:25700172; http://dx.doi.org/10.15252/ emmm.201404271 73.,Non-OADS,/arxiv_data1/oa_pdf/49/24/koni-05-12-1232236.PMC5214994.pdf
Nat Rev Cancer 2012; 12:237-51; PMID:22437869; http://dx.doi.org/10.1038/nrc3237 74.,Non-OADS,/arxiv_data1/oa_pdf/49/24/koni-05-12-1232236.PMC5214994.pdf
Sci Transl Med 2015; 7:277ra30; PMID:25739764; http://dx.doi.org/10.1126/scitranslmed.aaa1260e1232236-8 R. VUILLEFROY DE SILLY ET AL.,OADS,/arxiv_data1/oa_pdf/49/24/koni-05-12-1232236.PMC5214994.pdf
Email: pgav7461@yahoo.com  doi: https://doi.org/10.14740/jocmr2804w,Non-OADS,/arxiv_data1/oa_pdf/63/c7/jocmr-09-081.PMC5215011.pdf
Email: HTARIQ@bronxleb.org doi: https://doi.org/10.14740/jocmr2832w,Non-OADS,/arxiv_data1/oa_pdf/97/42/jocmr-09-092.PMC5215012.pdf
Email: miuras@cis.fukuoka-u.ac.jp doi: https://doi.org/10.14740/jocmr2838w,Non-OADS,/arxiv_data1/oa_pdf/fd/57/jocmr-09-098.PMC5215013.pdf
Email: marianne.klemp@medisin.uio.no  doi: https://doi.org/10.14740/jocmr2817w,Non-OADS,/arxiv_data1/oa_pdf/b2/9a/jocmr-09-104.PMC5215014.pdf
Available from: http://www.nephro.no/nnr.,Non-OADS,/arxiv_data1/oa_pdf/b2/9a/jocmr-09-104.PMC5215014.pdf
Legemiddelsok 2013  [Available from: http://www.legemiddelverket.no/ Legemiddelsoek/Sider/default.aspx].,Non-OADS,/arxiv_data1/oa_pdf/b2/9a/jocmr-09-104.PMC5215014.pdf
Available from: http://www.nho.no/getfile.,Non-OADS,/arxiv_data1/oa_pdf/b2/9a/jocmr-09-104.PMC5215014.pdf
"Lonn for ansatte i private helse- og sosialtjenester, 2013  [Available from: http://www.ssb.no/lonnhelse/].",Non-OADS,/arxiv_data1/oa_pdf/b2/9a/jocmr-09-104.PMC5215014.pdf
Email:  HTARIQ@bronxleb.org doi: https://doi.org/10.14740/jocmr2847w,Non-OADS,/arxiv_data1/oa_pdf/80/43/jocmr-09-117.PMC5215015.pdf
2013 [cited; Available from: https://www.health.ny.gov/statistics/chac/birth/b13_58.htm.,OADS,/arxiv_data1/oa_pdf/80/43/jocmr-09-117.PMC5215015.pdf
2012 [cited; Available from: http://www.cdc.gov/nchs/fastats/teen-births.htm.,Non-OADS,/arxiv_data1/oa_pdf/80/43/jocmr-09-117.PMC5215015.pdf
State and County Quickfacts 2014 [cited 2014 July 2014]; Available from: http://quickfacts.cen - sus.gov/qfd/states/36/36005.html.,OADS,/arxiv_data1/oa_pdf/80/43/jocmr-09-117.PMC5215015.pdf
Email: Fatahi.j49@gmail.com doi: https://doi.org/10.14740/jocmr2796w,Non-OADS,/arxiv_data1/oa_pdf/39/b2/jocmr-09-124.PMC5215016.pdf
Available from: http://nuclearsafety.gc.ca/eng/resources/radiation/intro-duction-to-radiation/radiation-doses.cfm.,OADS,/arxiv_data1/oa_pdf/39/b2/jocmr-09-124.PMC5215016.pdf
Email: devecchis.erre@virgilio.it doi: https://doi.org/10.14740/jocmr2851w,Non-OADS,/arxiv_data1/oa_pdf/f4/aa/jocmr-09-130.PMC5215017.pdf
"Statistical analysis Statistical analysis was performed using Review Manager  5.0.4 software (available from Cochrane Collaboration at http://www.cochrane.org) and Stata version 10 (Stata Corp LP, College station, TX, USA).",OADS,/arxiv_data1/oa_pdf/f4/aa/jocmr-09-130.PMC5215017.pdf
Email: lavi.oud@ttuhsc.edu doi: https://doi.org/10.14740/jocmr2854w,Non-OADS,/arxiv_data1/oa_pdf/d1/e7/jocmr-09-143.PMC5215018.pdf
Available at: http://www.cdc.gov/nchs/data/NVSR/ NVSR61/NVSR61_01.pdf.,OADS,/arxiv_data1/oa_pdf/d1/e7/jocmr-09-143.PMC5215018.pdf
Available at: http://www.cdc.gov/re - productivehealth/maternalinfanthealth/severematernal- morbidity.html.,Non-OADS,/arxiv_data1/oa_pdf/d1/e7/jocmr-09-143.PMC5215018.pdf
Available at: http://www.dshs.state.tx.us/thcic/hospitals/Inpatientpudf.shtm.,Non-OADS,/arxiv_data1/oa_pdf/d1/e7/jocmr-09-143.PMC5215018.pdf
Available at: https://www.dshs.state.tx.us/chs/vstat/annrpts.shtm.,Non-OADS,/arxiv_data1/oa_pdf/d1/e7/jocmr-09-143.PMC5215018.pdf
Available at: http://www.ppip.co.za/wp-content/uploads/Saving-Babies-2008-9.pdf.,Non-OADS,/arxiv_data1/oa_pdf/d1/e7/jocmr-09-143.PMC5215018.pdf
Available at: http://www.dshs.state.tx.us/thcic/publications/hospitals/statisti - calreports.shtm 41.,Non-OADS,/arxiv_data1/oa_pdf/d1/e7/jocmr-09-143.PMC5215018.pdf
Email: dito@saitama-med.ac.jp doi: https://doi.org/10.14740/jocmr2875w,Non-OADS,/arxiv_data1/oa_pdf/81/d4/jocmr-09-154.PMC5215019.pdf
Email: fionasan@rediffmail.com doi: https://doi.org/10.14740/jocmr2829w,Non-OADS,/arxiv_data1/oa_pdf/2a/81/jocmr-09-163.PMC5215020.pdf
Email: Navkiran.shokar@ttuhsc.edu doi: https://doi.org/10.14740/jocmr2868w,Non-OADS,/arxiv_data1/oa_pdf/0e/c5/jocmr-09-170.PMC5215021.pdf
"2010. https://www.dshs.state.tx.us/Layouts/ContentPage.aspx?pageid=35474&year=10&ris k=170&area=ElPaso, 2010.",Non-OADS,/arxiv_data1/oa_pdf/0e/c5/jocmr-09-170.PMC5215021.pdf
Email: heyman@cc.huji.ac.il doi: https://doi.org/10.14740/jocmr2849w,Non-OADS,/arxiv_data1/oa_pdf/ad/03/jocmr-09-176.PMC5215022.pdf
Email: dyanai@hospk.ncgm.go.jp doi: https://doi.org/10.14740/jocmr2857w,Non-OADS,/arxiv_data1/oa_pdf/64/1c/jocmr-09-178.PMC5215023.pdf
"Ministry of Health, La-bour and Welfare, 2015. http://rhino3.med.yamanashi.ac.jp/sukoyaka2/english.html (December 13, 2016).",Non-OADS,/arxiv_data1/oa_pdf/85/d4/jocmr-09-180.PMC5215024.pdf
Email: czg83542@mopera.ne.jp doi: https://doi.org/10.14740/jocmr2883w,Non-OADS,/arxiv_data1/oa_pdf/85/d4/jocmr-09-180.PMC5215024.pdf
https://www.nice.org.uk/guidance/ng28/resources/ type-2-diabetes-in-adults-management-1837338615493.,Non-OADS,/arxiv_data1/oa_pdf/9c/01/DOM-19-3.PMC5215074.pdf
2016. http://www.ema.,Non-OADS,/arxiv_data1/oa_pdf/9c/01/DOM-19-3.PMC5215074.pdf
https://clinicaltrials.gov/ct2/show/NCT02536859?te rm=NCT02536859&rank=1.,Non-OADS,/arxiv_data1/oa_pdf/9c/01/DOM-19-3.PMC5215074.pdf
http://www.hanmipharm.,Non-OADS,/arxiv_data1/oa_pdf/9c/01/DOM-19-3.PMC5215074.pdf
"To view a copy of this license, visit http://creativecom mons.org/licenses/by-nc-nd/4.0/ rThe Author(s) 2017 The Supplementary Information that accompanies this paper is available on the Immunology and Cel l Biology website (http://www.nature.com/icb)NFAT5 regulates Th17 and IFN γresponses in T cells MA l b e r d i et al 67 Immunology and Cell Biology",Non-OADS,/arxiv_data1/oa_pdf/ba/65/icb201669a.PMC5215110.pdf
"See: http://creativecommons.org/ licenses/by ­ nc/4.0/ Manuscript source:  Invited manuscript Correspondence to: Stefano Caruso, MD,  Department of  General Surgery and Surgical Specialties, Unit of General Surgery,  “Santa Maria Annunziata” Hospital, ASL Firenze, Via dell’Antella Submit a Manuscript: http://www.wjgnet.com/esps/ Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx DOI:   0.4253/wjge.v9.i  .",Non-OADS,/arxiv_data1/oa_pdf/8d/da/WJGE-9-1.PMC5215113.pdf
"World J Gastrointest Endosc  2017; 9(1): 1­11   Available from: URL:  http://www.wjgnet.com/1948 ­ 5190/full/v9/ i1/1.htm  DOI: http://dx.doi.org/10.4253/wjge.v9.i1.1 INTRODUCTION In 1991, Kitano et al[1] performed the first lapar o scopically  assisted gastrectomy for gastric cancer .",Non-OADS,/arxiv_data1/oa_pdf/8d/da/WJGE-9-1.PMC5215113.pdf
"© 2017 Baishideng Publishing Group Inc. All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx http://www.wjgnet.com",Non-OADS,/arxiv_data1/oa_pdf/8d/da/WJGE-9-1.PMC5215113.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ Manuscript source:  Invited manuscript Correspondence to: Rintaro Mikata, MD, PhD, Assistant  Professor of Medicine, Department of Gastroenterology and  Nephrology, Graduate School of Medicine, Chiba University, Submit a Manuscript: http://www.wjgnet.com/esps/ Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx DOI: 10.4253/wjge.v9.i1.12World J Gastrointest Endosc   2017 January 16; 9(1): 12-18 ISSN 1948-5190 (online) © 2017 Baishideng Publishing Group Inc. All rights reserved.",Non-OADS,/arxiv_data1/oa_pdf/eb/e9/WJGE-9-12.PMC5215114.pdf
"World  J Gastrointest Endosc  2017; 9(1): 12-18  Available from: URL:   http://www.wjgnet.com/1948-5190/full/v9/i1/12.htm  DOI: http:// dx.doi.org/10.4253/wjge.v9.i1.12 INTRODUCTION Chronic pancreatitis (CP) is characterized by progressive  inflammation of the pancreas, which leads to perma­ nent damage of pancreatic structure, function, or both,  resulting in episodic or intractable abdominal pain with  progressive exocrine and endocrine insufficiency[1].",Non-OADS,/arxiv_data1/oa_pdf/eb/e9/WJGE-9-12.PMC5215114.pdf
"© 2017 Baishideng Publishing Group Inc. All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx http://www.wjgnet.com",Non-OADS,/arxiv_data1/oa_pdf/eb/e9/WJGE-9-12.PMC5215114.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ Manuscript source:  Invited manuscript Correspondence to: Walid M Chalhoub, MD, Division of  Gastroenterology, Medstar Georgetown University Hospital, 3800  Reservoir Rd NW, Washington, DC 20007,  United States.",Non-OADS,/arxiv_data1/oa_pdf/3d/ef/WJGE-9-19.PMC5215115.pdf
walid.m.chalhoub@gunet.georgetown.eduSubmit a Manuscript: http://www.wjgnet.com/esps/ Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx DOI: 10.4253/wjge.v9.i1.19World J Gastrointest Endosc   2017 January 16; 9(1): 19-25 ISSN 1948-5190 (online) © 2017 Baishideng Publishing Group Inc. All rights reserved.,Non-OADS,/arxiv_data1/oa_pdf/3d/ef/WJGE-9-19.PMC5215115.pdf
"World J Gastrointest Endosc  2017; 9(1):  19-25  Available from: URL:  http://www.wjgnet.com/1948-5190/ full/v9/i1/19.htm  DOI: http://dx.doi.org/10.4253/wjge.v9.i1.19 Introduct Ion Gastric antral web (GAW), or antral diaphragm, is an  uncommon endoscopic finding and a rare cause of gastric  outlet obstruction (GOO).",Non-OADS,/arxiv_data1/oa_pdf/3d/ef/WJGE-9-19.PMC5215115.pdf
"© 2017 Baishideng Publishing Group Inc. All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx http://www.wjgnet.com",Non-OADS,/arxiv_data1/oa_pdf/3d/ef/WJGE-9-19.PMC5215115.pdf
"It is distributed in accordance with the Creative  Commons Attribution Non Commercial (CC BY-NC 4.0) license,  which permits others to distribute, remix, adapt, build upon this  work non-commercially, and license their derivative works on Submit a Manuscript: http://www.wjgnet.com/esps/ Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx DOI: 10.4253/wjge.v9.i1.26World J Gastrointest Endosc   2017 January 16; 9(1): 26-33 ISSN 1948-5190 (online) © 2017 Baishideng Publishing Group Inc. All rights reserved.",Non-OADS,/arxiv_data1/oa_pdf/a4/25/WJGE-9-26.PMC5215116.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ Manuscript source:  Invited manuscript Correspondence to: Christos Konstantakis, MD, Department  of Gastroenterology, General Hospital of Patras, 1 Tsertidou St,  26335 Patras, Greece.",Non-OADS,/arxiv_data1/oa_pdf/a4/25/WJGE-9-26.PMC5215116.pdf
World  J Gastrointest Endosc  2017; 9(1): 26-33  Available from: URL:   http://www.wjgnet.com/1948-5190/full/v9/i1/26.htm  DOI: http:// dx.doi.org/10.4253/wjge.v9.i1.26INTRODUCTION Endoscopic retrograde cholangiopancreatography  (ERCP) is widely accepted as the modality of choice for  the endoscopic removal of bile duct stones.,Non-OADS,/arxiv_data1/oa_pdf/a4/25/WJGE-9-26.PMC5215116.pdf
"© 2017 Baishideng Publishing Group Inc. All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx http://www.wjgnet.com",Non-OADS,/arxiv_data1/oa_pdf/a4/25/WJGE-9-26.PMC5215116.pdf
Conflict-of-interest statement:  The authors declare that there is  no conflict of intere sts regarding the publication of this paper.Submit a Manuscript: http://www.wjgnet.com/esps/ Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx DOI: 10.4253/wjge.v9.i1.34World J Gastrointest Endosc   2017 January 16; 9(1): 34-40 ISSN 1948-5190 (online) © 2017 Baishideng Publishing Group Inc. All rights reserved.,Non-OADS,/arxiv_data1/oa_pdf/ca/ad/WJGE-9-34.PMC5215117.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ Manuscript source:  Invited manuscript Correspondence to: Sara Monteiro, MD,  Department of  Gastroenterology, Hospital da Senhora da Oliveira-Guimarães, Rua  dos Cutileiros, Creixomil, 4835-044 Guimarães,  Portugal.",Non-OADS,/arxiv_data1/oa_pdf/ca/ad/WJGE-9-34.PMC5215117.pdf
"wjgnet.com/1948 -5190/full/v9/i1/34.htm  DOI: http://dx.doi.org/10.4253/wjge.v9.i1.34 INTRODUCTION The differential diagnosis of Crohn’s disease (CD) and  ulcerative colitis (UC) relies on a combination of clinical,  analytical, imaging, endoscopic and histologic data[1,2].",Non-OADS,/arxiv_data1/oa_pdf/ca/ad/WJGE-9-34.PMC5215117.pdf
"© 2017 Baishideng Publishing Group Inc. All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx http://www.wjgnet.com",Non-OADS,/arxiv_data1/oa_pdf/ca/ad/WJGE-9-34.PMC5215117.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/ae/2e/jpr-10-065.PMC5215120.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/ae/2e/jpr-10-065.PMC5215120.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Journal of Pain Research  2017:10 65–72Journal of Pain Research Dovepress submit your manuscript | www.dovepress.com Dovepress  65 ORIGINAL RESEARCH open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/JPR.S122601Pain acceptance potentially mediates the  relationship between pain catastrophizing  and post-surgery outcomes among  compensated lumbar fusion patients Cassie Dance1  M. Scott DeBerard1 Jessica Gundy Cuneo2 1Department of Psychology,   Utah State University, Logan, UT,   2Department of Psychiatry, University  of California, San Diego, CA, USAPurpose: Chronic low back pain is highly prevalent and often treatment recalcitrant condition,  particularly among workers’ compensation patients.",Non-OADS,/arxiv_data1/oa_pdf/ae/2e/jpr-10-065.PMC5215120.pdf
"5  Chronic pain often co-occurs with mental health challenges, particularly anxiety and Correspondence: M. Scott DeBerard  Department of Psychology, Utah State University, Logan, UT 84322-2810, USATel +1 435 797 1462Fax +1 435 797 1448Email scott.deberard@usu.eduJournal name: Journal of Pain Research  Article Designation: ORIGINAL RESEARCHY ear: 2017V olume: 10Running head verso: Dance et alRunning head recto: Pain acceptance as a potential mediator in post-surgery outcomesDOI: http://dx.doi.org/10.2147/JPR.S122601",Non-OADS,/arxiv_data1/oa_pdf/ae/2e/jpr-10-065.PMC5215120.pdf
Available from: https://www.ncbi.nlm.nih.gov/pubmed/27779603.,Non-OADS,/arxiv_data1/oa_pdf/ae/2e/jpr-10-065.PMC5215120.pdf
"Journal of Pain Research  2017:10submit your manuscript | www.dovepress.com Dovepress Dovepress Journal of Pain Research  Publish your work in this journal Submit your manuscript here:  https://www.dovepress.com/journal-of-pain-research-journal The Journal of Pain Research is an international, peer reviewed, open  access, online journal that welcomes laboratory and clinical findings   in the fields of pain research and the prevention and management of pain.",Non-OADS,/arxiv_data1/oa_pdf/ae/2e/jpr-10-065.PMC5215120.pdf
Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.Dovepress 72 Dance et al  30.,Non-OADS,/arxiv_data1/oa_pdf/ae/2e/jpr-10-065.PMC5215120.pdf
Available from: http://sullivan-painresearch.mcgill.ca/pcs1.php.,Non-OADS,/arxiv_data1/oa_pdf/ae/2e/jpr-10-065.PMC5215120.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ Manuscript source: Invited manuscript Correspondence to:  Antonios H Tzamaloukas, MD, MACP,  Section of Nephrology, Medicine Service (111C), Raymond G.  Murphy Veterans Affairs Medical Center, 1501 San Pedro, SE,  Albuquerque, NM 87108,  United States.",Non-OADS,/arxiv_data1/oa_pdf/89/75/WJN-6-1.PMC5215203.pdf
"antonios.tzamaloukas@va.gov Telephone:  +1-505-2651711 Fax: +1-505-2566441 Received: June 13, 2016 Peer-review started: June 16, 2016 First decision:  July 27, 2016 Revised: October 17, 2016World Journal of  Nephrology WJN Submit a Manuscript: http://www.wjgnet.com/esps/ Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx DOI: 0.5527/wjn.v6.i.World J Nephrol   207 January 6; 6(): -3 ISSN 2220-624 (online) © 207 Baishideng Publishing Group Inc. All rights reserved.",Non-OADS,/arxiv_data1/oa_pdf/89/75/WJN-6-1.PMC5215203.pdf
"World J Nephrol  2017; 6(1): 1-13  Available from:  URL:  http://www.wjgnet.com/2220-6124/full/v6/i1/1.htm  DOI:  http://dx.doi.org/10.5527/wjn.v6.i1.1 INTRODUCTION A previous report discussed pathophysiological aspects,  quantitative predictions and experimental testing of  hypertonicity[1].",Non-OADS,/arxiv_data1/oa_pdf/89/75/WJN-6-1.PMC5215203.pdf
"© 2017 Baishideng Publishing Group Inc. All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx http://www.wjgnet.com",Non-OADS,/arxiv_data1/oa_pdf/89/75/WJN-6-1.PMC5215203.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ Manuscript source: Invited manuscript Correspondence to: Nobuhiko Satoh, MD, Department of  Internal Medicine, Faculty of Medicine, the University of Tokyo  Hospital, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-8655,  Japan.",Non-OADS,/arxiv_data1/oa_pdf/4e/48/WJN-6-14.PMC5215204.pdf
"Core tip: Chloride channel 5 (CLC-5) mutations cause  Dent’s disease, which is characterized by renal proximal World Journal of  Nephrology WJN Submit a Manuscript: http://www.wjgnet.com/esps/ Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx DOI: 10.5527/wjn.v6.i1.14World J Nephrol   2017 January 6; 6(1): 14-20 ISSN 2220-6124 (online) © 2017 Baishideng Publishing Group Inc. All rights reserved.",Non-OADS,/arxiv_data1/oa_pdf/4e/48/WJN-6-14.PMC5215204.pdf
wjgnet.com/2220-6124/full/v6/i1/14.htm  DOI: http://dx.doi.,OADS,/arxiv_data1/oa_pdf/4e/48/WJN-6-14.PMC5215204.pdf
"© 2017 Baishideng Publishing Group Inc. All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx http://www.wjgnet.com",Non-OADS,/arxiv_data1/oa_pdf/4e/48/WJN-6-14.PMC5215204.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ Manuscript   source:   Invited   manuscriptCorrespondence to: Dr. Simon JM Welham, Division  of Nutritional Sciences, School of Biosciences, University  of Nottingham, Sutton Bonington Campus, Loughborough,  Leicestershire LE12 5RD,  United Kingdom.",Non-OADS,/arxiv_data1/oa_pdf/99/66/WJN-6-21.PMC5215205.pdf
Whole- mount labelling to fluorescently detect laminin enabled  crude determination o f epithelial branching using confocal World Journal of  Nephrology WJN Submit a Manuscript: http://www.wjgnet.com/esps/ Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx DOI: 10.5527/wjn.v6.i1.21World J Nephrol   2017 January 6; 6(1): 21-28 ISSN 2220-6124 (online) © 2017 Baishideng Publishing Group Inc. All rights reserved.,Non-OADS,/arxiv_data1/oa_pdf/99/66/WJN-6-21.PMC5215205.pdf
World J Nephrol  2017; 6(1):  21-28  Available from: URL:  http://www.wjgnet.com/2220-6124/ full/v6/i1/21.htm  DOI: http://dx.doi.org/10.5527/wjn.v6.i1.21 INTRODUCTION Non-steroidal anti-inflammatory drugs (NSAIDs) such  as aspirin and ibuprofen are commonly used analgesics  for the treatment of low-grade pain and inflammation.,Non-OADS,/arxiv_data1/oa_pdf/99/66/WJN-6-21.PMC5215205.pdf
"© 2017 Baishideng Publishing Group Inc. All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx http://www.wjgnet.com",Non-OADS,/arxiv_data1/oa_pdf/99/66/WJN-6-21.PMC5215205.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ Manuscript source: Invited manuscript Correspondence to: Marcelo Roberto Choi, MD, PhD,  Professor of Human Anatomy and Histology, School of Pharmacy  and Biochemistry, University of Buenos Aires, Marcelo T de  Alvear 2270, 4º Piso, Buenos Aires C1122AAJ,  Argentina.",Non-OADS,/arxiv_data1/oa_pdf/e7/2e/WJN-6-29.PMC5215206.pdf
"Mean arterial pressure (MAP), glomerular World Journal of  Nephrology WJN Submit a Manuscript: http://www.wjgnet.com/esps/ Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx DOI: 10.5527/wjn.v6.i1.29World J Nephrol   2017 January 6; 6(1): 29-40 ISSN 2220-6124 (online) © 2017 Baishideng Publishing Group Inc. All rights reserved.",Non-OADS,/arxiv_data1/oa_pdf/e7/2e/WJN-6-29.PMC5215206.pdf
World J Nephrol  2017; 6(1): 29-40  Available from: URL:  http:// www.wjgnet.com/2220-6124/full/v6/i1/29.htm  DOI: http://dx.doi.,OADS,/arxiv_data1/oa_pdf/e7/2e/WJN-6-29.PMC5215206.pdf
"© 2017 Baishideng Publishing Group Inc. All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx http://www.wjgnet.com",Non-OADS,/arxiv_data1/oa_pdf/e7/2e/WJN-6-29.PMC5215206.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ Manuscript source:  Invited manuscript Correspondence to:  Rajiv Sinha, MD, FRCPCH (UK), CCT,  Associate professor, Department of Pediatric Nephrology,  Institute of Child Health, 11, Dr Biresh Guha Street, Kolkata  700017, India.",Non-OADS,/arxiv_data1/oa_pdf/43/6a/WJN-6-41.PMC5215207.pdf
Published by Baishideng Publishing  Group Inc. All  rights reserved.World Journal of  Nephrology WJN Submit a Manuscript: http://www.wjgnet.com/esps/ Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx DOI: 10.5527/wjn.v6.i1.41World J Nephrol   2017 January 6; 6(1): 41-44 ISSN 2220-6124 (online) © 2017 Baishideng Publishing Group Inc. All rights reserved.,Non-OADS,/arxiv_data1/oa_pdf/43/6a/WJN-6-41.PMC5215207.pdf
wjgnet.com/2220-6124/full/v6/i1/41.htm  DOI: http://dx.doi.,OADS,/arxiv_data1/oa_pdf/43/6a/WJN-6-41.PMC5215207.pdf
"© 2017 Baishideng Publishing Group Inc. All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx http://www.wjgnet.com",Non-OADS,/arxiv_data1/oa_pdf/43/6a/WJN-6-41.PMC5215207.pdf
"See: http://creativecommons.org/licenses/by-nc/4.0/ Manuscript source:  Invited manuscript Correspondence to: Georgios Tsoulfas, MD, PhD, Assistant  Professor of Surgery, Department of Surgery, Aristotle University  of Thessaloniki, 66 Tsimiski Street, 54622 Thessaloniki,  Greece.",Non-OADS,/arxiv_data1/oa_pdf/da/bb/WJN-6-45.PMC5215208.pdf
World Journal of  Nephrology WJN Submit a Manuscript: http://www.wjgnet.com/esps/ Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx DOI: 10.5527/wjn.v6.i1.45World J Nephrol   2017 January 6; 6(1): 45-52 ISSN 2220-6124 (online) © 2017 Baishideng Publishing Group Inc. All rights reserved.,Non-OADS,/arxiv_data1/oa_pdf/da/bb/WJN-6-45.PMC5215208.pdf
World J Nephrol   2017; 6(1): 45-52  Available from: URL:  http://www.wjgnet.,Non-OADS,/arxiv_data1/oa_pdf/da/bb/WJN-6-45.PMC5215208.pdf
"com/2220-6124/full/v6/i1/45.htm  DOI: http://dx.doi.org/10.5527/ wjn.v6.i1.45 INTRODUCTION Laparoscopic living donor nephrectomy (LLDN) is not a  novel procedure, since the first one was performed in  1995 by Ratner et al[1] and it was subsequently made  easier to learn with the description of the hand-assisted  approach by Wolf et al[2] and Slakey et al[3].",Non-OADS,/arxiv_data1/oa_pdf/da/bb/WJN-6-45.PMC5215208.pdf
Available  from: URL: http://esceincenews.com/articles/2009/02/02/hopkins.,Non-OADS,/arxiv_data1/oa_pdf/da/bb/WJN-6-45.PMC5215208.pdf
"© 2017 Baishideng Publishing Group Inc. All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx http://www.wjgnet.com",Non-OADS,/arxiv_data1/oa_pdf/da/bb/WJN-6-45.PMC5215208.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ Manuscript  source:  Invited  manuscript Correspondence to: Moses S Elisaf, MD, FASA, FRPSH,  Professor  of Medicine, Department of Internal Medicine, Medical  School, University of Ioannina, Stavros Niarchos Avenue, 45110  Ioannina, Greece.",Non-OADS,/arxiv_data1/oa_pdf/b0/32/WJN-6-53.PMC5215209.pdf
Severe hyperkalemia World Journal of  Nephrology WJN Submit a Manuscript: http://www.wjgnet.com/esps/ Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx DOI: 10.5527/wjn.v6.i1.53World J Nephrol   2017 January 6; 6(1): 53-56 ISSN 2220-6124 (online) © 2017 Baishideng Publishing Group Inc. All rights reserved.,Non-OADS,/arxiv_data1/oa_pdf/b0/32/WJN-6-53.PMC5215209.pdf
World J Nephrol   2017; 6(1): 53-56  Available from: URL:  http://www.wjgnet.,Non-OADS,/arxiv_data1/oa_pdf/b0/32/WJN-6-53.PMC5215209.pdf
com/2220-6124/full/v6/i1/53.htm  DOI: http://dx.doi.,OADS,/arxiv_data1/oa_pdf/b0/32/WJN-6-53.PMC5215209.pdf
"© 2017 Baishideng Publishing Group Inc. All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx http://www.wjgnet.com",Non-OADS,/arxiv_data1/oa_pdf/b0/32/WJN-6-53.PMC5215209.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ Manuscript source: Unsolicited manuscript Correspondence to: Usama AA Sharaf El Din, MD, Professor ,  Department of Nephrology, School of Medicine, Cairo University,  58th Abbas El Akkad St., Nasr City, Cairo 11759,  Egypt.",Non-OADS,/arxiv_data1/oa_pdf/1e/ac/WJN-6-57.PMC5215210.pdf
"World J Nephrol  2017; 6(1): 57-58  Available  from: URL:  http://www.wjgnet.com/2220-6124/full/v6/i1/57.htm   DOI: http://dx.doi.org/10.5527/wjn.v6.i1.57 TO THE EDITOR In the September 6 issue of World J Nephrol , the review  article titled “Vascular calcification: When should we  interfere in chronic kidney disease patients and how?”  showed that the exact pathogenesis of inflammation  in chronic kidney disease (CKD) is not fully understood  and that many of the inflammatory markers and med­ iators can promote vascular calcification (VC) in CKD  patients.",Non-OADS,/arxiv_data1/oa_pdf/1e/ac/WJN-6-57.PMC5215210.pdf
Similar results were World Journal of  Nephrology WJN Submit a Manuscript: http://www.wjgnet.com/esps/ Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx DOI: 10.5527/wjn.v6.i1.57World J Nephrol   2017 January 6; 6(1): 57-58 ISSN 2220-6124 (online) © 2017 Baishideng Publishing Group Inc. All rights reserved.,Non-OADS,/arxiv_data1/oa_pdf/1e/ac/WJN-6-57.PMC5215210.pdf
Available from: URL: http://www.posters2view.,Non-OADS,/arxiv_data1/oa_pdf/1e/ac/WJN-6-57.PMC5215210.pdf
"© 2017 Baishideng Publishing Group Inc. All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx http://www.wjgnet.com",Non-OADS,/arxiv_data1/oa_pdf/1e/ac/WJN-6-57.PMC5215210.pdf
"10, 1608 –1619 http://dx.doi.org/10.1080/19440049.2016.1219071 © 2016 The Author(s).",Non-OADS,/arxiv_data1/oa_pdf/b8/30/tfac-33-1608.PMC5215223.pdf
"Published by Informa UK Limited, trading as Taylor & Francis Group This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License ( http://creativecommons.org/licenses/by-nc- nd/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.",Non-OADS,/arxiv_data1/oa_pdf/b8/30/tfac-33-1608.PMC5215223.pdf
"Available at https://cran.r-project.org/web/packages/MuMIn/index.html Bernhoft A, Torp M, Clasen PE, Løes AK, Kristoffersen AB.",Non-OADS,/arxiv_data1/oa_pdf/b8/30/tfac-33-1608.PMC5215223.pdf
"The variant is known in the Single Nucleotide Polymorphism Database (dbSNP; https://www.ncbi.nlm.nih.gov/SNP/, available in the public domain asrs143166696).",Non-OADS,/arxiv_data1/oa_pdf/77/fc/i1552-5783-57-15-6861.PMC5215230.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License ( http://creativecommons.org/licenses/by-nc/4.0/ ), which permits unre- stricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/3b/0b/koni-05-12-1238543.PMC5215235.pdf
"12, e1238543 (14 pages)http://dx.doi.org/10.1080/2162402X.2016.1238543",Non-OADS,/arxiv_data1/oa_pdf/3b/0b/koni-05-12-1238543.PMC5215235.pdf
ORCID Yizhan Guo http://orcid.org/0000-0001-7627-6423 Jinsheng Yu http://orcid.org/0000-0003-3377-4304 Beatrice Plougastel-Douglas http://orcid.org/0000-0002-6389-561X Leonard Maggi http://orcid.org/0000-0003-0138-0984 References 1.,Non-OADS,/arxiv_data1/oa_pdf/3b/0b/koni-05-12-1238543.PMC5215235.pdf
Lancet 2000; 356:1795-9; PMID:11117911; http://dx.doi.org/10.1016/S0140-6736(00)03231-1 2.,OADS,/arxiv_data1/oa_pdf/3b/0b/koni-05-12-1238543.PMC5215235.pdf
J Exp Med 2005; 202:1679-89; PMID:16352740; http://dx.doi.org/10.1084/jem.20051473 3.,OADS,/arxiv_data1/oa_pdf/3b/0b/koni-05-12-1238543.PMC5215235.pdf
Cancer Res 2012; 72:4311-7; PMID:22751136; http://dx.doi.org/10.1158/0008-5472.CAN-12-0908 4.,Non-OADS,/arxiv_data1/oa_pdf/3b/0b/koni-05-12-1238543.PMC5215235.pdf
"Frese-Schaper M, Keil A, Yagita H, Steiner SK, Falk W, Schmid RA, Frese S. In ﬂuence of natural killer cells and perforinmediated cytolysis on the development of chemically induced lung cancer in A/J mice.Cancer Immunol Immunother 2014; 63:571-80; PMID:24658838;http://dx.doi.org/10.1007/s00262-014-1535-x 5.",Non-OADS,/arxiv_data1/oa_pdf/3b/0b/koni-05-12-1238543.PMC5215235.pdf
Immunity 2007; 26:798-811; PMID:17540585; http://dx.doi.org/ 10.1016/j.immuni.2007.04.010 6.,OADS,/arxiv_data1/oa_pdf/3b/0b/koni-05-12-1238543.PMC5215235.pdf
Sci- ence 2013; 341:849-50; PMID:23970686; http://dx.doi.org/10.1126/ science.1244156 7.,OADS,/arxiv_data1/oa_pdf/3b/0b/koni-05-12-1238543.PMC5215235.pdf
Cell 1995; 82:697-700; PMID:7671299; http://dx.doi.org/10.1016/0092-8674(95)90466-2 8.,OADS,/arxiv_data1/oa_pdf/3b/0b/koni-05-12-1238543.PMC5215235.pdf
Seminars Immunol 1995; 7:89-101; PMID:7579199; http://dx.doi.org/10.1006/smim.1995.0013 9.,Non-OADS,/arxiv_data1/oa_pdf/3b/0b/koni-05-12-1238543.PMC5215235.pdf
Cancer Immunol Res 2014; 2:1142-7; PMID:25135909; http://dx.doi.org/10.1158/2326-6066.CIR-14-0091 10.,Non-OADS,/arxiv_data1/oa_pdf/3b/0b/koni-05-12-1238543.PMC5215235.pdf
Genes Immunity 2010; 11:637-48; PMID:20861859; http://dx.doi.org/10.1038/gene.2010.48 11.,OADS,/arxiv_data1/oa_pdf/3b/0b/koni-05-12-1238543.PMC5215235.pdf
Mol Cell Biol 2005; 25:9646-60; PMID:16227612; http://dx.doi.org/10.1128/MCB.25.21.9646-9660.2005 12.,Non-OADS,/arxiv_data1/oa_pdf/3b/0b/koni-05-12-1238543.PMC5215235.pdf
BMC Immunol 2009; 10:38; PMID:19604361; http://dx.doi.org/10.1186/1471-2172-10-3813.,Non-OADS,/arxiv_data1/oa_pdf/3b/0b/koni-05-12-1238543.PMC5215235.pdf
Eur J Immunol 2015; 45:3087-97;PMID:26306874; http://dx.doi.org/10.1002/eji.201545609 14.,Non-OADS,/arxiv_data1/oa_pdf/3b/0b/koni-05-12-1238543.PMC5215235.pdf
Biochim Et Biophys Acta 2001; 1520:89-93; PMID:11470164; http://dx.doi.org/10.1016/S0167-4781(01)00242-1 15.,OADS,/arxiv_data1/oa_pdf/3b/0b/koni-05-12-1238543.PMC5215235.pdf
Nature 2005; 436:709-13; PMID:16079848; http://dx.doi.org/ 10.1038/nature03847 16.,Non-OADS,/arxiv_data1/oa_pdf/3b/0b/koni-05-12-1238543.PMC5215235.pdf
Int J Cancer Suppl 1991; 6:38- 44; PMID:2066183; http://dx.doi.org/10.1002/ijc.2910470711 17.,Non-OADS,/arxiv_data1/oa_pdf/3b/0b/koni-05-12-1238543.PMC5215235.pdf
Blood 2009; 113:5488-96; PMID:19234143; http://dx.doi.org/10.1182/blood- 2008-10-187179 18.,Non-OADS,/arxiv_data1/oa_pdf/3b/0b/koni-05-12-1238543.PMC5215235.pdf
J Immunol 2001; 167:1141- 4; PMID:11466327; http://dx.doi.org/10.4049/jimmunol.167.3.1141 19.,Non-OADS,/arxiv_data1/oa_pdf/3b/0b/koni-05-12-1238543.PMC5215235.pdf
Blood 2007; 109:859-61; PMID:17003367; http://dx.doi.org/10.1182/blood- 2006-06-027490 21.,Non-OADS,/arxiv_data1/oa_pdf/3b/0b/koni-05-12-1238543.PMC5215235.pdf
Annual Rev Immunol 2006; 24:257-86; PMID:16551250; http://dx.doi.org/10.1146/annurev.immunol.24.021605.090700 22.,Non-OADS,/arxiv_data1/oa_pdf/3b/0b/koni-05-12-1238543.PMC5215235.pdf
Proc Natl Acad Sci U S A 1999; 96:14943-8; PMID:10611317; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/3b/0b/koni-05-12-1238543.PMC5215235.pdf
Nucleophosmin serves as a rate-limiting nuclear export chaperone for the Mammalian ribosome.Mol Cell Biol 2008; 28:7050-65; PMID:18809582; http://dx.doi.org/10.1128/MCB.01548-07 25.,Non-OADS,/arxiv_data1/oa_pdf/3b/0b/koni-05-12-1238543.PMC5215235.pdf
Nat Struct Biol 2003; 10:614-21;PMID:12858164; http://dx.doi.org/10.1038/nsb956 26.,OADS,/arxiv_data1/oa_pdf/3b/0b/koni-05-12-1238543.PMC5215235.pdf
DNA Repair (Amst) 2009; 8:1215-24; PMID:19656744; http://dx.doi.org/10.1016/j.dnarep.2009.07.003 27.,OADS,/arxiv_data1/oa_pdf/3b/0b/koni-05-12-1238543.PMC5215235.pdf
Splicing-factor oncopro- tein SRSF1 stabilizes p53 via RPL5 and induces cellular senescence.Mol Cell 2013; 50:56-66; PMID:23478443; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/3b/0b/koni-05-12-1238543.PMC5215235.pdf
Mol Cell Biol 2013; 33:4660-71; PMID:24061479; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/3b/0b/koni-05-12-1238543.PMC5215235.pdf
Nucleic Acids Res 2013; 41:7625-34; PMID:23804757; http://dx.doi.org/10.1093/nar/gkt548ONCOIMMUNOLOGY e1238543-13,Non-OADS,/arxiv_data1/oa_pdf/3b/0b/koni-05-12-1238543.PMC5215235.pdf
Nat Struct Mol Biol 2015; 22:11-9; PMID:25565028;http://dx.doi.org/10.1038/nsmb.2939 31.,OADS,/arxiv_data1/oa_pdf/3b/0b/koni-05-12-1238543.PMC5215235.pdf
Cell Rep 2013; 5:237- 47; PMID:24120868; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/3b/0b/koni-05-12-1238543.PMC5215235.pdf
Mol Cell Biol 2004; 24:7654-68; PMID:15314173; http://dx.doi.org/10.1128/MCB.24.17.7654-7668.2004 34.,Non-OADS,/arxiv_data1/oa_pdf/3b/0b/koni-05-12-1238543.PMC5215235.pdf
Cancer Cell 2003; 3:577-87; PMID:12842086; http://dx.doi.org/10.1016/S1535-6108(03)00134-X 35.,Non-OADS,/arxiv_data1/oa_pdf/3b/0b/koni-05-12-1238543.PMC5215235.pdf
Cold SpringHarb Symp Quant Biol 1994; 59:277-86; PMID:7587079; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/3b/0b/koni-05-12-1238543.PMC5215235.pdf
Nat Rev Mol Cell Biol 2008; 9:402-12;PMID:18431400; http://dx.doi.org/10.1038/nrm2395 38.,OADS,/arxiv_data1/oa_pdf/3b/0b/koni-05-12-1238543.PMC5215235.pdf
Immunity 2012; 36:55-67; PMID:22261438; http://dx.doi.org/10.1016/j.immuni.2011.11.016 40.,OADS,/arxiv_data1/oa_pdf/3b/0b/koni-05-12-1238543.PMC5215235.pdf
Cancer Res 2012; 72:1602-7; PMID:22282659; http://dx.doi.org/10.1158/0008-5472.CAN-11-3992 41.,Non-OADS,/arxiv_data1/oa_pdf/3b/0b/koni-05-12-1238543.PMC5215235.pdf
J Immu- nol 2010; 185:4783-92; PMID:20855875; http://dx.doi.org/10.4049/ jimmunol.1001287 42.,Non-OADS,/arxiv_data1/oa_pdf/3b/0b/koni-05-12-1238543.PMC5215235.pdf
J Exp Med 1998; 188:2243-56; PMID:9858511; http://dx.doi.org/10.1084/jem.188.12.2243 43.,Non-OADS,/arxiv_data1/oa_pdf/3b/0b/koni-05-12-1238543.PMC5215235.pdf
Front Immunol 2014;5:305; PMID:25071766; http://dx.doi.org/10.3389/ ﬁmmu.2014.00305 44.,Non-OADS,/arxiv_data1/oa_pdf/3b/0b/koni-05-12-1238543.PMC5215235.pdf
Oncogene 2003; 22:2972-83; PMID:12771949; http://dx.doi.org/10.1038/sj.onc.1206474 45.,Non-OADS,/arxiv_data1/oa_pdf/3b/0b/koni-05-12-1238543.PMC5215235.pdf
J Biol Chem 2003; 278:9267-75;PMID:12515807; http://dx.doi.org/10.1074/jbc.M211252200 47.,OADS,/arxiv_data1/oa_pdf/3b/0b/koni-05-12-1238543.PMC5215235.pdf
Br J Cancer 2006; 95:1419-23; PMID:17088907; http://dx.doi.org/10.1038/sj.bjc.6603452 48.,Non-OADS,/arxiv_data1/oa_pdf/3b/0b/koni-05-12-1238543.PMC5215235.pdf
Biochim Et Biophys Acta 2010; 1803:520-5;PMID:20144902; http://dx.doi.org/10.1016/j.bbamcr.2010.01.022 49.,OADS,/arxiv_data1/oa_pdf/3b/0b/koni-05-12-1238543.PMC5215235.pdf
Curr Opin Genet Dev 2013; 23:63-71; PMID:23490481; http://dx.doi.org/10.1016/j.gde.2013.02.001 51.,OADS,/arxiv_data1/oa_pdf/3b/0b/koni-05-12-1238543.PMC5215235.pdf
J Immunol 2000; 165:2432-43; PMID:10946268; http://dx.doi.org/10.4049/jimmunol.165.5.2432 52.,Non-OADS,/arxiv_data1/oa_pdf/3b/0b/koni-05-12-1238543.PMC5215235.pdf
Cell 1979; 17:43-52; PMID:222475; http://dx.doi.org/10.1016/0092-8674(79)90293-9 53.,OADS,/arxiv_data1/oa_pdf/3b/0b/koni-05-12-1238543.PMC5215235.pdf
Science1999; 285:1733-7; PMID:10481009; http://dx.doi.org/10.1126/ science.285.5434.1733 54.,Non-OADS,/arxiv_data1/oa_pdf/3b/0b/koni-05-12-1238543.PMC5215235.pdf
Nat Genet 2008; 40:963-70; PMID:18641651; http://dx.doi.org/10.1038/ng.188 55.,Non-OADS,/arxiv_data1/oa_pdf/3b/0b/koni-05-12-1238543.PMC5215235.pdf
BMC Genomics 2015; 16:464; PMID:26081755; http://dx.doi.org/10.1186/s12864-015-1643-9 56.,OADS,/arxiv_data1/oa_pdf/3b/0b/koni-05-12-1238543.PMC5215235.pdf
J Immunol 2002; 169:3667-75; PMID:12244159; http://dx.doi.org/10.4049/jimmunol.169.7.3667e1238543-14 S. AREFANIAN ET AL.,Non-OADS,/arxiv_data1/oa_pdf/3b/0b/koni-05-12-1238543.PMC5215235.pdf
"12, 1565–1585 http://dx.doi.org/10.1080/00140139.2016.1154189 Multi-modal demands of a smartphone used to place calls and enter addresses  during highway driving relative to two embedded systems Bryan Reimera, Bruce Mehlera, Ian Reaganb, David Kiddb and Jonathan Dobresa amiT AgeLab, new England University Transportation c enter, c ambridge, m A, UsA; binsurance i nstitute for Highway s afety, Arlington, VA, UsA ABSTRACT There is limited research on trade-offs in demand between manual and voice interfaces of embedded  and portable technologies.",Non-OADS,/arxiv_data1/oa_pdf/d4/5a/terg-59-1565.PMC5215240.pdf
"This is an open Access article distributed under the terms of the creative c ommons Attribution-nonc ommercial-noDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/),  which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.KEYWORDS Voice interface; visual  demand; distraction; workload; human machine interfaceARTICLE HISTORY received 17 February 2015 Accepted 5 February 2016 CONTACT Bryan reimer  reimer@mit.edu1.",Non-OADS,/arxiv_data1/oa_pdf/d4/5a/terg-59-1565.PMC5215240.pdf
doi: http://dx.doi.org/10.1080/00140139.2015.1081412 .,Non-OADS,/arxiv_data1/oa_pdf/d4/5a/terg-59-1565.PMC5215240.pdf
doi: http://dx.doi.org/10.1177/0018720812442086.,Non-OADS,/arxiv_data1/oa_pdf/d4/5a/terg-59-1565.PMC5215240.pdf
http://www.R-project.org/.,Non-OADS,/arxiv_data1/oa_pdf/d4/5a/terg-59-1565.PMC5215240.pdf
doi: http://dx.doi.org/10.1177/0018720812437274.,Non-OADS,/arxiv_data1/oa_pdf/d4/5a/terg-59-1565.PMC5215240.pdf
"Warrendale, PA: SAE  International SAE Technical Paper 2009-01-0786. doi: http://dx.doi.org/10.4271/2009-01-0786.",Non-OADS,/arxiv_data1/oa_pdf/d4/5a/terg-59-1565.PMC5215240.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License ( http://creativecommons.org/licenses/by-nc/3.0/ ), which permits unre- stricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/d9/f4/koni-05-12-1238557.PMC5215252.pdf
"12, e1238557 (12 pages)http://dx.doi.org/10.1080/2162402X.2016.1238557",Non-OADS,/arxiv_data1/oa_pdf/d9/f4/koni-05-12-1238557.PMC5215252.pdf
N Eng J Med 2011; 364:2507-16; PMID:21639808; http://dx.doi.org/10.1056/ NEJMoa1103782 2.,OADS,/arxiv_data1/oa_pdf/d9/f4/koni-05-12-1238557.PMC5215252.pdf
N Eng J Med 2012; 367:107-14; PMID:22663011; http://dx.doi.org/10.1056/NEJMoa1203421 3.,OADS,/arxiv_data1/oa_pdf/d9/f4/koni-05-12-1238557.PMC5215252.pdf
Invest New Drugs 2016; 34(5):596-603; PMID:27363843; http://dx.doi.org/10.1007/s10637-016-0371-6 4.,Non-OADS,/arxiv_data1/oa_pdf/d9/f4/koni-05-12-1238557.PMC5215252.pdf
Lancet Oncol 2015; 16:908-18; PMID:26115796; http://dx.doi.org/ 10.1016/S1470-2045(15)00083-2 5.,Non-OADS,/arxiv_data1/oa_pdf/d9/f4/koni-05-12-1238557.PMC5215252.pdf
N Eng J Med 2015; 372:320-30; PMID:25399552; http://dx.doi.org/10.1056/NEJMoa1412082 6.,Non-OADS,/arxiv_data1/oa_pdf/d9/f4/koni-05-12-1238557.PMC5215252.pdf
N Eng JMed 2014; 371:1867-76; PMID:25265494; http://dx.doi.org/10.1056/ NEJMoa1408868 7.,OADS,/arxiv_data1/oa_pdf/d9/f4/koni-05-12-1238557.PMC5215252.pdf
N Eng J Med 2015; 373(1):23-34; PMID:26027431; http://dx.doi.org/ 10.1056/NEJMoa1504030 8.,Non-OADS,/arxiv_data1/oa_pdf/d9/f4/koni-05-12-1238557.PMC5215252.pdf
N Eng J Med 2015; 372:2006-17; PMID:25891304; http://dx.doi.org/10.1056/NEJMoa1414428 9.,OADS,/arxiv_data1/oa_pdf/d9/f4/koni-05-12-1238557.PMC5215252.pdf
J Clin Oncol 2016; 34:871-8; PMID:26811525; http://dx.doi.org/10.1200/ JCO.2015.62.9345 10.,Non-OADS,/arxiv_data1/oa_pdf/d9/f4/koni-05-12-1238557.PMC5215252.pdf
Cancer immu-nol immunother 2011; 60:1359-71; PMID:21847631; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/d9/f4/koni-05-12-1238557.PMC5215252.pdf
J Clin Oncol 2014; 32:2248-54; PMID:24958825; http://dx.doi.org/10.1200/JCO.2013.52.1377 14.,Non-OADS,/arxiv_data1/oa_pdf/d9/f4/koni-05-12-1238557.PMC5215252.pdf
Cancer Res 2010; 70:5213-9;PMID:20551059; http://dx.doi.org/10.1158/0008-5472.CAN-10-0118 15.,Non-OADS,/arxiv_data1/oa_pdf/d9/f4/koni-05-12-1238557.PMC5215252.pdf
BRAF inhibition improves tumor recogni- tion by the immune system: Potential implications for combinatorial therapies against melanoma involving adoptive T-cell transfer.Oncoimmunology 2012; 1:1476-83; PMID:23264894; http://dx.doi.org/10.4161/onci.21940 17.,Non-OADS,/arxiv_data1/oa_pdf/d9/f4/koni-05-12-1238557.PMC5215252.pdf
Clin Cancer Res 2013; 19:1225-31; PMID:23307859; http://dx.doi.org/ 10.1158/1078-0432.CCR-12-163018.,Non-OADS,/arxiv_data1/oa_pdf/d9/f4/koni-05-12-1238557.PMC5215252.pdf
Cancer Cell 2015; 27:574-88; PMID:25873177; http://dx.doi.org/10.1016/j.ccell.2015.03.008 19.,Non-OADS,/arxiv_data1/oa_pdf/d9/f4/koni-05-12-1238557.PMC5215252.pdf
Oncoimmunology 2013; 2:e22890; PMID:3583938; http://dx.doi.org/10.4161/onci.22890 20.,Non-OADS,/arxiv_data1/oa_pdf/d9/f4/koni-05-12-1238557.PMC5215252.pdf
"Clin Cancer Res 2012; 18:1386-94; PMID:22156613; http://dx.doi.org/ 10.1158/1078-0432.CCR-11-2479 21. Cooper ZA, Juneja VR, Sage PT, Frederick DT, Piris A, Mitra D, Lo JA, Hodi FS, Freeman GJ, Bosenberg MW et al.",Non-OADS,/arxiv_data1/oa_pdf/d9/f4/koni-05-12-1238557.PMC5215252.pdf
Cancer Immunol Res 2014; 2:643-54;PMID:24903021; http://dx.doi.org/10.1158/2326-6066.CIR-13-0215 22.,Non-OADS,/arxiv_data1/oa_pdf/d9/f4/koni-05-12-1238557.PMC5215252.pdf
Oncoimmunology2012; 1:609-17; PMID:22934253; http://dx.doi.org/10.4161/onci.20226 23.,Non-OADS,/arxiv_data1/oa_pdf/d9/f4/koni-05-12-1238557.PMC5215252.pdf
J Clin Invest 2013;123:1371-81; PMID:23454771; http://dx.doi.org/10.1172/JCI66236 24.,Non-OADS,/arxiv_data1/oa_pdf/d9/f4/koni-05-12-1238557.PMC5215252.pdf
Cancer Res 2012; 72:3928-37; PMID:22693252; http://dx.doi.org/10.1158/0008-5472.CAN-11-2837 25.,Non-OADS,/arxiv_data1/oa_pdf/d9/f4/koni-05-12-1238557.PMC5215252.pdf
N Eng J Med 2013; 368:1365-6; PMID:23550685; http://dx.doi.org/10.1056/NEJMc1302338 26.,OADS,/arxiv_data1/oa_pdf/d9/f4/koni-05-12-1238557.PMC5215252.pdf
Oncoimmunology 2016; 5:e1101207; PMID:27141385; http://dx.doi.org/10.1080/2162402X.2015.1101207 27.,Non-OADS,/arxiv_data1/oa_pdf/d9/f4/koni-05-12-1238557.PMC5215252.pdf
Cancer Immu- nol Res 2014; 2:351-60; PMID:24764582; http://dx.doi.org/10.1158/2326-6066.CIR-13-0181 28.,Non-OADS,/arxiv_data1/oa_pdf/d9/f4/koni-05-12-1238557.PMC5215252.pdf
Sci Transl Med 2015; 7:279ra41; PMID:25787767; http://dx.doi.org/10.1126/scitranslmed.aaa4691 29.,Non-OADS,/arxiv_data1/oa_pdf/d9/f4/koni-05-12-1238557.PMC5215252.pdf
Immunity 2016; 44:609-21; PMID:26944201; http://dx.doi.org/10.1016/j.immuni.2016.01.024 30.,OADS,/arxiv_data1/oa_pdf/d9/f4/koni-05-12-1238557.PMC5215252.pdf
Clin Cancer Res 2015; 21:1639-51; PMID:25589619; http://dx.doi.org/10.1158/1078-0432.CCR-14-2339 31.,Non-OADS,/arxiv_data1/oa_pdf/d9/f4/koni-05-12-1238557.PMC5215252.pdf
Clin Cancer Res 2015; 21:3140-8; PMID:25609064; http://dx.doi.org/10.1158/1078-0432.CCR-14-2023 32.,Non-OADS,/arxiv_data1/oa_pdf/d9/f4/koni-05-12-1238557.PMC5215252.pdf
Nat Rev Mol Cell Biol 2012; 13:283-96; PMID:22473468; http://dx.doi.org/10.1038/nrm3330ONCOIMMUNOLOGY e1238557-11,Non-OADS,/arxiv_data1/oa_pdf/d9/f4/koni-05-12-1238557.PMC5215252.pdf
Cell Mol Life Sci 2012; 69:1475-91; PMID:22076652; http://dx.doi.org/10.1007/s00018-011-0878-0 34.,OADS,/arxiv_data1/oa_pdf/d9/f4/koni-05-12-1238557.PMC5215252.pdf
Cell 2012; 150:251-63; PMID:22817889;http://dx.doi.org/10.1016/j.cell.2012.06.024 35.,OADS,/arxiv_data1/oa_pdf/d9/f4/koni-05-12-1238557.PMC5215252.pdf
PloS One 2011; 6:e28973; PMID:22194965; http://dx.doi.org/10.1371/journal.pone.0028973 36.,Non-OADS,/arxiv_data1/oa_pdf/d9/f4/koni-05-12-1238557.PMC5215252.pdf
Cancer Res 2011; 71:2750-60; PMID:21317224; http://dx.doi.org/10.1158/0008-5472.CAN-10-2954 37.,Non-OADS,/arxiv_data1/oa_pdf/d9/f4/koni-05-12-1238557.PMC5215252.pdf
Euro J Med Chem 2016; 109:314-41; PMID:26807863; http://dx.doi.org/10.1016/j.ejmech.2016.01.012 38.,OADS,/arxiv_data1/oa_pdf/d9/f4/koni-05-12-1238557.PMC5215252.pdf
Clin Sci 2015; 129:895-914; PMID:26330617; http://dx.doi.org/10.1042/CS20150149 39.,Non-OADS,/arxiv_data1/oa_pdf/d9/f4/koni-05-12-1238557.PMC5215252.pdf
Cancer Discov 2015; 5:143-53; PMID:25472943; http://dx.doi.org/10.1158/2159-8290.CD-14-0856 40.,Non-OADS,/arxiv_data1/oa_pdf/d9/f4/koni-05-12-1238557.PMC5215252.pdf
J Clin Invest 2013; 123:5104- 18; PMID:24200692; http://dx.doi.org/10.1172/JCI69619 41.,Non-OADS,/arxiv_data1/oa_pdf/d9/f4/koni-05-12-1238557.PMC5215252.pdf
Cancer Discov 2016; 6:202-16;PMID:26645196; http://dx.doi.org/10.1158/2159-8290.CD-15-0283 42.,Non-OADS,/arxiv_data1/oa_pdf/d9/f4/koni-05-12-1238557.PMC5215252.pdf
Nature 2009; 460:108-12; PMID:19543266; http://dx.doi.org/10.1038/nature08155 43.,Non-OADS,/arxiv_data1/oa_pdf/d9/f4/koni-05-12-1238557.PMC5215252.pdf
Br J Cancer 2011; 104:643-52; PMID:21285988;http://dx.doi.org/10.1038/bjc.2011.15 44.,Non-OADS,/arxiv_data1/oa_pdf/d9/f4/koni-05-12-1238557.PMC5215252.pdf
Haematologica 2013; 98:1291-9; PMID:23242600; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/d9/f4/koni-05-12-1238557.PMC5215252.pdf
Cancer Res 2014; 74:2217-28; PMID:24574514; http://dx.doi.org/10.1158/0008- 5472.CAN-13-2928 46.,Non-OADS,/arxiv_data1/oa_pdf/d9/f4/koni-05-12-1238557.PMC5215252.pdf
OncoTargets Ther 2013; 6:1649-58; PMID:24348046; http://dx.doi.org/10.2147/OTT.S52552 47.,OADS,/arxiv_data1/oa_pdf/d9/f4/koni-05-12-1238557.PMC5215252.pdf
PigmentCell Melanoma Res 2014; 27:495-501; PMID:24460976; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/d9/f4/koni-05-12-1238557.PMC5215252.pdf
J Clin Invest 2014; 124:2246-59; PMID:24667641; http://dx.doi.org/10.1172/JCI73639 49.,Non-OADS,/arxiv_data1/oa_pdf/d9/f4/koni-05-12-1238557.PMC5215252.pdf
Pigment Cell Melanoma Res 2013;26:499-508; PMID:23557327; http://dx.doi.org/10.1111/pcmr.12098 50.,Non-OADS,/arxiv_data1/oa_pdf/d9/f4/koni-05-12-1238557.PMC5215252.pdf
Curr Opin Immunol 2013; 25:291-6; PMID:23561594; http://dx.doi.org/10.1016/j.coi.2013.02.011 51.,OADS,/arxiv_data1/oa_pdf/d9/f4/koni-05-12-1238557.PMC5215252.pdf
Pigment Cell Melanoma Res 2015;28:611-2; PMID:25996827; http://dx.doi.org/10.1111/pcmr.12383 52.,Non-OADS,/arxiv_data1/oa_pdf/d9/f4/koni-05-12-1238557.PMC5215252.pdf
N Eng J Med 2015; 372:2521-32;PMID:25891173; http://dx.doi.org/10.1056/NEJMoa1503093 53.,Non-OADS,/arxiv_data1/oa_pdf/d9/f4/koni-05-12-1238557.PMC5215252.pdf
N Eng JMed 2014; 371:1877-88; PMID:25265492; http://dx.doi.org/10.1056/NEJMoa1406037 54.,OADS,/arxiv_data1/oa_pdf/d9/f4/koni-05-12-1238557.PMC5215252.pdf
Nature 2014; 515:568-71; PMID:25428505; http://dx.doi.org/10.1038/nature13954 55.,Non-OADS,/arxiv_data1/oa_pdf/d9/f4/koni-05-12-1238557.PMC5215252.pdf
Nat Rev Immunol 2009; 9:324-37;PMID:19390566; http://dx.doi.org/10.1038/nri2546 56.,Non-OADS,/arxiv_data1/oa_pdf/d9/f4/koni-05-12-1238557.PMC5215252.pdf
Cancer Immunol Res 2013; 1:386- 92; PMID:24778131; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/d9/f4/koni-05-12-1238557.PMC5215252.pdf
Cancer Biol Ther 2008; 7:1952-8; PMID:18981735; http://dx.doi.org/10.4161/cbt.7.12.6944 61.,Non-OADS,/arxiv_data1/oa_pdf/d9/f4/koni-05-12-1238557.PMC5215252.pdf
Cancer Res 2004; 64:1140-5; PMID:14871849; http://dx.doi.org/10.1158/0008-5472.CAN-03-3259 62.,Non-OADS,/arxiv_data1/oa_pdf/d9/f4/koni-05-12-1238557.PMC5215252.pdf
Int Immunol 2005; 17:133-44; PMID:15611321;http://dx.doi.org/10.1093/intimm/dxh194 63.,Non-OADS,/arxiv_data1/oa_pdf/d9/f4/koni-05-12-1238557.PMC5215252.pdf
Sci Transl Med 2014; 6:254ra128; PMID:25232180; http://dx.doi.org/10.1126/scitranslmed.3008918 64.,Non-OADS,/arxiv_data1/oa_pdf/d9/f4/koni-05-12-1238557.PMC5215252.pdf
Cell 2016; 165:35-44; PMID:26997480; http://dx.doi.org/10.1016/j.cell.2016.02.065 65.,OADS,/arxiv_data1/oa_pdf/d9/f4/koni-05-12-1238557.PMC5215252.pdf
Am J Pathol 2012; 181:785-94; PMID:22796458; http://dx.doi.org/10.1016/j.ajpath.2012.06.002e1238557-12 M. A. DEKEN ET AL.,OADS,/arxiv_data1/oa_pdf/d9/f4/koni-05-12-1238557.PMC5215252.pdf
"desktop (3.06 GHz Intel Core 2 Duo) using MATLAB(MathWorks, Natick, MA) in conjunction with theMGL toolbox (http://gru.brain.riken.jp/mgl ).",OADS,/arxiv_data1/oa_pdf/14/7e/i1534-7362-16-15-30.PMC5215291.pdf
"First, we performed a univariate analysis, evaluating the association between the selected SNPs and acute rejection in the replication cohort using PLINK v1.07 (http://pngu.mgh.harvard.edu/purcell/plink/ [8]).",OADS,/arxiv_data1/oa_pdf/13/da/AJT-17-201.PMC5215306.pdf
"The National Patient Register 2012 [May 10, 2012]; Available at: http://www.socialstyrelsen.se/register/halsoda-taregister/patientregistret/inenglish.",Non-OADS,/arxiv_data1/oa_pdf/98/df/EAT-50-58.PMC5215312.pdf
"2013 [May 11, 2015]; Available at: http://www.scb.se/en_/Finding-statistics/Publishing-calendar/Show-detailed-information/?publobjid 5187411.",Non-OADS,/arxiv_data1/oa_pdf/98/df/EAT-50-58.PMC5215312.pdf
"2015 [May 11, 2015]; Available at: http://www.scb.se/en_/.",Non-OADS,/arxiv_data1/oa_pdf/98/df/EAT-50-58.PMC5215312.pdf
"Published with license by Taylor & Francis Group, LLC © Elise P. Salerno, Davide Bedognetti, Ileana S. Mauldin, Donna H. Deacon, So ﬁa M. Shea, Joel Pinczewski, Joseph M. Obeid, George Coukos, Ena Wang, Thomas Gajewski, Francesco M. Marincola and Craig L. Slingluff Jr.This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License ( http://creativecommons.org/licenses/by-nc/3.0/ ), which permits unre- stricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/75/3f/koni-05-12-1240857.PMC5215363.pdf
"12, e1240857 (14 pages)http://dx.doi.org/10.1080/2162402X.2016.1240857",Non-OADS,/arxiv_data1/oa_pdf/75/3f/koni-05-12-1240857.PMC5215363.pdf
"Also, the results published here are in part based upon data generated by the TCGA Research Network: http://cancergenome.nih.gov/ .",OADS,/arxiv_data1/oa_pdf/75/3f/koni-05-12-1240857.PMC5215363.pdf
ORCID Joel Pinczewski http://orcid.org/0000-0002-7752-9557 Ena Wang http://orcid.org/0000-0001-6606-6510 References 1.,Non-OADS,/arxiv_data1/oa_pdf/75/3f/koni-05-12-1240857.PMC5215363.pdf
Breast Cancer Res Treat 2012; 131:871-80; PMID:21479927; http://dx.doi.org/10.1007/s10549-011-1470-x 2.,Non-OADS,/arxiv_data1/oa_pdf/75/3f/koni-05-12-1240857.PMC5215363.pdf
J Clin Oncol 2008; 26:4410-7; PMID:18802153; http://dx.doi.org/10.1200/JCO.2007.15.0284 4.,Non-OADS,/arxiv_data1/oa_pdf/75/3f/koni-05-12-1240857.PMC5215363.pdf
Cancer Res 2012; 72:1070-80; PMID:22266112; http://dx.doi.org/10.1158/0008-5472.CAN-11- 3218 5.,Non-OADS,/arxiv_data1/oa_pdf/75/3f/koni-05-12-1240857.PMC5215363.pdf
Cancer Res 2009; 69:3077-85; PMID:19293190; http://dx.doi.org/10.1158/0008-5472.CAN-08-2281 7.,Non-OADS,/arxiv_data1/oa_pdf/75/3f/koni-05-12-1240857.PMC5215363.pdf
J Clin Oncol 2011; 29:1949-55;PMID:21483002; http://dx.doi.org/10.1200/JCO.2010.30.5037 8.,Non-OADS,/arxiv_data1/oa_pdf/75/3f/koni-05-12-1240857.PMC5215363.pdf
Breast Cancer Res Treat 2012; 132:793-805; PMID:21562709; http://dx.doi.org/10.1007/s10549-011- 1554-7 9.,Non-OADS,/arxiv_data1/oa_pdf/75/3f/koni-05-12-1240857.PMC5215363.pdf
Front Immunol 2013;4:241; PMID:23966998; http://dx.doi.org/10.3389/ ﬁmmu.2013.00241 13.,Non-OADS,/arxiv_data1/oa_pdf/75/3f/koni-05-12-1240857.PMC5215363.pdf
Clin Cancer Res 2009; 15:4521-8; PMID:19567593; http://dx.doi.org/10.1158/1078-0432.CCR-08-0543 14.,Non-OADS,/arxiv_data1/oa_pdf/75/3f/koni-05-12-1240857.PMC5215363.pdf
Nat Med 2008; 14:28-36;PMID:18157142; http://dx.doi.org/10.1038/nm1699 15.,Non-OADS,/arxiv_data1/oa_pdf/75/3f/koni-05-12-1240857.PMC5215363.pdf
Clin Cancer Res 2007;13:5256-61; PMID:17875753; http://dx.doi.org/10.1158/1078-0432.,Non-OADS,/arxiv_data1/oa_pdf/75/3f/koni-05-12-1240857.PMC5215363.pdf
Cancer Metastasis Rev 2011; 30:141-51; PMID:21298574; http://dx.doi.org/10.1007/s10555-011-9289-9 17.,Non-OADS,/arxiv_data1/oa_pdf/75/3f/koni-05-12-1240857.PMC5215363.pdf
Semin Cancer Biol 2012; 22:307-18; PMID:22387003; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/75/3f/koni-05-12-1240857.PMC5215363.pdf
331:1565-70; PMID:21436444; http://dx.doi.org/10.1126/science.,Non-OADS,/arxiv_data1/oa_pdf/75/3f/koni-05-12-1240857.PMC5215363.pdf
Semin Cancer Biol 2012; 22:319-26; PMID:22349515; http://dx.doi.org/10.1016/j.semcancer.2012.02.003 20.,Non-OADS,/arxiv_data1/oa_pdf/75/3f/koni-05-12-1240857.PMC5215363.pdf
Immunol Rev 2006; 213:23-35; PMID:16972894; http://dx.doi.org/10.1111/j.1600- 065X.2006.00439.x 21.,Non-OADS,/arxiv_data1/oa_pdf/75/3f/koni-05-12-1240857.PMC5215363.pdf
Semin Immunopathol 2008; 30:165-77;PMID:18305941; http://dx.doi.org/10.1007/s00281-008-0106-7 22.,Non-OADS,/arxiv_data1/oa_pdf/75/3f/koni-05-12-1240857.PMC5215363.pdf
Science 2012; 338:798-802; PMID:22997133; http://dx.doi.org/10.1126/science.1219969 24.,Non-OADS,/arxiv_data1/oa_pdf/75/3f/koni-05-12-1240857.PMC5215363.pdf
Prog Neurobiol 2002; 68:311-23; PMID:12531232; http://dx.doi.org/10.1016/S0301-0082 (02)00128-4 25.,OADS,/arxiv_data1/oa_pdf/75/3f/koni-05-12-1240857.PMC5215363.pdf
Lab Invest 2012; 92:1213-33; PMID:22641100; http://dx.doi.org/10.1038/labinvest.2012.80 26.,OADS,/arxiv_data1/oa_pdf/75/3f/koni-05-12-1240857.PMC5215363.pdf
F1000 Biol Rep 2010; 2:3; PMID:20948803; http://dx.doi.org/10.3410/B2-3 27.,OADS,/arxiv_data1/oa_pdf/75/3f/koni-05-12-1240857.PMC5215363.pdf
Curr Top Microbiol Immunol 2006; 305:25-50; PMID:16724799; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/75/3f/koni-05-12-1240857.PMC5215363.pdf
"Regulation of blood-tes- tis barrier dynamics by desmosome, gap junction, hemidesmo-some and polarity proteins: An unexpected turn of events.Spermatogenesis 2011; 1:105-15; PMID:22319658; http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/75/3f/koni-05-12-1240857.PMC5215363.pdf
Pharmacol Rev 2012; 64:16-64; PMID:22039149;http://dx.doi.org/10.1124/pr.110.002790 30.,Non-OADS,/arxiv_data1/oa_pdf/75/3f/koni-05-12-1240857.PMC5215363.pdf
PLoS One 2010; 5:e10566; PMID:20479946; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/75/3f/koni-05-12-1240857.PMC5215363.pdf
Br J Cancer 2011; 104:1013-9; PMID:21364582; http://dx.doi.org/10.1038/bjc.2011.28 33.,Non-OADS,/arxiv_data1/oa_pdf/75/3f/koni-05-12-1240857.PMC5215363.pdf
Hum Pathol 2011; 42:409-18; PMID:21193224;http://dx.doi.org/10.1016/j.humpath.2010.09.004 34.,OADS,/arxiv_data1/oa_pdf/75/3f/koni-05-12-1240857.PMC5215363.pdf
Pathol Int 2006; 56:62-70; PMID:16445817; http://dx.doi.org/10.1111/j.1440-1827.2006.01925.x 35.,Non-OADS,/arxiv_data1/oa_pdf/75/3f/koni-05-12-1240857.PMC5215363.pdf
"Maynadier M, Chambon M, Basile I, Gleizes M, Nirde P, Gary-Bobo M, Garcia M. Estrogens promote cell-cell adhesion of normal andmalignant mammary cells through increased desmosome formation.Mol Cell Endocrinol 2012; 364:126-33; PMID:22963885; http://dx.doi.",OADS,/arxiv_data1/oa_pdf/75/3f/koni-05-12-1240857.PMC5215363.pdf
Cancer Res 2005; 65:7102-10; PMID:16103059; http://dx.doi.org/10.1158/0008-5472.CAN-04-1877 37.,Non-OADS,/arxiv_data1/oa_pdf/75/3f/koni-05-12-1240857.PMC5215363.pdf
Med Oncol 2012; 29:1518-22; PMID:21947748; http://dx.doi.org/10.1007/s12032-011-0071-1 38.,Non-OADS,/arxiv_data1/oa_pdf/75/3f/koni-05-12-1240857.PMC5215363.pdf
BMC Geno- mics 2012; 13:156; PMID:22537248; http://dx.doi.org/10.1186/1471-2164-13-156 39.,OADS,/arxiv_data1/oa_pdf/75/3f/koni-05-12-1240857.PMC5215363.pdf
ClinCancer Res 2015; 21:2840-50; PMID:25712684; http://dx.doi.org/ 10.1158/1078-0432.CCR-14-2777 40.,Non-OADS,/arxiv_data1/oa_pdf/75/3f/koni-05-12-1240857.PMC5215363.pdf
J Immunother Cancer 2015; 3:43; PMID:26380088; http://dx.doi.org/10.1186/s40425-015-0089-6 41.,Non-OADS,/arxiv_data1/oa_pdf/75/3f/koni-05-12-1240857.PMC5215363.pdf
Nature 2015; 523:231-5;PMID:25970248; http://dx.doi.org/10.1038/nature14404 42.,OADS,/arxiv_data1/oa_pdf/75/3f/koni-05-12-1240857.PMC5215363.pdf
Sci Signal 2013; 6:pl1; PMID:23550210; http://dx.doi.org/10.1126/scisignal.2004088 44.,OADS,/arxiv_data1/oa_pdf/75/3f/koni-05-12-1240857.PMC5215363.pdf
N Eng J Med 2012; 366:2443-54; PMID:22658127; http://dx.doi.org/10.1056/NEJMoa1200690 46.,OADS,/arxiv_data1/oa_pdf/75/3f/koni-05-12-1240857.PMC5215363.pdf
Front Biosci (Elite Ed) 2012; 4:734-45; PMID:22201909; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/75/3f/koni-05-12-1240857.PMC5215363.pdf
J Clin Oncol 2007; 25:8519;PMID:17369575; http://dx.doi.org/10.1200/JCO.2006.08.1463 48.,Non-OADS,/arxiv_data1/oa_pdf/75/3f/koni-05-12-1240857.PMC5215363.pdf
Cancer 2009; 115:2891-902; PMID:19472394; http://dx.doi.org/10.1002/ cncr.24317 49.,Non-OADS,/arxiv_data1/oa_pdf/75/3f/koni-05-12-1240857.PMC5215363.pdf
Cancer Res 2010; 70:5213-9;PMID:20551059; http://dx.doi.org/10.1158/0008-5472.CAN-10-0118 50.,Non-OADS,/arxiv_data1/oa_pdf/75/3f/koni-05-12-1240857.PMC5215363.pdf
Can-cer Res 2012; 72:5209-18; PMID:22915761; http://dx.doi.org/10.1158/ 0008-5472.CAN-12-1187 51.,Non-OADS,/arxiv_data1/oa_pdf/75/3f/koni-05-12-1240857.PMC5215363.pdf
Clin Cancer Res 2009; 15:390-9; PMID:19118070; http://dx.doi.org/10.1158/1078-0432.CCR-08-0783ONCOIMMUNOLOGY e1240857-13,Non-OADS,/arxiv_data1/oa_pdf/75/3f/koni-05-12-1240857.PMC5215363.pdf
Clin Cancer Res 2012; 18:1386-94; PMID:22156613; http://dx.doi.org/ 10.1158/1078-0432.CCR-11-2479 53.,Non-OADS,/arxiv_data1/oa_pdf/75/3f/koni-05-12-1240857.PMC5215363.pdf
Nature 2014; 515:563-7;PMID:25428504; http://dx.doi.org/10.1038/nature14011 54.,Non-OADS,/arxiv_data1/oa_pdf/75/3f/koni-05-12-1240857.PMC5215363.pdf
Immunity 2013; 39:11-26; PMID:23890060; http://dx.doi.org/10.1016/j.immuni.2013.07.008e1240857-14 E. P. SALERNO ET AL.,OADS,/arxiv_data1/oa_pdf/75/3f/koni-05-12-1240857.PMC5215363.pdf
"Available: http://www.cabi.org/publishing-products/online-information-resources/cab- abstracts/ [2014, 12/29].",Non-OADS,/arxiv_data1/oa_pdf/7b/71/JRSM-7-433.PMC5215373.pdf
"Available from: http://www.nccmt.ca/registry/view/eng/116.html [2015, 02/05].",OADS,/arxiv_data1/oa_pdf/7b/71/JRSM-7-433.PMC5215373.pdf
Images and details ofthe specimens can be found at the website of the Kunstkamera:http://www.kunstkamera.ru/kuns t-catalogue/inde x.seam?c=RUYSH &page=1.,OADS,/arxiv_data1/oa_pdf/55/e5/AJMG-173-16.PMC5215407.pdf
"[11,14–16][*]Dr.J.E.Schmidt, D.Fu,Prof.Dr.B.M.Weckhuysen Debye Institute forNanomateria lsScience, Utrecht Universi ty Universit eitsweg 99,3584 CGUtrecht (The Netherla nds) E-mail :b.m.weckhu ysen@uu.nl Homepag e:http://www .anorg.chem .uu.nl Dr.M.W.Deem Department sofBioengin eering andPhysics &Astronomy Rice University ,Houston, TX77005 (USA) Supportin ginformation andtheORCID identification numbers for theauthors ofthisarticle canbefound under :http://dx.doi.org/ 10.",Non-OADS,/arxiv_data1/oa_pdf/bf/1c/ANIE-55-16044.PMC5215409.pdf
"12, 3196 –3201 http://dx.doi.org/10.1080/21645515.2016.1171439",Non-OADS,/arxiv_data1/oa_pdf/42/4c/khvi-12-12-1171439.PMC5215445.pdf
Map produced using Mapline (https://mapline.com/).3198 S. S. AHMED AND L. STEINMAN,Non-OADS,/arxiv_data1/oa_pdf/42/4c/khvi-12-12-1171439.PMC5215445.pdf
"PLoS One 2014; 9:e114361; PMID:25501681;http://dx.doi.org/10.1371/journal.pone.0114361 [4] van der Heide A, Verduijn W, Haasnoot GW, Drabbels JJ, Lammers GJ, Claas FH.",OADS,/arxiv_data1/oa_pdf/42/4c/khvi-12-12-1171439.PMC5215445.pdf
"HLA dosage effect in narcolepsy with cataplexy.Immunogenetics 2015; 67:1-6; PMID:25277311; http://dx.doi.org/ 10.1007/s00251-014-0808-z [5] de LL, Kilduff TS, Peyron C, Gao X, Foye PE, Danielson PE, Fuku- hara C, Battenberg EL, Gautvik VT, Bartlett FS, et al.",Non-OADS,/arxiv_data1/oa_pdf/42/4c/khvi-12-12-1171439.PMC5215445.pdf
"Cell1998; 92:573-85; PMID:9491897; http://dx.doi.org/10.1016/S0092-8674(00)80949-6 [7] Nishino S, Ripley B, Overeem S, Lammers GJ, Mignot E. Hypo- cretin (orexin) de ﬁciency in human narcolepsy.",OADS,/arxiv_data1/oa_pdf/42/4c/khvi-12-12-1171439.PMC5215445.pdf
"Lancet 2000; 355:39-40; PMID:10615891; http://dx.doi.org/10.1016/S0140-6736 (99)05582-8 [8] Peyron C, Faraco J, Rogers W, Ripley B, Overeem S, Charnay Y, Nev- simalova S, Aldrich M, Reynolds D, Albin R, et al.",OADS,/arxiv_data1/oa_pdf/42/4c/khvi-12-12-1171439.PMC5215445.pdf
"Nat Med 2000; 6:991-7; PMID:10973318; http://dx.doi.org/10.1038/79690 [9] Lin L, Faraco J, Li R, Kadotani H, Rogers W, Lin X, Qiu X, de Jong PJ, Nishino S, Mignot E. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene.",Non-OADS,/arxiv_data1/oa_pdf/42/4c/khvi-12-12-1171439.PMC5215445.pdf
"Cell 1999; 98:365-76; PMID:10458611; http://dx.doi.org/10.1016/S0092-8674(00)81965-0 [10] Willie JT, Chemelli RM, Sinton CM, Tokita S, Williams SC, Kisanuki YY, Marcus JN, Lee C, Elmquist JK, Kohlmeier KA, et al.",OADS,/arxiv_data1/oa_pdf/42/4c/khvi-12-12-1171439.PMC5215445.pdf
Neuron 2003; 38:715-30; PMID:12797957; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/42/4c/khvi-12-12-1171439.PMC5215445.pdf
"Cell 1999; 98:437-51; PMID:10481909; http://dx.doi.org/10.1016/S0092-8674(00)81973-X [12] Hara J, Beuckmann CT, Nambu T, Willie JT, Chemelli RM, Sinton CM, Sugiyama F, Yagami K, Goto K, Yanagisawa M, et al.",OADS,/arxiv_data1/oa_pdf/42/4c/khvi-12-12-1171439.PMC5215445.pdf
Neuron 2001; 30:345-54; PMID:11394998; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/42/4c/khvi-12-12-1171439.PMC5215445.pdf
Am J Med Genet B Neuropsychiatr Genet 2004; 129B:69-75;PMID:15274044; http://dx.doi.org/10.1002/ajmg.b.30047 [14] EudraVigilance management system (DBMS).,OADS,/arxiv_data1/oa_pdf/42/4c/khvi-12-12-1171439.PMC5215445.pdf
"Dev Med Child Neurol 2014; 56:1041-2; PMID:25052448; http://dx.doi.org/10.1111/dmcn.12543 [16] Ahmed SS, Schur PH, MacDonald NE, Steinman L. Narcolepsy, 2009 A(H1N1) pandemic in ﬂuenza, and pandemic in ﬂuenza vaccinations: what is known and unknown about the neurological disorder, the role for autoimmunity, and vaccine adjuvants.",Non-OADS,/arxiv_data1/oa_pdf/42/4c/khvi-12-12-1171439.PMC5215445.pdf
"J Autoimmun 2014; 50:1-11;PMID:24559657; http://dx.doi.org/10.1016/j.jaut.2014.01.033 [17] Winstone AM, Stellitano L, Verity C, Andrews N, Miller E, Stowe J, Shneerson J.",OADS,/arxiv_data1/oa_pdf/42/4c/khvi-12-12-1171439.PMC5215445.pdf
"Dev Med Child Neurol 2014; 56:1117-23; PMID:25041214; http://dx.doi.org/10.1111/dmcn.12522 [18] Stowe J, Miller E, Andrews N, Kosky C, Leschziner G, Shneerson JM, Hall A, Eriksson S, Reading P, Dennis G, et al.",OADS,/arxiv_data1/oa_pdf/42/4c/khvi-12-12-1171439.PMC5215445.pdf
"Yakugaku Zasshi 2011; 131:1733-41; PMID:22129867; http://dx.doi.org/10.1248/yakushi.131.1733 [20] European Center for Disease P, Control.",Non-OADS,/arxiv_data1/oa_pdf/42/4c/khvi-12-12-1171439.PMC5215445.pdf
"PLoS One 2014; 9:e108489; PMID:25264897; http://dx.doi.org/10.1371/journal.pone.0108489 [22] Hungs M, Fan J, Lin L, Lin X, Maki RA, Mignot E. Identi ﬁcation and functional analysis of mutations in the hypocretin (orexin) genes of narcoleptic canines.",OADS,/arxiv_data1/oa_pdf/42/4c/khvi-12-12-1171439.PMC5215445.pdf
"Genome Res 2001; 11:531-9; PMID:11282968; http://dx.doi.org/10.1101/gr.GR-1610R [23] Ahmed SS, Plotkin SA, Black S, Coffman RL.",OADS,/arxiv_data1/oa_pdf/42/4c/khvi-12-12-1171439.PMC5215445.pdf
"Scienti ﬁca (Cairo) 2012; 2012:1-18; http://dx.doi.org/10.6064/2012/215308 [25] Bui HH, Sidney J, Dinh K, Southwood S, Newman MJ, Sette A. Pre- dicting population coverage of T-cell epitope-based diagnostics and vaccines.",OADS,/arxiv_data1/oa_pdf/42/4c/khvi-12-12-1171439.PMC5215445.pdf
"BMC Bioinformatics 2006; 7:153; PMID:16545123; http://dx.doi.org/10.1186/1471-2105-7-153 [26] Tanaka S, Honda Y, Inoue Y, Honda M. Detection of autoantibodies against hypocretin, hcrtrl, and hcrtr2 in narcolepsy: anti-Hcrt system antibody in narcolepsy.",OADS,/arxiv_data1/oa_pdf/42/4c/khvi-12-12-1171439.PMC5215445.pdf
"The properties of thermostabilised G protein-coupled receptors (StaRs) and their use in drug discovery.Neuropharmacology 2011; 60:36-44; PMID:20624408; http://dx.doi.org/10.1016/j.neuropharm.2010.07.001 [28] de Hoog HP, Lin JieRong EM, Banerjee S, Decaillot FM, Nallani M. Conformational antibody binding to a native, cell-free expressedGPCR in block copolymer membranes.",OADS,/arxiv_data1/oa_pdf/42/4c/khvi-12-12-1171439.PMC5215445.pdf
"PLoS One 2014; 9:e110847;PMID:25329156; http://dx.doi.org/10.1371/journal.pone.0110847 [29] Ring AM, Manglik A, Kruse AC, Enos MD, Weis WI, Garcia KC, Kobilka BK.",OADS,/arxiv_data1/oa_pdf/42/4c/khvi-12-12-1171439.PMC5215445.pdf
"Nature 2013; 502:575-9; PMID:24056936; http://dx.doi.org/10.1038/nature12572[30] Hislop JN, von Zastrow M. Analysis of GPCR localization and traf- ﬁcking.",OADS,/arxiv_data1/oa_pdf/42/4c/khvi-12-12-1171439.PMC5215445.pdf
"Ann NY Acad Sci 2012;1274:92-8; PMID:23252902; http://dx.doi.org/10.1111/j.1749- 6632.2012.06789.x [32] Han F, Lin L, Schormair B, Pizza F, Plazzi G, Ollila HM, Nevsima- lova S, Jennum P, Knudsen S, Winkelmann J, et al.",OADS,/arxiv_data1/oa_pdf/42/4c/khvi-12-12-1171439.PMC5215445.pdf
"Proc Natl Acad Sci U S A 2016; 113:E368-77; PMID:26668381; http://dx.doi.org/ 10.1073/pnas.1521463112 [35] Brask J, Chauhan A, Hill RH, Ljunggren HG, Kristensson K. Effects on synaptic activity in cultured hippocampal neurons by in ﬂuenza A viral proteins.",OADS,/arxiv_data1/oa_pdf/42/4c/khvi-12-12-1171439.PMC5215445.pdf
"J Neurovirol 2005; 11:395-402; PMID:16162482;http://dx.doi.org/10.1080/13550280500186916 [36] Thannickal TC, Siegel JM, Nienhuis R, Moore RY.",OADS,/arxiv_data1/oa_pdf/42/4c/khvi-12-12-1171439.PMC5215445.pdf
"Brain Pathol 2003; 13:340-51; PMID:12946023; http://dx.doi.org/10.1111/j.1750-3639.2003.tb00033.x [37] Thannickal TC, Moore RY, Nienhuis R, Ramanathan L, Gulyani S, Aldrich M, Cornford M, Siegel JM.",Non-OADS,/arxiv_data1/oa_pdf/42/4c/khvi-12-12-1171439.PMC5215445.pdf
"Neuron 2000; 27:469-74;PMID:11055430; http://dx.doi.org/10.1016/S0896-6273(00)00058-1 [38] Wu MF, Nienhuis R, Maidment N, Lam HA, Siegel JM.",OADS,/arxiv_data1/oa_pdf/42/4c/khvi-12-12-1171439.PMC5215445.pdf
"J Neurosci 2011; 31:6305-10; PMID:21525270;http://dx.doi.org/10.1523/JNEUROSCI.0365-11.2011 [39] Yamanaka A, Tabuchi S, Tsunematsu T, Fukazawa Y, Tominaga M. Orexin directly excites orexin neurons through orexin 2 receptor.",OADS,/arxiv_data1/oa_pdf/42/4c/khvi-12-12-1171439.PMC5215445.pdf
"JNeurosci 2010; 30:12642-52; PMID:20861370; http://dx.doi.org/10.1523/JNEUROSCI.2120-10.2010 [40] Valko PO, Gavrilov YV, Yamamoto M, Reddy H, Haybaeck J, Mignot E, Baumann CR, Scammell TE.",OADS,/arxiv_data1/oa_pdf/42/4c/khvi-12-12-1171439.PMC5215445.pdf
Ann Neurol 2013; 74:794- 804; PMID:24006291; http://dx.doi.org/10.1002/ana.24019HUMAN VACCINES & IMMUNOTHERAPEUTICS 3201,Non-OADS,/arxiv_data1/oa_pdf/42/4c/khvi-12-12-1171439.PMC5215445.pdf
https://products.sano ﬁ.us/ lantus/lantus.html.,Non-OADS,/arxiv_data1/oa_pdf/37/4d/DOM-19-33.PMC5215447.pdf
2014. http://investor.lilly.com/releasedetail.cfm?ReleaseID=870088.,Non-OADS,/arxiv_data1/oa_pdf/37/4d/DOM-19-33.PMC5215447.pdf
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRe gulatoryInformation/Guidances/UCM291128.pdf.,Non-OADS,/arxiv_data1/oa_pdf/37/4d/DOM-19-33.PMC5215447.pdf
2015. http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM291134.pdf.,Non-OADS,/arxiv_data1/oa_pdf/37/4d/DOM-19-33.PMC5215447.pdf
Available from URL: http://www.rdaa.com.au/ Uploads/Documents/Maternity%20Services%20for%20Rural%20Australia_20101116031918.pdf.,Non-OADS,/arxiv_data1/oa_pdf/6a/b7/AJR-24-385.PMC5215449.pdf
Available from URL: https://www.parliament.nsw.gov.au/la/papers/Docu ments/2008/26-june-2008- votes-and-proceedings/079-VAP-S.pdf.,Non-OADS,/arxiv_data1/oa_pdf/6a/b7/AJR-24-385.PMC5215449.pdf
Available from URL: http://www.tweeddai lynews.com.au/news/apn-6000-cant-be-wrong-hospital/ 144741/ ©2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/6a/b7/AJR-24-385.PMC5215449.pdf
Availablefrom URL: http://www.abc.net.au/news/2009-02-06/nsw-hospital-suffers-mass-resignation/285154 18 Nursing and Midwifery Unit.,Non-OADS,/arxiv_data1/oa_pdf/6a/b7/AJR-24-385.PMC5215449.pdf
Available from URL: http://www.health.nsw.gov.au/nursing/projects/Publications/ midwifery-cont-carer-tk.pdf 19 Australian College of Midwives.,Non-OADS,/arxiv_data1/oa_pdf/6a/b7/AJR-24-385.PMC5215449.pdf
"Available from URL: https://www.health.gov.au/internet/main/publishing.nsf/content/8AF 951CE492C799FCA257BF0001 C1A4E/$File/maternityplan.pdf 26 Unpublished manuscript, University Centre for Rural Health North Coast.",Non-OADS,/arxiv_data1/oa_pdf/6a/b7/AJR-24-385.PMC5215449.pdf
Available at:http://ctep.cancer.gov/protocolDevelopment/elec-tronic_applications/docs/ctcaev3.pdf.,Non-OADS,/arxiv_data1/oa_pdf/22/5d/BJH-176-76.PMC5215488.pdf
"12, 3160 –3165 http://dx.doi.org/10.1080/21645515.2016.1216286",Non-OADS,/arxiv_data1/oa_pdf/6f/2e/khvi-12-12-1216286.PMC5215502.pdf
J GenVirol 2003; 84:3191-201; PMID:14645901; http://dx.doi.org/10.1099/vir.0.19532-0 [3] Koff RS.,OADS,/arxiv_data1/oa_pdf/6f/2e/khvi-12-12-1216286.PMC5215502.pdf
"Hepatitis A. Lancet 1998; 351:1643-9; PMID:9620732; http://dx.doi.org/10.1016/S0140-6736(98)01304-X [4] Hadler SC, McFarland L. Hepatitis in day care centers: epidemiology and prevention.",Non-OADS,/arxiv_data1/oa_pdf/6f/2e/khvi-12-12-1216286.PMC5215502.pdf
Rev Infect Dis 1986; 8:548-57; PMID:3018889; http://dx.doi.org/10.1093/clinids/8.4.548 [5] Jacobsen KH.,OADS,/arxiv_data1/oa_pdf/6f/2e/khvi-12-12-1216286.PMC5215502.pdf
Available at: http://www.who.int/wer/ 2012/wer8728_29.pdf?ua=1 .,Non-OADS,/arxiv_data1/oa_pdf/6f/2e/khvi-12-12-1216286.PMC5215502.pdf
Hepatitis Monthly 2012; 12:382-5; http://dx.doi.org/10.5812/hepatmon.5940 [9] WHO position paper on hepatitis A vaccines June 2012.,Non-OADS,/arxiv_data1/oa_pdf/6f/2e/khvi-12-12-1216286.PMC5215502.pdf
"Vaccine 1997; 15:944-7; PMID:9261939; http://dx.doi.org/10.1016/S0264-410X(96)00304-0 [14] Zhuang FC, Mao ZA, Jiang LM, Wu J, Chen YQ, Jiang Q, Chen NL, Chai SA, Mao JS.",Non-OADS,/arxiv_data1/oa_pdf/6f/2e/khvi-12-12-1216286.PMC5215502.pdf
Comparing live attenuated and inactivated hepatitis A vaccines: an immunogenicity study after one single dose.Vaccine 2011; 29:9098-103; PMID:21875638; http://dx.doi.org/10.1016/j.vaccine.2011.08.0783164 S. RAO ET AL.,Non-OADS,/arxiv_data1/oa_pdf/6f/2e/khvi-12-12-1216286.PMC5215502.pdf
"Hum Vaccin Immunother 2013; 9:1460-5; PMID:23571173; http://dx.doi.org/10.4161/hv.24366 [20] Wang XY, Xu ZY, Ma JC, von Seidlein L, Zhang Y, Hao ZY, Han OP, Zhang YL, Tian MY, Ouyang PY, et al.",OADS,/arxiv_data1/oa_pdf/6f/2e/khvi-12-12-1216286.PMC5215502.pdf
"Vaccine 2007; 25:446-9;PMID:16949710; http://dx.doi.org/10.1016/j.vaccine.2006.08.004 [21] Wang XY, Xu Z, Yao X, Tian M, Zhou L, He L, Wen Y.",Non-OADS,/arxiv_data1/oa_pdf/6f/2e/khvi-12-12-1216286.PMC5215502.pdf
"Vaccine 2004; 22:1941-5;PMID:15121306; http://dx.doi.org/10.1016/j.vaccine.2003.11.007 [22] Zhang Y, Liu X, Ma J.",Non-OADS,/arxiv_data1/oa_pdf/6f/2e/khvi-12-12-1216286.PMC5215502.pdf
"Indian Pediatr 2011; 48:135-7; PMID:21169655; http://dx.doi.org/10.1007/s13312- 011-0039-4 [28] Fangcheng Z, Xuanyi W, Mingding C, Liming J, Jie W, Qi J, Yuanping G, Wen Q, Yajuan X, Jiangsen M. Era of vaccination her- alds a decline in incidence of hepatitis A in high-risk groups in China.",Non-OADS,/arxiv_data1/oa_pdf/6f/2e/khvi-12-12-1216286.PMC5215502.pdf
"Hepatitis Monthly 2012; 12:100-5; PMID:22509186; http://dx.doi.org/10.5812/hepatmon.4907 [29] Arankalle VMM, Bhave S, Ghosh A, Balasubramanian S, Chatterjee S, Choudhury J, Chitkara A, Kadhe G, Mane A, Roy S. Changing epi-demiology of hepatitis A virus in Indian children.",Non-OADS,/arxiv_data1/oa_pdf/6f/2e/khvi-12-12-1216286.PMC5215502.pdf
"Vaccine 2013; 31:285-6; PMID:23142134; http://dx.doi.org/ 10.1016/j.vaccine.2012.10.102 [31] Mao JS, Dong DX, Zhang HY, Chen NL, Zhang XY, Huang HY, Xie RY, Zhou TJ, Wan ZJ, Wang YZ, et al.",Non-OADS,/arxiv_data1/oa_pdf/6f/2e/khvi-12-12-1216286.PMC5215502.pdf
"J Infect Dis 1989; 159:621-4; PMID:2538518; http://dx.doi.org/10.1093/infdis/159.4.621 [32] Mao JS, Xie RY, Huang HY, Chai SA, Chen NL, Yu PH, Wan XZ, Liu CJ, Cao YY, Dong DX, et al.",OADS,/arxiv_data1/oa_pdf/6f/2e/khvi-12-12-1216286.PMC5215502.pdf
"World J Gastroen- terol: WJG 2000; 6:829-32; http://dx.doi.org/10.3748/wjg.v6.i6.829 [37] Bhave S, Sapru A, Bavdekar A, Kapatkar V, Mane A.",OADS,/arxiv_data1/oa_pdf/6f/2e/khvi-12-12-1216286.PMC5215502.pdf
"Indian Pediatr 2015; 52:687-90; PMID:26388627;http://dx.doi.org/10.1007/s13312-015-0697-8 [38] Mitra M, Shah N, Faridi M, Ghosh A, Sankaranarayanan VS, Aggar- wal A, Chatterjee S, Bhattacharyya N, Kadhe G, Vishnoi G, et al.",Non-OADS,/arxiv_data1/oa_pdf/6f/2e/khvi-12-12-1216286.PMC5215502.pdf
Vaccine 2005; 23:5127-32; PMID:16054733; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/6f/2e/khvi-12-12-1216286.PMC5215502.pdf
"J Virol Methods 1993; 43:287-97; PMID:8408443; http://dx.doi.org/10.1016/ 0166-0934(93)90147-J [43] Wang X, Ma J, Zhang Y.",OADS,/arxiv_data1/oa_pdf/6f/2e/khvi-12-12-1216286.PMC5215502.pdf
"H2 strain attenuated live hepatitis A vac- cines: protective ef ﬁcacy in a hepatitis A outbreak ”World J Gastro- entero 2000; 6:829-32; http://dx.doi.org/10.3748/wjg.v6.i6.829 [46] Cui F, Liang X, Wang F, Zheng H, Hutin YJ, Yang W. Development, production, and postmarketing surveillance of hepatitis A vaccines in China.",Non-OADS,/arxiv_data1/oa_pdf/6f/2e/khvi-12-12-1216286.PMC5215502.pdf
"J Epidemiol / Japan Epidemiol Assoc 2014; 24:169-77;http://dx.doi.org/10.2188/jea.JE20130022 [47] Wang H, Sui H. The meta analysis of protective ef ﬁcacy of attenuated live Hepatitis A vaccine.",Non-OADS,/arxiv_data1/oa_pdf/6f/2e/khvi-12-12-1216286.PMC5215502.pdf
Vaccine 1990; 8:523-4; PMID:1965075; http://dx.doi.org/10.1016/0264-410X(90)90001-3 [49] WHO position paper on hepatitis A vaccines - June 2012.,Non-OADS,/arxiv_data1/oa_pdf/6f/2e/khvi-12-12-1216286.PMC5215502.pdf
Indian Pediatr 2014; 51:785-800; PMID:25362009; http://dx.doi.org/10.1007/s13312-014-0504-y [51] World Health Organization.,Non-OADS,/arxiv_data1/oa_pdf/6f/2e/khvi-12-12-1216286.PMC5215502.pdf
Available at: http://www.who.,Non-OADS,/arxiv_data1/oa_pdf/6f/2e/khvi-12-12-1216286.PMC5215502.pdf
"These stimuli were generated by the Moving Gratingv.1.3 software program (http://michaelbach.de/stim, in thepublic domain) with spatial frequency and contrast settings varied.",OADS,/arxiv_data1/oa_pdf/26/74/i1552-5783-57-15-6805.PMC5215506.pdf
Images were thresholded in ImageJ (http://imagej.nih.,OADS,/arxiv_data1/oa_pdf/26/74/i1552-5783-57-15-6805.PMC5215506.pdf
"12, 3072 –3078 http://dx.doi.org/10.1080/21645515.2016.1212143",Non-OADS,/arxiv_data1/oa_pdf/50/0b/khvi-12-12-1212143.PMC5215516.pdf
"J Virol 2004; 78:12817-28; PMID:15542634; http://dx.do i.org/10.1128/JVI.78.23.12817-12828.2004 [2] Rota PA, Wallis TR, Harmon MW, Rota JS, Kendal AP, Nerome K. Cocirculation of two distinct evolutionary lineages of in ﬂuenza type B virus since 1983.",Non-OADS,/arxiv_data1/oa_pdf/50/0b/khvi-12-12-1212143.PMC5215516.pdf
"Available from: http://www.cdc.gov/ ﬂu/weekly/pastreports.htm [4] Pepin S, Donazzolo Y, Jambrecina A, Salamand C, Saville M. Safety and immunogenicity of a quadrivalent inactivated in ﬂuenza vaccine in adults.",Non-OADS,/arxiv_data1/oa_pdf/50/0b/khvi-12-12-1212143.PMC5215516.pdf
Vaccine 2013; 31:5572-8; PMID:24016810; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/50/0b/khvi-12-12-1212143.PMC5215516.pdf
"Vaccine 2015; 33:2485-92;PMID:25843270; http://dx.doi.org/10.1016/j.vaccine.2015.03.065[6] Klein SL, Pekosz A. Sex-based biology and the rational design of inﬂuenza vaccination strategies.",Non-OADS,/arxiv_data1/oa_pdf/50/0b/khvi-12-12-1212143.PMC5215516.pdf
"J Infect Dis 2014; 209 Suppl 3:S114- 9; PMID:24966191; http://dx.doi.org/10.1093/infdis/jiu066 [7] Cecinati V, Principi N, Brescia L, Giordano P, Esposito S. Vaccine administration and the development of immune thrombocytopenic purpura in children.",Non-OADS,/arxiv_data1/oa_pdf/50/0b/khvi-12-12-1212143.PMC5215516.pdf
"Hum Vaccin Immunother 2013; 9:1158-62;PMID:23324619; http://dx.doi.org/10.4161/hv.23601 [8] Terrell DR, Beebe LA, Vesely SK, Neas BR, Segal JB, George JN.",OADS,/arxiv_data1/oa_pdf/50/0b/khvi-12-12-1212143.PMC5215516.pdf
"Am J Hematol2010; 85:174-80; PMID:20131303; http://dx.doi.org/10.1002/ ajh.21833 [9] Heikkinen T, Ikonen N, Ziegler T. Impact of in ﬂuenza B lineage- level mismatch between trivalent seasonal in ﬂuenza vaccines and circulating viruses, 1999-2012.",OADS,/arxiv_data1/oa_pdf/50/0b/khvi-12-12-1212143.PMC5215516.pdf
"Clin Infect Dis 2014; 59:1519-24; PMID:25139969; http://dx.doi.org/10.1093/cid/ciu664 [10] Chan PK, Chan MC, Cheung JL, Lee N, Leung TF, Yeung AC, Wong MC, Ngai KL, Nelson EA, Hui DS.",OADS,/arxiv_data1/oa_pdf/50/0b/khvi-12-12-1212143.PMC5215516.pdf
Clin Infect Dis 2013; 56:677-84; PMID:23074315; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/50/0b/khvi-12-12-1212143.PMC5215516.pdf
"Correspondence to: J. HubbuchContract grant sponsor: European Union’s Horizon 2020 Research and Innovation Programme Contract grant number: 635557Received 17 May 2016; Revision received 20 July 2016; Accepted 18 August 2016Accepted manuscript online 20 August 2016; Article ﬁrst published online 21 September 2016 in Wiley Online Library (http://onlinelibrary.wiley.com/doi/10.1002/bit.26078/abstract).DOI 10.1002/bit.26078ARTICLE 368 Biotechnology and Bioengineering, V ol.",Non-OADS,/arxiv_data1/oa_pdf/be/92/BIT-114-368.PMC5215519.pdf
Available athttp://www.romecriteria.org/assets/pdf/ 20_RomeIII_apB_899-916.pdf (accessed 2/4/2016).,Non-OADS,/arxiv_data1/oa_pdf/c4/83/APT-44-1114.PMC5215520.pdf
An important interaction observed in healthy cells asBOX 1 ARE SNAPSHOT ARE Classes Class classi ﬁcation: Class I: Dispersed AUUUA in U-rich contextClass II: Overlapping (AUUUA)nClass II: U-rich stretch Cluster classi ﬁcation (Revised): Cluster 1: WWWUAUUUAUWW Cluster 2: WWAUUUAUUUAWWCluster 3: AUUUAUUUAUUUACluster 4: WAUUUAUUUAUUUAUUUAWCluster 5: WAUUUAUUUAUUUAUUUAW Signaling regulating ARE –mRNA decay and translation Mitogen-activated protein kinase pathwayPhosphatidylinositol 3 (PI3)-kinase/AKT path- way Wnt signaling pathway RNA-binding proteins impacting ARE (examples) mRNA-stability promoting proteins ELAVL1 (HuR) RRM domainAUF1 RRM domain mRNA-decay promoting proteins ZFP36 (TTP) CCCH domain ZFP36L1 CCCH domain ZFP36L2 CCCH domainKSRP K homology domainAUF1 RRM domain Animal models or RNA-binding proteins See Box 3 Resources and databases AU-rich element-containing mRNA database (ARED): http://brp.kfshrc.edu.sa/ARED/ AREsite: http://nibiru.tbi.univie.ac.at/AREsite2/ welcome AREscore: http://arescore.dkfz.de/arescore.plAtlas for 3 0UTR regulatory activity (AURA): http://aura.science.unitn.it/cite/ Scan for Motifs: http://bioanalysis.otago.ac.nz/ sfm/sfm_main.pl CLIPdb: http://lulab.life.tsinghua.edu.cn/clipdb/UTRsite and UTRdb: http://utrsite.ba.itb.cnr.it/ http://utrdb.ba.itb.cnr.it/ RNA-binding proteins database: http://rbpdb.,Non-OADS,/arxiv_data1/oa_pdf/ba/9c/WRNA-8-0.PMC5215528.pdf
Available at: http://pi.lilly.com/us/effient.pdf.,Non-OADS,/arxiv_data1/oa_pdf/d5/ed/CCD-88-535.PMC5215531.pdf
Available at: http://www.azpicentral.com/brilinta/ brilinta.pdf#page ¼1.,Non-OADS,/arxiv_data1/oa_pdf/d5/ed/CCD-88-535.PMC5215531.pdf
Available from: http://srtr.transplant.hrsa.gov/annual_reports/ 2012/pdf/2012_SRTR_ADR.pdf.,OADS,/arxiv_data1/oa_pdf/b5/42/AJT-17-22.PMC5215533.pdf
‡Rates calculated based on 2012 and 2013 Indigenous population estimates for the 10 SLAs by the Queensland Government Statistician’s Ofﬁce (http://qrsis.oesr.qld.gov.au/pls/qis_public/QIS1110W$COLLGRP.Startup?p_user_id=edtert).,OADS,/arxiv_data1/oa_pdf/ad/ad/AJR-24-392.PMC5215535.pdf
From: http://CRAN.R-project.org/ package=lme4.,Non-OADS,/arxiv_data1/oa_pdf/12/4c/GPS-31-868.PMC5215547.pdf
From: http://www.R-project.org/.,Non-OADS,/arxiv_data1/oa_pdf/12/4c/GPS-31-868.PMC5215547.pdf
(a) Exons 12–21 encoding protein tyrosine kinase of CSF1R and the protein tyrosine kinase domain (TKD) are shown based on the information from UniProt (http://www.uniprot.org/uniprot/P07333).,Non-OADS,/arxiv_data1/oa_pdf/95/63/ENE-24-37.PMC5215554.pdf
The ORCID identification number(s) for the author(s) of this article can be found under http://dx.doi.org/10.1002/anie.201510610.,Non-OADS,/arxiv_data1/oa_pdf/86/01/ANIE-56-462.PMC5215561.pdf
"Available from:http://clinicaltrials.gov/show/NCT01901653 NLM Identifier:NCT01901653, 2013.",Non-OADS,/arxiv_data1/oa_pdf/86/01/ANIE-56-462.PMC5215561.pdf
"Keywords :Tryptophan ·IDO·Inhibitor ·Antiviral ·Antifungal ·Antibacterial ·Cancer ·Drug DesignSPECIAL ISSUE [a]F.A.Greco, A.Bournique, A.Coletti, C.Custodi, D.Dolciami, A.Carotti, A.Macchiarulo Dipartimento diScienze Farmaceutiche, University ofPerugia ViadelLiceo 1,06123 Perugia, Italy Tel+390755855160, Fax+390755855161 *e-mail :antonio.macchiarulo@unipg.it Supporting information forthisarticle isavailable ontheWWW under http://dx.doi.org/10.1002/minf.201501038.",Non-OADS,/arxiv_data1/oa_pdf/93/33/MINF-35-449.PMC5215573.pdf
"Conclusion The PK, ef ﬁcacy and safety of ixekizumab administered subcutaneously by PFS and autoinjector were similar.Clinicaltrials.gov number: NCT01777191 https://clinicaltrials.gov/ct2/show/NCT01777191 Received: 29 December 2015; Accepted: 21 March 2016 Conﬂicts of interest K. Callis Duf ﬁn has received grants and/or research support from Amgen, Eli Lilly and Company, Janssen, Stiefel, AbbVie, Bristol-Myers Squibb, Celgene, Novartis and XenoPort and has been a consultant and/or participated on an advisory board for Amgen, Eli Lilly and Company, Janssen, Stiefel, AbbVie, Bristol-MyersSquibb, Novartis, Celgene, P ﬁzer, Novartis and XenoPort.",Non-OADS,/arxiv_data1/oa_pdf/b2/8f/JDV-31-107.PMC5215575.pdf
"12, 3202 –3211 http://dx.doi.org/10.1080/21645515.2016.1231258",Non-OADS,/arxiv_data1/oa_pdf/f9/1c/khvi-12-12-1231258.PMC5215580.pdf
http://www.unaids.org/sites/default/ ﬁles/ media_asset/20150901_FactSheet_2015_en.pdf [2] CDC HIV/AIDS statistics.,Non-OADS,/arxiv_data1/oa_pdf/f9/1c/khvi-12-12-1231258.PMC5215580.pdf
http://www.cdc.gov/hiv/statistics/over view/ataglance.html [3] CDC news release.,Non-OADS,/arxiv_data1/oa_pdf/f9/1c/khvi-12-12-1231258.PMC5215580.pdf
"http://www.cdc.gov/nchhstp/newsroom/2016/ croi-2016.html [4] Gray GE, Laher F, Doherty T, Abdool Karim S, Hammer S, Mascola J, Beyrer C, Corey L. Which new health technologies do we need to achieve an end to HIV/AIDS?",Non-OADS,/arxiv_data1/oa_pdf/f9/1c/khvi-12-12-1231258.PMC5215580.pdf
"PLoS Biol 2016; 14:e1002372;PMID:26933962; http://dx.doi.org/10.1371/journal.pbio.1002372 [5] Grant R, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, Goicochea P, Casap /C19ıa M, Guanira-Carranza JV, Ramirez-Cardich ME, et al.",OADS,/arxiv_data1/oa_pdf/f9/1c/khvi-12-12-1231258.PMC5215580.pdf
"N Engl J Med 2010; 363:2587-99; PMID:21091279; http://dx.doi.org/10.1056/NEJMoa1011205 [6] Thigpen M, Kebaabetswe P, Paxton L, Smith D, Rose C, Segolodi T, Henderson F, Pathak S, Soud F, Chillag K, et al.",OADS,/arxiv_data1/oa_pdf/f9/1c/khvi-12-12-1231258.PMC5215580.pdf
"N Engl J Med 2012; 367:423-34; PMID:22784038; http://dx.doi.org/ 10.1056/NEJMoa1110711 [7] Baeten J, Donnell D, Ndase P, Mugo N, Campbell J, Wangisi J, Tappero J, Bukusi E, Cohen C, Katabira E, et al.",OADS,/arxiv_data1/oa_pdf/f9/1c/khvi-12-12-1231258.PMC5215580.pdf
"N Engl J Med 2012; 367:399-410; PMID:22784037; http://dx.doi.org/10.1056/NEJMoa1108524 [8] Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, Chiamwongpaet S, Kitisin P, Natrujirote P, Kitti-munkong S, et al.",OADS,/arxiv_data1/oa_pdf/f9/1c/khvi-12-12-1231258.PMC5215580.pdf
"Lancet 2013; 381:2083-90; PMID:23769234; http://dx.doi.org/10.1016/S0140-6736(13)61127-7 [9] McCormack S, Dunn D, Desai M, Dolling D, Gafos M, Gilson R, Sullivan A, Clarke A, Reeves I, Schembri G, et al.",OADS,/arxiv_data1/oa_pdf/f9/1c/khvi-12-12-1231258.PMC5215580.pdf
"N Engl J Med 2015; 373:2237-46;PMID:26624850; http://dx.doi.org/10.1056/NEJMoa1506273 [11] Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, Malahleha M, Owino F, Manongi R, Onyango J, et al.",OADS,/arxiv_data1/oa_pdf/f9/1c/khvi-12-12-1231258.PMC5215580.pdf
"N Engl J Med 2012; 367:411-22; PMID:22784040; http://dx.doi.org/10.1056/NEJMoa1202614 [12] Marrazzo J, Ramjee G, Richardson B, Gomez K, Mgodi N, Nair G, Palanee T, Nakabiito C, van der Straten A, Noguchi L, et al.",OADS,/arxiv_data1/oa_pdf/f9/1c/khvi-12-12-1231258.PMC5215580.pdf
http://www.fda.gov/NewsEvents/News room/PressAnnouncements/ucm312210.htm [14] CDC PrEP guidelines.,Non-OADS,/arxiv_data1/oa_pdf/f9/1c/khvi-12-12-1231258.PMC5215580.pdf
http://www.cdc.gov/hiv/pdf/PrEPguide lines2014.pdf [15] WHO HIV guidelines.,Non-OADS,/arxiv_data1/oa_pdf/f9/1c/khvi-12-12-1231258.PMC5215580.pdf
http://www.who.int/hiv/pub/guidelines/keypo pulations/en/ [16] CDC media release.,Non-OADS,/arxiv_data1/oa_pdf/f9/1c/khvi-12-12-1231258.PMC5215580.pdf
"http://www.cdc.gov/nchhstp/newsroom/2016/ croi-2016.html [17] Abdool Karim Q, Abdool Karim S, Frohlich J, Grobler A, Baxter C, Mansoor L, Kharsany A, Sibeko S, Mlisana K, Omar Z, et al.",Non-OADS,/arxiv_data1/oa_pdf/f9/1c/khvi-12-12-1231258.PMC5215580.pdf
"Science 2010; 329:1168-74.; http://dx.doi.org/10.1126/science.1193748 [18] Rees H, Delany-Moretlwe S, Lombard C, Baron D, Panchia R, Myer L, Schwartz J, Doncel GF, Gray G. FACTS 001 Phase III trial of peri-ocoital tenofovir 1% gel for HIV prevention in women.",OADS,/arxiv_data1/oa_pdf/f9/1c/khvi-12-12-1231258.PMC5215580.pdf
"N Engl J Med 2016; [epub ahead of print]; http://dx.doi.org/10.1056/ NEJMoa1506110 [20] Nel A, Kapiga S, Bekker LG, Devlin B, Borremans M, Rosenberg Z, for the IPM 027/Ring Study Research Center Teams.",OADS,/arxiv_data1/oa_pdf/f9/1c/khvi-12-12-1231258.PMC5215580.pdf
"PLos One 2016; 11:e0146387; PMID:26731116; http://dx.doi.org/10.1371/journal.pone.0146387 [22] Barouch DH, Michael NL.",OADS,/arxiv_data1/oa_pdf/f9/1c/khvi-12-12-1231258.PMC5215580.pdf
Cell 2014; 159:969-72; PMID:25416935; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/f9/1c/khvi-12-12-1231258.PMC5215580.pdf
"Am J Prev Med 2015; 49:S307-18; PMID:26590431; http://dx.doi.org/10.1016/j.amepre.2015.09.004 [24] Sheets R, Zhou T, I K. Review of ef ﬁcacy trials of HIV-1/AIDS vac- cines and regulatory lessons learned: A review from a regulatory per-spective.",Non-OADS,/arxiv_data1/oa_pdf/f9/1c/khvi-12-12-1231258.PMC5215580.pdf
"Biologicals 2015; 44:73-89; PMID:26776940; http://dx.doi.org/10.1016/j.biologicals.2015.10.004 [25] Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, van Griensven F, Hu D, Tappero JW, Choopanya K. Randomized, dou- ble-blind, placebo-controlled ef ﬁcacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bang- kok, Thailand.",OADS,/arxiv_data1/oa_pdf/f9/1c/khvi-12-12-1231258.PMC5215580.pdf
"Infect Dis 2006; 194:1661-71; http://dx.doi.org/ 10.1086/508748 [26] Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF.",OADS,/arxiv_data1/oa_pdf/f9/1c/khvi-12-12-1231258.PMC5215580.pdf
"J Infect Dis 2005; 191:654-65;PMID:15688278; http://dx.doi.org/10.1086/428404 [27] Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, Gilbert PB, Lama JR, Marmor M, Del Rio C, et al.",OADS,/arxiv_data1/oa_pdf/f9/1c/khvi-12-12-1231258.PMC5215580.pdf
"Ef ﬁcacy assess- ment of a cell-mediated immunity HIV-1 vaccine (the Step Study): adouble-blind, randomised, placebo-controlled, test-of-concept trial.Lancet 2008; 372:1881-93; PMID:19012954; http://dx.doi.org/ 10.1016/S0140-6736(08)61591-3 [28] Gray GE, Allen M, Moodie Z, Churchyard G, Bekker LG, Nchabeleng M, Mlisana K, Metch B, de Bruyn G, Latka MH, et al.3210 J. M. MCNICHOLL",Non-OADS,/arxiv_data1/oa_pdf/f9/1c/khvi-12-12-1231258.PMC5215580.pdf
"Lancet Infect Dis2011; 11:507-15; PMID:21570355; http://dx.doi.org/10.1016/S1473- 3099(11)70098-6 [29] Hammer SM, Sobieszczyk ME, Janes H, Karuna ST, Mulligan MJ, Grove D, Koblin BA, Buchbinder SP, Keefer MC, Tomaras GD, et al.",Non-OADS,/arxiv_data1/oa_pdf/f9/1c/khvi-12-12-1231258.PMC5215580.pdf
"N Engl J Med 2013; 369:2083-92; PMID:24099601; http://dx.doi.org/10.1056/NEJMoa1310566 [30] Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, et al.",OADS,/arxiv_data1/oa_pdf/f9/1c/khvi-12-12-1231258.PMC5215580.pdf
"N Engl J Med 2009; 361:2209-20; PMID:19843557; http://dx.doi.org/10.1056/NEJMoa0908492 [31] Gilbert PB, Berger JO, Stablein B, Becker S, Essex M, Hammer SM, Kim JM, DeGruttola VG.",OADS,/arxiv_data1/oa_pdf/f9/1c/khvi-12-12-1231258.PMC5215580.pdf
"N Engl J Med 2012; 366:1275-86; PMID:22475592; http://dx.doi.org/ 10.1056/NEJMoa1113425 [34] Corey L, Gilbert PB, Tomaras GD, Haynes BF, Pantaleo G, Fauci AS.",Non-OADS,/arxiv_data1/oa_pdf/f9/1c/khvi-12-12-1231258.PMC5215580.pdf
Biologicals 2015; 44:90-110; PMID:26732973; http://dx.doi.org/10.1016/j.biologicals.2015.11.003 [36] AIDS Vaccine Advocacy Coalition.,Non-OADS,/arxiv_data1/oa_pdf/f9/1c/khvi-12-12-1231258.PMC5215580.pdf
http://www.avac.or g/trial/hvtn-702 [37] HIV Prevention Trial Network.,Non-OADS,/arxiv_data1/oa_pdf/f9/1c/khvi-12-12-1231258.PMC5215580.pdf
"http://www.hptn.org/research_stu dies [38] Huang Y, DiazGranados C, Janes H, Huang Y, deCamp AC, Metch B, Grant S, Sanchez B, Phogat S, Koutsoukos M, et al.",OADS,/arxiv_data1/oa_pdf/f9/1c/khvi-12-12-1231258.PMC5215580.pdf
"Curr Opin Virol 2016; 17:57-65; PMID:26827165; http://dx.doi.org/ 10.1016/j.coviro.2016.01.007 [39] Excler J, Rida W, Priddy F, Gilmour J, McDermott A, Kamali A, Anzala O, Mutua G, Sanders E, Koff W, et al.",OADS,/arxiv_data1/oa_pdf/f9/1c/khvi-12-12-1231258.PMC5215580.pdf
"AIDS Res Hum Retrovi- ruses 2011; 27:669-80; PMID:21043994; http://dx.doi.org/10.1089/aid.2010.0206 [40] Janes H, Gilbert P, Buchbinder S, et al.",Non-OADS,/arxiv_data1/oa_pdf/f9/1c/khvi-12-12-1231258.PMC5215580.pdf
AIDS Res Hum Retroviruses 2013;11:1513-23; http://dx.doi.org/10.1089/aid.2012.0385 [41] Veazey RS.,Non-OADS,/arxiv_data1/oa_pdf/f9/1c/khvi-12-12-1231258.PMC5215580.pdf
"J Virol 2013; 87:1708-19; PMID:23175374; http://dx.doi.org/10.1128/JVI.02544-12 [43] Cheng-Mayer C, Huang Y, Gettie A, Tsai L, Ren W, Shakirzyanova M, Sina S, Trunova N, Blanchard J, Jenkins L, et al.",OADS,/arxiv_data1/oa_pdf/f9/1c/khvi-12-12-1231258.PMC5215580.pdf
AIDS 2011; 25:1833-41; PMID:21750420; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f9/1c/khvi-12-12-1231258.PMC5215580.pdf
"http://www.hptn.org/research_studies/hptn083.asp [51] Garc /C19ıa-Lerma J, Aung W, Cong M, Zheng Q, Youngpairoj A, Mitchell J, Holder A, Martin A, Kuklenyik S, Luo W, et al.",OADS,/arxiv_data1/oa_pdf/f9/1c/khvi-12-12-1231258.PMC5215580.pdf
"J Virol 2011; 85:6610-7; http://dx.doi.org/10.1128/JVI.00311-11 [52] Melchjorsen J, Risør MW, Søgaard OS, O ’Loughlin KL, Chow S, Paludan SR, Ellermann-Eriksen S, Hedley DW, Minderman H,Østergaard L, Tolstrup M. Tenofovir selectively regulates production of in ﬂammatory cytokines and shifts the IL-12/IL-10 balance in human primary cells.",OADS,/arxiv_data1/oa_pdf/f9/1c/khvi-12-12-1231258.PMC5215580.pdf
J Acquir Immune De ﬁc Syndr 2011; 57:265-75; PMID:21471820; http://dx.doi.org/10.1097/QAI.0b013e3182185276 [53] NIH news release.,Non-OADS,/arxiv_data1/oa_pdf/f9/1c/khvi-12-12-1231258.PMC5215580.pdf
http://www.niaid.nih.gov/news/newsreleases/ 2016/Pages/HOPE-trial.aspx [54] Initiative for Multipurpose Prevention Technology.,Non-OADS,/arxiv_data1/oa_pdf/f9/1c/khvi-12-12-1231258.PMC5215580.pdf
http://mpts101.org [55] Karim SSA.,Non-OADS,/arxiv_data1/oa_pdf/f9/1c/khvi-12-12-1231258.PMC5215580.pdf
Lancet 2013; 381(9883):2060 –2062; http://dx.doi.org/10.1016/S0140- 6736(13)61140-XHUMAN VACCINES & IMMUNOTHERAPEUTICS 3211,Non-OADS,/arxiv_data1/oa_pdf/f9/1c/khvi-12-12-1231258.PMC5215580.pdf
To view this mini commentary visit http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/73/ad/BJO-124-251.PMC5215631.pdf
NCT 00851513 (registered 25 February 2009) (https://clinicaltrials.gov/ct2/show/ study/NCT00851513?term=pudendal+neuralgia&rank=1).,Non-OADS,/arxiv_data1/oa_pdf/73/ad/BJO-124-251.PMC5215631.pdf
"Retrieved March 24, 2015, from http://research.agre.org/program/diag.cfm.",OADS,/arxiv_data1/oa_pdf/c4/74/AUR-9-1353.PMC5215637.pdf
"Retrieved March 24, 2015, from http://www.sdqinfo.com/ youth inmind (2013).",Non-OADS,/arxiv_data1/oa_pdf/c4/74/AUR-9-1353.PMC5215637.pdf
"Retrieved March 24, 2015, from http://www.sdqinfo.org/Adult/youth inmind (2015).",Non-OADS,/arxiv_data1/oa_pdf/c4/74/AUR-9-1353.PMC5215637.pdf
"Retrieved November 17,2015, from http://dawba.info/py/dawbainfo/b4.py Zigmond, A.S., & Snaith, R.P.",Non-OADS,/arxiv_data1/oa_pdf/c4/74/AUR-9-1353.PMC5215637.pdf
Available from URL: http://www.fda.,Non-OADS,/arxiv_data1/oa_pdf/10/79/APL-19-1157.PMC5215647.pdf
Available from URL: http://www.fda.- gov/downloads/Drugs/GuidanceComplianceRegulatoryIn- formation/Guidances/UCM338856.pdf.,Non-OADS,/arxiv_data1/oa_pdf/10/79/APL-19-1157.PMC5215647.pdf
Accessed 13 October 2015 at http://www.who.int/tb/ publications/global_report/en/.,Non-OADS,/arxiv_data1/oa_pdf/65/1a/JDV-31-89.PMC5215651.pdf
"Available at: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/NursingHomeQualityInits/NHQIQualityMeasures.html(accessed 11/05/14) Chodosh J, Edelen MO, Buchanan JL, et al.",Non-OADS,/arxiv_data1/oa_pdf/11/43/GPS-31-694.PMC5215684.pdf
Available at: http://www.fda.gov/drugs/drugsafety/ postmarketdrugsafetyinformationforpatientsandproviders/ucm053171 (accessed 5/15/15) Fort T. 2010.,Non-OADS,/arxiv_data1/oa_pdf/11/43/GPS-31-694.PMC5215684.pdf
"Available at: http://support.stroke.org/site/News2?page=NewsArticle&id=9577 (accessed 5/15/15) Green RL, McAllister TW, Bernat JL.",Non-OADS,/arxiv_data1/oa_pdf/11/43/GPS-31-694.PMC5215684.pdf
"M.Bochma nn Schoo lofChemistry ,University ofEast Anglia Norw ich,NR4 7TJ(United Kingdom ) (+44)16035-92 044 E-mail :J.Fernand ez-Cesta u@uea.ac .uk m.bo chmann@uea .ac.uk [b]H.Duckworth, Dr.T.J.Penfold Schoo lofChemistry ,Newcastle University Newcastle upon Tyne,NE1 7RU (United Kingdo m) E-mail :Tom.Penfold@ newcastle .ac.uk [c]S.T.E.Jones ,Dr.D.Credging ton Depar tment ofPhysic s,Caven dishLabor atory Cambridg eUniversity ,Camb ridge CB3 0HF (United Kingdo m) E-mail :djnc3@ cam.ac .uk Suppo rting informa tion (detailsofsynth esisand characte rization, X-ray cryst allograp hy,photophys icalprope rties, theoretic alcalculation s)and the ORCID identifica tion numbe r(s)fortheauthor (s)ofthisarticle canbefound under http://dx.doi.or g/10.1002/c hem.201 603841.",Non-OADS,/arxiv_data1/oa_pdf/a4/b9/CHEM-23-105.PMC5215685.pdf
https://www.gov.,Non-OADS,/arxiv_data1/oa_pdf/9f/41/UOG-48-765.PMC5215695.pdf
"Births in England and Wales, 2014. http://www.ons.",Non-OADS,/arxiv_data1/oa_pdf/9f/41/UOG-48-765.PMC5215695.pdf
2016https://www.nice.org.uk/guidance/dg23/chapter/1-Recommendations [Accessed May2016].,Non-OADS,/arxiv_data1/oa_pdf/9f/41/UOG-48-765.PMC5215695.pdf
Available at: http://www.SF-36.org/tools/sf36.shtml (accessed 21 October2014).,Non-OADS,/arxiv_data1/oa_pdf/3c/9f/APT-45-264.PMC5215718.pdf
Available at: http://www.ahrq.gov/ professionals/clinicians-providers/ resources/rice/EQ5Dscore.html-weights.Updated August 2005 (accessed 5 January 2015).,OADS,/arxiv_data1/oa_pdf/3c/9f/APT-45-264.PMC5215718.pdf
2016 Available at: http://www.c-surf.ch/en/1.html (accessed 19January 2016) (Archived at: http://www.webcitation.org/6ef2Kulth on 19 January 2016).,Non-OADS,/arxiv_data1/oa_pdf/0b/2f/ADD-111-1867.PMC5215781.pdf
Available at: (http://www.seco.admin.ch/ seco/de/home/Publikationen_Dienstleistungen/Publikationen_und_Formulare/Arbeit/Arbeitslosenversicherung/Die_Lage_auf_dem_Arbeitsmarkt/die-lage-auf-dem-arbeitsmarkt-2015.html) (Archived at: http://www.webcitation.org/6ef2uuqI2 on 19 January 2016).,Non-OADS,/arxiv_data1/oa_pdf/0b/2f/ADD-111-1867.PMC5215781.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/ by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/51/1f/main.PMC5215798.pdf
"Available online at www.sciencedirect.com ScienceDirect journal homepage: http://ees.elsevier.com/gendis/default.asp Genes &Diseases (2016) 3, 169e170 http://dx.doi.org/10.1016/j.gendis.2016.06.001 2352-3042/Copyright ª2016, Chongqing Medical University.",Non-OADS,/arxiv_data1/oa_pdf/51/1f/main.PMC5215798.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/51/1f/main.PMC5215798.pdf
2016 Jun 2. http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/51/1f/main.PMC5215798.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/ by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/e5/50/main.PMC5215801.pdf
"http://dx.doi.org/10.1016/j.gendis.2015.12.002 2352-3042/Copyright ª2015, Chongqing Medical University.",Non-OADS,/arxiv_data1/oa_pdf/e5/50/main.PMC5215801.pdf
"This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).HOSTED BY Available online at www.sciencedirect.com ScienceDirect journal homepage: http://ees.elsevier.com/gendis/default.asp Genes &Diseases (2016) 3,8 2e87",Non-OADS,/arxiv_data1/oa_pdf/e5/50/main.PMC5215801.pdf
2015 Nov 13;0. http://dx.doi.org/10.1080/15548627.2015.,Non-OADS,/arxiv_data1/oa_pdf/e5/50/main.PMC5215801.pdf
"Upon activation, Cdk1/CycB phosphorylates a large number of  This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).",Non-OADS,/arxiv_data1/oa_pdf/34/3d/emss-70831.PMC5215830.pdf
"Gene-Cloud of Biotechnology Information (https://www.gcbi.com.cn/gclib/html/index) was used to perform microarray data analysis.The microarray data were uploaded to the Gene Expression Omnibus (GSE81767, http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE81767).",OADS,/arxiv_data1/oa_pdf/cb/6a/AJT-17-255.PMC5215980.pdf
"Epidemiological data, Karnofsky index, stage of disease, presence and sites of metastases, ongoing oncologic treatment, and Enhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/ D517F0605B74E7B8 .",Non-OADS,/arxiv_data1/oa_pdf/d7/ab/12325_2016_Article_440.PMC5216057.pdf
"This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( http://creativecommons.org/licenses/ by-nc/4.0/ ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, andindicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/d7/ab/12325_2016_Article_440.PMC5216057.pdf
"This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( http://creativecommons.org/licenses/ by-nc/4.0/ ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The online version of the original article can be found under doi: 10.1007/s12325-016-0338-1 .",Non-OADS,/arxiv_data1/oa_pdf/e3/88/12325_2016_Article_437.PMC5216058.pdf
"Amongst individuals with complex brain-based disorders (e.g., mood disorders), the dimensions/domains most likely to beneﬁt with sirukumab are negative valence disturbances (e.g., anxiety,Enhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/B03 7F0607DF8812D .",Non-OADS,/arxiv_data1/oa_pdf/1f/49/12325_2016_Article_455.PMC5216059.pdf
"This article is distributed under the terms of the Creative CommonsAttribution-NonCommercial 4.0 International License ( http://creativecommons.org/licenses/ by-nc/4.0/ ), which permits anynoncommercial use, distribution, and repro- duction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the CreativeCommons license, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/1f/49/12325_2016_Article_455.PMC5216059.pdf
Device pressure (Pmax) had the greatest inﬂuence on injectate muscle penetration.Enhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/ 6427F0606404A394 .,Non-OADS,/arxiv_data1/oa_pdf/18/50/12325_2016_Article_452.PMC5216060.pdf
"License ( http://creativecommons.org/licenses/ by-nc/4.0/ ), which permits any noncommer- cial use, distribution, and reproduction in any medium, provided you give appropriate creditto the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/18/50/12325_2016_Article_452.PMC5216060.pdf
"In PSA, isavuconazole was cost saving in 80.2% of the simulations and cost-effective in 82.0% of the simulations at the $50,000 willingness to pay threshold per additional outcome.Enhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/ 0717F06062D4B7B0 .",Non-OADS,/arxiv_data1/oa_pdf/77/61/12325_2016_Article_443.PMC5216061.pdf
"This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( http://creativecommons.org/licenses/ by-nc/4.0/ ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/77/61/12325_2016_Article_443.PMC5216061.pdf
Available from: http://hcupnet.ahrq.gov/ .,OADS,/arxiv_data1/oa_pdf/77/61/12325_2016_Article_443.PMC5216061.pdf
"Available from: http://www.accessdata.fda.gov/drugsatfda_ docs/label/2015/207500s001,207501s001lbl.pdf .",Non-OADS,/arxiv_data1/oa_pdf/77/61/12325_2016_Article_443.PMC5216061.pdf
Available from: http://www.rubali.com/thomsonreuters/drug_ information/index.php?frame=ready_price.html .,Non-OADS,/arxiv_data1/oa_pdf/77/61/12325_2016_Article_443.PMC5216061.pdf
Availablefrom: http://data.bls.gov/cgi-bin/surveymost?cu .,OADS,/arxiv_data1/oa_pdf/77/61/12325_2016_Article_443.PMC5216061.pdf
Both study compounds provided similar pain relief and were well tolerated.Enhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/ C037F060697B3BB9 .,Non-OADS,/arxiv_data1/oa_pdf/d2/37/12325_2016_Article_456.PMC5216064.pdf
"This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( http://creativecommons.org/licenses/ by-nc/4.0/ ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/d2/37/12325_2016_Article_456.PMC5216064.pdf
"The Report of the International Narcotics Control Board for 2015 (E/INCB/2015/1), United Nations.https://www.incb.org/documents/Narcotic-Drugs/Technical-Publications/2015/NAR-tech_pub_2015.",Non-OADS,/arxiv_data1/oa_pdf/d2/37/12325_2016_Article_456.PMC5216064.pdf
https://www.thl.ﬁ/ documents/10531/95613/Raportti%202011%2015.,Non-OADS,/arxiv_data1/oa_pdf/d2/37/12325_2016_Article_456.PMC5216064.pdf
"This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( http://creativecommons.org/licenses/ by-nc/4.0/ ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit168 Adv Ther (2017) 34:156–170",Non-OADS,/arxiv_data1/oa_pdf/32/0f/12325_2016_Article_446.PMC5216065.pdf
http://www.cdc.gov/ .,Non-OADS,/arxiv_data1/oa_pdf/32/0f/12325_2016_Article_446.PMC5216065.pdf
http://www.cancer.org/ .,Non-OADS,/arxiv_data1/oa_pdf/32/0f/12325_2016_Article_446.PMC5216065.pdf
http://www.ahrq.gov/ .,Non-OADS,/arxiv_data1/oa_pdf/32/0f/12325_2016_Article_446.PMC5216065.pdf
http://www.dol.gov/ .,Non-OADS,/arxiv_data1/oa_pdf/32/0f/12325_2016_Article_446.PMC5216065.pdf
http://www.lung.org/ .,Non-OADS,/arxiv_data1/oa_pdf/32/0f/12325_2016_Article_446.PMC5216065.pdf
http://www.cdc.,Non-OADS,/arxiv_data1/oa_pdf/32/0f/12325_2016_Article_446.PMC5216065.pdf
"An increased incidence of adverse events (AEs) related to the mechanism of SGLT2 inhibition (i.e., genital mycotic infections, urinary tract infections, osmoticEnhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/ 3D07F0603A840C8F .",Non-OADS,/arxiv_data1/oa_pdf/6c/23/12325_2016_Article_434.PMC5216068.pdf
"This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( http://creativecommons.org/licenses/ by-nc/4.0/ ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit toAdv Ther (2017) 34:41–59 57",Non-OADS,/arxiv_data1/oa_pdf/6c/23/12325_2016_Article_434.PMC5216068.pdf
2015. http://www.tdctoolkit.org/algorithms- guidelines/ .,Non-OADS,/arxiv_data1/oa_pdf/6c/23/12325_2016_Article_434.PMC5216068.pdf
Keywords: Ayurveda; CAM; Complementary and alternative medicine; Diabetes; Herbal medicine; Supplements; TM; Traditional medicineEnhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/ 5517F0607657C47F .,Non-OADS,/arxiv_data1/oa_pdf/41/ff/12325_2016_Article_439.PMC5216071.pdf
"For individuals exploring supplements, FDA documents such as, ‘‘Tips for the savvy supplement user,’’ ‘‘Tips for older dietary supplement users,’’ ‘‘questions and answers on dietary supplements,’’ and so on, might be helpful (accessible at http://www.fda.",Non-OADS,/arxiv_data1/oa_pdf/41/ff/12325_2016_Article_439.PMC5216071.pdf
"This article is distributed under the terms of the Creative CommonsAttribution-NonCommercial 4.0 International License ( http://creativecommons.org/licenses/ by-nc/4.0/ ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, andindicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/41/ff/12325_2016_Article_439.PMC5216071.pdf
USA: National Center for Complementary and Integrative Health; 2016[updated June 2016 cited 2016 27.09.16]; Availablefrom: https://nccih.nih.gov/health/integrative- health .,OADS,/arxiv_data1/oa_pdf/41/ff/12325_2016_Article_439.PMC5216071.pdf
India: The HufﬁngtonPost; 2014. http://www.hufﬁngtonpost.in/entry/ corruption-and-culture-in_b_5897042 .,Non-OADS,/arxiv_data1/oa_pdf/41/ff/12325_2016_Article_439.PMC5216071.pdf
"Rockville, MD: Agency for Healthcare Research and Quality;2007. https://www.ncbi.nlm.nih.gov/books/ NBK38360/ .",Non-OADS,/arxiv_data1/oa_pdf/41/ff/12325_2016_Article_439.PMC5216071.pdf
Statement on complementary and alternative medicine; 2011. https://www.mcnz.,Non-OADS,/arxiv_data1/oa_pdf/41/ff/12325_2016_Article_439.PMC5216071.pdf
"This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( http://creativecommons.org/licenses/ by-nc/4.0/ ), which permits any noncommercial use, distribution, and reproduction in anymedium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.Table 1 continued Variable Patients in Canada ITT population [9] (N5861)nab-P1Gem ( n533) Gem ( n530) Previous Whipple procedure, n(%) 3 (9) 2 (7) 62 (7) CA 19 -9carbohydrate antigen 19-9, Gem gemcitabine, ITT intent-to-treat, KPS Karnofsky performance status, nab-Pnab-paclitaxel, ULN upper limit of normal aTotal evaluable patients =858 bTotal evaluable patients =750 cThis value was not reported in Ref.",Non-OADS,/arxiv_data1/oa_pdf/40/a8/12325_2016_Article_442.PMC5216084.pdf
There was no signiﬁcant differenceEnhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/ D527F06018B08E8F .,Non-OADS,/arxiv_data1/oa_pdf/da/f3/12325_2016_Article_453.PMC5216085.pdf
"This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( http://creativecommons.org/licenses/ by-nc/4.0/ ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/da/f3/12325_2016_Article_453.PMC5216085.pdf
"Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which per-mits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commonslicense, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/43/47/10620_2016_Article_4378.PMC5216086.pdf
"Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which per- mits any noncommercial use, distribution, and reproduction in anymedium, provided you give appropriate credit to the originalauthor(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/09/a1/40265_2016_Article_672.PMC5216088.pdf
3.6 Potential New Treatment Options There are currently several ongoing or recently completed clinical trials in HD ( http://www.clinicaltrials.gov [ac- cessed 16 August 2016]).,Non-OADS,/arxiv_data1/oa_pdf/27/d6/40265_2016_Article_670.PMC5216093.pdf
"R. A. C. Roos received research grants from the CHDIFoundation, Gossweiler Foundation, and Teva PharmaceuticalIndustries, Ltd. Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which per- mits any noncommercial use, distribution, and reproduction in anymedium, provided you give appropriate credit to the originalauthor(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/27/d6/40265_2016_Article_670.PMC5216093.pdf
"Conclusion : Overall, incretin therapy does not appear to increase risk for MACE in the short term.Enhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/ 2217F06076ED4121 .",Non-OADS,/arxiv_data1/oa_pdf/53/22/12325_2016_Article_432.PMC5216099.pdf
"This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 InternationalLicense ( http://creativecommons.org/licenses/ by-nc/4.0/ ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, providea link to the Creative Commons license, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/53/22/12325_2016_Article_432.PMC5216099.pdf
2008. http://1.usa.gov/ 1He4KFC .,Non-OADS,/arxiv_data1/oa_pdf/53/22/12325_2016_Article_432.PMC5216099.pdf
Keywords: Acute lymphoblastic leukemia; Blinatumomab; Hematology; Long-term survival; OncologyEnhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/ 6227F0606C3830D5 .,Non-OADS,/arxiv_data1/oa_pdf/84/bd/12325_2016_Article_447.PMC5216100.pdf
"This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( http://creativecommons.org/licenses/ by-nc/4.0/ ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, andindicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/84/bd/12325_2016_Article_447.PMC5216100.pdf
Blinatumomab USPI: http://pi.amgen.com/united_ states/blincyto/blincyto_pi_hcp_english.pdf .,Non-OADS,/arxiv_data1/oa_pdf/84/bd/12325_2016_Article_447.PMC5216100.pdf
Blinatumomab EPAR: http://www.ema.europa.eu/ docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/003731/WC500198227.,Non-OADS,/arxiv_data1/oa_pdf/84/bd/12325_2016_Article_447.PMC5216100.pdf
Correlation of patients’ beliefs about treatment and other factors with adherence were evaluated by multivariable regression analyses.Enhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/ 2617F0604A1D4360 .,Non-OADS,/arxiv_data1/oa_pdf/5b/a9/12325_2016_Article_441.PMC5216107.pdf
"This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( http://creativecommons.org/licenses/ by-nc/4.0/ ), which permits any noncommercial use, distribution, and reproduction in anymedium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/5b/a9/12325_2016_Article_441.PMC5216107.pdf
http://dmorisky.bol.ucla.edu/MMAS_scale.,OADS,/arxiv_data1/oa_pdf/5b/a9/12325_2016_Article_441.PMC5216107.pdf
Additional information Supplementary Information accompanies this paper at http://www.nature.com/ naturecommunications Competing ﬁnancial interests: The authors declare no competing ﬁnancial interests.,Non-OADS,/arxiv_data1/oa_pdf/f2/58/ncomms13878.PMC5216112.pdf
"Reprints and permission information is available online at http://npg.nature.com/ reprintsandpermissions/ How to cite this article: Ooi, K. J.",Non-OADS,/arxiv_data1/oa_pdf/f2/58/ncomms13878.PMC5216112.pdf
"Toview the details of this license, please visi t (https://creativecommons.org/licenses/ by-nc-nd/4.0/).",Non-OADS,/arxiv_data1/oa_pdf/ae/5d/1349-7235-55-3413.PMC5216136.pdf
⡥2016 The Japanese Society of Internal Medicine http://www.naika.or.jp/imonline/index.html,Non-OADS,/arxiv_data1/oa_pdf/ae/5d/1349-7235-55-3413.PMC5216136.pdf
"Toview the details of this license, please visi t (https://creativecommons.org/licenses/ by-nc-nd/4.0/).",Non-OADS,/arxiv_data1/oa_pdf/66/76/1349-7235-55-3421.PMC5216137.pdf
⡥2016 The Japanese Society of Internal Medicine http://www.naika.or.jp/imonline/index.html,Non-OADS,/arxiv_data1/oa_pdf/66/76/1349-7235-55-3421.PMC5216137.pdf
"Toview the details of this license, please visi t (https://creativecommons.org/licenses/ by-nc-nd/4.0/).",Non-OADS,/arxiv_data1/oa_pdf/cd/f0/1349-7235-55-3427.PMC5216138.pdf
⡥2016 The Japanese Society of Internal Medicine http://www.naika.or.jp/imonline/index.html,Non-OADS,/arxiv_data1/oa_pdf/cd/f0/1349-7235-55-3427.PMC5216138.pdf
"Guidelines for the use of antiretroviral agents in HIV-1-infected adults andadolescents, 2015 at: http://AIDSinfo.nih.gov 6.European AIDS Clinical Society (EACS).",Non-OADS,/arxiv_data1/oa_pdf/5d/64/1349-7235-55-3435.PMC5216139.pdf
"Toview the details of this license, please visi t (https://creativecommons.org/licenses/ by-nc-nd/4.0/).",Non-OADS,/arxiv_data1/oa_pdf/5d/64/1349-7235-55-3435.PMC5216139.pdf
⡥2016 The Japanese Society of Internal Medicine http://www.naika.or.jp/imonline/index.html,Non-OADS,/arxiv_data1/oa_pdf/5d/64/1349-7235-55-3435.PMC5216139.pdf
"Toview the details of this license, please visi t (https://creativecommons.org/licenses/ by-nc-nd/4.0/).",Non-OADS,/arxiv_data1/oa_pdf/43/d4/1349-7235-55-3441.PMC5216140.pdf
⡥2016 The Japanese Society of Internal Medicine http://www.naika.or.jp/imonline/index.html,Non-OADS,/arxiv_data1/oa_pdf/43/d4/1349-7235-55-3441.PMC5216140.pdf
"Toview the details of this license, please visi t (https://creativecommons.org/licenses/ by-nc-nd/4.0/).",Non-OADS,/arxiv_data1/oa_pdf/7a/80/1349-7235-55-3445.PMC5216141.pdf
⡥2016 The Japanese Society of Internal Medicine http://www.naika.or.jp/imonline/index.html,Non-OADS,/arxiv_data1/oa_pdf/7a/80/1349-7235-55-3445.PMC5216141.pdf
"Toview the details of this license, please visi t (https://creativecommons.org/licenses/ by-nc-nd/4.0/).",Non-OADS,/arxiv_data1/oa_pdf/2e/f9/1349-7235-55-3453.PMC5216142.pdf
⡥2016 The Japanese Society of Internal Medicine http://www.naika.or.jp/imonline/index.html,Non-OADS,/arxiv_data1/oa_pdf/2e/f9/1349-7235-55-3453.PMC5216142.pdf
"Toview the details of this license, please visi t (https://creativecommons.org/licenses/ by-nc-nd/4.0/).",Non-OADS,/arxiv_data1/oa_pdf/f7/f9/1349-7235-55-3459.PMC5216143.pdf
⡥2016 The Japanese Society of Internal Medicine http://www.naika.or.jp/imonline/index.html,Non-OADS,/arxiv_data1/oa_pdf/f7/f9/1349-7235-55-3459.PMC5216143.pdf
"Toview the details of this license, please visi t (https://creativecommons.org/licenses/ by-nc-nd/4.0/).",Non-OADS,/arxiv_data1/oa_pdf/15/d2/1349-7235-55-3465.PMC5216144.pdf
⡥2016 The Japanese Society of Internal Medicine http://www.naika.or.jp/imonline/index.html,Non-OADS,/arxiv_data1/oa_pdf/15/d2/1349-7235-55-3465.PMC5216144.pdf
"Toview the details of this license, please visi t (https://creativecommons.org/licenses/ by-nc-nd/4.0/).",Non-OADS,/arxiv_data1/oa_pdf/9d/9e/1349-7235-55-3471.PMC5216145.pdf
⡥2016 The Japanese Society of Internal Medicine http://www.naika.or.jp/imonline/index.html,Non-OADS,/arxiv_data1/oa_pdf/9d/9e/1349-7235-55-3471.PMC5216145.pdf
"Toview the details of this license, please visi t (https://creativecommons.org/licenses/ by-nc-nd/4.0/).",Non-OADS,/arxiv_data1/oa_pdf/33/e8/1349-7235-55-3475.PMC5216146.pdf
⡥2016 The Japanese Society of Internal Medicine http://www.naika.or.jp/imonline/index.html,Non-OADS,/arxiv_data1/oa_pdf/33/e8/1349-7235-55-3475.PMC5216146.pdf
"Toview the details of this license, please visi t (https://creativecommons.org/licenses/ by-nc-nd/4.0/).",Non-OADS,/arxiv_data1/oa_pdf/bf/56/1349-7235-55-3479.PMC5216147.pdf
⡥2016 The Japanese Society of Internal Medicine http://www.naika.or.jp/imonline/index.html,Non-OADS,/arxiv_data1/oa_pdf/bf/56/1349-7235-55-3479.PMC5216147.pdf
"Toview the details of this license, please visi t (https://creativecommons.org/licenses/ by-nc-nd/4.0/).",Non-OADS,/arxiv_data1/oa_pdf/c5/5b/1349-7235-55-3485.PMC5216148.pdf
⡥2016 The Japanese Society of Internal Medicine http://www.naika.or.jp/imonline/index.html,Non-OADS,/arxiv_data1/oa_pdf/c5/5b/1349-7235-55-3485.PMC5216148.pdf
"Toview the details of this license, please visi t (https://creativecommons.org/licenses/ by-nc-nd/4.0/).",Non-OADS,/arxiv_data1/oa_pdf/30/5c/1349-7235-55-3491.PMC5216149.pdf
⡥2016 The Japanese Society of Internal Medicine http://www.naika.or.jp/imonline/index.html,Non-OADS,/arxiv_data1/oa_pdf/30/5c/1349-7235-55-3491.PMC5216149.pdf
https://www.pmda.go.jp/ The Internal Medicine is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.,Non-OADS,/arxiv_data1/oa_pdf/7a/5f/1349-7235-55-3495.PMC5216150.pdf
"Toview the details of this license, please visi t (https://creativecommons.org/licenses/ by-nc-nd/4.0/).",Non-OADS,/arxiv_data1/oa_pdf/7a/5f/1349-7235-55-3495.PMC5216150.pdf
⡥2016 The Japanese Society of Internal Medicine http://www.naika.or.jp/imonline/index.html,Non-OADS,/arxiv_data1/oa_pdf/7a/5f/1349-7235-55-3495.PMC5216150.pdf
"Toview the details of this license, please visi t (https://creativecommons.org/licenses/ by-nc-nd/4.0/).",Non-OADS,/arxiv_data1/oa_pdf/76/1b/1349-7235-55-3499.PMC5216151.pdf
⡥2016 The Japanese Society of Internal Medicine http://www.naika.or.jp/imonline/index.html,Non-OADS,/arxiv_data1/oa_pdf/76/1b/1349-7235-55-3499.PMC5216151.pdf
"Toview the details of this license, please visi t (https://creativecommons.org/licenses/ by-nc-nd/4.0/).",Non-OADS,/arxiv_data1/oa_pdf/e1/d3/1349-7235-55-3505.PMC5216152.pdf
⡥2016 The Japanese Society of Internal Medicine http://www.naika.or.jp/imonline/index.html,Non-OADS,/arxiv_data1/oa_pdf/e1/d3/1349-7235-55-3505.PMC5216152.pdf
"2011. http://www.accessdata.fda.gov/cdrh_docs/pdf10/H100006b.pdf (accessed June 30, 2015).",OADS,/arxiv_data1/oa_pdf/8a/5e/1349-7235-55-3511.PMC5216153.pdf
"Toview the details of this license, please visi t (https://creativecommons.org/licenses/ by-nc-nd/4.0/).",Non-OADS,/arxiv_data1/oa_pdf/8a/5e/1349-7235-55-3511.PMC5216153.pdf
⡥2016 The Japanese Society of Internal Medicine http://www.naika.or.jp/imonline/index.html,Non-OADS,/arxiv_data1/oa_pdf/8a/5e/1349-7235-55-3511.PMC5216153.pdf
"Toview the details of this license, please visi t (https://creativecommons.org/licenses/ by-nc-nd/4.0/).",Non-OADS,/arxiv_data1/oa_pdf/11/92/1349-7235-55-3515.PMC5216154.pdf
⡥2016 The Japanese Society of Internal Medicine http://www.naika.or.jp/imonline/index.html,Non-OADS,/arxiv_data1/oa_pdf/11/92/1349-7235-55-3515.PMC5216154.pdf
"Toview the details of this license, please visi t (https://creativecommons.org/licenses/ by-nc-nd/4.0/).",Non-OADS,/arxiv_data1/oa_pdf/14/16/1349-7235-55-3521.PMC5216155.pdf
⡥2016 The Japanese Society of Internal Medicine http://www.naika.or.jp/imonline/index.html,Non-OADS,/arxiv_data1/oa_pdf/14/16/1349-7235-55-3521.PMC5216155.pdf
"Toview the details of this license, please visi t (https://creativecommons.org/licenses/ by-nc-nd/4.0/).",Non-OADS,/arxiv_data1/oa_pdf/2c/33/1349-7235-55-3525.PMC5216156.pdf
⡥2016 The Japanese Society of Internal Medicine http://www.naika.or.jp/imonline/index.html,Non-OADS,/arxiv_data1/oa_pdf/2c/33/1349-7235-55-3525.PMC5216156.pdf
"Toview the details of this license, please visi t (https://creativecommons.org/licenses/ by-nc-nd/4.0/).",Non-OADS,/arxiv_data1/oa_pdf/70/41/1349-7235-55-3529.PMC5216157.pdf
⡥2016 The Japanese Society of Internal Medicine http://www.naika.or.jp/imonline/index.html,Non-OADS,/arxiv_data1/oa_pdf/70/41/1349-7235-55-3529.PMC5216157.pdf
"Toview the details of this license, please visi t (https://creativecommons.org/licenses/ by-nc-nd/4.0/).",Non-OADS,/arxiv_data1/oa_pdf/61/08/1349-7235-55-3535.PMC5216158.pdf
⡥2016 The Japanese Society of Internal Medicine http://www.naika.or.jp/imonline/index.html,Non-OADS,/arxiv_data1/oa_pdf/61/08/1349-7235-55-3535.PMC5216158.pdf
"Toview the details of this license, please visi t (https://creativecommons.org/licenses/ by-nc-nd/4.0/).",Non-OADS,/arxiv_data1/oa_pdf/cd/7f/1349-7235-55-3539.PMC5216159.pdf
⡥2016 The Japanese Society of Internal Medicine http://www.naika.or.jp/imonline/index.html,Non-OADS,/arxiv_data1/oa_pdf/cd/7f/1349-7235-55-3539.PMC5216159.pdf
"To view the details of this license, please visi t (https://creativecommons.org/licenses/ by-nc-nd/4.0/).",Non-OADS,/arxiv_data1/oa_pdf/8d/48/1349-7235-55-3543.PMC5216160.pdf
⡥2016 The Japanese Society of Internal Medicine http://www.naika.or.jp/imonline/index.html,Non-OADS,/arxiv_data1/oa_pdf/8d/48/1349-7235-55-3543.PMC5216160.pdf
"Toview the details of this license, please visi t (https://creativecommons.org/licenses/ by-nc-nd/4.0/).",Non-OADS,/arxiv_data1/oa_pdf/ea/2d/1349-7235-55-3545.PMC5216161.pdf
"Third Department of Internal Medicine, Hokkaido P.W .F.A.C., Obihiro-Kosei General Hospital, Japan Received for publication March 14, 2016; Accepted for publication April 12, 2016Correspondence to Dr. Michihito Kono, m-kono@med.hokudai.ac.jp⡥2016 The Japanese Society of Internal Medicine Journal W ebsite: http://www.naika.or.jp/imonline/index.html",Non-OADS,/arxiv_data1/oa_pdf/ea/2d/1349-7235-55-3545.PMC5216161.pdf
"Toview the details of this license, please visi t (https://creativecommons.org/licenses/ by-nc-nd/4.0/).",Non-OADS,/arxiv_data1/oa_pdf/57/4e/1349-7235-55-3547.PMC5216162.pdf
"Department of Infectious Diseases, Tokyo Metropolitan Komagome Hospital, Japan Received for publication February 17, 2016; Accepted for publication April 19, 2016Correspondence to Dr. Naoki Yanagisawa, naokiy-97@umin.ac.jp⡥2016 The Japanese Society of Internal Medicine Journal W ebsite: http://www.naika.or.jp/imonline/index.html",Non-OADS,/arxiv_data1/oa_pdf/57/4e/1349-7235-55-3547.PMC5216162.pdf
"Toview the details of this license, please visi t (https://creativecommons.org/licenses/ by-nc-nd/4.0/).",Non-OADS,/arxiv_data1/oa_pdf/9f/e0/1349-7235-55-3549.PMC5216163.pdf
"Department of General Medicine, Kurashiki Central Hospital, Japan Received for publication April 11, 2016; Accepted for publication April 18, 2016Correspondence to Dr. Akira Kuriyama, akira.kuriyama.jpn@gmail.com⡥2016 The Japanese Society of Internal Medicine Journal W ebsite: http://www.naika.or.jp/imonline/index.html",Non-OADS,/arxiv_data1/oa_pdf/9f/e0/1349-7235-55-3549.PMC5216163.pdf
"© 2016 The Author(s) Published by S. Karger AG, BaselPublished online: De cemb er 5, 2016EX TR A Dr. Peter Hobson Academic Unit, Care of the Elderly Glan Clwyd Hospital, Sarn Lane Bodelwyddan, Denbighshire LL18 5UJ (UK) E-Mail peter.hobson  @  wales.nhs.ukwww.karger.com/dee This article is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 Interna-   tional License (CC BY-NC-ND) (http://www.karger.com/Services/OpenAccessLicense).",Non-OADS,/arxiv_data1/oa_pdf/e4/1a/dee-0006-0541.PMC5216187.pdf
"© 2016 The Author(s)   Published by S. Karger AG, Basel   Published online: D ecember 5, 2016EXTRA  Dr. Coralie Barbe   Pôle Recherche et Santé Publique, Unité D’aide Méthodologique   CHU de Reims – Hôpital Robert Debré   Avenue du Général Koenig, FR–51092 Reims (France)   E-Mail cbarbe   @   chu-reims.fr www.karger.com/dee  This article is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 Interna- tional License (CC BY-NC-ND) (http://www.karger.com/Services/OpenAccessLicense).",Non-OADS,/arxiv_data1/oa_pdf/53/44/dee-0006-0549.PMC5216188.pdf
2011. https://www.nice.org.,Non-OADS,/arxiv_data1/oa_pdf/53/44/dee-0006-0549.PMC5216188.pdf
2007. http://www.has-sante.fr/portail/upload/doc s/application/pdf/synthese_denutrition_ personnes_agees.pdf.,Non-OADS,/arxiv_data1/oa_pdf/53/44/dee-0006-0549.PMC5216188.pdf
"© 2016 The Author(s) Published by S. Karger AG, BaselPublished online: Novemb er 25, 2016EX TR A Henrik Schirmer Department of Cardiology, Division of Cardiothoracic and Respiratory Disease University Hospital of North Norway PO Box 26, NO–9038 Tromsø (Norway)E-Mail Henrik.Schirmer  @  unn.nowww.karger.com/dee This article is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 Interna - tional License (CC BY-NC-ND) (http://www.karger.com/Services/OpenAccessLicense).",Non-OADS,/arxiv_data1/oa_pdf/6d/10/dee-0006-0529.PMC5216191.pdf
"The NeuroQuant software package release 1.1.0.1123 (http://www.cortechs.net/) was  used for fully automatic volume measurements of total intracranial volume (ICV), cerebral  cortical gray matter, cerebral white matter and several subcortical structures including the",OADS,/arxiv_data1/oa_pdf/6d/10/dee-0006-0529.PMC5216191.pdf
"Memory impairment is one of the most common symptoms in pa tients in the early stages  of AD; it is characterized by explicit memory deficit, particul arly episodic and working  Published online: December 9, 2016 EXTRA  Márcia L.F. Chaves   Rua Ramiro Barcelos, 2350, sala 2040   Porto Alegre, RS 90035-091 (Brazil)   E-Mail mchaves   @   hcpa.edu.br    www.karger.com/dee DOI: 10.1159/000450601  This article is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 Interna- tional License (CC BY-NC-ND) (http://www.karger.com/Services/OpenAccessLicense).",Non-OADS,/arxiv_data1/oa_pdf/c6/c5/dee-0006-0559.PMC5216193.pdf
"The NeuroQuant comput er-automated analysis  routinely provides volume data on 9 brain regions, left and rig ht sides, for a total of 18 volume  measurements (http://www.cortechs.net/products/neuroquant.php).",OADS,/arxiv_data1/oa_pdf/c6/c5/dee-0006-0559.PMC5216193.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/c6/b5/pvw031.PMC5216196.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/9e/60/pvw032.PMC5216197.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/86/2c/ehw122.PMC5216198.pdf
"   Case Rep Dermatol 2016;8:344 –349  DOI: 10.1159/000447481   Published online: December 1, 2016  © 2016 The Author(s)   Published by S. Karger AG, Basel   www.karger.com/cde   This article is licensed under  the Creative Commons Attribution -NonCommercial 4.0  International License (CC BY -NC) (http://www.karger.com/Services/OpenAccessLicense).",Non-OADS,/arxiv_data1/oa_pdf/aa/a9/cde-0008-0344.PMC5216202.pdf
"   Case Rep Oncol 2016;9:802 –805  DOI: 10.1159/000453448   Published online: November 25, 2016  © 2016 The Author(s)   Published by S. Karger AG, Basel   www.karger.com/cro   This article is licensed under the Creative Commons Attribution -NonCommercial 4.0  International License (CC BY -NC) (http://www.karger.com/Services/OpenAccessLi cense).",Non-OADS,/arxiv_data1/oa_pdf/a8/63/cro-0009-0802.PMC5216205.pdf
"   Case Rep Ophthalmol 2016;7:284 –288  DOI: 10.1159/000453392   Published online: December 8, 2016  © 2016 The Author(s)   Published by S. Karger AG, Basel   www.karger.com/cop   This article is licensed under the Creative Commo ns Attribution -NonCommercial 4.0  International License (CC BY -NC) (http://www.karger.com/Services/OpenAccessLicense).",Non-OADS,/arxiv_data1/oa_pdf/8a/e5/cop-0007-0284.PMC5216206.pdf
"   Case Rep Neurol 2016;8:251 –257  DOI: 10.1159/000453545   Published online: December 13, 2016  © 2016 The Author(s)   Published by S. Karger AG, Basel   www.karger.com/crn   This article is licensed under the Creative Commons Attribution -NonCommercial 4.0  International License (CC BY -NC) (http://www.karger.com/Services/OpenAccessLicense).",Non-OADS,/arxiv_data1/oa_pdf/45/0d/crn-0008-0251.PMC5216207.pdf
"   Case Rep Gastroenterol 2016;10:728 –732  DOI: 10.1159/000452201   Published online: November 25, 2016  © 2016 The Author(s)   Published by S. Karger AG, Basel   www.karger.com/crg   This article is licensed under the Creative Commons Attribution -NonCommercial 4.0   International License (CC BY -NC) (http://www.karger.com/Services/OpenAccessLicense).",Non-OADS,/arxiv_data1/oa_pdf/52/df/crg-0010-0728.PMC5216208.pdf
"   Case Rep Ophthalmol 2016;7:256 –264  DOI: 10.1159/000452968   Published online: November 25, 2016  © 2016 The Author(s)   Published by S. Karger AG, Basel   www.karger.com/cop   This article is licensed under the Creative Commons Attribution -NonCommercial 4.0  International License (CC BY -NC) (http://www.karger.com/Services/OpenAccessLicense).",Non-OADS,/arxiv_data1/oa_pdf/e5/46/cop-0007-0256.PMC5216209.pdf
"   Case Rep Oncol 2016;9:792 –795  DOI: 10.1159/000452969   Published online: November 25, 2016  © 2016 The Author(s)   Published by S. Karger AG, Basel   www.karger.com/cro   This article is licensed under the Creative Commons Attribution -NonCommercial 4.0  International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense).",Non-OADS,/arxiv_data1/oa_pdf/17/6c/cro-0009-0792.PMC5216210.pdf
"   Case Rep Gastroenterol 2016;10:760 –768  DOI: 10.1159/000448875   Published online: December 13, 2016  © 2016 The Author(s)   Published by S. Karger AG, Basel   www.karger.com/crg   This arti cle is licensed under the Creative Commons Attribution -NonCommercial 4.0  International License (CC BY -NC) (http://www.karger.com/Services/OpenAccessLicense).",Non-OADS,/arxiv_data1/oa_pdf/fc/b6/crg-0010-0760.PMC5216211.pdf
"   Case Rep Neurol 2016;8:243 –250  DOI: 10.1159/000453254   Published online: December 13, 2016  © 2016 The Author(s)   Published by S. Karger AG, Basel   www.karger.com/crn   This article  is licensed under the Creative Commons Attribution -NonCommercial 4.0  International License (CC BY -NC) (http://www.karger.com/Services/OpenAccessLicense).",Non-OADS,/arxiv_data1/oa_pdf/79/79/crn-0008-0243.PMC5216213.pdf
Boulevard 29   DK–5000 Odense C (Denmark)   E-Mail KennethBruunPedersen   @   gmail.com www.karger.com/cee DOI: 10.1159/000451035  This article is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 Interna- tional License (CC BY-NC-ND) (http://www.karger.com/Services/OpenAccessLicense).,Non-OADS,/arxiv_data1/oa_pdf/69/14/cee-0006-0140.PMC5216214.pdf
"   Case Rep Oncol 2016;9:796 –801  DOI: 10.1159/000452946   Published online: November 25, 2016  © 2016 The Author(s)   Published by S. Karger AG, Basel   www.karger.com/cro   This article is licensed under the Creative Commons Attribution -NonCommercial 4.0  International License (CC BY -NC) (http://www.karger.com/Services/OpenAccessLicense).",Non-OADS,/arxiv_data1/oa_pdf/e5/65/cro-0009-0796.PMC5216215.pdf
"UpToDate, Waltham, 2016,  http://www.uptodate.com /contents/breast -sarcoma -treatment.",Non-OADS,/arxiv_data1/oa_pdf/e5/65/cro-0009-0796.PMC5216215.pdf
"   Case Rep Gastroenterol 2016;10:706 –713  DOI: 10.1159/000452209   Published online: November 25, 2016  © 2016 The Author(s)   Published by S. Karger AG, Basel   www.karger.com/crg   This article is licensed under the Creative Commons Attribution -NonCommercial 4.0  International License (CC BY -NC) (http://www.karger.com/Services/OpenAccessLicense).",Non-OADS,/arxiv_data1/oa_pdf/98/32/crg-0010-0706.PMC5216216.pdf
11 Nippo -yakuhin: http://www.nippo -yakuhin.jp/hinmok u_detail/01210.html.,Non-OADS,/arxiv_data1/oa_pdf/98/32/crg-0010-0706.PMC5216216.pdf
12 FDA U.S. Food and Drug Administration:  http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022206s000_MedR_P2.pdf.,OADS,/arxiv_data1/oa_pdf/98/32/crg-0010-0706.PMC5216216.pdf
13 Nippo -yakuhin: http://www.nippo -yakuhin.jp/jacko/element.,Non-OADS,/arxiv_data1/oa_pdf/98/32/crg-0010-0706.PMC5216216.pdf
"   Case Rep Dermatol 2016;8:262 –266  DOI: 10.1159/000450848   Published online: October 4, 2016  © 2016 The Author(s)   Published by S. Karger AG, Basel   www.karger.com/cde   This article is licensed under the Creative Commons Attribution -NonCommercial 4.0  International License (CC BY -NC) (http://www.karger.com/Services/OpenAccessLicense).",Non-OADS,/arxiv_data1/oa_pdf/b2/15/cde-0008-0262.PMC5216217.pdf
"   Case Rep Ophthalmol 2016;7:277 –283  DOI: 10.1159/000453391   Published online: December 1, 2016  © 2016 The Author(s)   Published by S. Karger AG, Basel   www.karger.com/cop   This article is licensed under the Creative Commons Attribution -NonCommercial 4.0  International License (CC BY -NC) (http://www.karger.com/Services/OpenAccessLicen se).",Non-OADS,/arxiv_data1/oa_pdf/e7/7d/cop-0007-0277.PMC5216218.pdf
"   Case Rep Dermatol 2016;8:341 –343  DOI: 10.1159/000449033   Published online: December 1, 2016  © 2016 The Author(s)   Published by S. Karger AG, Basel   www.karger.com/cde   This article is licensed under the Creative Commons Attribution -NonCommercial 4.0  International License (CC BY -NC) (http://www.karger.com/Services/OpenAccessLicense).",Non-OADS,/arxiv_data1/oa_pdf/f8/da/cde-0008-0341.PMC5216222.pdf
"   Case Rep Gastroenterol 2016;10:714 –719  DOI: 10.1159/000452736   Published online: November 25, 2016  © 2016 The Author(s)   Published by S. Karger AG, Basel   www.karger.com/crg   This article is licensed under the Creative Commons Attribution -NonCommercial 4.0  International License (CC BY -NC) (http://www.karger.com/Services/OpenAccessLicense).",Non-OADS,/arxiv_data1/oa_pdf/9c/73/crg-0010-0714.PMC5216223.pdf
2016.  http://www.uptodate.com/contents/clinical -manifestatio ns-and-diagnosis -of-sphincter -of-oddi - dysfunction.,Non-OADS,/arxiv_data1/oa_pdf/9c/73/crg-0010-0714.PMC5216223.pdf
2016.  http://www.uptodate.com/contents/laparoscopic -cholecystectomy?source=search_result&search=   7%09Soper+N%2C+Malladi+P%3A+Laparoscopic+cholecystectomy&selectedTitle= 2%7E64.,Non-OADS,/arxiv_data1/oa_pdf/9c/73/crg-0010-0714.PMC5216223.pdf
"   Case Rep Ophthalmol 2016;7:265 –269  DOI: 10.1159/000452993   Published online: November 29, 2016  © 2016 The Author(s)   Published by S. Karger AG, Basel   www.karger.com/cop   This article is licensed under the Creative Commons Attribution -NonCommercial 4.0  International License (CC BY -NC) (http://www.karger.com/Services/OpenAccessLicense).",Non-OADS,/arxiv_data1/oa_pdf/0c/77/cop-0007-0265.PMC5216224.pdf
"   Case Rep Ophthalmol 2016;7:251 –255  DOI: 10.1159/000452941   Published online: November 25, 2016  © 2016 The Author(s)   Published by S. Karger AG, Basel   www.karger.com/cop   This article is licensed under the Creative Commons Attribution -NonCommercial 4.0  International License (CC BY -NC) (http://www.karger.com/Services/OpenAccessLicense).",Non-OADS,/arxiv_data1/oa_pdf/b3/83/cop-0007-0251.PMC5216225.pdf
"   Case Rep Oncol 2016;9:786 –791  DOI: 10.1159/000452945   Published online: November 25, 2016  © 2016 The Author(s)   Published by S. Karger AG, Basel   www.karger.com/cro   This article is licensed under the Creative Commons Attribution -NonCommercial 4.0  International License (C C BY -NC) (http://www.karger.com/Services/OpenAccessLicense).",Non-OADS,/arxiv_data1/oa_pdf/ef/e0/cro-0009-0786.PMC5216226.pdf
"   Case Rep Dermatol 2016;8:250 –253  DOI: 10.1159/000449365   Published online: October 4, 2016  © 2016 The Author(s)   Published by S. Karger AG, Basel   www.karger.com/cde   This article is licensed under the Creative Com mons Attribution -NonCommercial 4.0  International License (CC BY -NC) (http://www.karger.com/Services/OpenAccessLicense).",Non-OADS,/arxiv_data1/oa_pdf/59/43/cde-0008-0250.PMC5216227.pdf
"   Case Rep Ophthalmol 2016;7:208 –212  DOI: 10.1159/000450824   Published online: October 11, 2016  © 2016 The Author(s)   Published by S. Karger AG, Basel   www.karger.com/cop   This article is licensed under the Creative Commons Attribution -NonCommercial 4.0  International License (CC BY -NC) (http://www.karger.com/Services/OpenAccessLicense).",Non-OADS,/arxiv_data1/oa_pdf/98/d3/cop-0007-0208.PMC5216228.pdf
"   Case Rep Nephrol Dial 2016;6:83 –88  DOI: 10.1159/000446393   Published online: June 10, 2016  © 2016 The Author(s)   Published by S. Karger AG, Basel   www.karger.com/cnd   This article is licensed under the Creative Commons Attribution -NonCommercial 4.0  International License (CC BY -NC) (http://www.karger.com/Services/OpenAccessLicense).",Non-OADS,/arxiv_data1/oa_pdf/e0/fa/cnd-0006-0083.PMC5216229.pdf
"   Case Rep Gastroenterol 2016;10:749 –754  DOI: 10.1159/000452760   Published online: December 13, 2016  © 2016 The Author(s)   Published by S. Karger AG, Basel   www.karger.com/crg   This article is licensed under the Creative Commons Attribution -NonCommercial 4.0  International License (CC BY -NC) (http://www.karger.com/Services/OpenAccessLicense).",Non-OADS,/arxiv_data1/oa_pdf/fc/e0/crg-0010-0749.PMC5216230.pdf
"   Case Rep Oncol 2016;9:806 –814  DOI: 10.1159/000452792   Published online: November 29, 2016  © 2016 The Author(s)   Published by S. Karger AG, Basel   www.karger.com/cro   This article is licensed und er the Creative Commons Attribution -NonCommercial 4.0  International License (CC BY -NC) (http://www.karger.com/Services/OpenAccessLicense).",Non-OADS,/arxiv_data1/oa_pdf/12/7d/cro-0009-0806.PMC5216231.pdf
"   Case Rep Gastroenterol 2016;10:755 –759  DOI: 10.1159/000452199   Published online: December 13, 2016  © 2016 The Author(s)   Published by S. Karger AG, Basel   www.karger.com/crg   This article is licensed under the Creative Commons Attribution -NonCommercial 4.0  International License (CC BY -NC) (http://www.karger.com/Services/OpenAccessLicense).",Non-OADS,/arxiv_data1/oa_pdf/f3/29/crg-0010-0755.PMC5216232.pdf
"   Case Rep Oncol 2016;9:826 –832  DOI: 10.1159/000453314   Published online: December 8, 2016  © 2016 The Author(s)   Published by S. Karger AG, Basel   www.karger.com/cro   This article is licensed under the Creative Commons Attribution -NonCommercial 4.0  International License (CC BY -NC) (http://www.karger.com/Services/OpenAccessLicense).",Non-OADS,/arxiv_data1/oa_pdf/e2/8c/cro-0009-0826.PMC5216233.pdf
"   Case Rep Gastroenterol 2016;10:743 –748  DOI: 10.1159/000450539   Published online: December 13, 2016  © 2016 The Author(s)   Published by S. Karger AG, Basel   www.karger.com/crg   This article is licensed under the Creative Commons Attribution -NonCommercial 4.0  International License (CC BY -NC) (http://www.karger.com/Services/OpenAccessLicense).",Non-OADS,/arxiv_data1/oa_pdf/41/18/crg-0010-0743.PMC5216234.pdf
"   Case Rep Gastroenterol 2016;10:769 –774  DOI: 10.1159/000452757   Published online: December 13, 2016  © 2016 The Author(s)   Published by S. Karger AG, Basel   www.karger.com/crg   This articl e is licensed under the Creative Commons Attribution -NonCommercial 4.0  International License (CC BY -NC) (http://www.karger.com/Services/OpenAccessLicense).",Non-OADS,/arxiv_data1/oa_pdf/1d/26/crg-0010-0769.PMC5216235.pdf
"   Case Rep Ophthalmol 2016;7:213 –217  DOI: 10.1159/000449124   Published online: October 11, 2016  © 2016 The Author(s)   Published by S. Karger AG, Basel   www.karger.com/cop   This article is licensed under the Creative Commons Attribution -NonCommercial 4.0  International License (CC BY -NC) (http://www.karger.com/Services/OpenAccessLicense).",Non-OADS,/arxiv_data1/oa_pdf/54/84/cop-0007-0213.PMC5216236.pdf
"   Case Rep Ophthalmol 2016;7:270 –276  DOI: 10.1159/000453393   Published online: December 1, 2016  © 2016 The Author(s)   Published by S. Karger AG, Basel   www.karger.com/cop   This article is licensed under the Creative Commons Attribution -NonCommercial 4.0  International License (CC BY -NC) (http://www.karger.com/Services/OpenAccessLice nse).",Non-OADS,/arxiv_data1/oa_pdf/a1/23/cop-0007-0270.PMC5216237.pdf
"   Case Rep Gastroenterol 2016;10:733 –742  DOI: 10.1159/000452200   Published online: December 8, 2016  © 2016 The Author(s)   Published by S. Karger AG, Basel   www.karger.com/crg   This article is licensed under the Creative Commons Attribution -NonCommercial 4.0  International License (CC BY -NC) (http://www.karger.com/Services/OpenAccessLicense).",Non-OADS,/arxiv_data1/oa_pdf/ae/1f/crg-0010-0733.PMC5216238.pdf
"   Case Rep Oncol 2016;9:847 –853  DOI: 10.1159/000452655   Published online: December 14, 2016  © 2016 The Author(s)   Published by S. Karger AG, Basel   www.karger.com/cro   This article is licensed under the Creative Commons Attribution -NonCommercial 4.0  International License (CC BY -NC) (http://www.karger.com/Services/OpenAc cessLicense).",Non-OADS,/arxiv_data1/oa_pdf/0d/4e/cro-0009-0847.PMC5216239.pdf
"   Case Rep Ophthalmol 2016;7:292 –300  DOI: 10.1159/000453447   Published online: December 13, 2016  © 2016 The Author(s)   Published by S. Karger AG, Basel   www.karger.com/cop   This article is licensed under the Creative Commons Attribution -NonCommercial 4.0  International License (CC BY -NC) (http://www.karger.com/Services/OpenAccessLicense).",Non-OADS,/arxiv_data1/oa_pdf/1e/0f/cop-0007-0292.PMC5216240.pdf
"   Case Rep Dermatol 2016;8:267 –271  DOI: 10.1159/000450698   Published online: October 4, 2016  © 2016 The Author(s)   Published by S. Karger AG, Basel   www.karger.com/cde   This article is licensed under the Creative Commons Attribution -NonCommercial 4.0  International License (CC BY -NC) (http://www.karger.com/Services/OpenAccessLicense).",Non-OADS,/arxiv_data1/oa_pdf/ac/41/cde-0008-0267.PMC5216241.pdf
"   Case Rep Ophthalmol 2016;7:289 –291  DOI: 10.1159/000453524   Published online: December 13, 2016  © 2016 The Author(s)   Published by S. Karger AG, Basel   www.karger.com/cop   This article is licensed under the Creative Commons Attribution -NonCommercial 4.0  International License (CC BY -NC) (http://www.karger.com/Services/OpenAccessLicense).",Non-OADS,/arxiv_data1/oa_pdf/f4/65/cop-0007-0289.PMC5216242.pdf
"   Case Rep Nephrol Dial 2016;6:143 –148  DOI: 10.1159/000454946   Published online: December 20, 2016  © 2016 The Author(s)   Published by S. Karger AG, Basel   www.karger.com/cnd   This article is licensed under the Creative Commons Attribution -NonCommercial 4.0  International License (CC BY -NC) (http://www.karger.com/Services/OpenAccessLicense).",Non-OADS,/arxiv_data1/oa_pdf/a5/73/cnd-0006-0143.PMC5216244.pdf
"   Case Rep Ophthalmol 2016;7:193 –197  DOI: 10.1159/000450675   Published online: October 11, 2016  © 2016 The Author(s)   Published by S. Karger AG, Basel   www.karger.com/cop   This article is licensed under the Creative Commons Attribution -NonCommercial 4.0  International License (CC BY -NC) (http://www.karger.com/Services/OpenAccessLicense).",Non-OADS,/arxiv_data1/oa_pdf/60/ae/cop-0007-0193.PMC5216245.pdf
"   Case Rep Gastroenterol 2016;10:720 –727  DOI: 10.1159/000450538   Published online: November 25, 2016  © 2016 The Author(s)   Published by S. Karger AG, Basel   www.karger.com/crg   This article is licensed under the Creative Commons Attribution -NonCommercial 4.0  International License (CC BY -NC) (http://www.karger.com/Services/OpenAccessLice nse).",Non-OADS,/arxiv_data1/oa_pdf/da/dc/crg-0010-0720.PMC5216246.pdf
"   Case Rep Dermatol 2016;8:363 –368  DOI: 10.1159/000452323   Published online: December 13, 2016  © 2016 The Author(s)   Published by S. Karger AG, Basel   www.karger.com/cde   This article is licensed under the Creative Commons Attribution -NonCommercial 4.0  Internation al License (CC BY -NC) (http://www.karger.com/Services/OpenAccessLicense).",Non-OADS,/arxiv_data1/oa_pdf/24/b4/cde-0008-0363.PMC5216247.pdf
"   Case Rep Dermatol 2016;8:354 –357  DOI: 10.1159/000452829   Published online: December 7, 2016  © 2016 The Author(s)   Published by S. Karger AG, Basel   www.karger.com/cde   This article is licensed under the Creative Commons Attribution -NonCommercial 4.0  International License (CC BY -NC) (http://www.karger.com/Services/OpenAccessLicense).",Non-OADS,/arxiv_data1/oa_pdf/35/37/cde-0008-0354.PMC5216248.pdf
"   Case Rep Dermatol 2016;8:254 –261  DOI: 10.1159/000450723   Published online: October 4, 2016  © 2016 The Author(s)   Published by S. Karger AG, Basel   www.karger.com/cde   This article is licensed under the Creative Commons Attribution -NonCommercial 4.0  International License (CC BY -NC) (http://www.karger.com/Services/OpenAccessLicense).",Non-OADS,/arxiv_data1/oa_pdf/5b/60/cde-0008-0254.PMC5216249.pdf
"   Case Rep Oncol 2016;9:833 –839  DOI: 10.1159/000452944   Published online: December 8, 2016  © 2016 The Author(s)   Published by S. Karger AG, Basel   www.karger.com/cro   This article is licensed under the Creative Commons Attribution -NonCommercial 4.0  International License (CC BY -NC) (http://www.karger.com/Services/OpenAccessLicense).",Non-OADS,/arxiv_data1/oa_pdf/0e/10/cro-0009-0833.PMC5216251.pdf
"   Case Rep Ophthalmol 2016;7:198 –202  DOI: 10.1159/000450638   Published online: October 11, 2016  © 2016 The Author(s)   Published by S. Karger AG, Basel   www.karger.com/cop   This article is licensed under the Creative Commons Attribution -NonCommercial 4.0  International License (CC BY -NC) (http://www.karger.com/Services/OpenAccessLicense).",Non-OADS,/arxiv_data1/oa_pdf/71/62/cop-0007-0198.PMC5216252.pdf
"   Case Rep Dermatol 2016;8:350 –353  DOI: 10.1159/000452826   Published online: December 1, 2016  © 2016 The Author(s)   Published by S. Karger AG, Basel   www.karger.com/cde   This article is licensed under the Creative Commons Attribution -NonCommercial 4.0  International License (CC BY -NC) (http://www.karger.com/Services/OpenAccessLicense).",Non-OADS,/arxiv_data1/oa_pdf/b9/da/cde-0008-0350.PMC5216253.pdf
Supportin ginformation (including experimen taldetails) forthis article canbefound under : http://dx.do i.org/10.1002/a nie.2016026 39.,Non-OADS,/arxiv_data1/oa_pdf/b9/22/ANIE-55-10518.PMC5216445.pdf
Available from: http://www.cdc.gov/ flu/avian/gen‑info/avian‑flu‑humans.htm.,Non-OADS,/arxiv_data1/oa_pdf/06/fb/JRMS-21-51.PMC5216463.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/ licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/6c/22/ddw206.PMC5216611.pdf
Many of the markers that associated with onset of familial PD map to sequences that are identiﬁed by the RoadmapEpigenomics Project (http://genomebrowser.wustl.edu) andENCODE ( 48) as being active regulatory elements in the brain (Figs 7 and 8).,Non-OADS,/arxiv_data1/oa_pdf/6c/22/ddw206.PMC5216611.pdf
"The variants were not found in eQTL or mQTL databases Genevar ( 49), eqtl (http://eqtl.uchicago.edu/cgi-bin/ gbrowse/eqtl/), SCAN ( 50), or BRAINEAC ( 51), likely due to their low frequencies, thus we could not test their association withthe expression or methylation of LHFPL2 ,TPM1 , or adjacent genes.",Non-OADS,/arxiv_data1/oa_pdf/6c/22/ddw206.PMC5216611.pdf
"811,597 SNPs passed quality-control measures (genotype and phenotype data for NGRC are available on dbGaP; http://www.ncbi.nlm.nih.gov/gap, accession number phs000196.v2.p1).Principal component analysis (PCA) was conducted with HelixTree (http://www.goldenhelix.com) using a pruned subset of104,064 SNPs, as described previously ( 13).",OADS,/arxiv_data1/oa_pdf/6c/22/ddw206.PMC5216611.pdf
Imputation was conducted using the IMPUTEv2.2.2 software (https://mathgen.stats.ox.ac.uk/im pute/impute_v2.html) ( 62) and the 1000 Genomes Phase I inte- grated variant set release v3.,OADS,/arxiv_data1/oa_pdf/6c/22/ddw206.PMC5216611.pdf
Linear regression was performed in ProbABEL v. 0.1-9d software (http://www.genabel.org/packages/ProbABEL) ( 65).,OADS,/arxiv_data1/oa_pdf/6c/22/ddw206.PMC5216611.pdf
PS program was used for power calculation (http://biostat.mc.,OADS,/arxiv_data1/oa_pdf/6c/22/ddw206.PMC5216611.pdf
We examined Epigenomics Roadmap (via http://genomebrowser.wustl.edu) and ENCODE (via http://genome.ucsc.edu/index.html) ( 48) annotations of putative regula- tory elements in the regions of our associated signals.,OADS,/arxiv_data1/oa_pdf/6c/22/ddw206.PMC5216611.pdf
"uchicago.edu/cgi-bin/gbrowse/eqtl/), SCAN (http://www.scandb.org/newinterface/about.html) ( 50) and BRAINEAC (http://www.",OADS,/arxiv_data1/oa_pdf/6c/22/ddw206.PMC5216611.pdf
"1   January,  2017pISSN: 2093-0879   eISSN: 2093-0887https://doi.org/10.5056/jnm 16209 EditorialJournal of Neurogastroenterology and Motility  ⓒ 2017 The Korean Society of Neurogastroenterology and Motility J Neurogastroenterol Motil, Vol.",Non-OADS,/arxiv_data1/oa_pdf/c9/53/jnm-23-001.PMC5216626.pdf
"Available from  URL: http://grants.nih.gov/grants/funding/women_min/guidelines_amended_10_2001.htm (accessed 6 December, 2016).",Non-OADS,/arxiv_data1/oa_pdf/c9/53/jnm-23-001.PMC5216626.pdf
"1   January,  2017pISSN: 2093-0879   eISSN: 2093-0887https://doi.org/10.5056/jnm 16215 EditorialJournal of Neurogastroenterology and Motility  ⓒ 2017 The Korean Society of Neurogastroenterology and Motility J Neurogastroenterol Motil, Vol.",Non-OADS,/arxiv_data1/oa_pdf/82/71/jnm-23-003.PMC5216627.pdf
"1   January,  2017pISSN: 2093-0879   eISSN: 2093-0887https://doi.org/10.5056/jnm 16121 ReviewJournal of Neurogastroenterology and Motility  ⓒ 2017 The Korean Society of Neurogastroenterology and Motility J Neurogastroenterol Motil, Vol.",Non-OADS,/arxiv_data1/oa_pdf/64/cb/jnm-23-005.PMC5216628.pdf
"1   January,  2017pISSN: 2093-0879   eISSN: 2093-0887https://doi.org/10.5056/jnm 16124 ReviewJournal of Neurogastroenterology and Motility  ⓒ 2017 The Korean Society of Neurogastroenterology and Motility J Neurogastroenterol Motil, Vol.",Non-OADS,/arxiv_data1/oa_pdf/30/3e/jnm-23-009.PMC5216629.pdf
"1   January,  2017pISSN: 2093-0879   eISSN: 2093-0887https://doi.org/10.5056/jnm 16135 ReviewJournal of Neurogastroenterology and Motility  ⓒ 2017 The Korean Society of Neurogastroenterology and Motility J Neurogastroenterol Motil, Vol.",Non-OADS,/arxiv_data1/oa_pdf/8a/61/jnm-23-020.PMC5216630.pdf
"1   January,  2017pISSN: 2093-0879   eISSN: 2093-0887https://doi.org/10.5056/jnm 16008 Original ArticleJournal of Neurogastroenterology and Motility  ⓒ 2017 The Korean Society of Neurogastroenterology and Motility J Neurogastroenterol Motil, Vol.",Non-OADS,/arxiv_data1/oa_pdf/f7/f3/jnm-23-027.PMC5216631.pdf
"1   January,  2017pISSN: 2093-0879   eISSN: 2093-0887https://doi.org/10.5056/jnm 16028 Original ArticleJournal of Neurogastroenterology and Motility  ⓒ 2017 The Korean Society of Neurogastroenterology and Motility J Neurogastroenterol Motil, Vol.",Non-OADS,/arxiv_data1/oa_pdf/b3/66/jnm-23-034.PMC5216632.pdf
"1   January,  2017pISSN: 2093-0879   eISSN: 2093-0887https://doi.org/10.5056/jnm 16057 Original ArticleJournal of Neurogastroenterology and Motility  ⓒ 2017 The Korean Society of Neurogastroenterology and Motility J Neurogastroenterol Motil, Vol.",Non-OADS,/arxiv_data1/oa_pdf/58/2b/jnm-23-041.PMC5216633.pdf
"1   January,  2017pISSN: 2093-0879   eISSN: 2093-0887https://doi.org/10.5056/jnm 16063 Original ArticleJournal of Neurogastroenterology and Motility  ⓒ 2017 The Korean Society of Neurogastroenterology and Motility J Neurogastroenterol Motil, Vol.",Non-OADS,/arxiv_data1/oa_pdf/42/72/jnm-23-049.PMC5216634.pdf
"1   January,  2017pISSN: 2093-0879   eISSN: 2093-0887https://doi.org/10.5056/jnm 16062 Original ArticleJournal of Neurogastroenterology and Motility  ⓒ 2017 The Korean Society of Neurogastroenterology and Motility J Neurogastroenterol Motil, Vol.",Non-OADS,/arxiv_data1/oa_pdf/37/1b/jnm-23-055.PMC5216635.pdf
"1   January,  2017pISSN: 2093-0879   eISSN: 2093-0887https://doi.org/10.5056/jnm 16047 Original ArticleJournal of Neurogastroenterology and Motility  ⓒ 2017 The Korean Society of Neurogastroenterology and Motility J Neurogastroenterol Motil, Vol.",Non-OADS,/arxiv_data1/oa_pdf/83/16/jnm-23-064.PMC5216636.pdf
"1   January,  2017pISSN: 2093-0879   eISSN: 2093-0887https://doi.org/10.5056/jnm 16119 Original ArticleJournal of Neurogastroenterology and Motility  ⓒ 2017 The Korean Society of Neurogastroenterology and Motility J Neurogastroenterol Motil, Vol.",Non-OADS,/arxiv_data1/oa_pdf/6b/cd/jnm-23-072.PMC5216637.pdf
"1   January,  2017pISSN: 2093-0879   eISSN: 2093-0887https://doi.org/10.5056/jnm 16020 Original ArticleJournal of Neurogastroenterology and Motility  ⓒ 2017 The Korean Society of Neurogastroenterology and Motility J Neurogastroenterol Motil, Vol.",Non-OADS,/arxiv_data1/oa_pdf/86/84/jnm-23-080.PMC5216638.pdf
"Available from URL: http://www.ncbi.nlm.nih.gov/ books/NBK51962 (accessed 8 August, 2016).",Non-OADS,/arxiv_data1/oa_pdf/86/84/jnm-23-080.PMC5216638.pdf
"1   January,  2017pISSN: 2093-0879   eISSN: 2093-0887https://doi.org/10.5056/jnm 16066 Original ArticleJournal of Neurogastroenterology and Motility  ⓒ 2017 The Korean Society of Neurogastroenterology and Motility J Neurogastroenterol Motil, Vol.",Non-OADS,/arxiv_data1/oa_pdf/5a/4c/jnm-23-092.PMC5216639.pdf
"1   January,  2017pISSN: 2093-0879   eISSN: 2093-0887https://doi.org/10.5056/jnm 16027 Original ArticleJournal of Neurogastroenterology and Motility  ⓒ 2017 The Korean Society of Neurogastroenterology and Motility J Neurogastroenterol Motil, Vol.",Non-OADS,/arxiv_data1/oa_pdf/04/73/jnm-23-101.PMC5216640.pdf
"1   January,  2017pISSN: 2093-0879   eISSN: 2093-0887https://doi.org/10.5056/jnm 16003 Original ArticleJournal of Neurogastroenterology and Motility  ⓒ 2017 The Korean Society of Neurogastroenterology and Motility J Neurogastroenterol Motil, Vol.",Non-OADS,/arxiv_data1/oa_pdf/24/49/jnm-23-109.PMC5216641.pdf
"1   January, 2017 (109-116)ogy and Motility  at http://www.jnmjournal.org/, and at https://doi.",Non-OADS,/arxiv_data1/oa_pdf/24/49/jnm-23-109.PMC5216641.pdf
"1   January,  2017pISSN: 2093-0879   eISSN: 2093-0887https://doi.org/10.5056/jnm 16012 Original ArticleJournal of Neurogastroenterology and Motility  ⓒ 2017 The Korean Society of Neurogastroenterology and Motility J Neurogastroenterol Motil, Vol.",Non-OADS,/arxiv_data1/oa_pdf/5e/0b/jnm-23-117.PMC5216642.pdf
"1   January,  2017pISSN: 2093-0879   eISSN: 2093-0887https://doi.org/10.5056/jnm 16042 Original ArticleJournal of Neurogastroenterology and Motility  ⓒ 2017 The Korean Society of Neurogastroenterology and Motility J Neurogastroenterol Motil, Vol.",Non-OADS,/arxiv_data1/oa_pdf/63/8e/jnm-23-124.PMC5216643.pdf
"Supplementary Material   Note: T o access the supplementary table mentioned in this article, visit the online version of Journal of Neurogastroenterol- ogy and Motility  at http://www.jnmjournal.org/, and at https://doi.",Non-OADS,/arxiv_data1/oa_pdf/63/8e/jnm-23-124.PMC5216643.pdf
"1   January,  2017pISSN: 2093-0879   eISSN: 2093-0887https://doi.org/10.5056/jnm 16105 Original ArticleJournal of Neurogastroenterology and Motility  ⓒ 2017 The Korean Society of Neurogastroenterology and Motility J Neurogastroenterol Motil, Vol.",Non-OADS,/arxiv_data1/oa_pdf/20/36/jnm-23-135.PMC5216644.pdf
"1   January,  2017 pISSN: 2093-0879   eISSN: 2093-0887https://doi.org/10.5056/jnm 16143 Letter to the EditorJournal of Neurogastroenterology and Motility  ⓒ 2017 The Korean Society of Neurogastroenterology and Motility J Neurogastroenterol Motil, Vol.",Non-OADS,/arxiv_data1/oa_pdf/dc/02/jnm-23-144.PMC5216645.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/ licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/16/4a/kfw193.PMC5216653.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which per- mits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/18/98/kfw224.PMC5216657.pdf
"This is an Open Access article distribut ed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by- nc/4.0/), which permits non-commercial re- use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/fe/df/msw228.PMC5216669.pdf
We used the Chao 1 estimator (the ACE and Chao1 estimates were identical) calculated using EstimateS v9.0.0 (http://viceroy.eeb.uconn.edu/estima tes/) for these analyses.,OADS,/arxiv_data1/oa_pdf/fe/df/msw228.PMC5216669.pdf
2011 ) using the online parasite clearance calculator (http://www.wwarn.org/tools-re sources/toolkit/analyse/parasite-clearance-estimator-pce).,OADS,/arxiv_data1/oa_pdf/fe/df/msw228.PMC5216669.pdf
[cited 2013 Apr 12] Availablefrom: http://purl.oc lc.org/estimates.,OADS,/arxiv_data1/oa_pdf/fe/df/msw228.PMC5216669.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/01/17/ijn-12-207.PMC5216680.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of Nanomedicine 2017:12 207–216International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  207OrIg INal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/IJN.S11863 7 Impact of nanostructured thin ZnO film  in ultraviolet protection Morteza sasani ghamsari1 sanaz alamdari1 Wooje han2 hyung-ho Park2 1laser and Optics research school,   Nuclear science and Technology  research Institute, T ehran, Iran;   2Department of Materials science and  engineering, Y onsei University, seoul,   south KoreaAbstract:  Nanoscale ZnO is one of the best choices for ultraviolet (UV) protection, not only  because of its antimicrobial properties but also due to its potential application for UV preser - vation.",Non-OADS,/arxiv_data1/oa_pdf/01/17/ijn-12-207.PMC5216680.pdf
"However, the low stability of the  polymer matrices commonly used to embed the absorbers upon UV irradiation limits  their application severely.6,7 In order to provide an effective protection against UV  radiation, one of the requirements of UV -absorber molecules is the ability to transform  the absorbed radiation energy in less damaging thermal energy via a photophysical  process.8 With regard to delamination and the time it takes to occur (closely related to correspondence: Morteza sasani  ghamsari laser and Optics research school,  Nuclear science and Technology  research Institute, North Karegar  avenue, Tehran 11155, Iran Tel +98 21 8800 8592 Fax +98 21 8822 1082 email msasani@aeoi.org.i r  hyung-ho Park Department of Materials science and  engineering, Yonsei University, 50  Yonsei-ro, seodaemun-gu, seoul 120749,  south Korea Tel +82 2 2123 2853 Fax +82 2 312 5375 email hhpark@yonsei.ac.k r Journal name: International Journal of Nanomedicine Article Designation: Original Research Y ear: 2017 Volume: 12 Running head verso: Sasani Ghamsari et al Running head recto: Nanostructured ZnO films and UV protection DOI: http://dx.doi.org/10.2147/IJN.S118637",Non-OADS,/arxiv_data1/oa_pdf/01/17/ijn-12-207.PMC5216680.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology   in diagnostics, therapeutics, and drug delivery systems throughout   the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/01/17/ijn-12-207.PMC5216680.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/01/17/ijn-12-207.PMC5216680.pdf
"Available from: http://www.koboproductsinc.com/Downloads/ (q)TiO2_ZnO_UV_Bal_InCos08.pd f. Accessed December 1, 2016.",Non-OADS,/arxiv_data1/oa_pdf/01/17/ijn-12-207.PMC5216680.pdf
Available from:  http://standards.globalspec.com/ std/9895207/aatcc-18 3.,Non-OADS,/arxiv_data1/oa_pdf/01/17/ijn-12-207.PMC5216680.pdf
SUPPLEMENTARY MATERIALS Supplementary material for this article is available at http://advances.sciencemag.org/cgi/ content/full/3/1/e1601207/DC1fig.,Non-OADS,/arxiv_data1/oa_pdf/cd/45/1601207.PMC5216687.pdf
Data and materials availability: Buoy and ship data are available from ICOADS at http://icoads.noaa.gov/products.html; ESA-CCI data areavailable from the Centre for Environmental Data Analysis at http://gws-access.ceda.ac.uk/public2/nceo_uor/sst/L3S/EXP1.2/; ARC-SST data are available at http://catalogue.ceda.ac.uk/uuid/ff8a7f27b827c108dd9756adffaaa942; Argo data are available from the APDRC athttp://apdrc.soest.hawaii.edu/projects/Argo/data/gridded/On_standard_levels/index-1.html; Argo data are available from the Japan Agency for Marine-Earth Science and Technology (H2008) at http://www.jamstec.go.jp/ARGO/argo_web/argo/?page_id=83&lang=en; Argo dataare available from Roemmich and Gilson (RG2009) at http://sio-argo.ucsd.edu/RG_Climatology.html; ERSSTv4 data are available at http://www1.ncdc.noaa.gov/pub/data/cmb/ersst/v4/netcdf/;ERSSTv3b data are available at http://www1.ncdc.noaa.gov/pub/data/cmb/ersst/v3b/netcdf/;HadSST3 data are available at http://www.metoffice.gov.uk/hadobs/hadsst3/data/download.html; COBE-SST data are available at http://ds.data.jma.go.jp/tcc/tcc/products/elnino/cobesst/ cobe-sst.html; and the Python code used in this analysis is available at http://www-users.york.,OADS,/arxiv_data1/oa_pdf/cd/45/1601207.PMC5216687.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/ licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/64/b9/sbw151.PMC5216865.pdf
"2016;21(4):297-309 https://doi.org/10.3746/pnf.2016.21.4.297 pISSN 2287-1098 ㆍeISSN 2287-8602Review Article Received 21 September 2016; Accepted 13 November 2016; Published online 31 December 2016 Correspondence to Jieun E. Kim, Tel: +82-2-3277-6932, E-mail: kjieun@ewha.ac.kr Copyright © 2016 by The Korean Society of Food Science and Nutrition.",Non-OADS,/arxiv_data1/oa_pdf/43/d7/pnfs-21-297.PMC5216880.pdf
"2016;21(4):310-316 https://doi.org/10.3746/pnf.2016.21.4.310 pISSN 2287-1098 ㆍeISSN 2287-8602 Received 27 September 2016; Accepted 28 November 2016; Published online 31 December 2016 Correspondence to Chul-yung Choi, Tel: +82-61-860-2620, E-mail: blockstar@hanmail.net Copyright © 2016 by The Korean Society of Food Science and Nutrition.",Non-OADS,/arxiv_data1/oa_pdf/de/aa/pnfs-21-310.PMC5216881.pdf
"2016;21(4):317-322 https://doi.org/10.3746/pnf.2016.21.4.317 pISSN 2287-1098 ㆍeISSN 2287-8602 Received 4 July 2016; Accepted 21 August 2016; Published online 31 December 2016 Correspondence to Yangha Kim, Tel: +82-2-3277-3101, E-mail: yhmoon@ewha.ac.kr Copyright © 2016 by The Korean Society of Food Science and Nutrition.",Non-OADS,/arxiv_data1/oa_pdf/7a/f6/pnfs-21-317.PMC5216882.pdf
"2016;21(4):323-329 https://doi.org/10.3746/pnf.2016.21.4.323 pISSN 2287-1098 ㆍeISSN 2287-8602 Received 8 July 2016; Accepted 13 September 2016; Published online 31 December 2016 Correspondence to Kyung Dong Lee, Tel: +82-61-330-3261, E-mail: leek-d@hanmail.net Copyright © 2016 by The Korean Society of Food Science and Nutrition.",Non-OADS,/arxiv_data1/oa_pdf/af/60/pnfs-21-323.PMC5216883.pdf
"2016;21(4):330-337 https://doi.org/10.3746/pnf.2016.21.4.330 pISSN 2287-1098 ㆍeISSN 2287-8602 Received 29 June 2016; Accepted 31 August 2016; Published online 31 December 2016 Correspondence to Eun-Sun Hwang, Tel: +82-31-670-5182, E-mail: ehwang@hknu.ac.kr Copyright © 2016 by The Korean Society of Food Science and Nutrition.",Non-OADS,/arxiv_data1/oa_pdf/34/30/pnfs-21-330.PMC5216884.pdf
"2016;21(4):338-347 https://doi.org/10.3746/pnf.2016.21.4.338 pISSN 2287-1098 ㆍeISSN 2287-8602 Received 20 July 2016; Accepted 8 August 2016; Published online 31 December 2016 Correspondence to Yoon Hyuk Chang, Tel: +82-2-961-0552, E-mail: yhchang@khu.ac.kr Copyright © 2016 by The Korean Society of Food Science and Nutrition.",Non-OADS,/arxiv_data1/oa_pdf/af/72/pnfs-21-338.PMC5216885.pdf
"2016;21(4):348-354 https://doi.org/10.3746/pnf.2016.21.4.348 pISSN 2287-1098 ㆍeISSN 2287-8602 Received 1 August 2016; Accepted 10 October 2016; Published online 31 December 2016 Correspondence to Ok-Ju Kang, Tel: +82-55-249-2235, E-mail: koj117@kyungnam.ac.kr Copyright © 2016 by The Korean Society of Food Science and Nutrition.",Non-OADS,/arxiv_data1/oa_pdf/44/0c/pnfs-21-348.PMC5216886.pdf
"2016;21(4):355-360 https://doi.org/10.3746/pnf.2016.21.4.355 pISSN 2287-1098 ㆍeISSN 2287-8602 Received 15 June 2016; Accepted 31 August 2016; Published online 31 December 2016 Correspondence to Solomon Akinremi Makanjuola, Tel: +234-8-034-684-871, E-mail: makakins2001@yahoo.com Copyright © 2016 by The Korean Society of Food Science and Nutrition.",Non-OADS,/arxiv_data1/oa_pdf/42/4c/pnfs-21-355.PMC5216887.pdf
http://www.synergytaste.com/ sites/synergytaste.com/files/SEN-TN-0002-Measuring_Tea _Color_Using_A_Simple_Spectrometric_Assay.pdf.,OADS,/arxiv_data1/oa_pdf/42/4c/pnfs-21-355.PMC5216887.pdf
"2016;21(4):361-366 https://doi.org/10.3746/pnf.2016.21.4.361 pISSN 2287-1098 ㆍeISSN 2287-8602 Received 30 September 2016; Accepted 23 November 2016; Published online 31 December 2016 Correspondence to Na-Young Lee, Tel: +82-63-469-1826, E-mail: nylee@kunsan.ac.kr Copyright © 2016 by The Korean Society of Food Science and Nutrition.",Non-OADS,/arxiv_data1/oa_pdf/db/ea/pnfs-21-361.PMC5216888.pdf
"2016;21(4):367-372 https://doi.org/10.3746/pnf.2016.21.4.367 pISSN 2287-1098 ㆍeISSN 2287-8602 Received 30 September 2016; Accepted 23 November 2016; Published online 31 December 2016 Correspondence to Byoungseung Yoo, Tel: +82-31-961-5141, E-mail: bsyoo@dongguk.edu Copyright © 2016 by The Korean Society of Food Science and Nutrition.",Non-OADS,/arxiv_data1/oa_pdf/4c/7c/pnfs-21-367.PMC5216889.pdf
"2016;21(4):373-377 https://doi.org/10.3746/pnf.2016.21.4.373 pISSN 2287-1098 ㆍeISSN 2287-8602Research Note Received 7 July 2016; Accepted 1 September 2016; Published online 31 December 2016 Correspondence to Woojin Jun, Tel: +82-62-530-1337, E-mail: wjjun@chonnam.ac.kr Copyright © 2016 by The Korean Society of Food Science and Nutrition.",Non-OADS,/arxiv_data1/oa_pdf/12/21/pnfs-21-373.PMC5216890.pdf
"2016;21(4):378-383 https://doi.org/10.3746/pnf.2016.21.4.378 pISSN 2287-1098 ㆍeISSN 2287-8602Research Note Received 26 July 2016; Accepted 6 December 2016; Published online 31 December 2016 Correspondence to Un Ju Jung, Tel: +82-51-629-5850, E-mail: jungunju@pknu.ac.kr Copyright © 2016 by The Korean Society of Food Science and Nutrition.",Non-OADS,/arxiv_data1/oa_pdf/65/3e/pnfs-21-378.PMC5216891.pdf
"2016;21(4):384-388 https://doi.org/10.3746/pnf.2016.21.4.384 pISSN 2287-1098 ㆍeISSN 2287-8602Research Note Received 27 September 2016; Accepted 29 November 2016; Published online 31 December 2016 Correspondence to Hyun Young Kim, Tel: +82-55-751-3277, E-mail: hykim@gntech.ac.kr*These authors contributed equally to this work.",Non-OADS,/arxiv_data1/oa_pdf/dd/c1/pnfs-21-384.PMC5216892.pdf
"2016;21(4):389-392 https://doi.org/10.3746/pnf.2016.21.4.389 pISSN 2287-1098 ㆍeISSN 2287-8602Research Note Received 6 July 2016; Accepted 13 November 2016; Published online 31 December 2016 Correspondence to Ji-Sang Kim, Tel: +82-55-249-2185, E-mail: jisangkim@kyungnam.ac.kr Copyright © 2016 by The Korean Society of Food Science and Nutrition.",Non-OADS,/arxiv_data1/oa_pdf/13/30/pnfs-21-389.PMC5216893.pdf
"2016;21(4):393-397 https://doi.org/10.3746/pnf.2016.21.4.393 pISSN 2287-1098 ㆍeISSN 2287-8602Research Note Received 18 July 2016; Accepted 21 October 2016; Published online 31 December 2016 Correspondence to Induck Choi, Tel: +82-31-695-0605, E-mail: ichoi829@korea.kr Copyright © 2016 by The Korean Society of Food Science and Nutrition.",Non-OADS,/arxiv_data1/oa_pdf/ae/e9/pnfs-21-393.PMC5216894.pdf
"2016;21(4):398-405 https://doi.org/10.3746/pnf.2016.21.4.398 pISSN 2287-1098 ㆍeISSN 2287-8602Research Note Received 8 November 2016; Accepted 2 December 2016; Published online 31 December 2016 Correspondence to Ok-Ju Kang, Tel: +82-55-249-2235, E-mail: koj117@kyungnam.ac.kr Copyright © 2016 by The Korean Society of Food Science and Nutrition.",Non-OADS,/arxiv_data1/oa_pdf/f8/ae/pnfs-21-398.PMC5216895.pdf
2016;21(4):406 https://doi.org/10.3746/pnf.2016.21.4.406 pISSN 2287-1098 ㆍeISSN 2287-8602Erratum Copyright © 2016 by The Korean Society of Food Science and Nutrition.,Non-OADS,/arxiv_data1/oa_pdf/77/d1/pnfs-21-406.PMC5216896.pdf
SUPPLEMENTARY MATERIALS Supplementary material for this article is available at http://advances.sciencemag.org/cgi/ content/full/3/1/e1601666/DC1fig.,Non-OADS,/arxiv_data1/oa_pdf/35/dc/1601666.PMC5217057.pdf
The GISTEMP data are pu blicly available at http://data.giss.nasa.gov/ gistemp/.,OADS,/arxiv_data1/oa_pdf/35/dc/1601666.PMC5217057.pdf
The ECCO-v4 data arepublicly available at http://www.ecco-group.org .,OADS,/arxiv_data1/oa_pdf/35/dc/1601666.PMC5217057.pdf
The SODA 2.2.4 data are publicly available at https://iridl.ldeo.columbia.edu/SOURCES/.CARTON-GIESE/.SODA/.v2p2p4/ index.html?Set-Language=en.,OADS,/arxiv_data1/oa_pdf/35/dc/1601666.PMC5217057.pdf
The CMIP5 data are publicly available through the portal of the U.S. Earth System Grid Center for Enabling Technologies on the page http://pcmdi9.llnl.gov/.,OADS,/arxiv_data1/oa_pdf/35/dc/1601666.PMC5217057.pdf
Available from:http://www.ginasthma.org/documents/5/doc- uments_variants/37.,Non-OADS,/arxiv_data1/oa_pdf/f3/38/ALL-72-77.PMC5217067.pdf
"Nonetheless, the Lectin Frontier DataBase (L fDB: http://jcggdb.jp/rcmg/glycodb/LectinSearch) is deemed to provide comprehensive glycan-lectin binding information to guide the most suitable probe toward a targeted glycoform.",Non-OADS,/arxiv_data1/oa_pdf/38/e5/PMIC-16-3062.PMC5217075.pdf
http://www.fda.gov/downloads/MedicalDevices/ DeviceRegulationandGuidance/GuidanceDocuments/ ucm071455.pdf.,Non-OADS,/arxiv_data1/oa_pdf/38/e5/PMIC-16-3062.PMC5217075.pdf
"1  55–74 https://doi.org/10.1085/jgp.201611603 55Int Roduct Ion Huntington’s disease (HD) is a fatal degenerative disor - der caused by an expanded CAG repeat sequence at the  5′ end of the Huntingtin  gene (MacDonald et al., 1993).",Non-OADS,/arxiv_data1/oa_pdf/99/e3/JGP_201611603.PMC5217084.pdf
"1  149–170 https://doi.org/10.1085/jgp.201611607 149Introduct Ion Astrocytes fine-tune synaptic transmission and plas - ticity through Ca2+ signaling and releasing molecules,  e.g., via vesicular exocytosis.",Non-OADS,/arxiv_data1/oa_pdf/d8/a1/JGP_201611607.PMC5217085.pdf
"1  75–84 https://doi.org/10.1085/jgp.201611653 75Int Roduct Ion In the pancreatic β cell, ATP-sensitive K+ (K ATP) chan - nels play a critical role in coupling membrane excit - ability to glucose-stimulated insulin secretion, and  thereby maintaining blood glucose in a narrow range.",Non-OADS,/arxiv_data1/oa_pdf/d2/5c/JGP_201611653.PMC5217086.pdf
1  1–36 https://doi.org/10.1085/jgp.201611654 1Introduction A unique characteristic of eukaryotes is the presence  of membrane-enclosed compartments that isolate the  content within their lumen from the rest of the cell  and whose membranes have a high concentration of  enzymes or structural proteins that are specific to the  function of each compartment.,Non-OADS,/arxiv_data1/oa_pdf/76/62/JGP_201611654.PMC5217087.pdf
1  85–103 https://doi.org/10.1085/jgp.201611673 85Int Roduct Ion Neuromuscular acetylcholine (ACh) receptors (AChRs)  have two transmitter-binding sites (TBSs) in the extra - cellular domain (ECD) and a gate in the transmem - brane domain (TMD).,Non-OADS,/arxiv_data1/oa_pdf/7a/83/JGP_201611673.PMC5217088.pdf
1  37–47 https://doi.org/10.1085/jgp.201611696 37A single cilium is about the size of a bacterium pro - truding from the surface of a cell (Fig. 1).,OADS,/arxiv_data1/oa_pdf/3e/ea/JGP_201611696.PMC5217089.pdf
1  105–119 https://doi.org/10.1085/jgp.201611702 105Int Roduct Ion One of the major functions of proteins is to bind other  molecules.,Non-OADS,/arxiv_data1/oa_pdf/71/b0/JGP_201611702.PMC5217090.pdf
"1  121–147 https://doi.org/10.1085/jgp.201611703 121Int Roduct Ion The thermodynamic theory of ligands binding to mac - romolecules containing multiple binding sites is re - viewed in several monographs (Poland, 1978; Hill,  1985; Wyman and Gill, 1990; Ben-Naim, 2010).",Non-OADS,/arxiv_data1/oa_pdf/b3/59/JGP_201611703.PMC5217091.pdf
"1  49–53 https://doi.org/10.1085/jgp.201611728 49In the early 1990s, several genetically inherited disor - ders were found to result from trinucleotide repeat ex - pansions (increases in the length of normally short  regions of trinucleotide CNG repeats, e.g., CAG, CTG,  CCG, and CGG).",Non-OADS,/arxiv_data1/oa_pdf/3b/20/JGP_201611728.PMC5217092.pdf
python.org) while the statistical analysis was made using the R3.3.1 programming language (https://www.r-project.org).,Non-OADS,/arxiv_data1/oa_pdf/d3/ce/HIPO-27-89.PMC5217096.pdf
The model will be available for download in Model DB (acces- sion number: 206372) at http://dendrites.gr/en/publications-8/ software-23.,Non-OADS,/arxiv_data1/oa_pdf/d3/ce/HIPO-27-89.PMC5217096.pdf
A sample parameter file that was used for both data sets can be downloaded from http://elastix.bigr.nl/ wiki/index.php/Parameter_file_database .,OADS,/arxiv_data1/oa_pdf/43/e0/MRM-77-422.PMC5217098.pdf
"This is an Open Access article distributed under the terms of th e Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial u se, distribution, and reproduction in any medium, provided the original work is properly cited.SCANDINAVIAN JOURNAL OF PRIMARY HEALTH CARE, 2016 VOL.",Non-OADS,/arxiv_data1/oa_pdf/1f/23/ipri-34-360.PMC5217276.pdf
"4, 360 –367 http://dx.doi.org/10.1080/02813432.2016.1253819",Non-OADS,/arxiv_data1/oa_pdf/1f/23/ipri-34-360.PMC5217276.pdf
"This is an Open Access article distributed under the terms of th e Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial u se, distribution, and reproduction in any medium, provided the original work is properly cited.SCANDINAVIAN JOURNAL OF PRIMARY HEALTH CARE, 2016 VOL.",Non-OADS,/arxiv_data1/oa_pdf/27/e4/ipri-34-453.PMC5217277.pdf
"4, 453 –458 http://dx.doi.org/10.1080/02813432.2016.1248622",Non-OADS,/arxiv_data1/oa_pdf/27/e4/ipri-34-453.PMC5217277.pdf
"This is an Open Access article distributed under the terms of th e Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial u se, distribution, and reproduction in any medium, provided the original work is properly cited.SCANDINAVIAN JOURNAL OF PRIMARY HEALTH CARE, 2016 VOL.",Non-OADS,/arxiv_data1/oa_pdf/79/2f/ipri-34-385.PMC5217278.pdf
"4, 385 –393 http://dx.doi.org/10.1080/02813432.2016.1249064",Non-OADS,/arxiv_data1/oa_pdf/79/2f/ipri-34-385.PMC5217278.pdf
Available from:http://www.globalfamilydoctor.com/AboutWonca/brief.aspx .,Non-OADS,/arxiv_data1/oa_pdf/79/2f/ipri-34-385.PMC5217278.pdf
"This is an Open Access article distributed under the terms of th e Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial u se, distribution, and reproduction in any medium, provided the original work is properly cited.SCANDINAVIAN JOURNAL OF PRIMARY HEALTH CARE, 2016 VOL.",Non-OADS,/arxiv_data1/oa_pdf/4d/ca/ipri-34-434.PMC5217279.pdf
"4, 434 –442 http://dx.doi.org/10.1080/02813432.2016.1248635",Non-OADS,/arxiv_data1/oa_pdf/4d/ca/ipri-34-434.PMC5217279.pdf
"This is an Open Access article distributed under the terms of th e Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial u se, distribution, and reproduction in any medium, provided the original work is properly cited.SCANDINAVIAN JOURNAL OF PRIMARY HEALTH CARE, 2016 VOL.",Non-OADS,/arxiv_data1/oa_pdf/18/34/ipri-34-368.PMC5217280.pdf
"4, 368 –376 http://dx.doi.org/10.1080/02813432.2016.1249055",Non-OADS,/arxiv_data1/oa_pdf/18/34/ipri-34-368.PMC5217280.pdf
Available from: http://www.stat.fi/til/vaenn/2009/vaenn_2009_2009-09-30_tie_001_en.html .,OADS,/arxiv_data1/oa_pdf/18/34/ipri-34-368.PMC5217280.pdf
Available from: http://apps.who.int/medicine- docs/documents/s19762en/s19762en.pdf .,Non-OADS,/arxiv_data1/oa_pdf/18/34/ipri-34-368.PMC5217280.pdf
Available from: http://www.fimea.fi/download/17702_ julkaisut_Kapseli35.pdf .,Non-OADS,/arxiv_data1/oa_pdf/18/34/ipri-34-368.PMC5217280.pdf
Available from: http://www.fimea.fi/kehittaminen/laakeinformaa-tion_kehittaminen/iakkaiden_laakityksen_tietokanta/ iakkaiden_laakityksen_hakupalvelu .,Non-OADS,/arxiv_data1/oa_pdf/18/34/ipri-34-368.PMC5217280.pdf
Available from:http://urn.fi/URN :ISBN:978-952-245-784-4.,Non-OADS,/arxiv_data1/oa_pdf/18/34/ipri-34-368.PMC5217280.pdf
[cited 2015 Jun 14].Available from: http://www.euro.who.int/__data/assets/ pdf_file/0006/186756/Towards-people-centred-health- systems-an-innovative-approach-for-better-health-out-comes.pdf .,Non-OADS,/arxiv_data1/oa_pdf/18/34/ipri-34-368.PMC5217280.pdf
"This is an Open Access article distributed under the terms of th e Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial u se, distribution, and reproduction in any medium, provided the original work is properly cited.SCANDINAVIAN JOURNAL OF PRIMARY HEALTH CARE, 2016 VOL.",Non-OADS,/arxiv_data1/oa_pdf/a3/cc/ipri-34-343.PMC5217281.pdf
"4, 343 –351 http://dx.doi.org/10.1080/02813432.2016.1248632",Non-OADS,/arxiv_data1/oa_pdf/a3/cc/ipri-34-343.PMC5217281.pdf
"Available from: http://www.tilastokeskus.fi/til/vrm.html [21] Sepponen K, Vilen T, Kiviniemi L. Ty €ott€omyyden pitkit- tyminen on monen tekij €an summa.",Non-OADS,/arxiv_data1/oa_pdf/a3/cc/ipri-34-343.PMC5217281.pdf
"Available from: http://www.theseus.fi/bitstream/han-dle/10024/47372/oamk_tkjulkaisu_50.pdf?sequence ¼1 [22] Berglind H, Gerner U.",OADS,/arxiv_data1/oa_pdf/a3/cc/ipri-34-343.PMC5217281.pdf
"This is an Open Access article distributed under the terms of th e Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial u se, distribution, and reproduction in any medium, provided the original work is properly cited.SCANDINAVIAN JOURNAL OF PRIMARY HEALTH CARE, 2016 VOL.",Non-OADS,/arxiv_data1/oa_pdf/01/ac/ipri-34-401.PMC5217282.pdf
"4, 401 –419 http://dx.doi.org/10.1080/02813432.2016.1249056",Non-OADS,/arxiv_data1/oa_pdf/01/ac/ipri-34-401.PMC5217282.pdf
"Available from: http://www.gmc-uk.org/guidance/ [6] Irwig L, McCaffery K, Salkeld G, et al.",Non-OADS,/arxiv_data1/oa_pdf/01/ac/ipri-34-401.PMC5217282.pdf
[Internet] Available from: http://www.ssi.dk/Aktuelt/Nyhedsbreve/EPI-NYT/2013/Uge%2020%20-%202013.aspx .,Non-OADS,/arxiv_data1/oa_pdf/01/ac/ipri-34-401.PMC5217282.pdf
Available from: http://danskemedier.dk/ nyhed/smartphone-alle-har-den-og-alle-bruger-den/ .,OADS,/arxiv_data1/oa_pdf/01/ac/ipri-34-401.PMC5217282.pdf
"This is an Open Access article distributed under the terms of th e Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial u se, distribution, and reproduction in any medium, provided the original work is properly cited.SCANDINAVIAN JOURNAL OF PRIMARY HEALTH CARE, 2016 VOL.",Non-OADS,/arxiv_data1/oa_pdf/de/17/ipri-34-336.PMC5217283.pdf
"4, 336 –342 http://dx.doi.org/10.1080/02813432.2016.1248649",Non-OADS,/arxiv_data1/oa_pdf/de/17/ipri-34-336.PMC5217283.pdf
[Internet] Available from: http://urn.fi/URN:NBN:fi-fe201204193537 .,Non-OADS,/arxiv_data1/oa_pdf/de/17/ipri-34-336.PMC5217283.pdf
[Internet] Available from: http://urn.fi/URN:ISBN:978-952-245-566-6342 R. SIREN ET AL.,Non-OADS,/arxiv_data1/oa_pdf/de/17/ipri-34-336.PMC5217283.pdf
"This is an Open Access article distributed under the terms of th e Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial u se, distribution, and reproduction in any medium, provided the original work is properly cited.SCANDINAVIAN JOURNAL OF PRIMARY HEALTH CARE, 2016 VOL.",Non-OADS,/arxiv_data1/oa_pdf/50/73/ipri-34-352.PMC5217284.pdf
"4, 352 –359 http://dx.doi.org/10.1080/02813432.2016.1248628",Non-OADS,/arxiv_data1/oa_pdf/50/73/ipri-34-352.PMC5217284.pdf
Available from: http://www.malmo.se/Commission-for-a-Socially-Sustainable- Malmoe-in-English.html .,Non-OADS,/arxiv_data1/oa_pdf/50/73/ipri-34-352.PMC5217284.pdf
Available from: http://www.goteborgstad.sta- tistik.se.html .,Non-OADS,/arxiv_data1/oa_pdf/50/73/ipri-34-352.PMC5217284.pdf
"This is an Open Access article distributed under the terms of th e Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial u se, distribution, and reproduction in any medium, provided the original work is properly cited.SCANDINAVIAN JOURNAL OF PRIMARY HEALTH CARE, 2016 VOL.",Non-OADS,/arxiv_data1/oa_pdf/83/77/ipri-34-394.PMC5217285.pdf
"4, 394 –400 http://dx.doi.org/10.1080/02813432.2016.1249060",Non-OADS,/arxiv_data1/oa_pdf/83/77/ipri-34-394.PMC5217285.pdf
Available from: http://www.landlaeknir.,Non-OADS,/arxiv_data1/oa_pdf/83/77/ipri-34-394.PMC5217285.pdf
"This is an Open Access article distributed under the terms of th e Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial u se, distribution, and reproduction in any medium, provided the original work is properly cited.SCANDINAVIAN JOURNAL OF PRIMARY HEALTH CARE, 2016 VOL.",Non-OADS,/arxiv_data1/oa_pdf/9f/ae/ipri-34-377.PMC5217286.pdf
"4, 377 –384 http://dx.doi.org/10.1080/02813432.2016.1249047",Non-OADS,/arxiv_data1/oa_pdf/9f/ae/ipri-34-377.PMC5217286.pdf
Available from: https://lovdata.no/dokument/SF/forskrift/2015-03-20-231?q ¼ akuttmedisinforskriften .,Non-OADS,/arxiv_data1/oa_pdf/9f/ae/ipri-34-377.PMC5217286.pdf
"This is an Open Access article distributed under the terms of th e Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial u se, distribution, and reproduction in any medium, provided the original work is properly cited.SCANDINAVIAN JOURNAL OF PRIMARY HEALTH CARE, 2016 VOL.",Non-OADS,/arxiv_data1/oa_pdf/56/61/ipri-34-327.PMC5217287.pdf
"4, 327 –335 http://dx.doi.org/10.1080/02813432.2016.1249057",Non-OADS,/arxiv_data1/oa_pdf/56/61/ipri-34-327.PMC5217287.pdf
Available from: https://www.sundhed.dk/sundhedsfaglig/laege- haandbogen/om-laegehaandbogen/in-english/ .,Non-OADS,/arxiv_data1/oa_pdf/56/61/ipri-34-327.PMC5217287.pdf
Available from: http://pro.medicin.dk/ Artikler/Artikel/52 .,Non-OADS,/arxiv_data1/oa_pdf/56/61/ipri-34-327.PMC5217287.pdf
Available from: http://www.irf.dk/en/about_irf/om_irf.,OADS,/arxiv_data1/oa_pdf/56/61/ipri-34-327.PMC5217287.pdf
"This is an Open Access article distributed under the terms of th e Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial u se, distribution, and reproduction in any medium, provided the original work is properly cited.SCANDINAVIAN JOURNAL OF PRIMARY HEALTH CARE, 2016 VOL.",Non-OADS,/arxiv_data1/oa_pdf/7f/db/ipri-34-428.PMC5217288.pdf
"4, 428 –433 http://dx.doi.org/10.1080/02813432.2016.1249065",Non-OADS,/arxiv_data1/oa_pdf/7f/db/ipri-34-428.PMC5217288.pdf
"4, 325 –326 http://dx.doi.org/10.1080/02813432.2016.1253824",Non-OADS,/arxiv_data1/oa_pdf/98/2a/ipri-34-325.PMC5217289.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution- NonCommercial License (http://creativecommons.org/licenses/by-nc/ 4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.326 EDITORIAL",Non-OADS,/arxiv_data1/oa_pdf/98/2a/ipri-34-325.PMC5217289.pdf
"This is an Open Access article distributed under the terms of th e Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial u se, distribution, and reproduction in any medium, provided the original work is properly cited.SCANDINAVIAN JOURNAL OF PRIMARY HEALTH CARE, 2016 VOL.",Non-OADS,/arxiv_data1/oa_pdf/49/cb/ipri-34-420.PMC5217290.pdf
"4, 420 –427 http://dx.doi.org/10.1080/02813432.2016.1249059",Non-OADS,/arxiv_data1/oa_pdf/49/cb/ipri-34-420.PMC5217290.pdf
Available from: http://www.eapcnet.eu/LinkClick.aspx?fileticket ¼ f63pXXzVNEY ¼&tabid ¼735.,Non-OADS,/arxiv_data1/oa_pdf/49/cb/ipri-34-420.PMC5217290.pdf
Available from: http://vejledninger.dsam.dk/palliation/ .,Non-OADS,/arxiv_data1/oa_pdf/49/cb/ipri-34-420.PMC5217290.pdf
Available from: http://www.who.int/cancer/palliative/definition/en/ .,Non-OADS,/arxiv_data1/oa_pdf/49/cb/ipri-34-420.PMC5217290.pdf
Available from: http://pavi.dk/Palliativguiden.aspx#here .,Non-OADS,/arxiv_data1/oa_pdf/49/cb/ipri-34-420.PMC5217290.pdf
Available from: http://pavi.dk/Files/Udgivelser PAVI/Dødssted og dødsårsager i Danmark 2007-2011.pdf .,OADS,/arxiv_data1/oa_pdf/49/cb/ipri-34-420.PMC5217290.pdf
"This is an Open Access article distributed under the terms of th e Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial u se, distribution, and reproduction in any medium, provided the original work is properly cited.SCANDINAVIAN JOURNAL OF PRIMARY HEALTH CARE, 2016 VOL.",Non-OADS,/arxiv_data1/oa_pdf/5c/bb/ipri-34-443.PMC5217291.pdf
"4, 443 –452 http://dx.doi.org/10.1080/02813432.2016.1253820",Non-OADS,/arxiv_data1/oa_pdf/5c/bb/ipri-34-443.PMC5217291.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/3d/dc/lctt-4-043.PMC5217442.pdf
"Permissions beyond the scope of the License are administered by Dove Medical Press Ltd. Information on how to  request permission may be found at: http://www.dovepress.com/permissions.phpLung Cancer: Targets and Therapy 2013:4 43–53Lung Cancer: Targets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  43Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/LCTT .S4960 3Development of personalized treatments   in lung cancer: focusing on the EGFR   mutations and beyond Kenichi Suda1,2 Tetsuya Mitsudomi1 1Division of Thoracic Surgery,  Department of Surgery, Kinki  University Faculty of Medicine,  Osaka-Sayama, Japan; 2Department  of Surgery and Science, Graduate  School of Medical Sciences, Kyushu  University, Fukuoka, Japan Correspondence: Kenichi Suda   Division of Thoracic Surgery,   Department of Surgery, Kinki University  Faculty of Medicine, 377-2 Ohno-Higashi,   Osaka-Sayama 589-8511, Japan   Tel +81 72 366 0221   Fax +81 72 367 7771   email ascaris@surg2.med.kyushu-u.ac.j pAbstract:  Lung cancers with epidermal growth factor receptor  (EGFR)  gene mutation account  for ∼40% of adenocarcinoma in East Asians and ∼15% of that in Caucasians, which makes them  one of the most common molecularly defined lung cancer subsets.",Non-OADS,/arxiv_data1/oa_pdf/3d/dc/lctt-4-043.PMC5217442.pdf
Available from: http://clinicaltrials.gov/show/NCT01544179.,Non-OADS,/arxiv_data1/oa_pdf/3d/dc/lctt-4-043.PMC5217442.pdf
Available  from: http://clinicaltrials.gov/show/NCT00775385.,Non-OADS,/arxiv_data1/oa_pdf/3d/dc/lctt-4-043.PMC5217442.pdf
Visit http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/3d/dc/lctt-4-043.PMC5217442.pdf
Submit your manuscript here:  http://www.dovepress.com/lung-cancer-targets--therapy-journa l Lung Cancer: Targets and Therapy 2013:4submit your manuscript | www.dovepress.co m Dove press Dove press Dove pres s 53An update of EGFR-mutated lung cancers,Non-OADS,/arxiv_data1/oa_pdf/3d/dc/lctt-4-043.PMC5217442.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/af/d7/lctt-4-071.PMC5217444.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpLung Cancer: Targets and Therapy 2013:4 71–82Lung Cancer: Targets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  71Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/LCTT .S2321 6Potential toxicity and safety evaluation   of nanomaterials for the respiratory   system and lung cancer Thomais vlachogianni1 Konstantinos Fiotakis1 Spyridon Loridas1 Stamatis Perdicaris2 Athanasios valavanidis1 1Department of Chemistry, Free  Radicals Research Group, 2Faculty  of Pharmacy, Department of  Pharmacognosy and Natural Product  Chemistry, University of Athens,   Athens, Greece Correspondence: Athanasios valavanidis   Department of Chemistry, University   of Athens, University Campus Zografou,  15784 Athens, Greece   Tel +30 210 727 4763   Fax +30 210 727 4761   email valavanidis@chem.uoa.g rAbstract:  Engineered nanomaterials (ENMs) are a diverse group of materials finding   increasing use in manufacturing, computing, food, pharmaceuticals, and biomedicine due to  their very small size and exceptional properties.",Non-OADS,/arxiv_data1/oa_pdf/af/d7/lctt-4-071.PMC5217444.pdf
Available from: http://www.bccresearch.,Non-OADS,/arxiv_data1/oa_pdf/af/d7/lctt-4-071.PMC5217444.pdf
"Available  from: http://www.cdc.gov/niosh/docs/2013-145/pdfs/2013-145.pd f.  Accessed September 30, 2013.",OADS,/arxiv_data1/oa_pdf/af/d7/lctt-4-071.PMC5217444.pdf
"Available from: http://www.cdc.gov/niosh/docs/20 07-12 3/ pdfs/2007-123.pd f. Accessed September 30, 2013.",OADS,/arxiv_data1/oa_pdf/af/d7/lctt-4-071.PMC5217444.pdf
"Available from: https://osha.europa.eu/en/publications/literature_reviews/ workplace_exposure_to_nanoparticle s. Accessed September 30, 2013.",Non-OADS,/arxiv_data1/oa_pdf/af/d7/lctt-4-071.PMC5217444.pdf
Available  from: http://www.epa.gov/nanoscience /.,OADS,/arxiv_data1/oa_pdf/af/d7/lctt-4-071.PMC5217444.pdf
Available from: http://www.fda.,Non-OADS,/arxiv_data1/oa_pdf/af/d7/lctt-4-071.PMC5217444.pdf
Available from: http:// www.oecd.org/science/nanosafet y/ (Users can access the database  through an internet interface at: http://webnet.oecd.org/NanoMaterial s).,OADS,/arxiv_data1/oa_pdf/af/d7/lctt-4-071.PMC5217444.pdf
"Available from: http://search.oecd.org/officialdocuments/ displaydocumentpdf/?cote=env/jm/mono(2013)2&doclanguage=e n.  Accessed October 17, 2013.",OADS,/arxiv_data1/oa_pdf/af/d7/lctt-4-071.PMC5217444.pdf
"Lung Cancer: Targets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/lung-cancer-targets--therapy-journa lLung Cancer: Targets and Therapy is an international, peer-reviewed, open access  journal focusing on lung cancer research, identification of therapeutic targets and  the optimal use of preventative and integrated treatment interventions to achieve  improved outcomes, enhanced survival and quality of life for the cancer patient.",Non-OADS,/arxiv_data1/oa_pdf/af/d7/lctt-4-071.PMC5217444.pdf
Visit http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/af/d7/lctt-4-071.PMC5217444.pdf
(Cell Mol Gastroenterol Hepatol 2017;3:82 –98;http://dx.doi.org/10.1016/ j.jcmgh.2016.09.001 ) Keywords: Neutrophils; Endothelium; Fibronectin; Collagen.,Non-OADS,/arxiv_data1/oa_pdf/c8/93/main.PMC5217470.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c8/93/main.PMC5217470.pdf
2352-345X http://dx.doi.org/10.1016/j.jcmgh.2016.09.001,OADS,/arxiv_data1/oa_pdf/c8/93/main.PMC5217470.pdf
"Microarray Study and Pathway Analysis Proximal small intestine (upper one-third of the gut) was harvested and processed for RNA extraction and microarrays (Affymetrix GeneChip Mouse Expression Set 430 2.0 array; Affymetrix Bioscience, San Diego, CA).Parametric Analysis of Gene Set Enrichment (PAGE), aspreviously described, 21used KEGG and C2: curated gene sets ( http://www.broad.mit.edu/gsea/msigdb/ msigdb_index.html ).",OADS,/arxiv_data1/oa_pdf/c8/93/main.PMC5217470.pdf
All data were analyzed by the R statisticalsoftware package ( http://www.bioconductor.org ).Pvalue <.05 was considered signi ﬁcant.,OADS,/arxiv_data1/oa_pdf/c8/93/main.PMC5217470.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/69/8d/lctt-5-001.PMC5217505.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpLung Cancer: Targets and Therapy 2014:5 1–9Lung Cancer: Targets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  1Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/LCTT .S4081 7Prevalence of driver mutations in non-small-cell   lung cancers in the People’s Republic of China Lan-Ying Gou1,2 Yi-Long wu1 1Guangdong Lung Cancer institute,   Guangdong General Hospital and  Guangdong Academy of Medical  Sciences, 2Southern Medical  University, Guangzhou, People’s  Republic of China Correspondence: Yi-Long wu   Guangdong Lung Cancer institute,   Guangdong General Hospital   and Guangdong Academy of Medical   Sciences, Guangzhou 510080,   People’s Republic of China   Tel +86 20 8387 7855   Fax +86 20 8382 7712   email syylwu@live.c nAbstract:  Lung cancer is a leading cause of cancer-related mortality worldwide and in the  People’ s Republic of China.",Non-OADS,/arxiv_data1/oa_pdf/69/8d/lctt-5-001.PMC5217505.pdf
Visit http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/69/8d/lctt-5-001.PMC5217505.pdf
Submit your manuscript here:  http://www.dovepress.com/lung-cancer-targets--therapy-journa l Lung Cancer: Targets and Therapy 2014:5submit your manuscript | www.dovepress.co m Dove press Dove press Dove pres s 9Prevalence of driver mutations in NSCLC in China  40.,Non-OADS,/arxiv_data1/oa_pdf/69/8d/lctt-5-001.PMC5217505.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/d6/ab/lctt-5-035.PMC5217506.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpLung Cancer: Targets and Therapy 2014:5 35–42Lung Cancer: Targets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  35Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/LCTT .S5041 4New options in the management of intrac table  ALK(+) metastatic non-small-cell lung cancer Amy M weise Shirish Gadgeel Department of Oncology, Karmanos  Cancer institute, wayne State  University, Detroit, M i, USA Correspondence: Amy M weise   Department of Oncology, Karmanos  Cancer institute, wayne State University,   4100 John R,  4HwCRC, Detroit,   Mi 48201, USA   email weisea@karmanos.or g Abstract:  Non-small-cell lung cancer (NSCLC) is a heterogeneous disease and a challenging  malignancy to treat, as many patients have advanced disease at the time of diagnosis.",Non-OADS,/arxiv_data1/oa_pdf/d6/ab/lctt-5-035.PMC5217506.pdf
gov IdentifierStudy   agentPatient population   ALK (+)Study type NCT01871805 CH5424802/   RO5424802Failed crizotinib Phase i/ii NCT01947608 LDK378 (±) prior ALK TKi expanded access NCT01970865 PF-06463922 (±) prior ALK/ROS1 Phase i/ii NCT01752400 AUY922 Failed ALK TKi Phase i/ii NCT01712217 AT13387 ( ±)   crizotinib(±) prior therapies Randomized   3-part Phase i/ii Note:  Data from http://www.clinicaltrials.gov .,Non-OADS,/arxiv_data1/oa_pdf/d6/ab/lctt-5-035.PMC5217506.pdf
"Lung Cancer: Targets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/lung-cancer-targets--therapy-journa lLung Cancer: Targets and Therapy is an international, peer-reviewed, open access  journal focusing on lung cancer research, identification of therapeutic targets and  the optimal use of preventative and integrated treatment interventions to achieve  improved outcomes, enhanced survival and quality of life for the cancer patient.",Non-OADS,/arxiv_data1/oa_pdf/d6/ab/lctt-5-035.PMC5217506.pdf
Visit http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/d6/ab/lctt-5-035.PMC5217506.pdf
"A vailable at  https://www.iaslc.org/sites/default/files/wysiwyg-assets/cap_iaslc_amp_ summary_of_recommendations.pd f. Accessed May  22, 2014.",Non-OADS,/arxiv_data1/oa_pdf/d6/ab/lctt-5-035.PMC5217506.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/0f/37/lctt-5-011.PMC5217507.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpLung Cancer: Targets and Therapy 2014:5 11–20Lung Cancer: Targets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  11OriginaL  researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/ 10.2147/LCTT .S5759 4gastroesophageal junction adenocarcinoma  displays abnormalities in homologous  recombination and nucleotide excision repair robin i Dewalt1 Kenneth a Kesler2 Zane T hammoud3 Leeann Baldridge4 eyas M hattab4 shadia i Jalal1,5 1Division of hematology/ Oncology, Department of Medicine,   2Cardiothoracic Division, Department  of surgery, indiana University school  of Medicine, indianapolis, in, Usa;   3henry Ford hospital, Detroit, M i,   Usa; 4Department of Pathology  and Laboratory Medicine, indiana  University school of Medicine,   indianapolis, in, Usa; 5indiana  University Melvin and Bren simon  Cancer Center, indianapolis, in, Usa Correspondence: shadia i Jalal   indiana University Melvin and Bren simon  Cancer Center, 980 W Walnut street,  indianapolis, in 46202, Usa   Tel +1 317 274 3589   Fax +1 317 274 0396   email sjalal@iupui.ed uObjective:  Esophageal adenocarcinoma (EAC) continues to be a disease associated with high  mortality.",Non-OADS,/arxiv_data1/oa_pdf/0f/37/lctt-5-011.PMC5217507.pdf
"Lung Cancer: Targets and Therapy 2014:5submit your manuscript | www.dovepress.co m Dove press Dove press 14Dewalt et al Oncomine database search The Oncomine Cancer Profiling Database version 4.4.3,  September 2012 data release ( http://www.oncomine.or g;  Life Technologies, Carlsbad, CA, USA), was used to profile  the gene EME1 .",Non-OADS,/arxiv_data1/oa_pdf/0f/37/lctt-5-011.PMC5217507.pdf
"Our  study illustrates that although EME1  shows increased expres - sion in EAC, its partner MUS81  showed either decreased Table  3 summary of Oncomine database search  results of  tumors with increased EME1  expression Data set and   cancer typeNumber   of samplesEME1   expression  fold changeP-value French brain   anaplastic   oligoastrocytoma33 2.615 8.5e-5  Oligodendroglioma 33 2.3 8.24e-7 Murat brain  glioblastoma 84 2.968 1.31e-7 richardson breast 2  Ductal carcinoma 47 2.770 2.62e-9 TCga  breast  invasive ductal carcinoma 47 2.165 2.08e-27  invasive lobular carcinoma 47 2.071 1.71e-8 Pyeon multicarcinoma  Tonsillar carcinoma 84 2.162 4.28e-5 Ye head-neck   Tongue squamous   cell carcinoma38 2.172 3.02e-6 TCga renal   Papillary renal cell  carcinoma88 2.380 3.06e-7 Compagno lymphoma   Diffuse large B cell  lymphoma136 2.459 1.50e-14 Note:  Data available from: http://www.oncomine.or g.34 Abbreviation:  TCga, the cancer genome atlas.",Non-OADS,/arxiv_data1/oa_pdf/0f/37/lctt-5-011.PMC5217507.pdf
"Available from: https://www.oncomine.org/resource/ login.htm l. Accessed February 2, 2014.",Non-OADS,/arxiv_data1/oa_pdf/0f/37/lctt-5-011.PMC5217507.pdf
"Lung Cancer: Targets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/lung-cancer-targets--therapy-journa lLung Cancer: Targets and Therapy is an international, peer-reviewed, open access  journal focusing on lung cancer research, identification of therapeutic targets and  the optimal use of preventative and integrated treatment interventions to achieve  improved outcomes, enhanced survival and quality of life for the cancer patient.",Non-OADS,/arxiv_data1/oa_pdf/0f/37/lctt-5-011.PMC5217507.pdf
Visit http://www.dovepress.com/testimonials.php to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/0f/37/lctt-5-011.PMC5217507.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/48/23/lctt-5-051.PMC5217508.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pLung Cancer: Targets and Therapy 2014:5 51–57Lung Cancer: Targets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  51Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/LCTT .S4949 0Clinical potential of nintedanib for the second- line treatment of advanced non-small-cell lung  cancer: current evidence Sacha i Rothschild Department of internal Medicine,   Medical Oncology, University Hospital  Basel, Basel, Switzerland Correspondence: Sacha i Rothschild   Department of internal Medicine,   Medical Oncology, University Hospital   Basel, 4 Petersgraben, Basel 4031,   Switzerland   Tel +41 61 265 5074   Fax +41 61 265 5316   email sacha.rothschild@usb.c hAbstract:  The therapeutic landscape in non-small-cell lung cancer (NSCLC) is changing.",Non-OADS,/arxiv_data1/oa_pdf/48/23/lctt-5-051.PMC5217508.pdf
Lung Cancer: Targets and Therapy 2014:5submit your manuscript | www.dovepress.co m Dove press Dove press 55Nintedanib for NSCLC Table  2 Overview of major ongoing clinical trials with nintedanib including patients with lung cancer; from http://www.clinicaltrials.,Non-OADS,/arxiv_data1/oa_pdf/48/23/lctt-5-051.PMC5217508.pdf
Visit http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/48/23/lctt-5-051.PMC5217508.pdf
Submit your manuscript here:  http://www.dovepress.com/lung-cancer-targets--therapy-journa l Lung Cancer: Targets and Therapy 2014:5submit your manuscript | www.dovepress.co m Dove press Dove press Dove pres s 57Nintedanib for NSCLC  44.,Non-OADS,/arxiv_data1/oa_pdf/48/23/lctt-5-051.PMC5217508.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/31/55/lctt-5-021.PMC5217509.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpLung Cancer: Targets and Therapy 2014:5 21–31Lung Cancer: Targets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  21OriginaL  researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/LCTT .S5970 3The voice of postsurgical lung cancer patients  regarding supportive care needs amy J hoffman1 ruth ann Brintnall2 alexander von eye3 Julie Cooper2 Jean K Brown4 1College of nursing, Michigan state  University, east Lansing, M i, Usa;   2Kirkhof College of nursing, grand  Valley state University, grand rapids,   Mi, Usa; 3Psychology Department,   Michigan state University, east  Lansing, M i, Usa; 4school of n ursing,   state University of new York at  Buffalo, Buffalo, nY, Usa Correspondence: amy J hoffman   College of nursing, Michigan state  University, Office C246 Bott Building   for nursing education and research,   1355 Bogue street, east Lansing,   Mi 48824-1317, Usa   Tel +1 616 826 7820   Fax +1 616 682 5373   email amy.hoffman@hc.msu.ed uObjective:  Individuals with lung cancer present with multiple comorbid conditions and   complex treatment plans.",Non-OADS,/arxiv_data1/oa_pdf/31/55/lctt-5-021.PMC5217509.pdf
Visit http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/31/55/lctt-5-021.PMC5217509.pdf
Submit your manuscript here:  http://www.dovepress.com/lung-cancer-targets--therapy-journa l Lung Cancer: Targets and Therapy 2014:5submit your manuscript | www.dovepress.co m Dove press Dove press Dove pres s 31The voice of postsurgical lung cancer patients  18.,Non-OADS,/arxiv_data1/oa_pdf/31/55/lctt-5-021.PMC5217509.pdf
Available from: https://subscriptions.nccn.org/ gl_login.aspx?ReturnURL =http://www.nccn.org/professionals/physi - cian_gls/pdf/survivorship.pdf .,Non-OADS,/arxiv_data1/oa_pdf/31/55/lctt-5-021.PMC5217509.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/8e/09/lctt-5-067.PMC5217511.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pLung Cancer: Targets and Therapy 2014:5 67–72Lung Cancer: Targets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  67Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/LCTT .S4619 5Staging lung cancer: role of endobronchial  ultrasound T erunaga inage Takahiro Nakajima ichiro Y oshino Department of General Thoracic  Surgery, Graduate School of Medicine,   Chiba University, Chiba, Japan Correspondence: Takahiro Nakajima   Department of General Thoracic Surgery,  Graduate School of Medicine, Chiba  University, 1-8-1 inohana, Chuo-ku,  Chiba 260-8670, Japan   Tel +81 43 222 7171 ext 5464   Fax +81 43 226 2172   email tnakajima76@hotmail.co mAbstract:  Accurate staging is the first step in the management of lung cancer.",Non-OADS,/arxiv_data1/oa_pdf/8e/09/lctt-5-067.PMC5217511.pdf
"Lung Cancer: Targets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/lung-cancer-targets--therapy-journa lLung Cancer: Targets and Therapy is an international, peer-reviewed, open access  journal focusing on lung cancer research, identification of therapeutic targets and  the optimal use of preventative and integrated treatment interventions to achieve  improved outcomes, enhanced survival and quality of life for the cancer patient.",Non-OADS,/arxiv_data1/oa_pdf/8e/09/lctt-5-067.PMC5217511.pdf
Visit http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/8e/09/lctt-5-067.PMC5217511.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/61/d0/lctt-5-073.PMC5217512.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pLung Cancer: Targets and Therapy 2014:5 73–79Lung Cancer: Targets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  73Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/LCTT .S5067 1Targeted treatment of mutated EGFR-expressing  non-small-cell lung cancer: focus on erlotinib   with companion diagnostics Niki Karachaliou1 Rafael Rosell2 1Translational Research Unit,    Dr Rosell Oncology institute, Quirón  Dexeus University Hospital, 2Cancer  Biology and Precision Medicine  Program, Catalan institute of  Oncology, Hospital Germans Trias i  Pujol, Barcelona, Spain Correspondence: Rafael Rosell   Catalan institute of Oncology, Hospital  Germans Trias i Pujol, Ctra Canyet s/n,  Badalona, Barcelona 08916, Spain   email rrosell@iconcologia.ne tAbstract:  Deeper understanding of the pathobiology of non-small-cell lung cancer (NSCLC)  has led to the development of small molecules that target genetic mutations known to play  critical roles in the progression to metastatic disease.",Non-OADS,/arxiv_data1/oa_pdf/61/d0/lctt-5-073.PMC5217512.pdf
Visit http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/61/d0/lctt-5-073.PMC5217512.pdf
Submit your manuscript here:  http://www.dovepress.com/lung-cancer-targets--therapy-journa l Lung Cancer: Targets and Therapy 2014:5submit your manuscript | www.dovepress.co m Dove press Dove press Dove pres s 79Treatment of non-small-cell lung cancer  54.,Non-OADS,/arxiv_data1/oa_pdf/61/d0/lctt-5-073.PMC5217512.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/e8/47/lctt-6-027.PMC5217513.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pLung Cancer: Targets and Therapy 2015:6 27–34Lung Cancer: Targets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  27Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/LCTT .S6043 8AXL receptor tyrosine kinase as a therapeutic  target in NSCLC Ross A Okimoto1 Trever G Bivona1,2 1Division of Hematology and Medical  Oncology, University of California San  Francisco, San Francisco, CA, USA;   2Helen Diller Family Comprehensive  Cancer Center, University of  California San Francisco, San  Francisco, CA, USA Correspondence: Trever G Bivona   Room N212D, 600 16th Street,   San Francisco, CA 94158, USA   Tel +1 415 476 9907   Fax +1 415 514 0169   email trever.bivona@ucsf.ed uAbstract:  The AXL receptor tyrosine kinase and its ligand, Gas6, regulate key processes  in lung cancer growth, metastasis, and epithelial–mesenchymal transition-associated drug  resistance.",Non-OADS,/arxiv_data1/oa_pdf/e8/47/lctt-6-027.PMC5217513.pdf
"Lung Cancer: Targets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/lung-cancer-targets--therapy-journa lLung Cancer: Targets and Therapy is an international, peer-reviewed, open access  journal focusing on lung cancer research, identification of therapeutic targets and  the optimal use of preventative and integrated treatment interventions to achieve  improved outcomes, enhanced survival and quality of life for the cancer patient.",Non-OADS,/arxiv_data1/oa_pdf/e8/47/lctt-6-027.PMC5217513.pdf
Visit http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/e8/47/lctt-6-027.PMC5217513.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/71/2c/lctt-5-043.PMC5217514.pdf
Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpLung Cancer: Targets and Therapy 2014:5 43–50Lung Cancer: Targets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  43Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/ 10.2147/LCTT .S3798 1Video abstract Point your Smar tPhone at the code abo ve.,Non-OADS,/arxiv_data1/oa_pdf/71/2c/lctt-5-043.PMC5217514.pdf
"Or use: http://dvpr.es/1qlrgT xProfile of bavituximab and its potential in the  treatment of non-small-cell lung cancer irene Stasi Federico Cappuzzo Medical Oncology Department,   istituto T oscano T umori, Ospedale  Civile, Livorno, italy Correspondence: Federico Cappuzzo   istituto Toscano Tumori, Ospedale  Civile, Viale Alfieri  36, 57100,   Livorno, italy   Tel +39 058 622 3189  Fax +39 058 622 3457  email f.cappuzzo@gmail.co mAbstract:  Bavituximab is a an unconjugated, chimeric immunoglobulin G1 (IgG1) monoclonal  antibody directed against the phosphatidylserine (PS) expressed on tumor endothelium, with a  specific mechanism of action.",Non-OADS,/arxiv_data1/oa_pdf/71/2c/lctt-5-043.PMC5217514.pdf
"Available from:  http://www.cancer.org/cancer/lungcancer-non- smallcell/detailedguide/non-small-cell-lung-cancer-survival-rate s.  Accessed May 22, 2013.Table  2 Presented trials conducted in NSCLC patients Study Phase N Dose Treatment ORR (CR + PR + SD) PFS OS Shtivelband et al26ii R 121 1–3 mg/mq weekly Second line,   combination with D,  randomized to bavituximab   (E) or placebo (C)17.1% (e)   13.8% (C)4.5 m (e)   3.3 m (C)11.7 m (e)   7.3 m (C) Digumarti et al27ii 49 3 mg/mq weekly First line,   combination with P + C52.4% 6.2 m NA Abbreviations:  NSCLC, non-small-cell lung cancer; N, number of patients; R, randomized; mg, square meter; ORR, overall response rate; CR, complete response; PR,  partial response; SD, s table disease; PFS, progression free survival; OS, overall survival; D, docetaxel; P + C, paclitaxel + carboplatin; E, experimental arm; C, control arm;  NA, not available; m,  months.",Non-OADS,/arxiv_data1/oa_pdf/71/2c/lctt-5-043.PMC5217514.pdf
"Lung Cancer: Targets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/lung-cancer-targets--therapy-journa lLung Cancer: Targets and Therapy is an international, peer-reviewed, open access  journal focusing on lung cancer research, identification of therapeutic targets and  the optimal use of preventative and integrated treatment interventions to achieve  improved outcomes, enhanced survival and quality of life for the cancer patient.",Non-OADS,/arxiv_data1/oa_pdf/71/2c/lctt-5-043.PMC5217514.pdf
Visit http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/71/2c/lctt-5-043.PMC5217514.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/ae/44/lctt-6-035.PMC5217515.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pLung Cancer: Targets and Therapy 2015:6 35–42Lung Cancer: Targets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  35Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/LCTT .S6911 4Profile of ceritinib in the treatment of ALK +  metastatic non-small-cell lung cancer Mark w Burns Eric S Kim Wilmot Cancer Center, University of  Rochester, Rochester, NY, USA Correspondence: Eric S Kim   wilmot Cancer Center, University   of Rochester, 601 Elmwood Avenue,   Box 704, Rochester, NY 14642, USA   Tel +1 585 273 4150   Fax +1 585 273 1042   email eric_kim@urmc.rochester.ed uAbstract:  Lung cancer has become one of the leading causes of death in both men and  women in the United States, with approximately 230,000 new cases and 160,000 deaths  each year.",Non-OADS,/arxiv_data1/oa_pdf/ae/44/lctt-6-035.PMC5217515.pdf
Avail - able from: http://www.pharma.us.novartis.com/product/pi/pdf/zykadia.,Non-OADS,/arxiv_data1/oa_pdf/ae/44/lctt-6-035.PMC5217515.pdf
"Lung Cancer: Targets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/lung-cancer-targets--therapy-journa lLung Cancer: Targets and Therapy is an international, peer-reviewed, open access  journal focusing on lung cancer research, identification of therapeutic targets and  the optimal use of preventative and integrated treatment interventions to achieve  improved outcomes, enhanced survival and quality of life for the cancer patient.",Non-OADS,/arxiv_data1/oa_pdf/ae/44/lctt-6-035.PMC5217515.pdf
Visit http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/ae/44/lctt-6-035.PMC5217515.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/62/3c/lctt-6-001.PMC5217516.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pLung Cancer: Targets and Therapy 2015:6 1–11Lung Cancer: Targets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  1ORIGINAL RESEARCHopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/LCTT .S7067 9Hapten-enhanced therapeutic effect in advanced  stages of lung cancer by ultra-minimum incision  personalized intratumoral chemoimmunotherapy  therapy Baofa Yu1–3 Yuanfei Lu1 Feng Gao2 Peng Jing2 Han Wei1 Peicheng Zhang2 Guoliang Liu1 Ning Ru2 Guanghui Cui2 Xinhai Xu1 Chenglin Sun1 Changjiang Guan2 Yebing Che1 Yingli Wu2 Zhenlu Ma2 Qiang Fu1 Jian Liu2 Huan-Y ou Wang4 1Jinan Baofa Cancer Hospital, Jinan,   2TaiMei Baofa Cancer Hospital,   Dongping, 3Beijing Baofa Cancer  Hospital, Beijing, People’s Republic  of China; 4Department of Pathology,   University of California, San Diego,   CA, USA Correspondence: Baofa Yu   East 50, Wangzhuang Industrial Park,   Beijing Baofa Cancer Hospital,   Changping, Beijing 102206,   People’s Republic of China   Email bfyuchina@126.co mAim:  The objective of the study reported here was to evaluate the therapeutic effects of  hapten-enhanced chemoimmunotherapy in the treatment of advanced lung cancer by  ultra-minimum incision personalized intratumoral chemoimmunotherapy (UMIPIC) and to  analyze the effect of this immune booster.",Non-OADS,/arxiv_data1/oa_pdf/62/3c/lctt-6-001.PMC5217516.pdf
Visit http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/62/3c/lctt-6-001.PMC5217516.pdf
Submit your manuscript here:  http://www.dovepress.com/lung-cancer-targets--therapy-journa l Lung Cancer: Targets and Therapy 2015:6submit your manuscript | www.dovepress.co m Dove press Dove press Dove pres s 11UMIPIC therapy in advanced-stage lung cancer References  1.,Non-OADS,/arxiv_data1/oa_pdf/62/3c/lctt-6-001.PMC5217516.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/0d/4b/lctt-6-055.PMC5217517.pdf
Information on how to  request permission may be found at: http://www.dovepress.com/permissions.ph pLung Cancer: Targets and Therapy 2015:6 55–70Lung Cancer: Targets and Therapy Video abstract Point your Smar tPhone at the code abo ve.,Non-OADS,/arxiv_data1/oa_pdf/0d/4b/lctt-6-055.PMC5217517.pdf
"Or use: http://youtu.be/9UUNnpNMpG EDove press submit your manuscript | www.dovepress.co m Dove press  55Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/LCTT .S5517 6Targeting PD-1/PD-L1 in lung cancer: current  perspectives María González-Cao1 Niki Karachaliou1 Santiago viteri1 Daniela Morales-espinosa1 Cristina T eixidó2 Jesús Sánchez Ruiz3 Miquel Ángel Molina-vila2 Mariacarmela Santarpia4 Rafael Rosell1,2,5,6 1Translational Cancer Research Unit, instituto  Oncológico Dr Rosell, Quirón Dexeus University  Hospital, Barcelona, Spain;  2Pangaea Biotech SL,   Barcelona, Spain;  3Centro Nacional de investigación  Oncología (CN iO), Madrid, Spain;  4Medical  Oncology Unit, Human Pathology Department,   University of Messina, Messina, italy; 5Cancer  Biology and Precision Medicine Program, Catalan  institute of Oncology, Germans Trias i Pujol Health  Sciences institute and Hospital, Campus Can Ruti,   Badalona, Barcelona, Spain;  6Fundación Molecular  Oncology Research, Barcelona, Spain Correspondence: María González-Cao   Translational Cancer Research Unit,  instituto Oncológico Dr Rosell, Quirón  Dexeus University Hospital, Calle Sabino  Arana 5, 08028 Barcelona, Spain   Tel +34 93 546 01 35  Fax +34 93 546 01 96   email mgonzalezcao@oncorosell.co mAbstract:  Increased understanding of tumor immunology has led to the development of  effective immunotherapy treatments.",Non-OADS,/arxiv_data1/oa_pdf/0d/4b/lctt-6-055.PMC5217517.pdf
"Lung Cancer: Targets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/lung-cancer-targets--therapy-journa lLung Cancer: Targets and Therapy is an international, peer-reviewed, open access  journal focusing on lung cancer research, identification of therapeutic targets and  the optimal use of preventative and integrated treatment interventions to achieve  improved outcomes, enhanced survival and quality of life for the cancer patient.",Non-OADS,/arxiv_data1/oa_pdf/0d/4b/lctt-6-055.PMC5217517.pdf
Visit http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/0d/4b/lctt-6-055.PMC5217517.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/8f/46/lctt-6-013.PMC5217518.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pLung Cancer: Targets and Therapy 2015:6 13–25Lung Cancer: Targets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  13Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/LCTT .S7326 8Pemetrexed in maintenance treatment of advanced  non-squamous non-small-cell lung cancer Seigo Minami1 Takashi Kijima2 1Department of Respiratory Medicine,   Osaka Police Hospital, 2Department  of Respiratory Medicine, Allergy and  Rheumatic Diseases, Osaka University  Graduate School of Medicine, Osaka,   Japan Correspondence: Takashi Kijima   Department of Respiratory Medicine,  Allergy and Rheumatic Diseases,   Osaka University Graduate School   of Medicine, 2-2 Yamada-oka, Suita,  Osaka 565-0871, Japan   Tel +81 6 6879 3833   Fax +81 6 6879 3839   email tkijima@imed3.med.osaka-u.ac.j pAbstract:  Pemetrexed, a multitargeting antifolate cytotoxic drug, plays a leading role in  front-line chemotherapy for patients with advanced non-squamous non-small-cell lung cancer  (NSCLC).",Non-OADS,/arxiv_data1/oa_pdf/8f/46/lctt-6-013.PMC5217518.pdf
Available  from: http://www.who.int/mediacentre/factsheets/fs297/en /.,Non-OADS,/arxiv_data1/oa_pdf/8f/46/lctt-6-013.PMC5217518.pdf
Available from: http://www.nice.org.uk/guidance/ta18 1.,Non-OADS,/arxiv_data1/oa_pdf/8f/46/lctt-6-013.PMC5217518.pdf
Available from: http://www.nice.org.uk/guidance/ta19 0.,Non-OADS,/arxiv_data1/oa_pdf/8f/46/lctt-6-013.PMC5217518.pdf
Available from: http://www.nice.org.uk/guidance/ta30 9.,Non-OADS,/arxiv_data1/oa_pdf/8f/46/lctt-6-013.PMC5217518.pdf
Visit http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/8f/46/lctt-6-013.PMC5217518.pdf
Submit your manuscript here:  http://www.dovepress.com/lung-cancer-targets--therapy-journa l Lung Cancer: Targets and Therapy 2015:6submit your manuscript | www.dovepress.co m Dove press Dove press Dove pres s 25Pemetrexed as a maintenance strategy  34.,Non-OADS,/arxiv_data1/oa_pdf/8f/46/lctt-6-013.PMC5217518.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/15/06/lctt-6-071.PMC5217519.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pLung Cancer: Targets and Therapy 2015:6 71–82Lung Cancer: Targets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  71Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/LCTT .S6349 1First-line treatment of advanced ALK-positive  non-small-cell lung cancer Shipra Gandhi1 Hongbin Chen2 Yujie Zhao2 Grace K Dy2 1Department of internal Medicine,   State University of New Y ork,   2Department of Medicine, Roswell  Park Cancer institute, Buffalo, NY,   USA Correspondence: Grace K Dy   Department of Medicine, Roswell Park  Cancer institute, elm & Carlton Streets,  Buffalo, NY 14263, USA   Tel +1 716 845 2300 ext 3094   Fax +1 716 845 8935   email g race.dy@roswell park.or gAbstract:  Non-small-cell lung cancer (NSCLC) is one of the leading causes of cancer deaths,  both within the US and worldwide.",Non-OADS,/arxiv_data1/oa_pdf/15/06/lctt-6-071.PMC5217519.pdf
Available from: http://cancer.sanger.ac.uk/cos - mic/fusion.,Non-OADS,/arxiv_data1/oa_pdf/15/06/lctt-6-071.PMC5217519.pdf
Available from:  http://globocan.iarc.fr /.,Non-OADS,/arxiv_data1/oa_pdf/15/06/lctt-6-071.PMC5217519.pdf
Available from: https://clinicaltrials.gov/ct2/ show/results/NCT0182249 6.,Non-OADS,/arxiv_data1/oa_pdf/15/06/lctt-6-071.PMC5217519.pdf
Available at: https://clinicaltrials.gov/ct2/results?term =NCT0 1828099&Search =Searc h. NLM Identifier: NCT01828099.,Non-OADS,/arxiv_data1/oa_pdf/15/06/lctt-6-071.PMC5217519.pdf
Available from: http://news.bms.com/press-release/ rd-news/bristol-myers-squibb-announces-collaboration-evaluate- opdivo-nivolumab-combina .,Non-OADS,/arxiv_data1/oa_pdf/15/06/lctt-6-071.PMC5217519.pdf
"Lung Cancer: Targets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/lung-cancer-targets--therapy-journa lLung Cancer: Targets and Therapy is an international, peer-reviewed, open access  journal focusing on lung cancer research, identification of therapeutic targets and  the optimal use of preventative and integrated treatment interventions to achieve  improved outcomes, enhanced survival and quality of life for the cancer patient.",Non-OADS,/arxiv_data1/oa_pdf/15/06/lctt-6-071.PMC5217519.pdf
Visit http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/15/06/lctt-6-071.PMC5217519.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/9e/36/lctt-6-083.PMC5217520.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pLung Cancer: Targets and Therapy 2015:6 83–90Lung Cancer: Targets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  83OriginaL  researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/LCTT .S8965 5Combination chemotherapy of gemcitabine   and vinorelbine for pretreated non-small-   cell lung cancer: a retrospective study seigo Minami Y oshitaka Ogata suguru Yamamoto Kiyoshi Komuta Department of respiratory Medicine,   Osaka Police hospital, Osaka, Japan Correspondence: seigo Minami   Department of respiratory Medicine,  Osaka Police hospital,  10-31 Kitayama- cho, Tennoji-ku, Osaka-City,   Osaka  543-0035, Japan   Tel +81 6 6771 6051  Fax +81 6 6771 2838  email seigominami@oph.gr.j pBackground:  Advanced non-small-cell lung cancer (NSCLC) eventually progresses after  first-line chemotherapy, and usually requires salvage treatment.",Non-OADS,/arxiv_data1/oa_pdf/9e/36/lctt-6-083.PMC5217520.pdf
http://ctep.cancer.gov/protocolDevelopment/ electronic_applications/ctc.htm#ctc_4 0.,Non-OADS,/arxiv_data1/oa_pdf/9e/36/lctt-6-083.PMC5217520.pdf
"Lung Cancer: Targets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/lung-cancer-targets--therapy-journa lLung Cancer: Targets and Therapy is an international, peer-reviewed, open access  journal focusing on lung cancer research, identification of therapeutic targets and  the optimal use of preventative and integrated treatment interventions to achieve  improved outcomes, enhanced survival and quality of life for the cancer patient.",Non-OADS,/arxiv_data1/oa_pdf/9e/36/lctt-6-083.PMC5217520.pdf
Visit http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/9e/36/lctt-6-083.PMC5217520.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/7b/56/lctt-6-091.PMC5217521.pdf
"Information on how to  request permission may be found at: http://www.dovepress.com/permissions.ph pLung Cancer: Targets and Therapy 2015:6 91–98Lung Cancer: Targets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  91Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/LCTT .S6042 7epiregulin as a therapeutic target in non-small- cell lung cancer Noriaki Sunaga1,2 Kyoichi Kaira2,3 1Oncology Center, Gunma University  Hospital, 2Department of Medicine  and Molecular Science, 3Department  of Oncology Clinical Development,   Gunma University Graduate School   of Medicine, Gunma, Japan Correspondence: Noriaki Sunaga   Oncology Center, Gunma University  Hospital, 3-39-15, Showa-machi,  Maebashi, Gunma 371-8511, Japan   Tel +81 27 220 7928   Fax +81 27 220 8609   email nsunaga@gunma-u.ac.j pAbstract:  Epiregulin (EREG) belongs to the ErbB family of ligands.",Non-OADS,/arxiv_data1/oa_pdf/7b/56/lctt-6-091.PMC5217521.pdf
"Lung Cancer: Targets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/lung-cancer-targets--therapy-journa lLung Cancer: Targets and Therapy is an international, peer-reviewed, open access  journal focusing on lung cancer research, identification of therapeutic targets and  the optimal use of preventative and integrated treatment interventions to achieve  improved outcomes, enhanced survival and quality of life for the cancer patient.",Non-OADS,/arxiv_data1/oa_pdf/7b/56/lctt-6-091.PMC5217521.pdf
Visit http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/7b/56/lctt-6-091.PMC5217521.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/b0/89/lctt-6-043.PMC5217522.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pLung Cancer: Targets and Therapy 2015:6 43–53Lung Cancer: Targets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  43Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/LCTT .S6032 9Non-small-cell lung carcinoma: role of the   Notch signaling pathway Levi Barse Maurizio Bocchetta Department of Pathology, Oncology  institute, Loyola University Chicago,   Maywood, iL, USA Correspondence: Maurizio Bocchetta   Department of Pathology, Oncology  institute, Loyola University Chicago,   2160 South First Avenue, Maywood,   iL 60153, USA   Tel +1 708 327 3362   Fax +1 708 327 3238   email mbocche@luc.ed uAbstract:  Notch signaling plays a pivotal role during embryogenesis.",Non-OADS,/arxiv_data1/oa_pdf/b0/89/lctt-6-043.PMC5217522.pdf
Visit http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/b0/89/lctt-6-043.PMC5217522.pdf
Submit your manuscript here:  http://www.dovepress.com/lung-cancer-targets--therapy-journa l Lung Cancer: Targets and Therapy 2015:6submit your manuscript | www.dovepress.co m Dove press Dove press Dove pres s 53Role of the Notch signaling pathway  58.,Non-OADS,/arxiv_data1/oa_pdf/b0/89/lctt-6-043.PMC5217522.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/fb/48/jew014.PMC5217739.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/bd/ae/lctt-5-059.PMC5217745.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pLung Cancer: Targets and Therapy 2014:5 59–66Lung Cancer: Targets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  59OriginaL  researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/ 10.2147/LCTT .S6639 5hypofractionated stereotactic body radiation  therapy for elderly patients with stage  iiB–iV  nonsmall cell lung cancer who are ineligible   for or refuse other treatment modalities sana D Karam1 Zachary D horne2 robert L hong2 Don Mcrae2 David Duhamel3 nadim M nasr2 1Department of radiation Oncology,   University of Colorado, Denver,   CO, Usa;  2Department of radiation  Oncology,  3Department of Pulmonary/ Critical Care Medicine, Virginia  hospital Center, arlington, V a, Usa Correspondence: nadim M nasr   Department of radiation Oncology,  Virginia hospital Center  1701 n george  Mason Dr, arlington, Va  22205, Usa   email nmnasr@gmail.co mObjective:  In elderly patients with stage  IIB–IV nonsmall cell lung cancer who cannot tolerate  chemotherapy, conventionally fractionated radiotherapy is the treatment of choice.",Non-OADS,/arxiv_data1/oa_pdf/bd/ae/lctt-5-059.PMC5217745.pdf
"Lung Cancer: Targets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/lung-cancer-targets--therapy-journa lLung Cancer: Targets and Therapy is an international, peer-reviewed, open access  journal focusing on lung cancer research, identification of therapeutic targets and  the optimal use of preventative and integrated treatment interventions to achieve  improved outcomes, enhanced survival and quality of life for the cancer patient.",Non-OADS,/arxiv_data1/oa_pdf/bd/ae/lctt-5-059.PMC5217745.pdf
Visit http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/bd/ae/lctt-5-059.PMC5217745.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/4d/06/main.PMC5217770.pdf
http://dx.doi.org/10.1016/j.nicl.2016.12.002 2213-1582/© 2016 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/4d/06/main.PMC5217770.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/4d/06/main.PMC5217770.pdf
http://dx.doi.org/10.1523/jneurosci.4040-10.2010 .,Non-OADS,/arxiv_data1/oa_pdf/4d/06/main.PMC5217770.pdf
12 (1):26 –41.http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/4d/06/main.PMC5217770.pdf
http://dx.doi.org/10.1016/j.nicl.2015.02.009 .,OADS,/arxiv_data1/oa_pdf/4d/06/main.PMC5217770.pdf
http://dx.doi.org/ 10.1126/science.1152882 .,Non-OADS,/arxiv_data1/oa_pdf/4d/06/main.PMC5217770.pdf
Neuron 74 (3):467 –474.http://dx.doi.org/10.,OADS,/arxiv_data1/oa_pdf/4d/06/main.PMC5217770.pdf
93 (1):74. http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/4d/06/main.PMC5217770.pdf
http://dx.doi.org/10.1212/01.wnl.0000150885.00929.7e .,Non-OADS,/arxiv_data1/oa_pdf/4d/06/main.PMC5217770.pdf
http://dx.doi.org/10.1056/ nejm200008173430701 .,OADS,/arxiv_data1/oa_pdf/4d/06/main.PMC5217770.pdf
Psychiatry 10 (1):44 –51.http://dx.doi.org/10.1097/00019442-200201000-00006 .,Non-OADS,/arxiv_data1/oa_pdf/4d/06/main.PMC5217770.pdf
Neurology 24 (11):1019. http://dx.doi.org/10.1212/wnl.24.11.1019 .,Non-OADS,/arxiv_data1/oa_pdf/4d/06/main.PMC5217770.pdf
http://dx.doi.org/10.1523/jneurosci.2250-06.2006 .,OADS,/arxiv_data1/oa_pdf/4d/06/main.PMC5217770.pdf
http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/4d/06/main.PMC5217770.pdf
"http://dx.doi.org/10.1016/j.jalz.2009.07.003 .Dickerson, B.C., Salat, D.H., Bates, J.F., Atiya, M., Killiany, R.J., Greve, D.N., ... Sperling, R.A., 2004.",OADS,/arxiv_data1/oa_pdf/4d/06/main.PMC5217770.pdf
56 (1):27 –35.http://dx.doi.org/10.1002/ana.20163 .,Non-OADS,/arxiv_data1/oa_pdf/4d/06/main.PMC5217770.pdf
http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/4d/06/main.PMC5217770.pdf
Synapse 52 (1): 53–61.http://dx.doi.org/10.1002/syn.20004 .,OADS,/arxiv_data1/oa_pdf/4d/06/main.PMC5217770.pdf
http://dx.doi.org/10.1016/j.tins.2011.05.005 .,OADS,/arxiv_data1/oa_pdf/4d/06/main.PMC5217770.pdf
http://dx.doi.org/10.1016/0022-3956(75)90026-6 .,OADS,/arxiv_data1/oa_pdf/4d/06/main.PMC5217770.pdf
http://dx.doi.org/10.1136/jnnp.65.1.103 .,OADS,/arxiv_data1/oa_pdf/4d/06/main.PMC5217770.pdf
21 (6):929 –934 ( http://doi.org/10.1016/j.conb.2011.10.021 ).,OADS,/arxiv_data1/oa_pdf/4d/06/main.PMC5217770.pdf
http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/4d/06/main.PMC5217770.pdf
http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/4d/06/main.PMC5217770.pdf
"262(841), 23 –81.http://dx.doi.org/10.1098/rstb.1971.0078 Miller, S.L., Celone, K., DePeau, K., Diamond, E., Dickerson, B.C., Rentz, D., ... Sperling, R.A., 2008.",Non-OADS,/arxiv_data1/oa_pdf/4d/06/main.PMC5217770.pdf
Neurology http://dx.doi.org/10.1212/wnl.43.11.2412-a .,Non-OADS,/arxiv_data1/oa_pdf/4d/06/main.PMC5217770.pdf
http://dx.doi.org/10.1001/archneurol.2009.15 .,Non-OADS,/arxiv_data1/oa_pdf/4d/06/main.PMC5217770.pdf
http://dx.doi.org/10.1111/j.1365-2796.2004.01388.x .,Non-OADS,/arxiv_data1/oa_pdf/4d/06/main.PMC5217770.pdf
http://dx.doi.org/10.1523/jneurosci.4740-11.2011 .,Non-OADS,/arxiv_data1/oa_pdf/4d/06/main.PMC5217770.pdf
http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/4d/06/main.PMC5217770.pdf
http://dx.doi.org/10.1016/j.neuropsychologia.2007.11.035 .,OADS,/arxiv_data1/oa_pdf/4d/06/main.PMC5217770.pdf
Neuroepidemiology 38 (1):1 –17.http://dx.doi.org/10.1159/000334607 .,Non-OADS,/arxiv_data1/oa_pdf/4d/06/main.PMC5217770.pdf
Psychological Corporation http://dx.doi.org/10.1016/0887-6177(88)90053-4 .,Non-OADS,/arxiv_data1/oa_pdf/4d/06/main.PMC5217770.pdf
http://dx.doi.org/10.1523/JNEUROSCI.1744-05.2005 .,Non-OADS,/arxiv_data1/oa_pdf/4d/06/main.PMC5217770.pdf
http://dx.doi.org/10.1016/j.tins.2006.10.002 .,OADS,/arxiv_data1/oa_pdf/4d/06/main.PMC5217770.pdf
http://dx.doi.org/10.1016/j.neuroimage.2010.03.040 .245 T.T.,OADS,/arxiv_data1/oa_pdf/4d/06/main.PMC5217770.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/9c/ec/main.PMC5217771.pdf
1936-5233/17http://dx.doi.org/10.1016/j.tranon.2016.11.008,OADS,/arxiv_data1/oa_pdf/9c/ec/main.PMC5217771.pdf
Gene expression data was analyzed with the Limmapackage from Bioconductor ( http://www.bioconductor.org )[26].,OADS,/arxiv_data1/oa_pdf/9c/ec/main.PMC5217771.pdf
Microarray and RNA sequencing data are available at the Gene Expression Omnibus ( http://www.ncbi.n lm.nih.gov/geo/ )u n d e r accession number GSE82299.,OADS,/arxiv_data1/oa_pdf/9c/ec/main.PMC5217771.pdf
http://dx.doi.org/10.1038/nature15748 .,Non-OADS,/arxiv_data1/oa_pdf/9c/ec/main.PMC5217771.pdf
http://dx.doi.org/10.1038/nature16064 .,Non-OADS,/arxiv_data1/oa_pdf/9c/ec/main.PMC5217771.pdf
http://dx.doi.org/10.1038/sj.onc.1208927 .,Non-OADS,/arxiv_data1/oa_pdf/9c/ec/main.PMC5217771.pdf
http://dx.doi.org/10.1371/journal.pone.0062310 .,Non-OADS,/arxiv_data1/oa_pdf/9c/ec/main.PMC5217771.pdf
"Curr Opin Oncol 25(1), 76–84.http://dx.doi.org/10.1097/CCO.0b013e32835b6371 .",Non-OADS,/arxiv_data1/oa_pdf/9c/ec/main.PMC5217771.pdf
"BMC Cancer 13, 108. http://dx.doi.org/10.1186/1471-2407-13-108 .",Non-OADS,/arxiv_data1/oa_pdf/9c/ec/main.PMC5217771.pdf
http://dx.doi.org/10.1016/j.ygyno.2014.02.034 .,OADS,/arxiv_data1/oa_pdf/9c/ec/main.PMC5217771.pdf
http://dx.doi.org/10.1158/1078-0432.CCR-06-0038 .,Non-OADS,/arxiv_data1/oa_pdf/9c/ec/main.PMC5217771.pdf
http://dx.doi.org/10.1158/0008-5472.CAN-08-4312 .,Non-OADS,/arxiv_data1/oa_pdf/9c/ec/main.PMC5217771.pdf
http://dx.doi.org/10.1016/j.ajpath.2012.08.011 .,OADS,/arxiv_data1/oa_pdf/9c/ec/main.PMC5217771.pdf
"Gastric Cancer 19(1), 53 –62.http://dx.doi.org/10.1007/s10120-014-0444-1 .",Non-OADS,/arxiv_data1/oa_pdf/9c/ec/main.PMC5217771.pdf
"Med Oncol 32(1), 447. http://dx.doi.org/10.1007/s12032-014-0447-0 .",Non-OADS,/arxiv_data1/oa_pdf/9c/ec/main.PMC5217771.pdf
http://dx.doi.org/10.4161/cc.8.23.10086 .,Non-OADS,/arxiv_data1/oa_pdf/9c/ec/main.PMC5217771.pdf
http://dx.doi.org/10.1158/2159-8290.CD-13-0945 .,Non-OADS,/arxiv_data1/oa_pdf/9c/ec/main.PMC5217771.pdf
"J Antimicrob Chemother 47(1), 1 –13.http://dx.doi.org/10.1093/jac/47.1.1 .",OADS,/arxiv_data1/oa_pdf/9c/ec/main.PMC5217771.pdf
http://dx.doi.org/10.1038/ncb1691 .,Non-OADS,/arxiv_data1/oa_pdf/9c/ec/main.PMC5217771.pdf
http://dx.doi.org/10.4161/15384047.2014.986967 .,Non-OADS,/arxiv_data1/oa_pdf/9c/ec/main.PMC5217771.pdf
http://dx.doi.org/10.1186/gb-2004-5-10-r80 .,Non-OADS,/arxiv_data1/oa_pdf/9c/ec/main.PMC5217771.pdf
"Bioinformatics 29(1), 15 –21.http://dx.doi.org/10.1093/bioinformatics/bts635 .",Non-OADS,/arxiv_data1/oa_pdf/9c/ec/main.PMC5217771.pdf
http://dx.doi.org/10.1093/bioinformatics/btt656 .,OADS,/arxiv_data1/oa_pdf/9c/ec/main.PMC5217771.pdf
http://dx.doi.org/10.1038/sj.onc.1210289 .,Non-OADS,/arxiv_data1/oa_pdf/9c/ec/main.PMC5217771.pdf
http://dx.doi.org/10.1016/j.radonc.2009.06.018 .,OADS,/arxiv_data1/oa_pdf/9c/ec/main.PMC5217771.pdf
"Nat Rev Cancer 16(1), 1. http://dx.doi.org/10.1038/nrc.2015.6 .",Non-OADS,/arxiv_data1/oa_pdf/9c/ec/main.PMC5217771.pdf
http://dx.doi.org/10.1101/gr.152322.112 .,Non-OADS,/arxiv_data1/oa_pdf/9c/ec/main.PMC5217771.pdf
http://dx.doi.org/10.1517/ 14728222.2012.728207 .,Non-OADS,/arxiv_data1/oa_pdf/9c/ec/main.PMC5217771.pdf
http://dx.doi.org/10.1158/0008-5472.CAN-10-4261 .,Non-OADS,/arxiv_data1/oa_pdf/9c/ec/main.PMC5217771.pdf
http://dx.doi.org/10.4161/cbt.5.7.2967 .,Non-OADS,/arxiv_data1/oa_pdf/9c/ec/main.PMC5217771.pdf
http://dx.doi.org/10.1007/s00109-011-0855-y .,Non-OADS,/arxiv_data1/oa_pdf/9c/ec/main.PMC5217771.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: ND2 Exercise intoleranceComplex I de ﬁciency 1.,Non-OADS,/arxiv_data1/oa_pdf/55/e2/main.PMC5217772.pdf
Contents lists available at ScienceDirect Molecular Genetics and Metabolism Reports journal homepage: www.elsevier.com/locate/ymgmr http://dx.doi.org/10.1016/j.ymgmr.2016.11.009 2214-4269/© 2017 Published by Elsevier Inc.,Non-OADS,/arxiv_data1/oa_pdf/55/e2/main.PMC5217772.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/55/e2/main.PMC5217772.pdf
"Wong, M. Milone, Exercise intolerance due to cytochrome b mutation, Muscle Nerve 42 (1) (2010) 136 –140, http://dx.doi.org/10.1002/mus.21649 .",Non-OADS,/arxiv_data1/oa_pdf/55/e2/main.PMC5217772.pdf
This  is  an  open  access  article  under  the  CC  BY-NC-ND license  (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ce/ec/main.PMC5217773.pdf
http://dx.doi.org/10.1016/j.idcr.2016.11.006 2214-2509/©  2016  The  Authors.,Non-OADS,/arxiv_data1/oa_pdf/ce/ec/main.PMC5217773.pdf
This  is  an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).IDCases  7  (2017)  23–24 Contents  lists  available  at  ScienceDirect IDCases journal  homepage:  www.elsevier.com/locate/idcr,Non-OADS,/arxiv_data1/oa_pdf/ce/ec/main.PMC5217773.pdf
This  is  an  open access article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/21/7a/main.PMC5217789.pdf
Liver  biopsy  was  not  done.We  could  not  diagnose  it  deﬁni- tively  as  FNH  from  the  results  of  imaging  studies;  so  for  the  size http://dx.doi.org/10.1016/j.ijscr.2016.10.073 2210-2612/© 2016  The  Authors.,Non-OADS,/arxiv_data1/oa_pdf/21/7a/main.PMC5217789.pdf
"This knowledge  Letter to the editor Key Words lifestyle, multimodal treatment, metabolic syndromeISSN 2093-6966 [Print], ISSN 2234-6856 [Online] Journal of Pharmacopuncture 2016;19[4]:291-292 DOI: https://doi.org/10.3831/KPI.2016.19.029    This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/)which permits unrestricted noncommercial use, distribution, and reproduction in anymedium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/13/d0/2093-6966-v19-n04-291.PMC5217802.pdf
"Department of Medical Pharmacology, American University of Antigua College of Medicine, St. John’s, Antigua and Barbuda.Tel: +1-268-484-8900   Fax: +1-268-484-8910E-mail: pemmineti@yahoo.com ⓒ 2016 Korean Pharmacopuncture Institute                      http://www.journal.ac1 Department of Medical Pharmacology, American University of Antigua College of Medicine & Manipal University, St. John’s, Antigua and  Barbuda 2  Department of Medical Physiology, American University of Antigua College of Medicine, St. John’s, Antigua and Barbuda 3  Department of Pharmacology, Kasturba Medical College, Manipal University, Mangalore, India 4  Department of Pharmacology, Kasturba Medical College, Manipal University, Mangalore, India 5  Department of Behavioural Sciences and Neuroscience, AUA College of Medicine, St. John’s, Antigua and Barbuda Received: Aug 19, 2016    Reviewed: Aug 29, 2016    Accepted: Sep 06, 2016",Non-OADS,/arxiv_data1/oa_pdf/13/d0/2093-6966-v19-n04-291.PMC5217802.pdf
"http://www.journal.ac292 has evolved from basic research in medical science com- bined with genetic and clinical epidemiological research,  an approach that must become more widely used if we are  to effectively stem the tide of the current T2DM epidemic.",Non-OADS,/arxiv_data1/oa_pdf/13/d0/2093-6966-v19-n04-291.PMC5217802.pdf
Available from: http://www.idf.org/about-diabetes/ facts-figures.,Non-OADS,/arxiv_data1/oa_pdf/13/d0/2093-6966-v19-n04-291.PMC5217802.pdf
"Electronic Physician (ISSN: 2008 -5842) http://www.ephysician.ir November2016, Volume: 8, Issue:11, Pages:3156-3163,DOI:http://dx.doi.org/10.19082/ 3156 Corresponding author: Dr. Fatemeh Assarian.",Non-OADS,/arxiv_data1/oa_pdf/2c/1a/epj-08-3156.PMC5217806.pdf
Clinical trial registration: The trial was registered at the Iranian Registry of Clinical Trials (http://www.irct.ir) with the Irct ID: IRCT2013091014619N1.,Non-OADS,/arxiv_data1/oa_pdf/2c/1a/epj-08-3156.PMC5217806.pdf
http://www.ephysician.ir Page3158Sample size was calculated at 29 in each group based on th e sexual dysfunction prevalence (50% –80%) in patients treated with SSRIs (13) and sexual dysfunction in OCD (26%) (8) and confidence interval of 95% and power of 90%.,OADS,/arxiv_data1/oa_pdf/2c/1a/epj-08-3156.PMC5217806.pdf
http://www.ephysician.ir Page3160from the data in Table 4 that the mean score of desire before and after intervention was significant in CBT (p=0.039) but not in fluoxetine group (p=0.35).,Non-OADS,/arxiv_data1/oa_pdf/2c/1a/epj-08-3156.PMC5217806.pdf
Clinical trial registration: The trial was registered at the Iranian Registry of Clinical Trials (http://www.irct.ir) with the Irct ID: IRCT2013091014619N1.,Non-OADS,/arxiv_data1/oa_pdf/2c/1a/epj-08-3156.PMC5217806.pdf
"http://www.ephysician.ir Page3162Acknowledgments: This study was the postgraduate thesis of the first author, Dr. Zahra Sabetnejad, for psychiatry specialty, which was supported by Kashan University of Medical Science, school of medicine, Kashan, Iran.",Non-OADS,/arxiv_data1/oa_pdf/2c/1a/epj-08-3156.PMC5217806.pdf
"Electronic Physician (ISSN: 2008 -5842) http://www.ephysician.ir November2016, Volume: 8, Issue:11, Pages:3164-3169,DOI:http://dx.doi.org/10.19082/ 3164 Corresponding author: Dr. Montaser Mohamed Mohamed, Faculty of Medicine, Sohag University, Egypt.",Non-OADS,/arxiv_data1/oa_pdf/4d/82/epj-08-3164.PMC5217807.pdf
http://www.ephysician.ir Page31662.5.,Non-OADS,/arxiv_data1/oa_pdf/4d/82/epj-08-3164.PMC5217807.pdf
"http://www.ephysician.ir Page3168responsible for 37% of cases with DCMP, while 25% of cases with HCMP have identified causes (IDM, Friedreich`s ataxia).",Non-OADS,/arxiv_data1/oa_pdf/4d/82/epj-08-3164.PMC5217807.pdf
"Electronic Physician (ISSN: 2008 -5842) http://www.ephysician.ir November2016, Volume: 8, Issue:11, Pages:3170-3176,DOI:http://dx.doi.org/10.19082/3170 Corresponding author: Assistant Professo r Dr. Mahmood Moosazadeh, Health Science Research Center, Faculty of Health, Mazandaran University of  Medical Sciences, Sari, Iran.",Non-OADS,/arxiv_data1/oa_pdf/29/32/epj-08-3170.PMC5217808.pdf
http://www.ephysician.ir Page31722.4.,Non-OADS,/arxiv_data1/oa_pdf/29/32/epj-08-3170.PMC5217808.pdf
http://www.ephysician.ir Page3174 Figure 2.,Non-OADS,/arxiv_data1/oa_pdf/29/32/epj-08-3170.PMC5217808.pdf
http://www.ephysician.ir Page31766)Thomas DR. Prevention and treatment of pressure ulcers: what works?,Non-OADS,/arxiv_data1/oa_pdf/29/32/epj-08-3170.PMC5217808.pdf
"Electronic Physician (ISSN: 2008 -5842) http://www.ephysician.ir November2016, Volume: 8, Issue:11, Pages:3177-3183,DOI:http://dx.doi.org/10.19082/ 3177 Corresponding author: Assistant Professor Dr. Seyedeh Zahra Masoumi, Research Center for Child & Maternity Care, School of Nursing and Midwifery, Hamadan University of Medical Sciences, Hamadan, Iran.",Non-OADS,/arxiv_data1/oa_pdf/62/02/epj-08-3177.PMC5217809.pdf
Trial registra tion:The trial was registered at the Iranian Registry of Clinical Trials (http://www.irct.ir) with the IRCTID: IRCT2015012513405N9.,Non-OADS,/arxiv_data1/oa_pdf/62/02/epj-08-3177.PMC5217809.pdf
http://www.ephysician.ir Page3178positively affect the mother and infant’s health (7).,Non-OADS,/arxiv_data1/oa_pdf/62/02/epj-08-3177.PMC5217809.pdf
http://www.ephysician.ir Page31802.6.,Non-OADS,/arxiv_data1/oa_pdf/62/02/epj-08-3177.PMC5217809.pdf
http://www.ephysician.ir Page3182mothers to receive some food groups (received energy and proteins).,Non-OADS,/arxiv_data1/oa_pdf/62/02/epj-08-3177.PMC5217809.pdf
Trial registratio n: The trial was registered at the Iranian Registry of Clinical Trials (http://www.irct.ir) with the IRCTID: IRCT2015012513405N9.,Non-OADS,/arxiv_data1/oa_pdf/62/02/epj-08-3177.PMC5217809.pdf
"Electronic Physician (ISSN: 2008 -5842) http://www.e physician.ir November2016, Volume: 8, Issue:11, Pages:3184-3192,DOI:http://dx.doi.org/10.19082/ 3184 Corresponding author: Assistant Professor Dr. Sepideh Miraj, Faculty of Medicine, Shahrekord University of Medical Sciences, Shahrekord, Iran.Tel: +98.9126509952, Fax: +98.32225456, Email: miraj.sepide@gmail.com Received: April 03, 2016 , Accepted: September 04, 2016 , Published: November 2016 iThenticate screening: September 02, 2016 , English editing: September 28, 2016 , Quality control: October 16, 2016 © 2016The Authors.",Non-OADS,/arxiv_data1/oa_pdf/ba/fb/epj-08-3184.PMC5217810.pdf
http://www.ephysician.ir Page3186foreach of the subjects by individual interviews.,Non-OADS,/arxiv_data1/oa_pdf/ba/fb/epj-08-3184.PMC5217810.pdf
http://www.ephysician.ir Page3188of Pap smear showed that the group of Premarin had the most reduction in the parabasal ce lls of the vagina and improvement of vaginal atrophy.,Non-OADS,/arxiv_data1/oa_pdf/ba/fb/epj-08-3184.PMC5217810.pdf
"http://www.ephysician.ir Page3190dryness, though temporarily.",Non-OADS,/arxiv_data1/oa_pdf/ba/fb/epj-08-3184.PMC5217810.pdf
Clinical trial registration: The trial was registered at the Iranian Registry of Clinical Trials (http://www.irct.ir) with the IRCD code: 2014112220043n1.,Non-OADS,/arxiv_data1/oa_pdf/ba/fb/epj-08-3184.PMC5217810.pdf
"http://www.ephysician.ir Page319220)Cumming GP, Currie HD, Moncur R, Lee AJ.",Non-OADS,/arxiv_data1/oa_pdf/ba/fb/epj-08-3184.PMC5217810.pdf
"Electronic Physic ian (ISSN: 2008 -5842) http://www.ephysician.ir November2016, Volume: 8, Issue:11, Pages:3198-3204,DOI:http://dx.doi.org/10.190 82/3198 Corresponding author: Heshmatollah Asadi ,Department of Health Management and Eco nomics, School of Public Health, Tehran University of Medical Sciences .Tel:+98.9373754220 ,E-mail:heshmat.asadi64@gmail.com Received: March 08, 2016 , Accepted: June 15, 2016 , Published: November 2016 iThenticate screening: June 15, 2016 , English editing :September 15, 2016 , Quality control: October 08, 2016 © 2016The Authors.",Non-OADS,/arxiv_data1/oa_pdf/3e/d9/epj-08-3198.PMC5217811.pdf
"http://www.ephysician.ir Page3200(eight items), public utility resource (15 items), safety and alarm systems (11 items), security systems (five items), communications and transportation systems (four item), public information systems (nine item), plans for emergency and disaster (18 i tems), human resources (11 items), monitoring and evaluation (three items) in  a total of 139 questions.",OADS,/arxiv_data1/oa_pdf/3e/d9/epj-08-3198.PMC5217811.pdf
"http://www.ephysician.ir Page3202level of preparedness in terms of safety of equipment and hazardous materials, planning of needed equipment and consuming goods (22).",Non-OADS,/arxiv_data1/oa_pdf/3e/d9/epj-08-3198.PMC5217811.pdf
"Available from: http://apps.who.int/bookorders/anglais/detart1.jsp?sesslan=1&codlan=1&codcol=52&codcch=98# 14)Mulyasari F, Inoue S, Prashar S, Isayama K, Basu M, Srivastava N, et al.",OADS,/arxiv_data1/oa_pdf/3e/d9/epj-08-3198.PMC5217811.pdf
"http://www.ephysician.ir Page320415)Lakbala P. Hospit al Workers Disaster Management and Hospital Nonstructural: A Study in Bandar Abbas, Iran.",Non-OADS,/arxiv_data1/oa_pdf/3e/d9/epj-08-3198.PMC5217811.pdf
"Electronic Physician (ISSN: 2008 -5842) http://www.ephysician.ir November2016, Volume: 8, Issue:10, Pages:3205-3213,DOI:http://dx.doi.org/10.19082/ 3205 Corresponding author: Professor Dr. Heidarali Abedi.",Non-OADS,/arxiv_data1/oa_pdf/e4/47/epj-08-3205.PMC5217812.pdf
http://www.ephysician.ir Page3206the problems by using inappropriate behaviors in seeking treatment.,Non-OADS,/arxiv_data1/oa_pdf/e4/47/epj-08-3205.PMC5217812.pdf
"http://www.ephysician.ir Page3208Table 1.Frequency of the target group on the basis of gender, marital status ,and education Demographic Self-curingn%p-value Man (n = 165) Yes 10671.220.558 No 5329.88 Women (n =185) Yes 12271.56 No 6128.44 Marital status (n = 89) Yes 471.220.001 No 16129.88 3.2.",Non-OADS,/arxiv_data1/oa_pdf/e4/47/epj-08-3205.PMC5217812.pdf
http://www.ephysician.ir Page3210show the acceptance of self -therapy and self -medication among different communities.,Non-OADS,/arxiv_data1/oa_pdf/e4/47/epj-08-3205.PMC5217812.pdf
"http://www.ephysician.ir Page3212References : 1)Karimy M, Heidarnia AR, Ghofranipour F. Factors influencing self -medication elderiy urban centers in Zarandie based on health belief model.",Non-OADS,/arxiv_data1/oa_pdf/e4/47/epj-08-3205.PMC5217812.pdf
"Electronic Physician (ISSN: 2008 -5842) http://www.ephysician.ir November2016, Volume: 8, Issue:11, Pages:3214-3221,DOI:http://dx.doi.org/10.19082/ 3214 Corresponding author: Bijan Pirnia, Department Of Psychology, Faculty of Humanities, University of Science and Culture, Tehran, Iran.",Non-OADS,/arxiv_data1/oa_pdf/98/eb/epj-08-3214.PMC5217813.pdf
http://www.ephysician.ir Page32162.4.,Non-OADS,/arxiv_data1/oa_pdf/98/eb/epj-08-3214.PMC5217813.pdf
http://www.ephysician.ir Page3218simultaneous cocaine -alcohol users had a similarity to the control condition.,Non-OADS,/arxiv_data1/oa_pdf/98/eb/epj-08-3214.PMC5217813.pdf
"http://www.ephysician.ir Page322022)Robles E, Stitzer ML, Strain EC, Bigelow GE, Silverman K. Voucher -based reinforcement of opiate abstinence during methadone detoxification.",Non-OADS,/arxiv_data1/oa_pdf/98/eb/epj-08-3214.PMC5217813.pdf
"Electronic Physician (ISSN: 2008 -5842) http://www.ephysician.ir November2016, Volume: 8, Issue:11, Pages:3222-3227,DOI:http://dx.doi.org/10.19082/ 3222 Corresponding author: Assistant Professor Dr. Seyed Mahmoud Amin Marashi, in Medical Bacteriology Department of Microbiology and Immunology Albo rz University o f medical sciences, Karaj, Iran.",Non-OADS,/arxiv_data1/oa_pdf/07/9f/epj-08-3222.PMC5217814.pdf
http://www.ephysician.ir Page32242.4.,Non-OADS,/arxiv_data1/oa_pdf/07/9f/epj-08-3222.PMC5217814.pdf
http://www.ephysician.ir Page3226Acknowledgments: This article was extracted from a Ph.D. thesis at Babol University of Medical Sciences.,Non-OADS,/arxiv_data1/oa_pdf/07/9f/epj-08-3222.PMC5217814.pdf
"Electronic Physician (ISSN: 2 008-5842) http://www.ephysician.ir November2016, Volume: 8, Issue:11, Pages:3228-3233,DOI:http://dx.doi.org/10.19082/ 3228 Corresponding author: Hamed Biglari, Department of Environmental Health Engineering, School of P ublic Health, Social Development & Health Promotion Research Center, Gonabad University of Medical Sciences, Gonabad, Iran.",Non-OADS,/arxiv_data1/oa_pdf/df/fe/epj-08-3228.PMC5217815.pdf
http://www.ephysician.ir Page32303.,Non-OADS,/arxiv_data1/oa_pdf/df/fe/epj-08-3228.PMC5217815.pdf
http://www.ephysician.ir Page32325.,Non-OADS,/arxiv_data1/oa_pdf/df/fe/epj-08-3228.PMC5217815.pdf
"Electronic Physician (ISSN: 2008 -5842) http://www.ephysician.ir November2016, Volume: 8, Issue:11, Pages:3234-3239,DOI:http://dx.doi.org/10.19082/ 3234 Correspo nding author: Farangis Sharifi, Department of Midwifery, Kazerun Branch, Islamic Azad University, Kazerun, Iran.",Non-OADS,/arxiv_data1/oa_pdf/c8/49/epj-08-3234.PMC5217816.pdf
http://www.ephysician.ir Page3236two groups in terms of nutritional status of infants (p = 0.229).,Non-OADS,/arxiv_data1/oa_pdf/c8/49/epj-08-3234.PMC5217816.pdf
"http://www.ephysician.ir Page3238Acknowledgments: We thank the personnel of Islamic Azad University, Kazerun Branch, Fars, Iran and Kazerun health network staff who helped us with sampling and procedures during the study.",Non-OADS,/arxiv_data1/oa_pdf/c8/49/epj-08-3234.PMC5217816.pdf
"Electronic Physician (ISSN: 2008 -5842) http://www.ephysician.ir November2016, Volume: 8, Issue:11, Pages:3240-3247,DOI:http://dx.doi.org/10.19082/ 3240 Corresponding author: Sara Kiani, Cellular and Molecular Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran.",Non-OADS,/arxiv_data1/oa_pdf/2a/75/epj-08-3240.PMC5217817.pdf
http://www.ephysician.ir Page3242al-safan (flaccidity of scrotum); istirkha’ al -qadib (flaccidity of the penis) (23).,Non-OADS,/arxiv_data1/oa_pdf/2a/75/epj-08-3240.PMC5217817.pdf
"http://www.ephysician.ir Page3244unbearable fatigue, headache, nuchal rigidity, flatulence, impaired digestion, palpitation, etc.",Non-OADS,/arxiv_data1/oa_pdf/2a/75/epj-08-3240.PMC5217817.pdf
"http://www.ephysician.ir Page32467)Bhuyan KC, Bhuyan DK.",Non-OADS,/arxiv_data1/oa_pdf/2a/75/epj-08-3240.PMC5217817.pdf
"Electronic Physician (ISSN: 2008 -5842) http://www.ephysician.ir November2016, Volume: 8, Issue:11, Pages:3248-3256,DOI:http://dx.doi.org/10.19082/ 3248 Corresponding author: Hamed Biglari, Department of Environmental Health Engineering, School of Public Health, Social Development & Health Promotion Research Center, Gonabad University of Medical Science, Gonabad, Iran .",Non-OADS,/arxiv_data1/oa_pdf/d2/6e/epj-08-3248.PMC5217818.pdf
http://www.ephysician.ir Page32503.1.Investigation of pH effect on efficiency of the adsorbent Figure 1illustrates the impact of initial pH of the solution on phenol adsorption efficiency by pomegranate peel ash.,Non-OADS,/arxiv_data1/oa_pdf/d2/6e/epj-08-3248.PMC5217818.pdf
http://www.ephysician.ir Page3252absorption happens in certain homogeneous places within the absorbent.,Non-OADS,/arxiv_data1/oa_pdf/d2/6e/epj-08-3248.PMC5217818.pdf
http://www.ephysician.ir Page3254of the phenol adsorbed by solid phase when the two phases are in equilibrium state.,Non-OADS,/arxiv_data1/oa_pdf/d2/6e/epj-08-3248.PMC5217818.pdf
"http://www.ephysician.ir Page325633)Glesceria LA, Greenberg E, Eaton AD.",Non-OADS,/arxiv_data1/oa_pdf/d2/6e/epj-08-3248.PMC5217818.pdf
"Electronic Physician (ISSN: 2008 -5842) http://www.ephysician.ir November2016, Volume: 8, Issue:11, Pages:3257-3265,DOI:http://dx.doi.org/10.19082/ 3257 Corresponding author: Associate Professor Dr. Ali Mellat A rdekani, Neurology Department, Shahid Sadoughi Hospital, Yazd University of Medical Science, Yazd, Iran, Tel: +98.9133514543, Email: ali_mellat@yahoo.com Received: December 12, 201 5, Accepted: February 16, 2016 , Published: November 2016 iThenticate screening: March 01, 2016 , English editing: October 09, 2016 , Quality control: November 04, 2016 © 2016The Authors.",Non-OADS,/arxiv_data1/oa_pdf/cd/79/epj-08-3257.PMC5217819.pdf
"http://www.ephysician.ir Page3258which is primarily used for treatment of seizures, bipolar disorders and trigeminal neuralgia.",Non-OADS,/arxiv_data1/oa_pdf/cd/79/epj-08-3257.PMC5217819.pdf
"http://www.ephysician.ir Page3260Table 3.Duration of drug use in each group Duration of drug use Carbamazepine Sodium Valproate Total 2-5 years 13 (31.7%) 18 (43.9%) 31 (37.8) 6-8 years 9 (22%) 10 (24.4%) 19 (32.2) More than 9 years 19 (46.3%) 13 (31.7%) 32 (39%) Total 41 (100% 41 (100%) 82 (100%) Table 4.Relation between duration of drug use and bone markers Variable and time duration (year) in years Carbamazep inep-valueSodium Valproate p-value Mean SD Mean SD Calcium 2-59.38 0.1121 0.831 9.094 0.1514 0.62 6-89.033 0.1581 9.220 0.221 >99.005 0.1929 9.038 0.1805 Total9.022 0.1605 9.107 0.1876 Phosphor 2-53.523 0.3113 0.826 0.822 0.337 0.061 6-83.511 0.3100 0.580 0.3957 >93.568 0.1945 0.892 0.4536 Total3.541 0.2569 0.768 0.4101 Alkalin phosphatase 2-5156 28.888 0.016 191.83 139.299 0.296 6-8148.78 33.003 146.50 12.695 >9188.42 43.847 143.85 17.339 Total169.44 40.734 165.56 98.488 Paratormone 2-525.488 6.9573 0.05 31.866 12.8090 0.657 6-830.909 7.50 29.260 11.0578 >934.22 7.63 34.477 15.9166 total30.57 8.27 13.058 13.3086 Femoral Bone density2-50.85715 0.11604 0.062 0.9207 0.82859 0.000 6-80.78356 0.067 0.7775 0.10 >90.76 0.123 0.8092 0.055 total0.796 0.11 0.857 01028 T.score 2-5-0.3 0.7059 0.80 0.188 0.6432 0.002 6-8-0.644 0.6616 -0.920 0.9211 >9-1.061 1.017 -0.482 0.625 Total-0.707 0.8962 -0.291 0.8592 Lumbar bone mineral density 2-51.015 0.822 0.501 1.02 0.08 0.027 6-81.013 0.0529 0.96630 0.069 >90.986 0.079 0.929 0.133 total1.0016 0.074 0.9815 0.1038 T.score 2-5-0.308 0.743 0.208 -0.217 0.7778 0.036 6-8-0.167 0.7018 -0.830 1.2065 >9-0.653 0.7396 -1.000 0.584 Total-0.437 0.7446 -0.615 0.9046 However, other biochemical markers of bone had no significant relationship with increased length of treatment.",Non-OADS,/arxiv_data1/oa_pdf/cd/79/epj-08-3257.PMC5217819.pdf
http://www.ephysician.ir Page3262Babayi Jit et al.,OADS,/arxiv_data1/oa_pdf/cd/79/epj-08-3257.PMC5217819.pdf
"http://www.ephysician.ir Page3264Acknowledgments: We thank the library of Shahid Sadoughi University of Medical Sciences for their help in literature review, and all the patients and neurology ward nurses who helped us to conduct t his study.",Non-OADS,/arxiv_data1/oa_pdf/cd/79/epj-08-3257.PMC5217819.pdf
"Electronic Physician (ISSN: 2008 -5842) http://www.ephysician.ir November2016, Volume: 8, Issue:11, Pages:3272-3278,DOI:http://dx.doi.org/10.19082/ 3272 Corresponding author: Assistant Professor Dr. Fatemeh.",Non-OADS,/arxiv_data1/oa_pdf/07/28/epj-08-3272.PMC5217820.pdf
http://www.ephysician.ir Page32742.2.2.Patients’ satisfac tion questionnaire: This questionnaire consists of eighteen statements.,Non-OADS,/arxiv_data1/oa_pdf/07/28/epj-08-3272.PMC5217820.pdf
"http://www.ephysician.ir Page3276the reduction in anxiety of CABG patient sthrough effective communication with them, need assessment, participatory decision -making (for educating all patients), increased motivation of patients for learning and increased motivation of nurses for teaching.",Non-OADS,/arxiv_data1/oa_pdf/07/28/epj-08-3272.PMC5217820.pdf
"http://www.ephysician.ir Page327823)Yeganeh khah MR, Abedini A, Akbari H, Ziyayi Nezhad MT.",Non-OADS,/arxiv_data1/oa_pdf/07/28/epj-08-3272.PMC5217820.pdf
"Electronic Physician (ISSN: 2008 -5842) http://www.ephysician.ir November2016, Volume: 8, Issue:11, Pages:3279-3288,DOI:http://dx.doi.org/10.19082/3279 Corresponding aut hor: Robab Latifnejad Roudsari, Ebne-SinaStreet, School of Nursing and Midwifery, Mashhad University of Medical Sciences, Mashhad, Iran.",Non-OADS,/arxiv_data1/oa_pdf/95/23/epj-08-3279.PMC5217821.pdf
"http://www.ephysician.ir Page3280fetal and maternal outcomes and reduces pregnancy complications, birth defects, fetal death, low birth weight, and pre-term labor (1).",Non-OADS,/arxiv_data1/oa_pdf/95/23/epj-08-3279.PMC5217821.pdf
http://www.ephysician.ir Page32823.,Non-OADS,/arxiv_data1/oa_pdf/95/23/epj-08-3279.PMC5217821.pdf
"http://www.ephysician.ir Page3284not willing to ask about sexual issues beca use of cultural restrictions, shyness, etc.",Non-OADS,/arxiv_data1/oa_pdf/95/23/epj-08-3279.PMC5217821.pdf
http://www.ephysician.ir Page3286study.,Non-OADS,/arxiv_data1/oa_pdf/95/23/epj-08-3279.PMC5217821.pdf
Available from: http://www.un.org/popin/unfpa/taskforce/guide/iatfreph.gdl.html.,Non-OADS,/arxiv_data1/oa_pdf/95/23/epj-08-3279.PMC5217821.pdf
"http://www.ephysician.ir Page328826)Riazi H, Bashirian S, Amini L. Awareness of pregnant women about folic acid supplementation in Iran.",Non-OADS,/arxiv_data1/oa_pdf/95/23/epj-08-3279.PMC5217821.pdf
"Electronic Physician (ISSN: 2008 -5842) http://www.ephysician.ir November2016, Volume: 8, Issue:11, Pages:3289-3295,DOI:http://dx.doi.org/10.19082/ 3289 Corresponding author: Assistant Professor Dr. Mitra Tabari,  Dental Materials Research Center, Department of Pediatric Dentistry, Faculty of Dentistry, Babol University of Medica l Sciences, Babol, Iran.",Non-OADS,/arxiv_data1/oa_pdf/5c/ac/epj-08-3289.PMC5217822.pdf
http://www.ephysician.ir Page3290preventing the further deve lopment of the caries in the adjacent pits and fissures is the preventive resin restoration technique (2 -5).,Non-OADS,/arxiv_data1/oa_pdf/5c/ac/epj-08-3289.PMC5217822.pdf
"http://www.ephysician.ir Page3292measurements, the surface area of the sticks was measured in mm2using a digital vernier caliper (Mitutoyo, Japan).",OADS,/arxiv_data1/oa_pdf/5c/ac/epj-08-3289.PMC5217822.pdf
"http://www.ephysician.ir Page3294addition, the penetration of dye seems to be better than that of bacteria and its byproducts.",Non-OADS,/arxiv_data1/oa_pdf/5c/ac/epj-08-3289.PMC5217822.pdf
"Electronic Physician (ISSN: 2008 -5842) http://www.ephysician.ir November2016, Volume: 8, Issue:11, Pages:3296-3301,DOI:http://dx.doi.org/10.19082/ 3296 Corresponding author: Associate Professor Dr. Maryam Ghasempour.",Non-OADS,/arxiv_data1/oa_pdf/8d/72/epj-08-3296.PMC5217823.pdf
"http://www.ephysician.ir Page3298parental section ,it was 2.35 ± 2.78 (Tables 1 and 2).",OADS,/arxiv_data1/oa_pdf/8d/72/epj-08-3296.PMC5217823.pdf
http://www.ephysician.ir Page3300Acknowledgments: We thank staff of the Research Center at Babol University of Medical Sciences.,Non-OADS,/arxiv_data1/oa_pdf/8d/72/epj-08-3296.PMC5217823.pdf
"Electronic Physician (ISSN: 2008 -5842) http://www.ephysician.ir November2016, Volume: 8, Issue:11, Pages:3302-3308,DOI:http://dx.doi.org/10.19082/3302 Corresponding author: Houshyar Zeinab, Department of Research, Faculty of Nurs ing, Torbat Jam Faculty of Medical Sciences, Torbat Jam, Iran.",Non-OADS,/arxiv_data1/oa_pdf/50/1b/epj-08-3302.PMC5217824.pdf
"http://www.ephysician.ir Page3304the participants being Arabs, a native assisted us with data collection.",Non-OADS,/arxiv_data1/oa_pdf/50/1b/epj-08-3302.PMC5217824.pdf
http://www.ephysician.ir Page33064.Discussion This study was aimed at determining the relationship between body image preoccupations and sexual function in middle-aged women.,Non-OADS,/arxiv_data1/oa_pdf/50/1b/epj-08-3302.PMC5217824.pdf
"http://www.ephysician.ir Page330812)Sotoudeh G, Niyazi E, Khosravi Sh, Kha jeh Nasiri F, Koohdani F. Prevalence and determinants of obesity and overweight in pre -and post-menopausal women in Islamshahr: a population -based study.",Non-OADS,/arxiv_data1/oa_pdf/50/1b/epj-08-3302.PMC5217824.pdf
"Therapy has to be provided without delay, becausethe absence of early glycemic control after the diagnosis of†Present address: National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan.Quoted from English-language edition of Treatment Guide for Diabetes 2014-2015, 13-14 (Bunkodo, Tokyo, Japan, 2016 http://www.fa.kyorin.co.jp/jds/uploads/Treatment_Guide_for_Diabetes_2014-2015.pdf) edited by Japan Diabetes Society.This is the official published version of that report, and has been jointly published in Diabetology International (the official Engl ish journal of JDS) and Journal of Diabetes Investigation (the official journal of the Asian Association for the Study of Diabetes).Received 9 November 2016; revised 17 November 2016; accepted 17 November2016 ª2016 Japan Diabetes Society (JDS).",Non-OADS,/arxiv_data1/oa_pdf/1e/14/JDI-8-123.PMC5217866.pdf
http://onlinelibrary.wiley.com/journal/jdi,Non-OADS,/arxiv_data1/oa_pdf/1e/14/JDI-8-123.PMC5217866.pdf
1 January 2017 125SPECIAL REPORT http://onlinelibrary.wiley.com/journal/jdi New glycemic targets in Japan,Non-OADS,/arxiv_data1/oa_pdf/1e/14/JDI-8-123.PMC5217866.pdf
1 January 2017 85ORIGINAL ARTICLE http://onlinelibrary.wiley.com/journal/jdi Omarigliptin in Japanese men,Non-OADS,/arxiv_data1/oa_pdf/f3/98/JDI-8-84.PMC5217871.pdf
http://onlinelibrary.wiley.com/journal/jdi,Non-OADS,/arxiv_data1/oa_pdf/f3/98/JDI-8-84.PMC5217871.pdf
1 January 2017 87ORIGINAL ARTICLE http://onlinelibrary.wiley.com/journal/jdi Omarigliptin in Japanese men,Non-OADS,/arxiv_data1/oa_pdf/f3/98/JDI-8-84.PMC5217871.pdf
http://onlinelibrary.wiley.com/journal/jdi,Non-OADS,/arxiv_data1/oa_pdf/f3/98/JDI-8-84.PMC5217871.pdf
